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Preface 
 
The Biotechnology for Europe (Bio4EU) study was carried out in 2005-2007, responding to a 
request from the European Parliament, to provide information on the contribution of modern 
biotechnology to achieve major policy goals of the European Union (EU), and on its 
economic, social and environmental consequences.  
 
The study was developed and led by the European Commission Joint Research Centre’s 
(JRC) Institute for Prospective Technological Studies (IPTS). Much of the data providing the 
basis for the analysis presented in this report was collected by the European Techno-
Economic Policy Support Network (ETEPS), which also contributed to the analysis. 
Furthermore, European stakeholder organisations provided input to the study.  
 
These contributions as well as other relevant reports and information are available on the 
Bio4EU website (http://bio4eu.jrc.ec.europa.eu/). 
 
 
The present document, the Bio4EU Analysis Report, complements the Bio4EU synthesis 
report1, providing more detailed data and analysis focussing on the contribution of modern 
biotechnology to the Lisbon Strategy and the Sustainable Development Strategy as the 
overarching EU policy goals. 
 
 
 
 
 
 
 
 
 
                                                 
1 Zika, E., Papatryfon, I., Wolf, O., Gómez-Barbero, M., Stein, AJ., Bock, AK. (2007). Consequences, 
opportunities and challenges of modern biotechnology for Europe. European Commission, IPTS, EUR 22728. 
http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1470. 
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Executive Summary 
 
Biotechnology is generally considered one of the key technologies of the 21st century, with a 
potentially wide range of applications in e.g. healthcare, agriculture, and industrial production 
processes. However, the diversity of sectors in which biotechnology is applied makes it 
difficult to investigate its actual degree of diffusion. Against this background and following a 
request from the European Parliament, the European Commission initiated the Biotechnology 
for Europe Study (Bio4EU Study). The study’s objectives are to assess the contributions of 
modern biotechnology to the achievement of major European policy goals, and to increase 
public awareness and understanding of modern biotechnology2. Furthermore, the study 
provides input to the ongoing discussion of the respective roles of biotechnology and life 
sciences in the renewed Lisbon Strategy. The Bio4EU study was carried out between autumn 
2005 and spring 20073 under the leadership of the European Commission’s Joint Research 
Centre (JRC), particularly by the Institute for Prospective Technological Studies (IPTS).  
 
This report presents an analysis of the collected data structured in accordance with the major 
EU policy goals economic growth and job creation (Lisbon Strategy), and environmental 
sustainability and public health (Sustainable Development Strategy). It is thus a background 
document for the Bio4EU synthesis report, which sets out the main findings of the study4.  
 
 
Application areas of modern biotechnology 
 
According to the statistical industrial sector classification5, the main biotechnology 
application areas are in the manufacturing sector (which represents approximately 17% of the 
EU’s Gross Value-added, GVA), the agriculture and forestry sectors (2%), and fisheries 
(0.04%). Within manufacturing, a number of different subsectors apply modern 
biotechnology, e.g. the chemical sector (including pharmaceuticals), textile, pulp and paper, 
and food. The major applications that target human and animal health are biopharmaceuticals, 
recombinant vaccines and diagnostics. Modern biotechnology can also be found in primary 
production (agriculture, forestry and fisheries) and agro-food, for example, in breeding 
activities, feed additives, veterinary products, diagnostics, and enzymes for food production. 
Furthermore, biocatalysis, the application of enzymes or whole cells in industrial production 
processes, is applied to fine and bulk chemicals, fuel, textiles, and pulp and paper, although its 
adoption varies greatly between sectors and individual processes. 
 
 
                                                 
2 European Commission COM (2005) 286 final: Report from the Commission to the European Parliament, the 
Council, the Committee of the Regions and the European Economic and Social Committee Life sciences and 
biotechnology – a strategy for Europe. Third progress report and future orientations. 
http://ec.europa.eu/prelex/detail_dossier_real.cfm?CL=en&DosId=193071 
3 The European Techno-Economic Policy Support network (ETEPS, http://www.eteps.net) carried out a large 
part of the data gathering and provided input to the analysis, whereas IPTS was responsible for the design and 
coordination of the study, as well as overall data analysis. 
http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1470.  
4 Zika, E., Papatryfon, I., Wolf, O., Gómez-Barbero, M., Stein, AJ., Bock, AK. (2007). Consequences, 
opportunities and challenges of modern biotechnology for Europe. European Commission, IPTS, EUR 22728. 
http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1470.  
5 NACE is the statistical classification of economic activities in the European Community. Version 1.1 from 
2002 is used in this report. http://ec.europa.eu/eurostat/ramon/nomenclatures/.  
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Contribution of modern biotechnology applications to the Lisbon Strategy6 
 
Regarding human health applications of modern biotechnology, biopharmaceuticals are the 
most important application in economic terms, with about 140 products available worldwide; 
this represents a turnover share of 9% of the EU pharmaceutical market, or EUR 11 billion. 
Average growth rates of the biopharmaceutical market are twice as high compared to the 
pharmaceutical market, and in the EU, the number of biopharmaceuticals on the market has 
more than doubled in the last ten years. Recombinant vaccines play a smaller role, delivering 
approximately 17% (EUR 259 million) of the vaccine sector's turnover. Modern 
biotechnology-based diagnostics mainly relate to immunoassays and DNA-based tests, which 
represent about 30% (EUR 1.7 billion) of the in vitro diagnostics sector.  
 
The pharmaceutical and in vitro diagnostic markets7 are dominated by the US, which have a 
market share of 65% and 51% respectively, compared to an EU share of 30% and 26%. 
Furthermore, only 15% of the currently available biopharmaceuticals were developed by EU 
companies, compared to a share of more than 50% developed by US companies. The 
biopharmaceutical pipeline further consolidates the picture: in 2005, EU companies had only 
about 50% of candidates in clinical trials compared with their US counterparts. However, the 
EU position is better regarding recombinant vaccines, with 26% of available products having 
originated from EU companies.  
 
Overall, modern biotechnology contributes about 5% of the EU pharmaceutical market’s 
GVA, and 0.04% to the EU’s GVA. This contribution is in the same order of magnitude as, 
for example, the contributions of the agrochemical or man-made fibre sectors, which indicates 
the high value of the comparatively low number of products. Indirect economic contributions 
via the sale and use of products in, e.g. pharmacies, hospitals, and the effects of using modern 
biotechnology in pharmaceutical R&D have not been calculated, but would add to this 
contribution. 
 
The agro-food sector (including the input sectors, primary production and food processing) is 
another major sector where modern biotechnology is applied. This refers primarily to the 
sectors that provide input to crop, livestock and fish production in the form of new varieties 
and breeds, feed additives, veterinary products and diagnostics, and to food production in the 
form of enzymes and diagnostics. Between 13% and 23% of the relevant input sector’s 
turnover is related to modern biotechnology, but adoption differs widely between 
applications. The use of modern biotechnology-derived products further downstream by the 
EU agro-food sector, e.g. in crop and livestock production, contributes to more than 30% of 
the sector’s turnover. Overall, by enabling new or better products and services and by 
contributing to the sector’s overall competitiveness, modern biotechnology in the agro-food 
sector is related to the generation of 1.3 - 1.55% of EU GVA.  
 
Manufacturing subsectors applying biocatalysis in industrial production processes, such as the 
production of fine and bulk chemicals, detergents, textiles, pulp and paper, and bioethanol, on 
the whole generate about 5.85% of EU GVA (without food processing).  Adoption rates of 
biocatalysis are specific for individual processes and products, and differ between 100% for 
                                                 
6 Lisbon European Council 23 and 24 March 2000 Presidency conclusions. 
http://consilium.europa.eu/ueDocs/cms_Data/docs/pressData/en/ec/00100-r1.en0.htm. And: European 
Commission COM (2005) 24: Communication to the Spring European Council - Working together for growth 
and jobs – a new start for the Lisbon Strategy. http://europa.eu/growthandjobs/pdf/COM2005_024_en.pdf. 
7 The markets include the EU, the US and Japan. 
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individual textile finishing steps and certain fine chemical compounds, and 0.4% for 
biotechnology-based polymer production. Aside from chemical production, for which no 
disaggregated data were available, and food processing, which has been included in the agro-
food sector, modern biotechnology in industrial production processes is estimated to 
contribute 0.08% of EU GVA or 14% of the subsectors’ GVA, indicating that biocatalysis is 
applied only to specific manufacturing steps and/or to a limited number of products. 
However, where applied, biocatalysis seems to increase labour productivity8 by 10 - 20% of 
the average value for the relevant sectors.  
 
The EU is the leading producer of enzymes, generating approximately 75% of worldwide 
production. In the case of the biotechnology-based production of fine chemicals, bioethanol 
and biotechnology-based polymers, the US, as well as Asian countries such as China, are 
moving into the market and are outpacing the EU’s production capacity growth. This is partly 
caused by the availability of cheaper raw materials, but is also due to targeted policy support 
towards the buildup of biomass-based alternatives to fossil fuel-based products.  
 
Considering all application areas, i.e. human and animal health, agro-food, and industrial 
production processes, the production and use of modern biotechnology-derived products 
relate to the generation of approximately 1.43 - 1.69% of EU GVA. 
 
In terms of employment, modern biotechnology’s contribution is mainly seen in the creation 
of higher qualified jobs. The quantitative effect of modern biotechnology is difficult to 
measure, mainly due to limited data availability and the difficulties of integrating indirect 
employment effects. However, employment effects are likely to correspond to the overall 
diffusion of modern biotechnology applications. Just as with the diffusion of biotechnology 
applications, it can be assumed that some of the newly generated jobs replace existing ones. 
 
 
Contribution of modern biotechnology to environmental sustainability9 
 
Modern biotechnology’s main contributions to environmental sustainability can be attributed 
to applications in industrial manufacturing, including bioethanol and the agro-food sector. 
The application of modern biotechnology in industrial processes (detergents, pulp and paper, 
textiles and fine chemicals, including antibiotics) leads generally to savings in energy and 
water usage, while at the same time reducing greenhouse gas (GHG) emissions, usually in the 
form of carbon dioxide emission reductions and chemical inputs. Generating energy for 
industrial processes emits twice as much GHG as the industrial processes themselves. 
Through energy savings generated by biocatalytic applications, these emissions could be 
reduced.  
 
The transport sector is, with 21%, one of the largest emitters of GHG; petrol, which 
potentially could be replaced by bioethanol, is responsible for more than one third of these 
emissions (7.9%). The use of bioethanol, currently manufactured in the EU from wheat, could 
lead to GHG emission reductions in the transport sector. 
 
                                                 
8 Labour productivity is defined as the ratio between labour input and GVA generation.  
9 European Commission (2001). The European Sustainable Development Strategy 2001. 
http://ec.europa.eu/sustainable/sds2001/index_en.htm. And: European Commission (2006). The renewed 
European Sustainable Development Strategy 2006. http://ec.europa.eu/sustainable/sds2001/index_en.htm. 
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Modern biotechnology applications in the agro-food sector usually target production 
efficiency and thus could lead to improvements in resource efficiency and reduced emissions, 
e.g. as in the case of the enzyme phytase added to animal feed. Also, breeding activities that 
aim to increase resistance to pathogens and abiotic stress factors are expected to have indirect 
environmental benefits. However, novel risks that may arise from the use of modern 
biotechnology also need to be assessed for their potential environmental relevance on a case 
by case basis.  
 
 
Contributions of modern biotechnology to public health 
 
Modern biotechnology applications in the human health sector directly affect public health 
through the provision of effective treatments, unique solutions for treatment and diagnostics 
(e.g. enzyme replacement therapy for Gaucher’s disease or HIV/AIDS diagnostic tests) or 
potentially safer available treatments that do not require animal or human sources (e.g. human 
recombinant insulin or recombinant hepatitis B vaccine). In addition, modern biotechnology 
enables the further development of drugs, with the aim of increasing patients’ quality for life 
(e.g. human insulin analogues).  
 
Analysing the cost-effectiveness studies of several modern biotechnology products provides a 
mixed picture. While some applications seem to be cost-effective (e.g. HIV testing for 
monitoring drug resistance or monoclonal antibodies against non-Hodgkin’s lymphoma), for 
other applications, conclusive studies are missing or analysis indicates that they provide no 
additional health benefit compared to their conventional counterparts (recombinant human 
insulin or recombinant hepatitis B vaccine), or the treatments are clearly not cost-effective but 
offer the only treatment available (enzyme replacement therapy for Gaucher’s disease).  
 
In the agro-food sector, modern biotechnology diagnostics and veterinary products – mainly 
vaccines – play a role in monitoring and controlling some of the most important zoonoses and 
food safety concerns (e.g. salmonella and BSE). Besides the direct impact on food safety and 
thus public health, these applications also have implications regarding the assurance of 
consumer confidence in the food chain and international commerce. 
 
 
Opportunities and challenges 
 
The Bio4EU study shows that modern biotechnology has been adopted to a considerable 
extent by many sectors. While some applications are not visible to the general public (e.g. 
marker assisted selection, MAS, inbreeding), others are in daily use (e.g. enzymes in 
detergents, bio-stonewashed jeans), and others have become the subject of controversy (e.g. 
genetically modified organisms, GMOs). Adoption rates differ between applications, and 
range from emerging applications such as biotechnology-based polymers, to well established 
processes such as biocatalysis in food processing.  
 
The economic and environmental benefits of modern biotechnology products and processes, 
as well as the potential to provide unique solutions, in particular in the field of human health, 
provide opportunities that have not yet been fully exploited. Applications currently under 
development, such as the use of ribonucleic acid molecules for therapies, or new biocatalysts, 
indicate that the potential of modern biotechnology is greater than the applications currently 
available. 
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However, modern biotechnology applications also pose challenges. The development of these 
applications entails high development and infrastructure costs which might pose a problem, 
e.g. for small and medium sized enterprises that lack the financial resources to carry out 
R&D, hire sufficiently skilled staff and invest in new infrastructure and equipment to 
introduce biocatalytic processes. In the agro-food sector as well, the return on comparatively 
expensive applications and related up-front investments in terms of staff and equipment, such 
as for breeders’ MAS, might materialise rather slowly. Regarding health applications, the 
generally high costs of biotechnology-based products might place economic strain on 
healthcare systems, thus stressing the importance of cost-effectiveness evaluations. 
 
Modern biotechnology applications raise new ethical questions, as well as environmental, 
socio-economic and legal issues. Examples include potential discrimination due to the misuse 
of personal genetic information, and the quality assurance of genetic testing. Consumers’ 
negative perception of GM foods raises the need for new regulatory initiatives such as those 
related to traceability and co-existence requirements. The EU has enacted specific legislation 
that requires comprehensive risk assessments to be carried out before putting products on the 
market, and is currently active in the further development of animal welfare-related guidelines 
and legislation.  
 
Another general issue concerns the limited availability of statistical data regarding modern 
biotechnology applications, their adoption rates and their relevant impacts, in particular for 
agro-food and industrial manufacturing applications. To facilitate monitoring modern 
biotechnology’s development and adoption, as well as their impacts, e.g. for evidence-based 
policy making, a comprehensive database needs to be developed.  
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1 Introduction 
 
Modern biotechnology is considered one of the key enabling technologies of the 21st century 
with a potentially wide range of applications, in e.g. healthcare, agriculture, and industrial 
processes. At the same time modern biotechnology has contributed to major advances in basic 
science. In its simplest sense, modern biotechnology can be defined as the use of cellular, 
molecular and genetic processes in the production of goods and services, and its beginning 
dates back to the early 1970s when recombinant DNA technology was first developed. Unlike 
traditional biotechnology – which includes fermentation and plant and animal hybridisation – 
modern biotechnology is associated with a different set of technologies including the 
industrial use of recombinant DNA, cell fusion, tissue engineering and others.  
 
In healthcare, modern biotechnology techniques have opened new avenues for the 
development of innovative and more accurate diagnostics, and for the discovery of novel 
drugs (e.g. genetic tests, monoclonal antibodies). Additionally, modern biotechnology 
techniques are now being applied to plant breeding (e.g. development of cereal crops with 
increased protein yield or pest-resistant crops), and to the production of industrial goods (e.g. 
chemicals or textiles). It is evident that modern biotechnology offers unique opportunities to 
address many needs and could consequently serve as a major contributor in achieving 
European Union (EU) policy goals on economic growth and job creation, public health, 
environmental protection and sustainable development10.  
 
In spite of these observations, recent data on the economic performance as well as on R&D 
activities of the European biotechnology industry indicate that 2004 was a year of 
consolidation rather than growth11. Moreover, recent reports12 suggest that the actual adoption 
of modern biotechnologies by various European sectors may be lower than anticipated (e.g. 
genetically modified crops are hardly grown in Europe, stem cell-related applications are still 
in R&D phases, and gene therapy is currently not available outside clinical trials). In fact, it 
appears that modern biotechnology might have been successful primarily in niches where 
economically competitive alternatives do not exist (e.g. antibody-based pharmaceuticals). 
However, modern biotechnology today is still a developing, immature technology and 
extensive research and development programmes are under way to generate new products and 
new applications. Additionally, data on the actual uptake by various sectors (e.g. health, 
agriculture, and environment) and its socio-economic consequences in Europe are still scarce. 
 
Against this background, and following a request of the European Parliament, the European 
Commission announced in the Third Commission Biotechnology Progress Report13 that it will 
                                                 
10 European Commission COM (2002) 27: Communication form the Commission to the European Parliament, 
the Council, the Economic and Social Committee and the Committee of the Regions Life Sciences and 
Biotechnology – a strategy for Europe. 
http://ec.europa.eu/prelex/detail_dossier_real.cfm?CL=en&DosId=171079.  
11 Critical I (2005). Biotechnology in Europe: 2005 comparative study. Critical I, Banbury. 
http://www.europabio.org/CriticalI2006/Critical2006.pdf. And: van Beuzekom, B. (2004). Biotechnology 
statistics in OECD member countries: an inventory. OECD STI working paper 2004/8. OECD, Paris. 
http://dx.doi.org/10.1787/304575100848. 
12 Arundel, A. (2003). Biotechnology indicators and public policy. OECD STI working paper 2003/5. OECD, 
Paris. http://dx.doi.org/10.1787/262776281580.  
13 European Commission COM (2005) 286 final: Report from the Commission to the European Parliament, the 
Council, the Committee of the Regions and the European Economic and Social Committee Life sciences and 
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‘carry out a study into, and conduct a cost-benefit analysis of, biotechnology and genetic 
engineering, including genetically modified organisms, in the light of major European policy 
goals formulated in the Lisbon strategy, Agenda 21, and sustainable development’.  
 
It has also announced that ‘The purpose of this study is twofold. First of all, an evaluation of 
the consequences, opportunities and challenges of modern biotechnology for Europe, in terms 
of economic, social and environmental aspects, is important both for policy-makers and 
industry. The study would therefore constitute the primary input to [the reflection on the role 
of the Life Sciences and Biotechnology in the renewed Lisbon Agenda]. Secondly, this kind of 
independent study should help to increase public awareness and their understanding of life 
sciences and biotechnology.’ 
 
On this basis the Biotechnology for Europe (Bio4EU) study was developed by the European 
Commission's Joint Research Centre (JRC), in particular by the Institute for Prospective 
Technological Studies (IPTS). The study is designed in a way that allows identifying and 
quantifying, as far as possible, contributions of modern biotechnology to the achievement of 
major European policy objectives formulated in the Lisbon Strategy and in the Sustainable 
Development Strategy, in particular concerning economic growth and job creation, public 
health and food safety, food production and environment and energy. 
 
The study focuses on existing modern biotechnology14 applications including, for example, 
biopharmaceuticals, diagnostics and recombinant vaccines, marker assisted selection, 
propagation, biocatalysis and bioremediation. Modern biotechnology applications were 
studied in the three major application areas: human and animal health; primary production 
and agro-food; and industrial processes, energy and environment. 
 
Data gathering has been structured along different sets of indicators developed for the study to 
support the analysis of impacts, costs and benefits of biotechnology applications and to 
illustrate i) the high expectations of biotechnology in terms of public and private investments 
in the technology (input indicators), ii) the output of the investment in terms of modern 
biotechnology products and services (output indicators) and iii) the impact of the uptake of 
modern biotechnology in terms of support to achieving major EU policy goals (impact 
indicators) (see Annex 1 – Methodology).  
 
Data were collected mainly between April and October 2006 by the European Techno-
Economic Policy Support Network (ETEPS)15 and the IPTS. Twenty-nine case studies 
covering applications of modern biotechnology considered to have the highest current impact 
in economic, social and environmental terms were selected for in-depth analysis. The selected 
case studies comprise representative examples of modern biotechnology applications in 
human and animal health, primary production and agro-food and industrial processes, energy 
and environment (see Table 63 in Annex 1 – Methodology), and they were studied in-depth 
                                                                                                                                                        
biotechnology – a strategy for Europe. Third progress report and future orientations. 
http://ec.europa.eu/prelex/detail_dossier_real.cfm?CL=en&DosId=193071 
14 Modern biotechnology includes: biotechnologies covering DNA, proteins and other molecules, cell and tissue 
culture and engineering, process biotechnologies, and sub-cellular organisms, but excludes traditional 
biotechnology processes used, for example, in the food industry or for bioremediation. However, modern 
biotechnology used in combination with traditional biotechnology is included. 
15 European Techno-Economic Policy Support Network (ETEPS, http://www.eteps.net/). Institutes which 
participated in the Bio4EU study are listed at the beginning of the report. References to ETEPS reports either 
refer to the main report or to the application-specific case study reports in which 28 case studies are presented in 
detail (available on the Bio4EU study web site: http://bio4eu.jrc.ec.europa.eu/). 
The Bio4EU Analysis report 17 
with the aim of quantifying, as far as possible, their economic, social and environmental 
impacts. 
 
This report provides the results of the analysis of the data with a view to evaluating the 
contributions of modern biotechnology to major EU policy objectives formulated in the 
Lisbon Strategy16 and in the Sustainable Development Strategy17, in particular concerning 
economic growth and job creation, public health and food safety, and environment and 
energy. A mixed quantitative/qualitative methodology based on indicators is employed for the 
assessment of the economic, social, and environmental consequences of modern 
biotechnology applications (see also Annex 1 – Methodology). The quantitative approach is 
used wherever feasible but is further complemented by qualitative analyses, focusing on 
factors shaping costs and benefits.  
 
The contribution of modern biotechnology to economic growth, competitiveness and 
employment is presented in Chapter 2, whereas contributions to environment and energy, and 
public health and food safety are analysed in Chapters 3 and 4, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
16 Lisbon European Council 23 and 24 March 2000 Presidency conclusions. 
http://consilium.europa.eu/ueDocs/cms_Data/docs/pressData/en/ec/00100-r1.en0.htm. And: European 
Commission COM (2005) 24: Communication to the Spring European Council - Working together for growth 
and jobs – a new start for the Lisbon Strategy. http://europa.eu/growthandjobs/pdf/COM2005_024_en.pdf.  
17 European Commission (2001). The European Sustainable Development Strategy 2001. 
http://ec.europa.eu/sustainable/sds2001/index_en.htm. And: European Commission (2006). The renewed 
European Sustainable Development Strategy 2006. http://ec.europa.eu/sustainable/sds2001/index_en.htm.  
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2 Contribution of modern biotechnology to economic growth, 
competitiveness and employment 
2.1  General outline and overall contribution of modern biotechnology  
 
Since 2000, the overriding EU policy strategy has been the Lisbon Strategy, aiming at a 
leading position of the EU in several areas such as innovation, research, economic growth and 
employment18. The revision of the Strategy in 2005 has put more emphasis on growth and 
employment19, without neglecting other policy fields and the need for balanced progress in 
the sense of the different pillars of sustainable development20 (see Chapters 3 and 4). 
Biotechnology is one of the few explicitly mentioned high technology areas that is monitored 
closely by the Commission because of ‘its potential to create growth and new jobs and benefit 
a wide range of sectors, while at the same time contributing to our broader goals, such as 
sustainable development’21. 
 
From the underlying policy themes of economic growth, competitiveness and employment, the 
policy objectives of i) economic growth, ii) improved international competitiveness, iii) more 
and better employment and iv) higher labour productivity were derived. In the following 
analysis these objectives are matched with concrete policy indicators that have been 
developed to facilitate the measurement of the contribution of modern biotechnology to their 
achievement (see Annex 1 – Methodology).  
 
With regard to economic growth, the analysis confirmed that modern biotechnology 
applications are important contributors. Modern biotechnology enables the provision of new 
or improved products, thereby directly generating additional economic benefits. In the field of 
human and animal health, novel modern biotechnology products have become mainstream, 
contributing as much as 10 - 30% to the turnover of the respective market segments and 
partially growing at higher average rates than the respective non-biotechnology markets. 
Modern biotechnology additionally provides tools that enhance the efficiency of production 
processes, and thereby is an important factor in ensuring the competitiveness of the various 
sectors of application. This is a significant role of modern biotechnology in the agro-food and 
industrial manufacturing sectors, although to varying extents among the different 
applications: in the agro-food sector, modern biotechnology is estimated to directly contribute 
to 13 - 23% of the overall turnover of the relevant input sectors, such as breeding or feed 
additive production, and the use of these biotechnology-based inputs affects about 32 - 38% 
of the agro-food sector’s total turnover. In the field of industrial manufacturing, the 
                                                 
18 Lisbon European Council 23 and 24 March 2000 Presidency conclusions. 
http://consilium.europa.eu/ueDocs/cms_Data/docs/pressData/en/ec/00100-r1.en0.htm. 
19 European Commission COM (2005) 24: Communication to the Spring European Council - Working together 
for growth and jobs – a new start for the Lisbon Strategy. 
http://europa.eu/growthandjobs/pdf/COM2005_024_en.pdf.  
20 European Commission COM (2001) 264 final: Communication from the Commission  A Sustainable Europe 
for a Better World: A European Union Strategy for Sustainable Development. http://europa.eu/eur-
lex/en/com/cnc/2001/com2001_0264en01.pdf; AND: Council of the European Union (2006) DOC 10917/06: 
Renewed EU Sustainable Development Strategy. 
http://register.consilium.europa.eu/pdf/en/06/st10/st10917.en06.pdf. 
21 European Commission COM (2003) 96: Communication from the Commission to the European Parliament, to 
the Council and to the European Economic and Social Committee - Life sciences and biotechnology – a strategy 
for Europe. Progress report and future orientations, p. 2. http://ec.europa.eu/biotechnology/pdf/com2003-
96_en.pdf. 
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importance of modern biotechnology is reflected in the turnover shares of individual 
applications that range from less than 1% in the case of biotechnology-based polymers, to 
10% in pulp and paper and 30% in detergents, and up to 100% in some food production 
processes (e.g. fruit juice). Moreover, the overall contribution of modern biotechnology to 
economic growth will also be reflected in the indirect impacts on the economic performance 
of the specific sectors, all along the production and services chain: for example, modern 
biotechnology-based diagnostics are instrumental in ensuring consumer confidence in the 
food chain and in the safeguarding of related trade activities.  
 
Dynamic developments provide additional insights on the contribution of modern 
biotechnology to economic growth. While the diffusion of some modern biotechnology 
applications is thought to have reached a plateau, the expectations in most cases are for 
increases in adoption and the emergence of novel applications. Moreover, some economic 
benefits are cumulative in time, such as those realised with the aid of modern biotechnology 
applied in selective breeding (e.g. embryo transfer and marker assisted selection). Similarly, 
in health biotechnology, the EU market for biopharmaceuticals grows on average at 23% 
annually, which is twice as much as the overall EU pharmaceuticals market average growth 
rate (11%). Given the different degrees of adoption, there is a potential for future modern 
biotechnology related turnover growth as far as modern biotechnology enables the provision 
of new or improved products or enhances efficiency.  
 
When it comes to the EU’s economic competitiveness, modern biotechnology brings direct 
benefits to the sectors concerned. However, an additional issue is the comparison with the 
competitive position of other global players, as in other countries several applications of 
modern biotechnology have experienced a more comprehensive and quicker adoption. There 
are some fields (such as the production of enzymes) where the EU holds a strong position, but 
from a global perspective on modern biotechnology, the US can be considered the leader in 
the field, with other countries like China, India, or Brazil catching up in one field of 
application or another. 
 
Quantifying the contribution of modern biotechnology to employment and labour productivity 
is hampered by the lack of data and cross-sectorial effects. In particular it is difficult to assess 
if job creation through modern biotechnology applications leads to additional jobs or has 
substitution effects. Yet, it is assumed that modern biotechnology related employment 
roughly corresponds to its overall diffusion rate in the various fields of application. 
Furthermore, the jobs that are created represent higher qualified jobs, i.e. the contribution of 
biotechnology in this context is more qualitative in nature. This is also reflected in a 
seemingly higher labour productivity per employee as compared to productivity when no 
modern biotechnology is used. Industrial manufacturing processes applying modern 
biotechnology are estimated to have on average a 10 - 20% higher labour productivity, which 
in turn may potentially improve competitiveness.  
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2.2 Human health biotechnology 
 
The contribution of health and healthcare towards the achievement of the Lisbon Strategy 
objectives is well recognised. A healthy and well educated working population is an essential 
prerequisite for economic growth. People in the EU live in better health and longer than ever 
before22. Life expectancy has increased to between 75 and 79 years in all Member States and 
infant mortality has fallen sharply in recent years23. This is an important development 
considering that increased life expectancy may also lead to an increase in economic growth 
(e.g. the World Health Organisation WHO predicts that a 10% increase in global life 
expectancy can increase economic growth by 0.35% a year24). A recent study investigating 
the link between health and the economy in the EU indicates four main channels through 
which health may influence economy: higher productivity, greater supply of labour, higher 
skills, and more savings available for more capital formation (e.g. in anticipation of a longer 
life expectancy after retirement)25. However, apart from these potential effects on economic 
growth, which is only a means in itself, better healthcare, better therapies and more prevention 
contribute to an improvement in the quality of life and to overall welfare.  
 
Modern biotechnology impacts human health by facilitating the development of novel and 
improved therapies and preventives, as well as better and more accurate diagnostics. Apart 
from indirectly acting through health improvements on economic growth, biotechnology also 
has a direct impact on the pharmaceutical sector (NACE26 DG 24.427), which in 2002 
employed 579 500 persons and created EUR 58 billion of value-added28, and represents a 
share of about 4% of the total value-added of the manufacturing sector (NACE D).  
 
The analysis of the economic relevance of modern biotechnology applications in the area of 
human health is primarily based on the assessment of direct impacts (see Annex 1 – 
Methodology) that arise from the use of modern biotechnology in the private sector, e.g. by 
the pharmaceutical industry (NACE DG 24.4) for the development of medical products. The 
analysis considers direct impacts of health-related biotechnology adoption in the context of 
the pharmaceutical sector at a disaggregated level (i.e. biopharmaceuticals and vaccines, and 
diagnostics). The indicators that were selected for measuring modern biotechnology uptake 
and its direct economic impact are the following: 
 
                                                 
22 Byrne, D. (2004). Enabling good health for all: a reflection process for a new EU health strategy. Paper by the 
Commissioner for health and consumer protection. European Communities, Luxembourg. 
http://ec.europa.eu/health/ph_overview/Documents/pub_good_health_en.pdf. 
23 European Commission COM (2000) 285 final: Communication from the Commission to the Council, the 
European Parliament, the European Economic and Social Committee and the Committee of the Regions on the 
health strategy of the European Community. http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2000:0285:FIN:EN:PDF. 
24 Sachs, J.D. (2001). Macroeconomics and health: investing in health for economic development. Report of the 
Commission on Macroeconomics and Health, World Health Organisation, Geneva. 
http://whqlibdoc.who.int/publications/2001/924154550X.pdf. 
25 Suhrcke, M. et al. (2005). The contribution of health to the economy in the European Union. European 
Commission, DG Health and Consumer Protection. 
http://ec.europa.eu/health/ph_overview/Documents/health_economy_en.pdf. 
26 NACE is the statistical classification of economic activities in the European Community. Version 1.1 of 2002 
is used in this report. http://ec.europa.eu/eurostat/ramon/nomenclatures/ 
27 It includes the manufacture of basic pharmaceutical products and pharmaceutical preparations, such as 
medicaments, vaccines, homeopathic preparations, dental fillings, bandages and dressings.  
28 Eurostat. http://epp.eurostat.ec.europa.eu/   
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• number (and share) of biotechnology-based products 
• number of companies active in biotechnology 
• economic share(s) of modern biotechnology applications (e.g. in terms of turnover, 
gross value added - GVA). 
 
Indirect impacts resulting, for example, from the end-use of biotechnology-based products for 
health are discussed only qualitatively, due to the limited availability of quantitative data.  
 
Relevant data were obtained from official statistics, databases and market reports of 
commercial origin (biopharmaceuticals, vaccines). Additional data were obtained through 
specific case studies on biopharmaceuticals (recombinant insulin, interferon-beta for the 
treatment of multiple sclerosis, glucocerebrosidase for Gaucher’s disease, CD20 monoclonal 
antibodies for non-Hodgkin’s lymphoma), recombinant vaccines (hepatitis B vaccine), and 
modern biotechnology-based diagnostics (cardiac diagnostic assays, HIV testing, and genetic 
testing).  
 
 
2.2.1 Adoption of modern biotechnology applications 
 
Modern biotechnology applications in health encompass therapeutic products and preventives, 
but also diagnostics. Recombinant DNA technology (i.e. the ability to insert a specific DNA 
sequence into bacteria or mammalian cells allowing the expression of the corresponding 
protein) has been a milestone for the development and production of specific therapeutics, and 
has led to the launch of the first true biotechnology drug, recombinant human insulin, in 1982. 
Since then, about 165 biotechnology-based products, including vaccines and nucleic acid 
products, have reached the market in the US and the EU for the treatment of a range of 
conditions including rheumatoid arthritis, hepatitis and various cancers29, representing a 
market that has been constantly growing over the last decade. In addition, biotechnology 
provides a combination of enabling techniques utilised not only in identifying and validating 
putative targets and drug candidates, but throughout the whole drug development process.  
 
In spite of these observations, a clear picture of the significance of modern biotechnology 
applications in the pharmaceutical sector is lacking. A first indication for its importance can 
be derived by the degree of adoption as measured by i) the numbers and shares of 
biopharmaceuticals and recombinant vaccines, and ii) the numbers and shares of 
biopharmaceutical companies30. It is noted that, although biotechnology-derived vaccines (i.e. 
recombinant vaccines) are also often regarded as biopharmaceuticals, in this analysis, they are 
considered separately as they represent a distinct application (prevention). In a later section 
(Section 2.2.1.3), the adoption of modern biotechnology in diagnostics is also discussed, 
although for this area it has been difficult to retrieve disaggregated data.  
 
 
                                                 
29 Walsh, G. (2006). Nature Biotechnology 24: 769-776. http://dx.doi.org/10.1038/nbt0706-769. 
30 See Section 2.2.2 for a definition. 
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2.2.1.1 Number and share of biopharmaceuticals 
 
The number of available human health products based on modern biotechnology was analysed 
through the pharmaprojects31 database according to originating country (see Table 1). These 
fell into three main categories: biopharmaceuticals32, recombinant vaccines, and other 
products such as gene therapy vectors. Biopharmaceuticals represent the largest group of 
biotechnology-based pharmaceuticals both worldwide, and in individual regions (e.g. 78% of 
all biotechnology products that originated from the EU are biopharmaceuticals). In total, 142 
biopharmaceuticals are now available, the majority of which (54%) originated from the US, 
whereas 15% originated from the EU33. The complete list of biopharmaceuticals that 
originated in EU companies (as determined by headquarters) can be found in Table 65 of 
Annex 2 – Human Health. These products fall into four main groups: i) recombinant 
hormones (a total of five including two insulin products), ii) four monoclonal antibodies, iii) 
two recombinant interferons, and iv) recombinant growth factors (one product, 
erythropoietin). The remaining nine products varied from anticoagulants to enzymes, and also 
included one orphan drug, the enzyme replacement therapy for the Anderson-Fabry disease 
(an X chromosome-linked disorder caused by a genetic deficiency of the lysosomal enzyme  
α-galactosidase)34.  
 
Table 1: Biotechnology-based products marketed worldwide according to originating country (total 
available, 2005) 
 
 Total Originating in the US 
Originating 
in the EU 
Originating 
in Japan 
Originating 
in 
Switzerland 
Originating
in other 
countries 
(Australia, 
South Korea, 
India) 
Biotechnology  
products 183 88 27 11 19 7 
Biopharmaceuticals 142 76 21 8 15 5 
Recombinant  
vaccines 23 4 6 3 4 2 
Others (gene 
therapy vectors; 
cellular, DNA, RNA 
products) 
18 7 1 0 0 0 
 
Another indication for the degree of modern biotechnology uptake by the pharmaceutical 
industry comes from the number of new biotechnology-based products launched. An analysis 
based on the pharmaprojects database indicates that the number of new biopharmaceuticals 
                                                 
31 Data on pharmaceutical and biopharmaceutical products were retrieved by ETEPS from the PJB database 
pharmaprojects (http://www.pjbpubs.com/pharmaprojects/index.htm). The EU is covered as a group with the 
exception of Estonia, Latvia, Lithuania, Malta, Slovenia and Cyprus; for these countries no data are available in 
the pharmaprojects database. 
32 Biopharmaceuticals include: recombinant interferon, interleukin, growth factors, hormones, monoclonal 
antibodies, immunotoxins, immunoconjugates. 
33 In the pharmaprojects database an originator company is defined as ‘that company, academic institution or 
other non-industrial organisation responsible for discovering the drug.’ 
34 For one of these drugs (Scintimun) an application for marketing authorisation was pending at the EMEA but 
was recently withdrawn (http://www.emea.eu.int/humandocs/PDFs/EPAR/scintimun/18999206en.pdf). 
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launched in the EU has varied over the last 10 years from a maximum of 11 new products in 
1999 to a minimum of two in 2005. On average six new biopharmaceuticals per year are 
launched into the EU market (since 1996), representing a share of 9% out of all new 
pharmaceuticals launched per year (see Figure 1).  
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Figure 1: Share of biopharmaceuticals in all pharmaceuticals launched between 1996 and 2005 
Source: ETEPS35, IPTS calculations 
 
Based on these data, the number of available biopharmaceutical products on the market may 
be derived. In 2005, 85 biopharmaceuticals were available on the EU market, more than twice 
as many as in 1996 (see Figure 2). 
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Figure 2: Number of biopharmaceuticals available on the market  
Source: ETEPS35, IPTS calculations 
 
                                                 
35 ETEPS (2006). Bio4EU Task 2, main report.  
The Bio4EU Analysis report 25 
Since the launch of human recombinant insulin, biopharmaceuticals have amplified over the 
last years to encompass recombinant forms of several natural proteins. The main types are  
• blood factors and thrombolytics 
• hormones (e.g. insulin, somatotropin)  
• interferons and interleukins, and growth factors (e.g. erythropoietin) and  
• therapeutics based on monoclonal antibodies, targeting a broad range of conditions.  
 
A closer analysis of the indications of the currently available biopharmaceuticals identified 
through the pharmaprojects database, shows that cancer (24 biopharmaceuticals), metabolic 
(22 biopharmaceuticals), musculoskeletal and immune disorders (16 and 15 
biopharmaceuticals, respectively) are the predominant therapeutic fields.  
 
2.2.1.2 Number and share of recombinant vaccines 
 
A major group of preventive products is vaccines. Recent advances in biotechnology have 
made an impact on the development of new and improved vaccines. This includes the 
development of better delivery methods (e.g. viral vectors) and the identification of novel 
immunogens. In addition, the application of recombinant DNA technology led to the 
development of the recombinant hepatitis B vaccine, which has contributed to the reduction of 
infections36 (more detailed information on the public health impact of this vaccine is 
discussed in Chapter 4). Currently, there is growing interest in DNA vaccines which activate 
an immune response utilising DNA instead of proteins (several are in phase I clinical trials for 
AIDS, malaria and influenza).  
 
To date, recombinant vaccines represent a much smaller share of biotechnology-based 
products (12.5%) available worldwide, as compared to biopharmaceuticals (see Table 1). The 
majority of the currently available recombinant vaccines are targeting hepatitis B. One 
vaccine available on the market includes the recombinant cholera toxin B subunit, and 
recently a vaccine against diseases caused by the human papillomavirus, including cervical 
cancer, was approved in the US and the EU.  
 
After an initial phase of a growing number of recombinant vaccines that were available in the 
EU, their number seems to have stabilised over the last five years. In the US, the number of 
recombinant vaccines has increased by only two in the same period (see Figure 3). In general, 
there is a more dynamic development in the EU vaccines market overall, where more vaccines 
are available on the market from year to year. Due to this positive development in the overall 
market, the share of recombinant vaccines in all available vaccines in the EU fell from 25% to 
under 14% over the last ten years.  
 
                                                 
36 Chang, M.H. (2006). Journal of Clinical Virology 36: S45-S50. http://dx.doi.org/10.1016/S1386-
6532(06)80008-9.  
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Figure 3: Number of recombinant vaccines available on the market 
Source: ETEPS37 
 
2.2.1.3 The role of modern biotechnology in diagnostics 
 
In vitro diagnostics38 (IVDs) are tools (e.g. reagents, chips) for testing specimens taken from 
the body and intended for use in a broad spectrum of healthcare applications, including 
evaluation of an individual’s risk for developing specific diseases or conditions, their early 
detection and/or diagnosis, identification or quantification of treatment, monitoring of 
treatment effectiveness, etc. These diagnostics are grouped in five main categories (see Table 
2), which may vary depending on both the application of the test and the technology that is 
utilised39.  
 
Modern biotechnology diagnostics can be distinguished in two main groups: protein-based 
and DNA-based. The first category refers to tests that can be used to identify changes in the 
levels of proteins during disease (e.g. hepatitis, cancer). In addition, protein-based assays have 
been developed to identify foreign proteins during an infection (e.g. HIV tests). In general, 
this involves the detection of a protein by a specific antibody (e.g. immunoassays). DNA-
based tests (also often referred to as molecular diagnostics) identify alterations in the DNA 
sequence correlating with a disease or a higher risk for developing a disease.  
 
                                                 
37 ETEPS (2006). Bio4EU Task 2, main report.  
38 The US Food and Drug Administration (FDA) defines in vitro diagnostics as: reagents, instruments and 
systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of 
health, in order to cure, mitigate, treat or prevent disease or its sequelae. Such products are intended for use in 
the collection, preparation and examination of specimens taken from the human body.  
39 The Lewin Group (2005). The value of diagnostics, innovation, adoption and diffusion into healthcare. 
AdvaMed, Washington, DC. http://www.advamed.org/NR/rdonlyres/61EB858F-EC9E-4FAB-9547-
09DABF7D2A72/0/thevalueofdiagnostics.pdf.  
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Table 2: Categories and examples of in vitro diagnostic products 
Source: The Lewin Group 200540, adapted by IPTS  
 
Clinical segment Purpose Examples 
Immunochemistry 
Match antigen-antibody- response to 
detect presence or level of a protein 
(point of care testing, blood banking) 
• Immunoassay tests for 
troponin 
• HIV antibody testing 
• Tumour markers 
General (clinical) chemistry 
Measurements of base compounds in 
the body (often performed during 
patient entry into a hospital) 
• Calcium level testing 
• Cholesterol tests 
• Serum iron studies 
Haematology/cytology 
Study of the blood and blood-
producing organs. The most frequently 
ordered tests in clinical labs 
• Blood counts 
• CD4 cell counts 
• Papanicolaou (Pap) smear 
Microbiology/infectious 
disease 
Detection of disease-causing agents • SARS blood screening 
• Antibiotic susceptibility 
testing 
• West Nile Virus blood 
screening 
Molecular: genomic, 
proteomic, metabolomic 
Study of DNA and RNA to detect 
genetic sequences that may indicate 
presence or susceptibility to disease 
• BRCA1 and BRCA2 testing 
• Polymerase chain reaction 
• Pharmacogenetic testing 
using microarrays 
• Genomic disease 
management tests 
 
Diagnostics based on modern biotechnology are found in all categories described in Table 2. 
However, their most prominent application is in the area of immunochemistry and molecular 
testing. Immunochemistry tests are utilised in the detection of immune reactions by measuring 
the body’s antigen-antibody reaction to foreign agents. The main components of such tests are 
recombinant antibodies and these can be used to test for a broad range of conditions including 
cancer, allergies, and infectious diseases.  
 
The category molecular testing involves the investigation of disease association with a 
specific genotype. The most established application of this group of diagnostics is genetic 
testing for various monogenic disorders (e.g. muscular dystrophy) or other diseases such as 
cancer (e.g. tests used to identify a predisposition to breast cancer based on the genes BRCA1 
and BRCA2), and infectious diseases (e.g. HIV testing). Genetic tests performed for 
diagnostic, confirmatory or predictive purposes were recently estimated likely to be above 
700 000 per year in the EU with an economic dimension of around EUR 500 million41. 
Emerging applications of DNA-based tests include the investigation of genetic variation 
affecting drug response (with the aim of, e.g. adjusting drug dosage or selecting a specific 
                                                 
40 The Lewin Group (2005). The value of diagnostics, innovation, adoption and diffusion into healthcare. 
AdvaMed, Washington, DC. http://www.advamed.org/NR/rdonlyres/61EB858F-EC9E-4FAB-9547-
09DABF7D2A72/0/thevalueofdiagnostics.pdf. 
41 Ibarreta, D. et al. (2003). Towards quality assurance and harmonisation of genetic testing services in the EU. 
European Commission, IPTS, EUR 20977. http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1124 .  
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treatment). This application is known as pharmacogenetics/pharmacogenomics and is 
expected to impact tailor-made medicine.  
 
IVDs constitute a diverse group of products ranging from antibodies used in different assays 
to probes used in DNA amplification techniques (PCR) and microarrays42. Although these are 
still a newer technology, DNA microarray products have already reached the market, 
including a test (AmpliChip, Roche) that predicts drug metabolism by genotype analysis of 
the cytochrome P450 pathway, and distinguishes individuals who are poor, intermediate, 
extensive or ultrarapid metabolisers primarily of antidepressants. Based on the test, drug 
dosing can be adjusted according to the needs of different patient groups, ensuring minimum 
adverse reactions. Protein and metabolite microarrays are still less developed, although some 
products are already on the market.  
 
 
2.2.1.4 The role of modern biotechnology in drug development 
 
Drug development is a lengthy process (it can take up to 10-12 years before a drug reaches the 
market) consisting of the following two main steps: i) drug discovery and preclinical 
development (includes target identification and validation, lead screening and optimisation, 
preclinical studies), ii) clinical trials (phases I, II, and III)43. With respect to drug discovery, 
biotechnology provides a combination of enabling techniques utilised in identifying putative 
targets and drug candidates. Recent advances in ‘omics’ technologies (genomics, proteomics, 
etc.), in combination with bioinformatics, have improved our understanding of the genetic 
contribution to disease, leading to the identification and selection of multiple potential drug 
targets at the same time (high-throughput/microarray approach). Modern biotechnology has 
also impacted target validation. One important technology for this process has been the use of 
genetically modified (transgenic or knockout) animals (more commonly mice) for the 
validation of the drug targets (further discussed in Section 4.2.4). However, other techniques 
including antibody-based assays are also applied for this purpose. Finally, modern 
biotechnology is contributing to drug safety through improved delivery methods (e.g. for gene 
therapy and vaccines).  
 
At the clinical trial level, where the safety and efficacy of a drug candidate is tested, the use of 
pharmacogenetic approaches, i.e. the identification of the underlying genetic differences in 
patients’ drug responses in order to modulate therapy, is increasing. In the design of clinical 
trials, such information may help determine the appropriate drug dosage for a specific subset 
of patients, minimising adverse drug reactions44. Additionally, such approaches can be 
applied in the validation of predictive biomarkers, for example, in cancer treatment45. As a 
result, the use of pharmacogenetic data is considered to have a potentially positive impact, at 
least on the cost of clinical trials both by helping select the most appropriate patient 
                                                 
42 DNA microarrays (or chips) are a collection of DNA segments immobilised on a solid surface (e.g. glass, 
plastic or silicon chip) which allow the quantitative and high-throughput analysis of several thousands of genes 
through hybridisation to a set of specific probes.  
43 DiMasi, J.A., et al. (2003). Journal of Health Economics 22: 151-185. http://dx.doi.org/10.1016/S0167-
6296(02)00126-1.  
44 Hopkins, M.H. et al. (2006). Nature Biotechnology 24: 403-410. http://dx.doi.org/10.1038/nbt0406-403.  
45 Sargent, D. et al. (2005). Journal of Clinical Oncology 23: 2020-2027. 
http://dx.doi.org/10.1200/JCO.2005.01.112.  
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populations and by minimising toxicity effects46. In this context, the European Medicines 
Agency (EMEA) and the US Food and Drug Administration (FDA) have recently published 
guidelines for the submission of pharmacogenetic data47.  
 
In spite of the rapid development in science and the increased use of modern biotechnology in 
drug production as estimated by experts (see Section 2.2.6), the attrition rate remains high 
(only about one molecule out of every ten subjected to clinical trials is actually licensed)48 and 
the costs associated with drug development have increased (the average cost of developing a 
new biotechnology drug has recently been estimated at about EUR 1 billion)49, indicating a 
potentially widening gap between scientific advancement and bedside application. However, 
certain experts argue that the high attrition rates may stem from the complexity of the targeted 
diseases and the rather fragmented scientific knowledge related to them, whereas the high 
costs may be at least partly attributed to the long development times and design of large 
clinical trials to meet regulatory requirements (particularly regarding safety). At the same 
time, some analysts have also suggested that the application of new technologies may further 
increase costs (at least in the short term), as these might lead to the identification of numerous 
drug targets which are not currently well understood50. Thus, it is still unclear as to whether 
modern biotechnology has significantly improved the R&D process, but it is suggested that 
this potential can be further harvested through better co-ordinated interdisciplinary research 
which can also be directly translated in specific therapeutic products51.  
 
 
2.2.2 The (bio)pharmaceutical industry 
 
In 2003, the pharmaceutical industry amounted to about 4% of the total EU manufacturing 
value-added and totalled 4111 companies, with 75% of these situated in six EU countries (see 
Figure 4). The 2006 EU Industrial R&D Investment Scoreboard52 demonstrates a similar 
geographic concentration as the majority of the total 64 pharmaceutical companies ranked in 
the top 1000 by R&D investment, were located in Germany (11), the UK (22) and France (9). 
According to Eurostat, these countries are also the largest producers of pharmaceuticals in 
terms of value-added. The production value of the EU pharmaceutical industry has 
continuously grown since 1993, at a higher growth rate than the average in the chemicals 
                                                 
46 Lesko, L.J. and J. Woodcock (2002). The Pharmacogenomics Journal 2: 20-24. 
http://dx.doi.org/10.1038/sj/tpj/6500046.  
47 EMEA (2006). Guideline on pharmacogenetics briefing meetings. European Medicines Agency, London. 
http://www.emea.eu.int/pdfs/human/pharmacogenetics/2022704en.pdf. And: FDA (2005). Guidance for 
industry: pharmacogenomic data submissions. US Food and Drug Administration, Rockville, M.D. 
http://www.fda.gov/cber/gdlns/pharmdtasub.htm. And: EMEA (2006). Guiding principles processing Joint FDA-
EMEA Voluntary Genomic Data Submissions (VGDSs) within the framework of the confidentiality agreement. 
European Medicines Agency, London. http://www.emea.eu.int/pdfs/general/direct/pr/FDAEMEA.pdf.  
48 Climbing the helical staircase. A survey of biotechnology. The Economist (London), 29 March 2003, pp. 3-18. 
http://www.economist.com/surveys/displaystory.cfm?story_id=E1_TGQSVVG.  
49 CSDD (2006). Impact Report 8(6). Tufts Center for the Study of Drug Development. Tufts University, Boston, 
M.A. (Conversion: USD 1 = EUR 0.7765; 22 November 2006) 
50 DiMasi, J.A., et al. (2003). Journal of Health Economics 22: 151-185. http://dx.doi.org/10.1016/S0167-
6296(02)00126-1.  
51 Pisano, G.P. (2006). Harvard Business Review 84(10): 114-125. 
http://harvardbusinessonline.hbsp.harvard.edu/b02/en/common/item_detail.jhtml?id=R0610H.  
52 http://iri.jrc.es/research/scoreboard_2006.htm. 
30   The Bio4EU Analysis report 
sector53, and its trade surplus in 2004 was more than EUR 32 billion, having increased almost 
five times since 199054 (US, Switzerland and Japan are the top three trading partners).  
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Figure 4: Share of pharmaceutical companies in the EU (2003) 
Source: Data from Eurostat55 
 
Biopharmaceutical companies (i.e. active in biotechnology) fall in this sector and in this 
analysis they were identified through the pharmaprojects database56. These companies are in 
their majority focusing on the development of biotechnology-based products for human health 
whereas only three companies in the EU, two in the US and three in Japan were found to 
produce recombinant vaccines57. The biopharmaceutical sector in the EU has augmented over 
the last decade (see Table 3), as in 2005 the number of companies was more than double that 
in 1996. Additionally, biopharmaceutical companies represent a large – and constantly 
increasing – share of pharmaceutical companies. This observation potentially points to the 
increasing relevance of biotechnology for the pharmaceutical industry (as more companies opt 
to develop and produce biotechnology-based drugs) although it should be interpreted with 
caution as these data have not been weighted for the size of the companies identified (or their 
turnover).  
 
 
 
 
 
 
                                                 
53 Eurostat (2006). European business - facts and figures. 
http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-BW-05-001/EN/KS-BW-05-001-EN.PDF.  
54 EFPIA (2006). The pharmaceutical industry in figures. EFPIA, Brussels. 
http://www.efpia.org/Content/Default.asp?PageID=199. And: Eurostat, database.  
55 Eurostat. http://epp.eurostat.ec.europa.eu  
56 This includes all companies that have a minimum of one biotechnological product, i.e. biopharmaceuticals, 
recombinant vaccines, other (i.e. gene therapy, vectors, cellular products, DNA and RNA products) in clinical 
trials or launched. Includes both large pharmaceutical companies and biotech companies. Companies are 
assigned to a country according to their headquarters. 
57 In 2005 these were Sanofi-Aventis (France), Crucell (NL), GlaxoSmithKline (UK) in the EU. In the US two 
companies were mentioned in the pharmaprojects database (Biogen Idec and Merck & Co). In Japan three 
companies were listed (Mitsubishi Pharma, Kaketsuken, Research Development Corp). 
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Table 3: Increase in number of biopharmaceutical companies between 1996 and 2005 
Source: ETEPS58 
 
 Number of companies in 1996 Number of companies in 2005 Increase (%) 
EU 37 143 286 
US 102 281 175 
Japan 18 22 22 
 
Data on the size and turnover of all EU biopharmaceutical companies are not available. 
However, some insight may be gained by taking a closer look at the companies responsible 
for the development of the 21 biopharmaceutical products originating in the EU (the complete 
list of these can be found in Table 65 of Annex 2 – Human Health). These include both large 
pharmaceutical firms and small or medium-sized biotechnology companies (see Table 4)59.  
 
Table 4: Companies that have developed biopharmaceuticals originated in the EU 
 
 
Number 
of 
products 
Country Pharma Biotech
Number of 
employees 
(2005) 
Net sales 
(EUR billion, 
2005) 
R&D/Net 
sales ratio 
(%, 2005) 
Sanofi-Aventis* 4 France √  97 181 27.3 14.8 
Novo-Nordisk 4 Netherlands √  21 146 4.5 15.1 
Bayer 4 Germany √  61 300** 27.4** 7** 
Boehringer-Ingelheim 2 Germany √  37 406 9.5 14.3 
Shire 2 UK √  2090 1.4 18 
GlaxoSmithKline* 1 UK √  99 503 31.5 14.5 
Crucell* 1 Netherlands  √ 252 0.033 84.1 
AkzoNobel 1 Netherlands n.a. n.a. n.a. n.a. n.a. 
AstraZeneca 1 UK √  64 900 20.3 14.1 
BTG 1 UK  √ 95 0.073 16.2 
Total 21  7 2 383 873 153.51  
*These companies have also developed and market recombinant vaccines. **Data taken from Bayer 
(http://www.bayer.com/bayer-group/profile-and-organisation/page2351.htm), R&D/net sales ratio calculated by 
IPTS. n.a.: not available 
 
Together these companies employed 383 873 persons and generated more than EUR 153 
billion in net sales, in 2005. This represents a large share of the pharmaceutical sector in the 
EU, which employed 579 500 people and had a turnover of EUR 171 billion in 2002 (data for 
2005 are not available). The share of biotechnology-based product sales in the total sales of 
these companies may provide an indication of the relevance of biotechnology for the 
                                                 
58 ETEPS (2006). Bio4EU Task 2, main report.  
59 The classification was taken from the 2006 EU Industrial R&D Investment Scoreboard which ranks 64 
pharmaceutical companies and 57 biotechnology companies in the EU top 1000 R&D investors. However, the 
latter are not specific only for health applications. The classification of these companies has been made on the 
basis of the ICB (Industry Classification Benchmark) which is in turn based on the company’s own classification 
(i.e. how the company declared itself when it was first introduced in the stock exchange).  
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economic performance of this industry. Although such information is not available for all 
biopharmaceuticals originating in the EU, examples can be provided from the case studies. 
For instance, in 2005, sales of the human insulin analogue glargine reached almost EUR 1.2 
billion, accounting for 5.45% of Sanofi-Aventis’ total sales60. Human insulin sales accounted 
for over 40% (i.e. EUR 2 billion) of the total sales of Novo-Nordisk.  
 
2.2.3 Economic shares of biopharmaceuticals 
 
In this section the economic shares of biotechnology-based products which are grouped in 
three main categories, i.e. biopharmaceuticals, vaccines and diagnostics, are analysed. As 
discussed earlier, biopharmaceuticals represent the most predominant application area in 
terms of products on the market (see Table 1). The predominance of this group is also 
reflected in its turnover compared to recombinant vaccines and diagnostics (see Figure 561).  
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Figure 5: Turnover of modern biotechnology products in the EU (2005) 
Source: ETEPS62, revenues of diagnostics calculated by IPTS 
 
In 2005, the combined turnover63 of biopharmaceuticals in the EU, the US and Japan (which 
probably represents about 75% of the world market, similar to pharmaceuticals64), was EUR 
38.43 billion, representing a 10% share of the combined turnover of the pharmaceutical 
market of the EU, the US and Japan (see Table 5). The EU share of biopharmaceuticals was 
30%.  
                                                 
60 Sanofi-Aventis is also the originating company for three additional biotechnology drugs (lepirudin, rasburicase 
and somatropin) but sales data for these drugs individually were not available. Thus the total share of 
biotechnology drugs in the total sales of this company is likely to be underestimated. A similar issue applies to 
Novo-Nordisk from which three products originated in addition to insulin aspart biphasic.  
61 Data for diagnostics are for 2004 (estimated by IPTS, based on ETEPS (2006). Bio4EU Task 2, main report).  
62 ETEPS (2006). Bio4EU Task 2, main report.  
63 The analysis of (bio)pharmaceutical revenues on basis of the manufacturer ex-factory prices was carried out in 
the database IMS MIDAS, owned by IMS Health. All biotherapeutics (biopharmaceuticals without recombinant 
vaccines) approved by FDA or EMEA as listed by Walsh (see footnote 29) were used by their generic name(s) as 
basis for biopharmaceuticals. Of this list 16 products (among them 6 monoclonal antibodies, one insulin 
analogue, two growth hormones and three morphogeneic proteins) could not be found in the database. 
64 EFPIA reports that the worldwide pharmaceutical market was worth about EUR 455 billion in 2005. 
(http://www.efpia.org/6_publ/infigures2006.pdf). Additionally, the biopharmaceutical market is valued at a 
range of between EUR 50 billion (EPFIA) and EUR 59 billion (Visiongain (2005). World biotech market 
2005. Strategic report VIS020. Piribo, London).  
The Bio4EU Analysis report 33 
 
Table 5: Biopharmaceuticals and pharmaceuticals turnover in 2005 
Source: ETEPS65, IPTS calculations 
 
 
Turnover of 
biopharmaceuticals 
(EUR billion) 
Share of 
total (in %) 
Turnover of 
pharmaceuticals
(EUR billion) 
Share of 
total (in %) 
Share of 
biopharmaceuticals out of 
all pharmaceuticals (in %) 
EU 11 30 124 33 9 
US 25 65 202 54 12 
Japan 2 5 46 12 4 
Total 38 100 372 100 10 
 
An analysis of biopharmaceutical turnover in the last ten years (see Figure 6) indicates that 
their share out of all pharmaceuticals has been constantly growing both in the EU and in the 
US markets. This observation points to the economic success of biopharmaceuticals, in spite 
of the lower absolute number of such products on the market (as compared to the numbers of 
non-biotechnology derived pharmaceuticals), and is further supported when looking at the 
average turnover per biopharmaceutical available on the market.  
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Figure 6: Share of turnover of biopharmaceuticals from all pharmaceuticals 
Source: ETEPS65 
 
The analysis shows that the average turnover of the EU biopharmaceutical market has almost 
tripled between 1996 and 2005 (see Figure 7). Nevertheless, the absolute value of turnover 
per biopharmaceutical in the EU is consistently lower than in the US. This implies that 
although the numbers of available products in both markets have been comparable over the 
years (see Figure 2), biopharmaceuticals in the US seem to generate higher turnover. This 
could be at least partly attributed to differences in the pricing systems applied in the two 
regions. In the US, pricing follows the free market model and is thus considered a more 
                                                 
65 ETEPS (2006). Bio4EU Task 2, main report.  
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lucrative market. In the EU, pharmaceutical prices are regulated, in varying ways, resulting in 
lower prices paid by EU consumers, when compared with the US66.  
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Figure 7: Average turnover per biopharmaceutical on the market (EUR million) 
Source: ETEPS67, IPTS calculations 
 
The growth in turnover from biopharmaceuticals peaked around 2000, and has now reached 
comparable rates as in previous years, following a trend similar to the pharmaceutical market. 
However, more notably, the rate of the annual growth of biopharmaceuticals is outpacing that 
of pharmaceuticals (see Figure 8). In 2005, growth of the biopharmaceutical market in the EU 
was almost four times higher than that of pharmaceuticals. Moreover, the average annual 
growth rate of biopharmaceuticals over the last ten years is 23%, as compared to 11% for the 
EU pharmaceutical market during the same period.  
 
This effect is also observed in the US, where the average annual growth rate of 
biopharmaceuticals is double (28%) that of pharmaceuticals (14%) (see Figure 9). Thus 
biopharmaceuticals represent a highly dynamic and fast growing market in spite of its low 
volume in terms of products.  
 
This rapid increase in the biopharmaceutical market might be at least partly attributed to 
several blockbuster biotechnology-based drugs. The top 10 selling biopharmaceuticals 
represented more than half of the entire market value in 2005 having experienced an annual 
growth of 33.7% (see Table 6). There are two leading product classes: i) erythropoietin 
(Erypro/Procrit, Aranesp, Epogen) and ii) monoclonal antibodies (Mabthera/Rituxan, 
Remicade, Herceptin). Interferon (Avonex) and insulin (Lantus) products each represent 
about 6% of the total sales of these top 10 products.  
 
 
                                                 
66 Golec, J.H. and J.A. Vernon (2006). European pharmaceutical price regulation, firm profitability, and R&D 
spending. Working paper. Social Science Research Network, Rochester, N.Y. http://ssrn.com/abstract=932989.  
67 ETEPS (2006). Bio4EU Task 2, main report.  
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Figure 8: Turnover growth of biopharmaceuticals and pharmaceuticals in the EU 1996 - 2005 
Source: ETEPS68, IPTS calculations 
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Figure 9: Turnover growth of biopharmaceuticals and pharmaceuticals in the US 1996 - 2005 
Source: ETEPS68, IPTS calculations 
 
 
From the top 10 selling biopharmaceuticals, only Lantus, an insulin analogue, originated in 
the EU which might indicate the weaker position of the EU, at least in terms of generating 
blockbuster drugs. However, biopharmaceuticals produced and marketed in the EU are 
generating significant turnover. Support for this may be further provided by taking a closer 
look at the turnover of EU producers of insulin (including analogues) and interferon. Both 
                                                 
68 ETEPS (2006). Bio4EU Task 2, main report.  
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product groups are economically important, having generated together a total turnover of 
about EUR 7 billion69 (see Table 66 of Annex 2 – Human Health).  
 
Table 6: Top 10 biopharmaceuticals ranked by global sales in 2005 
Source: IMS Health, MIDAS, MAT Dec 2005 via EuroBio 2006 Press Kit70 
 
Top 10 products Type Country 
Sales  
(EUR 
million, 
2005) 
Change 
over 
2004 (%) 
CAGR 
2000 - 
2004 
Market 
share 
2005 (%)
Global biotech market  41 175 17.1 21.4 100 
Erypro/Procrit (Johnson & 
Johnson) Erythropoietin US 2897 -8.8 12.8 7 
Enbrel (Amgen/Wyeth) Cytokine US 2887 40.7 38.9 7 
Aranesp (Amgen) Erythropoietin US 2800 38 n.a. 7 
Remicade (Johnson & 
Johnson/ Schering-Plough) 
Monoclonal 
antibody US 2331 17.3 66.7 5.7 
Epogen (Amgen) Erythropoietin US 2240 -0.8 10.1 5.4 
Mabthera/Rituxan (Roche) Monoclonal antibody Switzerland 2112 23.6 49.6 5.1 
Neulasta (Amgen) Growth factor US 1925 31.7 n.a. 4.7 
Avonex (Biogen Idec) Interferon US 1188 9.6 16.1 2.9 
Lantus (Sanofi-Aventis) Insulin analogue France 1174 47.5 210.1 2.9 
Herceptin (Roche) Monoclonal antibody Switzerland 1106 48.2 49.6 2.7 
Total (top 10)  20 661 19.4 33.7 50.2 
CAGR = Compound Annual Growth Rate; n.a.: not available 
 
2.2.4 Economic shares of vaccines 
 
The relative decrease in the number of marketed recombinant vaccines in the EU is also 
reflected in the development of the share of recombinant vaccines in overall vaccine revenues 
(see Figure 10). Nevertheless, the turnover in 2005 was still higher than in earlier years. This 
may be an indication that the (relatively fewer) recombinant vaccines that have been recently 
marketed in the EU are bigger successes. Indeed, while the average turnover per recombinant 
vaccine in 1996 was EUR 7.2 million, it more than tripled over the next ten year period and 
was considered to reach a value of EUR 23.5 million in 2005, similar to the average turnover 
of vaccines marketed in the US (see Figure 11). In contrast, the average turnover of the other 
vaccines remained stable at around EUR 17 million. One possible explanation is that 
recombinant vaccines are increasingly used to prevent infectious diseases, either because they 
are cheaper, more effective or they are the only vaccine available.  
                                                 
69 This calculation is based on the turnover of NovoNordisk and Sanofi-Aventis for insulins and Schering and 
Sanofi-Aventis for interferon-beta.  
70 EuroBIO 2006 Press Kit. http://www.eurobio2006.com/DocBD/press/pdf/18.pdf; all conversions to EUR used 
this rate: USD 1 = EUR 0.7765 (22 November 2006). 
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Figure 10: Share of turnover of recombinant vaccines from all vaccines 
Source: ETEPS71 
 
The growth in turnover from recombinant vaccines relative to overall vaccine turnover shows 
a more positive growth path than the corresponding development of the recombinant vaccines 
market in terms of mere product numbers. After an initially strong growth of recombinant 
vaccine turnover relative to overall vaccine revenues, the growth curve flattens out and the 
share of recombinant vaccines in the overall vaccines market seems to stabilise at around 
17%. In absolute terms, the market value for recombinant vaccines in the EU has almost 
quadrupled over the last ten years, with revenues growing from EUR 65 million in 1996 to 
EUR 259 million in 2005. This would correspond to a share of 46% of the total recombinant 
vaccine market72, as compared to 54% for the US.  
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Figure 11: Average turnover per recombinant vaccine on the market (EUR million) 
Source: ETEPS71; IPTS calculations 
                                                 
71 ETEPS (2006). Bio4EU Task 2, main report.  
72 Includes the EU, the US and Japan.  
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Thus recombinant vaccines (which are used as a conservative proxy for analysing the 
economic impact of modern biotechnology on vaccines) have established themselves on the 
vaccines market in the EU, where they contribute about 17% of overall revenues. These 
revenues are generated by relatively fewer recombinant vaccines as compared to all vaccines, 
potentially indicating that recombinant vaccines tend to be more successful on the market and 
sell at higher quantities and/or prices than vaccines in general. Given that the economic 
relevance of vaccines in general for the pharmaceuticals sector is rather small (representing a 
share of 1.1% in all pharmaceuticals73), the economic potential of recombinant vaccines at a 
more aggregated level may be limited. Still, the over proportionally high revenues these 
vaccines generate, indicate that recombinant vaccines are sought after and important for 
disease prevention.  
 
 
2.2.5 Economic shares of modern biotechnology-based diagnostics 
 
The diagnostics sector is less well defined than the pharmaceutical sector, involving not only 
companies that develop and/or manufacture these products, but also hospitals and reference 
laboratories (which can be both service providers and consumers of diagnostic products). 
Moreover, due to the diversity of these diagnostic tests, it is difficult to obtain information on 
the absolute numbers of these products (data exist more typically for the types of applications 
rather than the tests per se). Thus, disaggregated economic data and statistical data specific for 
modern biotechnology-based diagnostics are scarce. However, data exist on the entire IVD 
sector74 and specific application areas. Based on this, the economic share of modern 
biotechnology in this sector can be estimated.  
 
The global IVD market was estimated to be more than EUR 22 billion in 200475 and is 
predicted to reach over EUR 33 billion in 2010, with an annual growth of 7.1% (see Table 7). 
This included diagnostic tests in the areas of clinical chemistry, immunochemistry, diabetes, 
microbiology, haematology, point of care testing, molecular diagnostics, etc76. The US had a 
42% share in all IVDs, and five EU countries (France, Spain, Germany, Italy and the UK) 
                                                 
73 Includes the EU, the US and Japan. 
74 This does not include medical device companies or manufacturers of diagnostic equipment.  
75 ETEPS (2006). Bio4EU Task 2, main report.  
76 The following definitions were applied: Clinical chemistry: Tests for cardiac enzymes, cholesterol, drugs of 
abuse (DOA), electrolytes, glucose, hepatic enzymes, lipids, proteins, and therapeutic drug monitoring (TDM) 
Diabetes testing: Lab tests that diagnose diabetes and monitor glucose levels, such as fructosamine and 
glycohaemoglobin (HB1Ac) tests Haematology: Tests for complete blood count (CBC), red blood cell (RBC) 
count, haemoglobin (Hb), haematocrit (Hct), platelet count, white blood cell (WBC) count, white blood cell 
differential (3-diff/5-diff), and blood and tissue groups Haemostasis: Tests for activated clotting time (ACT), 
activated partial thromboplastin time (aPTT), factors Xa and Iia (thrombin), low weight molecular heparins 
(LWMH), and prothrombin time (PT) Immunochemistry: Tests for allergies, anaemia markers, cancerous 
tumour markers, and hormones Microbiology: Tests based on culture techniques Molecular Diagnostics: 
Tests for bacteria (chlamydia trachomatis (CT), neisseria gonorrhoeae (GC), mycobacterium tuberculosis 
(MTB), viruses (HIV, hepatitis C virus (HCV), hepatitis B virus (HBV), including nucleic acid-based 
amplification tests (NATs)) Point of Care (POC): Tests for cardiology, coagulation, diabetes, drugs of abuse 
(DOA), Self-Monitoring Blood Glucose (SMBG): Device that obtains a drop of blood to test for blood sugar 
level. Most often used by diabetics for home testing. Urine testing: Tests done on urine in order to monitor the 
treatment of certain conditions such as diabetes, kidney stones, a urinary tract infection, hypertension, or some 
types of kidney or liver disease.  
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represented 26% (EUR 5.8 billion). Another recent report has estimated the value of the total 
IVD market in Europe to be EUR 8.9 billion in 200477.  
 
Table 7: Worldwide IVD market and growth forecasts 
Source: ETEPS78 
 
Segment 
Worldwide IVD 
market 
2004 
(EUR billion) 
Worldwide IVD 
market 
2010 
(EUR billion) 
CAGR (%) 
Clinical chemistry 5.2 6 2.6 
Immunochemistry 5.4 7.2 4.7 
Diabetes 0.35 0.48 5.5 
Microbiology 1.2 1.8 5.7 
Haematology 1.5 1.8 3.9 
POC 1.2 2.2 10.9 
Haemostasis 0.85 1.6 10.2 
Molecular diagnostics 1.2 2.8 15.3 
Urine 0.42 0.6 5.3 
SMBG 4.4 8.4 11.5 
Others 0.42 0.5 3.6 
Total 22.14 33.4 7.1 
CAGR = Compound Annual Growth Rate 
 
Although data on the share of modern biotechnology-based diagnostics in IVDs are not 
available, an estimate can be derived based on the information above. As discussed earlier 
(see Table 2), these products fall mainly in the category of immunochemistry and molecular 
diagnostics (other categories might also include modern biotechnology-based tests but their 
shares in these groups are probably much smaller and are thus not included in the following 
estimates). Thus, in 2004, modern biotechnology diagnostics represented a share of almost 
30% in all IVDs, with estimated revenues of EUR 6.6 billion. The five EU countries 
mentioned above held 26% of this market (i.e. tests in immunochemistry and molecular 
diagnostics) with EUR 1.7 billion in estimated revenues. The US held a share of 51%. Table 8 
summarises these findings.  
 
The two groups of diagnostics where modern biotechnology is mainly applied are expected to 
experience dynamic growth. Molecular diagnostics are predicted to grow at the fastest rate, 
when compared with all other groups of IVDs, and is likely driven by the emergence of 
‘omics’ high-throughput technologies (genomics, proteomics, metabolomics) allowing both 
earlier diagnosis (e.g. based on the correlation of specific biomarkers to a disease) as well as 
more tailor-made applications such as measuring individual responses to drugs, or predicting 
the risk of disease recurrence (e.g. Oncotype Dx is a test based on 16 genes used for 
                                                 
77 ETEPS (2006). Bio4EU Task 2, main report. Extrapolation was based on the following 14 countries: 
Germany, Italy, France, Spain, the UK, Switzerland, Belgium, the Netherlands, Austria, Portugal, Greece, 
Finland, Poland, Czech Republic.  
78 ETEPS (2006). Bio4EU Task 2, main report. Includes: US, Canada, Japan, Germany, Italy, France, Spain, the 
UK, China, Brazil, Russia, Mexico, India, Korea, Taiwan, Indonesia, and the rest of the world. 
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predicting the risk of recurrent breast cancer)79. In addition, immunochemistry tests are 
predicted to reach EUR 7.2 billion by 2010 at an annual growth of 4.7%.  
 
Table 8: Estimate of modern biotechnology-based diagnostics80 and IVDs revenues in 2004 
Source: ETEPS81 
 
 
Modern 
biotechnology-
based diagnostics 
(EUR billion) 
Share of 
total (in %) 
IVDs 
(EUR billion) 
Share of 
total (in %) 
Regional share 
of 
biotechnology 
in IVDs (in %) 
EU* 1.7 26 5.8 26 29 
US 3.4 51 9.3 42 37 
Others 1.5 23 7.04 32 24 
Total 6.6 100 22.14 100 30 
*Includes: the UK, France, Spain, Italy, and Germany 
 
As regards companies, it is difficult to delineate those that are exclusively dedicated to the 
development of diagnostics based on modern biotechnology. Thus, an evaluation of the 
economic relevance of such manufacturers is hampered. However, information exists on the 
leading IVD companies worldwide, based on revenues. The majority of the top 15 companies 
are based in the US, but two EU companies are also present. These are: i) Bayer Diagnostics 
(Germany) whose IVD sales of almost EUR 2 billion in 2005 represented 8% of its total sales, 
and ii) BioMerieux (France) whose total sales in 2005 resulted from IVDs (EUR 0.9 billion). 
Both of these companies produce molecular diagnostics products and immunodiagnostics 
(e.g. for HIV, hepatitis), although it is not clear what share out of all their diagnostic activity 
these represent.  
 
Overall the lack of more precise (disaggregated) information on, e.g. the absolute numbers 
and origin of diagnostic products based on modern biotechnology and the share of such 
products in all activity of IVD companies, hampers the detailed analysis of the economic 
relevance of this modern biotechnology application. Nevertheless, it represents a considerable 
economic activity in the EU with an estimated share of 29% in all IVDs in the EU and 26% of 
that worldwide. The contribution of this sector to the EU economy is further estimated in 
Section 2.2.6 below.  
 
 
2.2.6 Contribution of modern biotechnology applications to the EU economy 
 
The data presented thus far point to the growing economic significance of modern 
biotechnology applications (i.e. biopharmaceuticals, recombinant vaccines and diagnostics) 
for the EU pharmaceutical industry (NACE DG 24.4) which contributes 4% of the value-
added in total manufacturing. To assess the overall economic contribution of 
biopharmaceuticals and vaccines to the pharmaceutical sector, their share of value-added is 
                                                 
79 Batchelder, K. and P. Miller (2005). Nature Biotechnology 24: 922-926. http://dx.doi.org/10.1038/nbt0806-
922.  
80 Immunochemistry and molecular diagnostics.  
81 ETEPS (2006). Bio4EU Task 2, main report.  
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evaluated here (see Table 9). The revenues in the pharmaceutical industry totalled EUR 171 
billion for the EU in 2002 and the corresponding value-added was EUR 58 billion. Thus, the 
share of value-added in pharmaceutical revenues was 34%. Making the conservative 
assumption that the revenue share of value-added through biotechnology applications in the 
pharmaceuticals industry is the same (despite it being a newer technology that may, e.g. have 
efficiency advantages), the value-added from biopharmaceuticals and recombinant vaccines 
can be derived from the revenue these products generated in the same year82. A similar 
approach may be applied to derive the value-added of diagnostics. Modern biotechnology-
based diagnostics can be related to the pharmaceutical sector, as these products include 
reagents (e.g. antibodies) and kits (or their individual components)83, which are typically 
produced by the same companies that develop biopharmaceuticals and recombinant vaccines. 
The estimated revenues of diagnostics based on modern biotechnology in 2004, were EUR 6.6 
billion. Hence, an approximation for the overall contribution of biotechnology to the value-
added in the pharmaceuticals sector in 2002 would be more than 5% (see Figure 12), and its 
contribution to the value-added in the overall chemicals sector (NACE DG 24) would be 
almost 2%.  
1% 4%
0,2%
94,80%
All other pharmaceuticals Biopharmaceuticals Recombinant vaccines Diagnostics
 
 
Figure 12: Share of modern biotechnology products in pharmaceuticals gross value-added 
 
Biopharmaceuticals hold the largest share of value-added in the pharmaceuticals sector, which 
could be partly attributed to the commercial success of blockbuster biotechnology-based 
drugs such as interferon-beta. In addition, biopharmaceuticals contribute 0.2% to the total 
manufacturing value-added, which is comparable to two subsectors of chemicals, namely 
agrochemicals (NACE DG 24.2) and man-made fibres (NACE DG 24.7) (see Table 9). This 
finding indicates the significant economic value of these products, in spite of their low 
volume (in terms of products). Collectively, biotechnology-based products in the area of 
human health, contribute an estimated 0.25% to the total value-added of the manufacturing 
sector, and in turn about 0.04% to the value-added of the total EU economy.  
                                                 
82 It is noted that the contribution of biotechnology to the EU economy is estimated based on EU market shares 
(i.e. the total revenues of all biotechnology-based products marketed in the EU) rather than the revenues of those 
biotechnology-based products which are manufactured and produced by EU companies.  
83 Diagnostic instruments and testing systems have not been included in this analysis.  
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It should be noted though that the current analysis may underestimate the economic 
contribution of biopharmaceuticals, diagnostics and recombinant vaccines as it does not 
consider indirect economic impacts (i.e. economic impacts that result from their end use, like 
cost savings in hospitals, etc.). Some of these impacts will be discussed later in a more 
qualitative manner in Section 4.2.  
 
 
Table 9: Contribution of modern biotechnology-based applications to the EU economy  
 
EU – 2002 
Turnover 
(EUR 
billion) 
GVA 
(EUR 
billion) 
Share of 
chemicals 
GVA (%) 
Share of 
manufacturing 
GVA (%) 
Share of 
EU GVA
(%) 
EU (all economic activity)  8783   100 
Manufacturing (NACE D) 5799 1529  100 17.4 
Chemicals (NACE DG 24) 601 171 100 11 2 
Basic chemicals (NACE DG 24.1) 246 65 0.7 4 0.7 
Agrochemicals (NACE DG 24.2) 12 2.5 0.03 0.2 0.03 
Paints (NACE DG 24.3) 37 11 0.1 0.8 0.1 
Pharmaceuticals (NACE DG 24.4) 171 58 34 4 0.7 
Detergents (NACE DG 24.5) 68 17 0.2 1 0.2 
Other chemicals (NACE DG 24.6) 53 15 0.2 1 0.2 
Man-made fibres (NACE DG 24.7) 12 3 0.03 0.2 0.03 
Biotechnology-based products 
Biopharmaceuticals* 7 2.4 1.4 0.2 0.03 
Diagnostics** 1.7 0.6 0.06 0.04 0.01 
Recombinant vaccines 0.3 0.1 0.4 0.007 0.001 
Total biotech 9 3.1 1.86 0.25 0.04 
*EU-19; ** Includes: the UK, France, Spain, Italy, and Germany, 2004; figures in italics are estimates; GVA: 
gross value-added 
 
 
Other indirect impacts which could further augment the economic significance of 
biotechnology for the pharmaceutical sector are related to the application of biotechnology in 
the development and production of non-biotech drugs, e.g. small molecules. Although no 
quantitative data measuring this impact exist, the results of experts’ interviews84 indicated that 
the share of biotechnological processes related to chemical processes applied in production is 
estimated in a range of between 10% and 15%, and in the future the increase of this share is 
foreseen. However, the evaluation of the direct economic consequence of the use of biotech in 
small molecule drug development and production is, at the moment, not possible.  
                                                 
84 In total, 28 companies were approached. These included enzyme, fine chemicals and pharmaceutical 
companies. Companies whose main field of activities are enzymatic applications or chemistry in general were 
also included. ETEPS (2006). Bio4EU Task 2, main report. 
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2.2.7 Contribution of modern biotechnology to employment 
 
In 2002, the pharmaceutical sector employed 579 500 persons85; data for more recent years 
are not available. An indication for the size of the EU pharmaceutical sector in terms of 
employed persons in more recent years may be provided through the 2006 EU Industrial R&D 
Investment Scoreboard86. Based on this, the 62 out of the 64 pharmaceutical companies who 
ranked in the top 1000 by R&D investment employed 525 492 persons in 200587. In this 
context, due to limited data availability, it is difficult to evaluate whether and how much 
employment was created as a result of modern biotechnology adoption in the pharmaceutical 
sector.  
 
Some estimates may be made for the employment figures related to specific biotechnology-
based products on the basis of their sales as a proxy (e.g. for insulin and insulin analogues). 
However, such estimates would have to be treated with great caution, company personnel are 
not generally organised by product type. It is difficult to directly relate the staff employed in 
production, sales, management and administration to one single product. Additionally, it is 
not clear as to what extent R&D staff (which would be included in the estimates) are involved 
in work on these established products, or what share of the total employees in each company 
is actually employed within the EU, as the majority of these companies are present in several 
countries outside the EU as well. Finally, although biotechnology-based products may be 
marketed by EU companies, very few of these products have actually originated from the EU, 
which makes it more difficult to evaluate changes in employment that are associated with the 
introduction of modern biotechnology. The lack of such data also hampers the assessment of 
labour productivity (i.e. the relation of value-added to employment) in biotechnology-specific 
applications in the pharmaceutical industry.  
 
Health biotechnology applications may also indirectly influence employment through its 
impact on public health (see Section 4.2). Hence, irrespective of the general improvements in 
social welfare, in as much as better healthcare enables people to stay in their jobs, or to reduce 
times of absence, it also helps to maintain a productive workforce, which again, is a 
prerequisite for economic growth. However, the quantification of this indirect impact is also 
hampered by the lack of relevant statistics. 
 
 
2.2.8 EU - US comparison 
2.2.8.1 Performance of pharmaceutical industries 
 
The performance of the overall pharmaceutical industry in the EU and the US is quite 
different, not only in terms of value-added but more importantly as regards labour 
productivity. In 2000, the value-added of the US pharmaceutical industry was 40% higher 
than the value-added of its counterpart in the EU. At the same time, the EU pharmaceutical 
industry employed almost twice as many persons as the US, thus resulting in lower apparent 
                                                 
85 Eurostat, database. 
86 http://iri.jrc.es/research/scoreboard_2006.htm.  
87 Data for the two remaining companies were not available. 
44   The Bio4EU Analysis report 
labour productivity88. Although more recent data for these indicators are not available (at least 
for the US), similar trends are reported for 200189. The US pharmaceutical companies90 are 
leading in worldwide sales, with nine out of the top 20 pharmaceutical companies with the 
highest sales being US based. The EU compares well in that respect (in total six EU 
companies are found in the top 20)91. However, the US is also leading in terms of innovation, 
with consistently higher R&D investment in the last ten years, and having generated a higher 
share of new molecular entities92.  
 
A similar situation is reflected in the performance of the EU regarding modern biotechnology 
applications93. Although the current analysis indicates that modern biotechnology-based 
products are an important component of the pharmaceutical sector contributing to the total 
economy of the EU (discussed in Section 2.2.6), the EU is still lagging behind the US in its 
overall performance. In absolute numbers, fewer biopharmaceuticals have originated from the 
EU than the US, but the average number of products launched per year in the two markets is 
comparable.  
 
However, this corresponds to very different market values (see Table 10). The EU represents 
30% of the total94 turnover of biopharmaceuticals, and the US holds a 65% share (see Table 
5). Both markets have been constantly growing since 1996 at comparable average annual 
growth rates (23% in the EU and 28% in the US). This expansion may be also reflected in the 
increase of biopharmaceutical companies (see Table 3). In this context, the EU 
biopharmaceutical industry grew more dramatically than the US, although in absolute terms it 
still has fewer companies.  
 
As regards recombinant vaccines, the EU compares well with the US, having generated 26% 
of all the recombinant vaccines available worldwide as compared to 17% from the US. 
Moreover, the average turnover per recombinant vaccines in the EU has increased 
significantly over the last decade surpassing that in the US (see Figure 10). A detailed 
comparison between the EU and the US regarding diagnostics is rather hampered by the lack 
of disaggregated data, as discussed in Section 2.2.5. Nevertheless, it was estimated that the 
EU holds a 26% share in all modern biotechnology-based diagnostics, as compared to 51% 
held by the US (see Table 8).  
 
 
 
                                                 
88 Vekeman, G. (2005). Statistics in focus 44. European Communities, Luxembourg. 
http://epp.eurostat.ec.europa.eu/pls/portal/url/page/PGP_MISCELLANEOUS/PGE_DOC_DETAIL?p_product_
code=KS-NP-05-044.  
89 Pammolli, F. et al. (2004). European competitiveness in pharmaceuticals. European Commission, Brussels. 
http://ec.europa.eu/enterprise/phabiocom/docs/eupharma_28102004_1.pdf.  
90 The number of companies of the US pharmaceutical industry is not clear. The Pharmaceutical Research and 
Manufacturers of America (PhRMA) represents about 48 companies including pharmaceutical and biotech firms 
(http://www.phrma.org/about_phrma/member_company_list/members/).  
91 The top 20 companies include Pfizer, Johnson & Johnson, Merck & Co., Abbott, Bristol Myers Squibb, 
Wyeth, Eli Lilly, Amgen, and Schering-Plough from the US, GlaxoSmithKline, Sanofi-Aventis, AstraZeneca, 
Boehringer Ingelheim, Bayer, and Schering AG from the EU, Novartis and Roche from Switzerland, Takeda and 
Daiichi Sankyo from Japan and Teva from Israel.  
92 EFPIA (2006). The pharmaceutical industry in figures. EFPIA, Brussels. 
http://www.efpia.org/Content/Default.asp?PageID=199.  
93 The comparison does not include value-added or labour productivity related specifically to biotechnology 
applications due to the lack of statistical data.  
94 Includes the EU, US and Japan.  
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Table 10: Turnover of modern biotechnology-based products in the EU and the US 
Source: ETEPS95, revenues of diagnostics calculated by IPTS 
 
Turnover modern biotechnology-based products
(EUR billion) 
 EU US  
Biopharmaceuticals* 11 25 
Recombinant vaccines* 0.3 0.3 
Diagnostics** 1.7 3.4 
Total 13 28.7 
*Data from 2005; **Estimate; EU includes the UK, France, Spain, Italy and Germany, data from 2004 
 
In summary, the available data indicate the EU is still lagging behind the US regarding the 
generation of economic gain from biotechnology applications. Additional information also 
suggests that the future improvement of the EU’s position may be hampered by the limited 
innovativeness of EU companies compared with their US counterparts.  
 
 
2.2.8.2 Pharmaceutical markets and policies  
 
One reason that is mentioned as being potentially responsible for the different performance of 
EU and US pharmaceutical (and health biotechnology) companies, regarding, for example, 
their R&D activities and turnover, as discussed in Section 2.2.8.1, is the difference between 
the pharmaceutical markets in EU Member States and in the US. First, unlike in the US, 
within the EU there is no single market for pharmaceuticals; rather, in the EU this market is 
characterised by a distinction between national and European competences: while nearly 
every aspect of a drug’s development is subject to Community legislation, once the product 
has been authorised, its control largely falls within the national systems for important issues 
such as pricing, reimbursement and distribution96. Second, while in the US government 
policies rely more on competition and a less regulated market approach97, within the EU a 
broader mix of policies can be found: whether and how pharmaceutical prices are regulated 
varies from country to country, ranging from free pricing to fixed prices98.  
 
In the US, the view held is that the development of innovative pharmaceutical products (i.e. 
the quality aspect) plays a critical role in ensuring future health gains and increasing longevity 
– and that without economic incentives private companies, which bring the vast majority of 
new drugs to the market, would be less able to assume the risks and costs of continuing their 
R&D activities. Therefore incentives that favour innovation are provided through direct and 
indirect government funding, intellectual property laws and other policies. In this context, 
                                                 
95 ETEPS (2006). Bio4EU Task 2, main report.  
96 European Commission (2006). Evaluation of the G10 medicines initiative: interim evaluation. Evaluation 
report. Enterprise and Industry DG. http://ec.europa.eu/dgs/enterprise/pdf/Evaluation_of_approaches.pdf.  
97 US DOC (2004). Pharmaceutical price controls in OECD countries: implications for US consumers, pricing, 
research and development, and innovation. International Trade Administration, US Department of Commerce, 
Washington, D.C. http://www.ita.doc.gov/drugpricingstudy.  
98 Mrazek, M.F. (2002). Croatian Medical Journal 43: 453-461. http://www.cmj.hr/2002/43/4/12187524.pdf.  
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competitive pressure from a generic pharmaceutical industry is relied upon to lower drug 
prices99.  
 
In this context, in many EU Member States the emphasis is put on the importance of 
affordable drugs for all and on efficient public healthcare systems (i.e. on access and 
efficiency aspects), as these are fundamental for a widespread realisation of health gains and 
the achievement of a higher life expectancy. Therefore, in many countries attempts are made 
to control rising pharmaceutical and healthcare costs by regulating the pharmaceuticals 
market through different combinations of demand and supply interventions (e.g. price 
controls, restrictive reimbursement policies or the use of positive and negative lists). Another 
reason for regulatory interventions to contain drug costs are imperfections in the 
pharmaceuticals market that may lead to market failure100.  
 
Given the above-mentioned discussion, the actual outcomes of the healthcare systems in the 
US and in EU Member States in terms of relative expenditure on pharmaceuticals show a 
different picture (see Figure 13).  
 
While the US clearly has the most expensive healthcare system of all OECD countries (in 
2003 the US spent 15.2% of gross domestic product (GDP) on health, while Switzerland, the 
second ‘most expensive’ country, spent 11.5%, with South Korea spending the least on health, 
namely 5.5% of GDP), in terms of relative expenditure on pharmaceuticals, no clear 
distinction can be drawn between the various systems. For instance, France and Portugal, 
where pharmaceuticals are subject to price controls101, spend 2.0% and 2.2%, respectively, of 
GDP on pharmaceuticals, while the US, with a less regulated market, spend 1.9% of GDP. On 
the other hand, for instance the Netherlands and Ireland, where pharmaceuticals are also 
subject to price controls, spend only 1.0% and 0.8%, respectively, of GDP on 
pharmaceuticals, but New Zealand, where suppliers are able to market their products with no 
constraints on pricing102, spends only 1.1% of GDP as well.  
 
This situation may partly be explained by the fact that each system mixes regulatory 
components with free market approaches, although to a different extent. For instance, 
although in the US the federal government does not set or regulate the price pharmaceutical 
manufacturers can charge for prescription drugs, federal laws ensure that manufacturers 
extend significant price discounts to federal agencies and selected public sector purchasers103. 
And only recently the US government proposed to intensify the use of reference pricing in its 
                                                 
99 US DOC (2004). Pharmaceutical price controls in OECD countries: implications for US consumers, pricing, 
research and development, and innovation. International Trade Administration, US Department of Commerce, 
Washington, D.C. http://www.ita.doc.gov/drugpricingstudy. 
100 Mrazek, M.F. (2002). Croatian Medical Journal 43: 453-461. http://www.cmj.hr/2002/43/4/12187524.pdf. 
And: Kanavos, P. (2001). Overview of pharmaceutical pricing and reimbursement regulations in Europe. 
Enterprise and Industry DG, European Commission, Brussels. 
http://ec.europa.eu/enterprise/phabiocom/docs/synthesis.pdf. 
101 Kanavos, P. (2001). Overview of pharmaceutical pricing and reimbursement regulation in Europe. Enterprise 
and Industry DG, European Commission, Brussels. http://ec.europa.eu/enterprise/phabiocom/docs/synthesis.pdf. 
And: European Commission (2005). LSE study on healthcare in individual countries, G10 Medicines. Country 
profiles. Enterprise and Industry DG. http://ec.europa.eu/enterprise/phabiocom/p6.htm. 
102 Braee, R. (2005). LSE study on healthcare in individual countries, G10 Medicines. Country profile New 
Zealand: pharmaceutical pricing and reimbursement policies. Enterprise and Industry DG, European 
Commission, Brussels. http://ec.europa.eu/enterprise/phabiocom/p6.htm. 
103 Hansen, J. (2005). LSE study on healthcare in individual countries, G10 Medicines. Country profile United 
States: prescription drug and reimbursement policies. Enterprise and Industry DG, European Commission, 
Brussels. http://ec.europa.eu/enterprise/phabiocom/p6.htm. 
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Medicaid programme for low income people104, which is already a well established practice in 
the US for generically equivalent products (through the use of a ‘maximum allowable charge’ 
for reimbursement in managed care programmes)105. 
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Figure 13. Total expenditure on pharmaceuticals and other medical non-durables (OECD countries, 2003)  
Source: OECD (2006)106  
Note: EU Member States are depicted in blue, the US in red. For Hungary, the Czech Republic, Turkey, New 
Zealand, the UK and the Netherlands the last available figures (before 2003) were used. US$ (PPP) stands for 
USD that are expressed as ‘purchasing power parity’ to make the expenditures more comparable across 
countries.  
 
Still, the differences between the pharmaceutical pricing and reimbursement policies in 
different countries, especially between the US and elsewhere, have also given rise to 
accusations by the US side regarding other countries ‘free-riding’ on R&D that would be 
financed by the higher prices that could be charged by pharmaceutical companies in the 
US107. Yet, while the validity of such allegations has been questioned108, the concern on the 
EU side is more the increasing competitiveness of US companies in the pharmaceutical 
                                                 
104Pear, R. (2006). US is proposing to cut medicaid’s drug payments. The New York Times (New York), 18 
December. http://www.nytimes.com/2006/12/18/washington/18medicaid.html.  
105 Danzon, P.M. and Ketcham J. D. (2003). Reference pricing of pharmaceuticals for medicare: evidence from 
Germany, the Netherlands, and New Zealand.NBER Working Paper 10007. 
http://www.nber.org/papers/w10007.  
106 OECD Health Data 2006. Organisation for Economic Co-operation and Development, Paris. Available online 
at http://www.oecd.org/document/30/0,2340,en_2649_34631_12968734_1_1_1_1,00. html. 
107 McClellan, M.B. (2003). Speech before the first international colloquium on generic medicine, by the 
Commissioner of the US Food and Drug Administration, Washington, D.C., on 25 September. 
http://www.fda.gov/oc/speeches/2003/genericdrug0925.html. And: Aldonas, G.D. (2004). Testimony before the 
joint session of the Senate Finance Committee, Subcommittees on Health and Trade on "International Trade and 
Pharmaceuticals", by the Under Secretary of Commerce for International Trade of the US Department of 
Commerce, Washington, D.C., on April 27. http://www.mac.doc.gov/PressMain/Apr2004/27AprTestimony.htm. 
108 Light, D.W. and Lexchin J. (2005). British Medical Journal 331: 958-960. 
http://dx.doi.org/10.1136/bmj.331.7522.958; rapid responses http://www.bmj.com/cgi/eletters/331/7522/958.  
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sector, which historically has been a stronghold of the European industry. This is attributed to 
structural differences, like lower labour productivity and lower value-added activities in the 
EU pharmaceutical industry (due to less rationalisation), to slower demand growth in its home 
markets, to the failure of the EU industry to specialise and integrate vertically, and to 
inefficiencies that are induced by a lack of competition in the pharmaceutical markets of some 
EU Member States109. 
 
 
2.2.9 Regulatory issues 
2.2.9.1 Biosimilars 
 
The emergence of biogeneric drugs or biosimilars will be an important factor in the future 
economic performance of biopharmaceuticals, especially as several of the available 
biotechnology-based drugs are facing patent expiration in the next few years or patents have 
already expired (e.g. for Humulin, Epogen, Procrit)110. The introduction of biosimilars into the 
market is expected to increase competition which could, in turn, help reduce healthcare costs 
but could also contribute to the improvement of product quality111. At the same time, 
biosimilars (just like generics) appear to influence the emergence of new players in the world 
pharmaceutical market, such as India112, China and South Korea.  
 
However, several issues complicate the development and regulatory approval of biosimilars. 
The manufacturing of a recombinant protein drug is far more complex than that of small 
molecule drugs involving many steps which could influence its biological properties (e.g. 
stability, immunogenicity). In this context, some experts argue that two biopharmaceuticals 
based on the same protein can never be completely identical and therapeutically equivalent. 
The possibility to demonstrate bioequivalence (including safety and efficacy) is also debated. 
EMEA has issued recommendations on the approval of biosimilars (or biogenerics), stating 
that in cases where satisfactory equivalence cannot be demonstrated with existing analytical 
methods, a full preclinical and clinical data package would be required for approval113.  
 
Although the FDA has yet to publish recommendations on this, industry experts suggest that 
full clinical trial data must be required for the approval of biosimilars, as the pharmacokinetic 
equivalence of two proteins may not be sufficient to predict safety and efficacy. In spite of 
these uncertainties, the first biogeneric drug, Omnitrope (a recombinant growth hormone) was 
recently approved in the EU, following a positive evaluation by EMEA. It is also approved in 
Australia. In the US, Omnitrope received FDA approval as the first follow-on version of a 
                                                 
109 Gambardella, A., L. Orsenigo and Pammolli F. (2000). Global competitiveness in pharmaceuticals, a 
European perspective. Report. Enterprise and Industry DG, European Commission, Brussels. 
http://ec.europa.eu/enterprise/phabiocom/p3.htm. 
110 Schellekens, H. (2005). Nephrology Dialysis Transplantation 20: iv31-iv36. 
http://dx.doi.org/10.1093/ndt/gfh1085.  
111 Schellekens, H. (2004). Trends in Biotechnology 22: 406-410. 
http://dx.doi.org/10.1016/j.tibtech.2004.06.003.  
112 Jayaraman, K.S. (2003). Nature Biotechnology 21: 1115-1116. http://dx.doi.org/10.1038/nbt882.  
113 Committee for Proprietary Medicinal Products (2003). Guideline on comparability of medicinal products 
containing biotechnology derived proteins as active substances: quality issues. CPMP/BWP/3207/00. European 
Medicines Agency, London. http://www.emea.europa.eu/pdfs/human/bwp/320700en.pdf. And: Committee for 
Medicinal Products for Human Use (2005). Guideline on similar biological medicinal products. CHMP/437/04. 
European Medicines Agency, London. http://www.emea.europa.eu/pdfs/human/biosimilar/043704en.pdf. 
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previously approved recombinant drug, although a specific regulatory pathway for the 
approval of biogenerics in the US remains to be defined.  
 
 
2.2.9.2 Intellectual property 
 
Modern biotechnology advances have led to the development of new drugs and enabling tools 
for the diagnosis of diseases. Additionally, the completion of the human genome project has 
facilitated the association of specific genetic sequences to a disease, thus allowing the 
identification of novel putative drug targets. Because of their potentially significant economic 
(and public health) implications, modern biotechnology applications are increasingly being 
patented (some biotechnology patents are listed in Table 11).  
 
Table 11: Examples of biotechnology patents granted in the US 
Source: A. Cohen 2002114 
 
Patent Type Assignee 
Polymerase Chain 
Reaction (PCR) 
Process: automated multiplication of small 
amounts of DNA 
Initially Cetus Corp., now Hoffman La-
Roche (four patents in 1987, 1989, 1990) 
Oncomouse Animal model: genetically-modified mouse 
(through the insertion of an oncogene) for the 
study of cancer and related drug targets  
Harvard University, 1988 
Hepatitis B 
vaccine 
Proteins: intermediates triggering production 
of antibodies against the virus 
Biogen, Regents (1987) of the University 
of California (1988), Institute Pasteur 
(2000) (one patent each) 
HIV protease 
inhibitors 
Molecules inhibiting the action of HIV 
protease thus blocking viral replication 
Merck & Co. Inc. (1995) 
Human 
embryonic stem 
cells 
Isolation and culture process, cell line can 
differentiate into any type of tissue 
Wisconsin Alumni Research Foundation 
(2001) 
 
Patenting is considered to have a stimulating effect on innovation, by allowing the inventor 
‘freedom to operate’, which may in turn drive investment115. However, it is also suggested 
that patenting may limit patients’ access to novel treatments (e.g. as a result of high licensing 
fees which would influence the cost of the treatment), and inhibit research, especially as a 
result of the proliferation of DNA patents116. Drug patents are often under scrutiny especially 
when the drug in question is targeting a disease with important implications for public health, 
such as HIV/AIDS. In this context, the use of HIV protease inhibitors in the treatment of 
HIV/AIDS may cost up to USD 6000/year, but most annual healthcare budgets in developing 
countries, where the disease prevalence is very high, do not exceed USD 100 per patient117. 
Consequently, limited access to available therapy might have a negative impact on the control 
of the HIV/AIDS epidemic. To help regulate such situations, the Agreement on Trade-Related 
                                                 
114 A. Cohen (2002): Copying DNA; Mighty Mouse; Killing Hepatitis; The AIDS drug; Frosh cells; all accessed 
via http://www.law.com.  
115 Nunnally, A.C. et al. (2005). Community Genetics 8: 209-216. http://dx.doi.org/10.1159/000087957.  
116 Jensen, K. and Murray, F. (2005). Science 310: 239-240. http://dx.doi.org/10.1126/science.1120014.  
117 Schmidt, C.W. (2001). Modern Drug Discovery 4(6): 25-28. 
http://pubs.acs.org/subscribe/journals/mdd/v04/i06/html/06rules.html.  
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Aspects of Intellectual Property Rights (TRIPs)118 allows countries to break a patent under 
certain emergency conditions (e.g. a national epidemic). In addition, the provision of a 
‘compulsory license’ (with more favourable conditions for the licensee) is also foreseen, 
although this requires that the production of the patented product takes place in the country to 
which it is licensed (rather than the country of the patent holder). However, this requirement 
posed a problem mainly for developing countries lacking the necessary infrastructure for the 
production of drugs. To address this problem, the Doha declaration (adopted by the World 
Trade Organisation in 2001)119 allows that drugs under a compulsory license are 
manufactured in developed countries on the condition that they are exported to the least 
developed countries.  
 
With regard to gene patents, the most pertinent issues relate to the breadth of claims and the 
potential development of a patent thicket (a situation where different owners have overlapping 
patent rights, requiring multiple licenses) due to the rapid expansion of DNA patents. The 
scope of DNA patents may now include anything from the therapeutic utility to the 
application of knowledge related to a specific DNA sequence in a clinical setting and in 
research120. Similarly, the scope of other biotechnology patents may be quite broad. The 
Oncomouse is a typical example of such a case, where the patent claims not only the 
oncogene-modified mouse that was developed by the inventors, but any nonhuman mammal 
that carried an inserted oncogene (i.e. a gene that confers susceptibility to cancer). Such broad 
claims could inhibit research although a recent study indicates that currently there is not 
enough evidence to support this notion121. However, the future development of patent thickets 
cannot be ignored. With regard to diagnostics this is a critical issue. For example, multiple 
patents might affect the development of microarray tests, where a specific combination of 
genes is used to diagnose (or predict) disease. In such a case and if each gene to be used on 
the array has already been patented, then multiple licenses would be required prior to the 
development of the test to ensure no patent infringement takes place. This would probably 
affect the cost of the test, and perhaps its accessibility to services and patients.  
 
Licensing practices regarding genetic patents and diagnostics have varied. One example is 
that of Myriad Genetics who refused to license its patents on BRCA1 and BRCA2 (genes 
associated with the familial breast cancer) to any other laboratories. However, in the case of 
the CFTR gene (responsible for cystic fibrosis), free access to the gene sequences was granted 
for their use in mutation analysis (research) but not for their use in commercial tests. 
Alternative licensing models are seen as one of the best means to alleviate the problems 
created by the expansion of gene patenting. Two such models are currently attracting the 
interest of most experts: patent pools and clearing houses122. Patent pools are defined as 
agreements between at least two patent owners who agree to license their patents to one 
                                                 
118 The TRIPs agreement is a treaty administered by the World Trade Organisation (WTO) which outlines the 
minimum standards for intellectual property regulation at an international level. The complete text of the 
agreement can be found at: http://www.wto.org/english/tratop_e/trips_e/t_agm0_e.htm. 
119 DOHA WTO MINISTERIAL 2001: Ministerial Declaration WT/MIN(01)/DEC/1 20 November 2001. 
http://www.wto.org/English/thewto_e/minist_e/min01_e/mindecl_e.htm.  
120 Verbeure, B. et al. (2006). European Journal of Human Genetics 14: 26-33. 
http://dx.doi.org/10.1038/sj.ejhg.5201503.  
121 National Research Council (2005). Reaping the benefits of genomic and proteomic research: intellectual 
property rights, innovation, and public health. The National Academies Press, Washington D.C. 
http://books.nap.edu/catalog.php?record_id=11487.  
122 Van Overwalle, G. et al. (2006). Nature Reviews Genetics 7: 143-148. http://dx.doi.org/10.1038/nrg1765.  
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another and then as a package to a third party123. Recognised benefits of this approach might 
include the reduced number of licensing transactions which could also positively influence the 
number of litigation cases due to patent infringements. One successful example of a patent 
pool has been observed in the case of Golden Rice124 and a similar approach has been 
proposed to facilitate the development of intervention strategies in response to severe acute 
respiratory syndrome (SARS)125. Clearing houses126 are the second licensing model often 
proposed as a potential solution to patent thickets allowing information sharing among patent 
holders. However, these models are not as well explored thus far. A recent study outlining 
different clearing house models proposes that the ‘royalty collection model’ (meaning patent 
holders license their patents to the clearing house which then issues sub-licenses) would be 
useful in facilitating access to patents on genetic diagnostics127.  
 
On the EU level, the legal protection of biotechnological inventions is covered by Directive 
98/44/EC128 which came into force in 1998. This Directive allows patenting of gene 
sequences, but in the course of its transposition into national laws, some differences are 
observed at Member State level regarding the scope of protection129. The patent system is 
based on the European Patent Convention (EPC)130, which does not create uniform patents but 
provides protection in as many member states of the European Patent Organisation131 as 
required by the applicant. These patents are granted by the European Patent Office (EPO), but 
any related litigation must be taken to the national courts. The Community patent, allowing 
the applicant to obtain one uniform patent throughout the EU, would have an important 
impact on the reduction in patenting costs (in particular those relating to translation and 
filing), simplified protection of inventions and the establishment of a single centralised system 
of litigation, which together could further promote innovation and R&D investment. A 
proposal was put forward for a Council Regulation in 2000132, but no decisions have yet been 
reached.  
 
 
 
                                                 
123 Verbeure, B. et al. (2006). Trends in Biotechnology 24: 115-120. 
http://dx.doi.org/10.1016/j.tibtech.2006.01.002.  
124 Potrykus, I. (2001). Plant Physiology 125: 1157-1161. 
http://www.plantphysiol.org/cgi/content/full/125/3/1157. (Golden Rice is a type of genetically modified rice 
in which the grains are enriched with beta-carotene, a precursor of vitamin A. Due to this modification these 
rice grains have a yellow hue, hence the name.)  
125 Simon, J.H.M. et al. (2005). Bulletin of the World Health Organisation 83: 707-710. 
http://www.who.int/bulletin/volumes/83/9/. 
126 The term refers to any mechanism whereby providers and users of goods, services and/or information are 
matched.  
127 Van Zimmeren, E. et al. (2006). Bulletin of the World Health Organisation 84: 337-424. 
http://www.who.int/bulletin/volumes/84/5/.  
128 Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of 
biotechnological inventions. OJ 30.7.98 L 213/13. http://europa.eu/eur-
lex/pri/en/oj/dat/1998/l_213/l_21319980730en00130021.pdf 
129 European Commission COM (2005) 312: Report from the Commission to the Council and the European 
Parliament - Development and implications of patent law in the field of biotechnology and genetic engineering. 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2005:0312:FIN:EN:PDF.  
130 http://www.epo.org/patents/law/legal-texts/html/epc/1973/e/ma1.html.   
131 http://www.epo.org/about-us/epo/member-states.html  
132 European Commission COM (2000) 412 final: Proposal for a Council Regulation on the Community patent. 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2000:0412:FIN:EN:PDF. 
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2.2.10 Summary 
 
The application of modern biotechnology in the development of therapeutics, preventives, and 
diagnostics has made an overall positive impact on the pharmaceutical sector, representing an 
estimated total share of 0.04% in the EU’s total economic activity. Biopharmaceuticals are the 
economically most important application of modern biotechnology and they constitute a very 
dynamic market, experiencing two-digit growth, higher than the growth of other 
pharmaceuticals. Some biotechnology drugs (for a limited number of indications) have 
reached blockbuster status but only one of the top ten best selling biotechnology drugs 
originated in the EU. The economic relevance of biopharmaceuticals for the EU is important, 
as in 2005, they held a 9% share in all pharmaceuticals in the EU and a 30% turnover share of 
the EU, US and Japanese pharmaceutical markets combined. In 2002 the biopharmaceuticals' 
share in the EU’s total value-added was 0.03%, comparable to entire subsectors of chemicals 
(e.g. man-made fibres). Recombinant vaccines have a much smaller share in biotechnology-
based products, but represent an area of good performance in the EU: EU companies have 
developed 26% of all recombinant vaccines currently available. Moreover, diagnostics based 
on modern biotechnology hold an estimated 30% turnover share in all in vitro diagnostics, and 
are predicted to grow at a higher annual average rate. 
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2.3 Agro-food biotechnology 
2.3.1 The agro-food sector 
 
One of the main areas where biotechnology has been applied traditionally is primary 
production and the food chain (see Figure 14). This includes the producers of biotechnology 
products (such as breeders, recombinant vaccine producers, producers of diagnostic test kits, 
etc.) as well as the downstream users (such as farmers, food processors, diagnostic 
laboratories, retail chains, etc.). Therefore, and for capturing all the facets of the contribution 
of biotechnology to primary and agro-food production, the context of this study includes the 
sectors whose activities are directly involved in the production of food and related products, 
as well as the sectors which are indirectly involved, such as by providing input and services 
throughout the production, commercialisation and trade of food products.  
 
 
 
 
 
Figure 14: The agro-food chain 
 
There are also other reasons for choosing such a broad scope and for analysing primary 
production and the agro-food industry together. Firstly, there are complex inter-linkages and a 
strong interdependence among the various subsectors. Therefore, a change or disruption (e.g. 
from a technological innovation) in one part of the primary production and agro-food industry 
will impact on the others. Moreover, almost all biotechnology applications that have an 
impact on the primary production and food processing sectors are actually used by the input 
sectors, which then provide biotechnology-derived products to the various downstream users. 
This interdependence is also reflected in policies that are developed to take into account the 
complete food chain (farm to fork approach). Finally, another reason for following this 
approach is that data are often available at an aggregated level only.  
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Core production sectors, mainly primary sector and food manufacturing: 
• NACE A: Agriculture, hunting and forestry 
• NACE B: Fishing 
• NACE DA 15: Manufacture of food products and beverages. 
 
Input sectors to the primary sector and the agro-food chain: 
• NACE DG 24.15: Manufacture of fertilisers and nitrogen compounds 
• NACE DG 24.2: Manufacture of pesticides and other agro-chemical products  
• NACE DG 24.4: Manufacture of pharmaceuticals, medicinal chemicals and botanical 
products (e.g. as relevant for veterinary products) 
• NACE DG 24.66: Manufacture of other chemical products (e.g. as relevant for enzymes, 
amino acids, etc.) 
• NACE KA 74.30: Technical testing and analysis (as relevant for diagnostics in the food 
chain) 
• NACE NA 85.20: Veterinary activities. 
 
The two groups of sectors presented above present the scope of this study, and from now on 
will be referred to as the ‘agro-food’ sector for simplicity.  
 
The sectors involved in wholesale and retail services related to the agro-food sector will not 
be included per se, as they are not directly involved in the production or in the use of 
biotechnology-derived products. However, as they are important stakeholders in the agro-food 
chain, frequently influencing the upstream productive activities, due consideration to them 
will be provided where relevant. These sectors are represented in the NACE classification as 
follows:  
 
Relevant wholesale and retail services: 
• NACE GA 51.2: Wholesale of agricultural raw materials and live animals 
• NACE GA 51.3: Wholesale of food, beverages and tobacco (except NACE GA 51.35) 
• NACE GA 52.11: Retail sale in non-specialised stores with food, beverages or tobacco 
predominating   
• NACE GA 52.2: Retail sale of food, beverages and tobacco in specialised stores (except 
NACE GA 52.26) 
• NACE HA 55.3 to 55.5: Restaurants, bars, canteens and catering. 
 
 
2.3.2 The contribution of the agro-food sector to the EU economy 
 
Primary production and the food manufacturing sector contribute an estimated 4.12% to the 
EU’s gross value-added (GVA) (baseline year 2003). The primary sector alone contributes 
approximately half of this, but its contribution is more important in rural areas, where it rises 
to 5% of the rural area’s GVA133; this is even more pronounced in the 10 Member States that 
joined the EU in 2004, for which the contribution in rural areas rises to 7% of GVA. 
However, in general, even in rural areas, the majority of the economic activity depends on the 
                                                 
133 European Commission, DG Agriculture and Rural Development (2006): Rural Development in the European 
Union – Statistical and Economic Information Report 2006. 
http://ec.europa.eu/agriculture/agrista/rurdev2006/RD_Report_2006_Foreword_Content.pdf  
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services sector. Within the primary sector, agriculture is the most important contributor to the 
EU economy at 1.8% of the EU’s GVA (87% of the primary sector GVA), while the 
remaining 0.2% of the primary sector’s contribution to the EU’s GVA is provided by forestry 
and fisheries. The input sectors account for a much smaller share of the EU economy, 
representing only 0.1% of the EU’s GVA. In total, the sectors that are at the focus of this 
analysis contribute 4.22% of the EU’s GVA. In comparison, at 3.36% of total EU’s GVA, the 
food and beverage wholesale and retail sectors are almost as important as the primary sector 
to the EU economy (see Figure 15). 
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Figure 15: Economic significance of the agro-food sector and the food services sectors to the EU economy 
(relative to overall GVA) 
 
In terms of employment, the primary sector accounts for approximately 5% of EU 
employment, while the food processing industry contributes an additional 2.2%. The fisheries 
sector accounts for a small share of the primary sector, at only 0.13% of overall EU 
employment. Still, the sector is very important at a regional level, i.e. in fisheries-dependent 
areas134. The input sectors account for 0.5% of EU employment, bringing the total 
contribution of the agro-food sector to 7.8% of total EU employment. For comparison, the 
wholesale and retail sectors account for a similar share, at 7% of EU employment.  
 
A more detailed presentation of the relevance of the agro-food sector for the economy and 
employment in the EU is provided in Annex 3 – Agro-Food . 
 
The EU has traditionally held strong sectorial policies in primary production, mainly through 
the Common Agricultural Policy (CAP) and the Common Fisheries Policy (CFP). 
Nevertheless, the sectorial policies have been harmonised with the overarching policies such 
as the Lisbon Strategy, and therefore, the main policy objectives are the same.  
 
Food manufacturing is very important to the EU economy, as it is among the largest 
manufacturing sectors in terms of GVA and employment. The European Commission is 
therefore seeking to ensure the competitiveness of the EU food industries under the Lisbon 
                                                 
134 Salz, P. et al. (2006). Employment in the fisheries sector: current situation. European Commission, final 
report FISH/2004/4. http://ec.europa.eu/fisheries/publications/studies/employment_study_2006.pdf.  
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Strategy goals, in the context of the CAP and the CFP, along with the EU’s obligations in the 
World Trade Organisation.  
 
 
2.3.3 Modern biotechnology in the agro-food sector  
 
Biotechnology does not appear as a separate sector in the NACE classification. However, 
modern biotechnology in the agro-food sector as a horizontal enabling technology is applied 
in different parts of the agro-food sector. A description of agro-food biotechnology 
applications is provided in Annex 3 – Agro-Food . Their assignment to NACE categories is 
also described, broken down into two categories: users of modern biotechnology techniques 
and users of modern biotechnology-derived products. The economic contribution is therefore 
also separated to direct (users of biotechnology techniques) and indirect (users of modern 
biotechnology-derived products) impacts.  
 
The direct impact assessment aims to measure the economic impact (to the sector and to the 
whole economy) arising from the activity of companies applying modern biotechnology (also 
called modern biotechnology active companies). Examples of modern biotechnology active 
companies in the agro-food sector include breeding companies employing this technology for 
the production of seeds, embryos or eggs, diagnostic companies producing modern 
biotechnology test kits, and pharmaceutical companies producing modern biotechnology-
based vaccines. In general, users of modern biotechnology are only found in the input sectors 
of the agro-food industry, mainly involved in the following activities: 
• seeds and planting stock 
• nursery plants and flowers  
• animal breeding  
• fish breeding  
• manufacture of chemicals (including enzymes) 
• veterinary products and services  
• diagnostics in the agro-food sector. 
 
It is possible, therefore, to estimate the maximum direct contributions of modern 
biotechnology (see Table 12 and Figure 16) by calculating the relevant contributions of the 
sectors that use modern biotechnology techniques, at the most disaggregated sector level 
possible (NACE level if applicable).  
 
 
The direct contribution of biotechnology to the EU economy will be less than 2% of the EU 
agro-food turnover or less than 0.08% of the total EU-wide GVA. The respective value for 
employment is not available, but it is likely to be of a similar relative magnitude. 
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Table 12: Agro-food subsectors using modern biotechnology at the most disaggregated level possible 
 
Sectors Turnover (EUR million) 
Seeds and planting stock 1 6100 
Nursery plants and flowers 2 6400 
Animal breeding 3 2000 
Fish breeding 4 210 
Veterinary products/services 5 5200 
Manufacture of other agro-food chemical products (e.g. enzymes, food/feed additives) 6 2300 
Primary production and food related diagnostics 7 700 
Total of input sectors using biotechnology 22 910 
Total EU agro-food sector 1 193 763 
Total EU economy (GVA) 8 782 817 
Share of modern biotechnology-related input sector turnover in overall agro-food sector 
turnover of the EU  2% 
Share of modern biotechnology-related input sector GVA in overall EU’s GVA 9 0.08% 
1 The data from 2003 provided by the European Seed Association in their submission to the Bio4EU study 
(http://bio4eu.jrc.ec.europa.eu/documents/ESAsubmission.pdf) is used as the best estimate. 
2 From: Working Document of the Commission staff on the situation of the flowers and ornamental plants sector, 
European Commission, DG Agriculture and Rural Development, 2006. 
http://ec.europa.eu/agriculture/markets/fruitveg/flowers/analysis.pdf. This subsector is relevant for using modern 
biotechnology such as micropropagation and in vitro culture. 
3 Estimated from data obtained in the case studies provided by ETEPS; based on the sum of the total turnover of 
the largest breeding companies in the cattle (total estimated at EUR 600 million) and pig (total estimated at EUR 
800 million) sectors; the poultry breeding turnover (estimated at EUR 300 million) was based on the relative 
shares of livestock production in the EU which was in close agreement with expert opinion; the figure of EUR 
1800 million was then rounded up to EUR 2000 million to account for the remaining species, the smaller 
enterprises, and various other activities. 
4 As no possible breakdown to fish breeding and hatchery related activities is possible, the total of the NACE B 
05.02 Fish farming sector turnover (EUR 2770 million) multiplied by a conservative estimate of the share of 
hatchery costs (8%) is taken as the best estimate. 
5 The value that Eurostat provides (EUR 5187 million in 2003) is used as the best estimate for the economic 
activity ‘Veterinary expenses’. It should be noted that this includes both EU and non-EU sourced products and 
services; however, as EU companies have important shares in the international veterinary market (estimated at 
50%, see Section 2.3.5.3), it is assumed that the trade balance is neutral. This category may also include some 
animal breeding and animal diagnostic activities (e.g. embryo transfer related services, etc.) as they sometimes 
form part of veterinary services. 
6 The best estimate is taken as the sum of feed additives (enzymes, amino acids, vitamins, organic acids, etc) and 
food enzymes; see Section 2.3.5.3). 
7 No data are available at sector level, so a best estimate was taken from the data provided by: Blankenfeld-
Enkvist, G. and Brännback M. (2002). Technological trends and needs in food diagnostics. Technology Review 
132/2002, National Technology Agency, Helsinki. http://www.tekes.fi/julkaisut/Food_diagnostics.pdf. The 
report covers the food chain from raw material to end products (turnover of approximately EUR 500 million). 
Animal health diagnostics were estimated at 50% of the global market (reported at EUR 400 million, based on: 
BCC (2004). Animal therapeutics and diagnostics. Report HLC034A. BCC Research, Wellesley, M.A. 
http://www.bccresearch.com/hlc/HLC034A.asp). 
8 This includes the primary sectors, the food manufacturing sectors, and the inputs to the agro-food sectors (all 
but the wholesale and retail sectors of the total food chain). 
9 The total turnover of the input sectors was multiplied by 0.3 to estimate the GVA (0.3 is the average 
GVA:turnover ratio of the agro-food sectors involved in production activities, i.e. excluding the wholesale and 
retail sectors). 
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Figure 16: Turnover shares of agro-food input sectors using modern biotechnology  
 
Indirect impacts, on the other hand, mainly relate to the impacts arising from the use of 
biotechnology-derived products, and it mainly involves tracing the impacts at the farm gate 
and through food manufacturing, although indirect impacts on the economy may also find 
their way further downstream, e.g. through final retail sales and catering. As the users of 
biotechnology-derived products consist of the whole agro-food sector, it follows that the use 
of modern biotechnology-derived products and services may contribute more to the EU 
economy in terms of GVA and employment than the application of modern biotechnology to 
generate these products and services, i.e. the indirect contribution of modern biotechnology to 
the EU economy is likely to be larger than its direct contribution.  
 
In this study, data were obtained from official statistics and literature in the public domain, as 
well as from relevant market reports. Because of the lack of data on the agro-food sector, 
surveys were also conducted within the scope of the Bio4EU study to obtain additional 
insights for the analysis.  
 
 
2.3.4 Analysis at an aggregated level  
 
A first estimate of the direct economic and employment contributions of modern 
biotechnology to the agro-food sector is provided at an aggregated level.  
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2.3.4.1 Adoption of modern biotechnology applications  
 
As the economic impact of a biotechnology innovation is directly related to its uptake, a first 
indication of the economic impact is provided by assessing the actual use of modern 
biotechnology by the agro-food sector. Official statistics and reports were used to derive an 
estimate of the number of companies in the agro-food sector active in biotechnology (see 
Table 13). It was only possible to elaborate the corresponding data for nine EU Member 
States (Belgium, Finland, the UK, Denmark, Ireland, Germany, Poland, Sweden and France) 
for certain years (mostly 2003). Additionally, data for the US were derived as well.  
 
Table 13: Number of modern biotechnology active companies in the agro-food sector  
Source: ETEPS135, adapted by IPTS 
 
Country (year) 
Number of modern 
biotechnology 
companies in the  
agro-food sector 
Belgium (2003) 11 2 
Denmark (2003) 64 3 
Finland (2003) 22 2 
France (2003) 78 2 
Germany (2003) 149 2 
Ireland (2003) 11 4 
Poland (2003) 2 2 
Sweden (2003) 17 2 
United Kingdom (2003) 34 2 
Total of individual EU countries 388 
US (2001) 260 2 
Definitions of companies active in biotechnology vary and were given in the corresponding reports: 
1 LUC; ULG; Vlerick Management (2004): Report on the national Biopharma innovation system of Belgium. 
Report to the Federal Science Policy Office. 
2 Van Beuzekom, B.; Arundel, A. (2006): OECD Biotechnology Statistics – 2006. 
3 Biotechnology in Denmark: A Preliminary Report (2004): The Danish Centre for Studies in Research and 
Research Policy. 
4 InterTradeIreland (2003): Mapping the Bio-Island – A North/South study of the private biotechnology sector. 
 
The sources used do not always differentiate between modern biotechnology and conventional 
biotechnology. However, most countries whose data are provided (except for Denmark and 
Sweden) follow the OECD list-based definition or a modern biotechnology definition, both of 
which are similar to the definition of modern biotechnology used in this study. Moreover, the 
definition of what constitutes the agro-food sectors and of a biotechnology active company 
varied among the different countries. It is more probable that the coverage in the statistics has 
a narrower scope compared to the scope of this study, as in many countries only a company 
whose core activity is related to biotechnology is counted as a biotechnology active company. 
 
                                                 
135 ETEPS (2006). Bio4EU Task 2 Main report. 
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Most companies active in agro-food related biotechnology in the EU are located in Germany 
followed by France and Denmark. Compared to these countries, the remaining EU Member 
States have relatively fewer firms which are active in biotechnology. Furthermore, these data 
indicate that the EU compares favourably with the US.  
 
2.3.4.2 Economic shares of modern biotechnology applications 
 
The only available information related to an economic measure of the contribution of 
biotechnology active companies to the agro-food sector is the turnover, mainly from market 
reports provided by private consultancies, such as Datamonitor. Using as benchmarks i) the 
total turnover of sectors using modern biotechnology in the area of agro-food, ii) the total 
agro-food sector turnover, and iii) the total EU GVA, estimates i) of the economic 
contribution of modern biotechnology to the sectors that use modern biotechnology in the 
generation of products and services, ii) of the economic contribution of modern biotechnology 
to the agro-food sector, and iii) of the contribution of modern biotechnology to the EU 
economy can be obtained (see Table 14). 
 
Table 14: Direct impacts of modern biotechnology in the agro-food sector  
Source: ETEPS136, and IPTS calculations 
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 Total of 
listed EU 
countries 
Biotechnology-
related turnover 
(EUR million)1 
498 103 244 226 47 254 275 724 3022 
Total turnover of relevant input sectors of listed EU countries2 (EUR million) 18 144 
Share of biotechnology-related turnover over total turnover of modern biotechnology 
users (in %) 
17 
Turnover of agro-food sector of listed EU countries (EUR million) 953 982 
Contribution of modern biotechnology to the agro-food sector (in %) 0.3 
GVA of listed EU countries (EUR million) 7 026 254 
Contribution of modern biotechnology to the EU GVA (in %)3 0.01 
1 Data for all countries except Sweden are from Datamonitor (2005); for Sweden, data are from Sandström, A.; 
Norgren, L. (2003): Swedish Biotechnology – scientific publications, patenting and industrial development. 
VINNOVA Analysis. 
2 The EU totals were multiplied by 0.8 to estimate the turnovers representative for the eight countries (based on 
calculations indicating that the turnover of the eight countries is on average 80% of the EU turnover). 
3 The total turnover of the biotechnology producing sectors was multiplied by 0.3 to estimate the GVA (0.3 is the 
average GVA:turnover ratio of the primary production and agro-food sectors involved in production activities, 
i.e. excluding the wholesale and retail sectors). 
 
In 2004, the UK had by far the highest total biotechnology-related turnover (around EUR 724 
million) of biotechnology active firms in the agro-food sector, followed by Belgium with 
nearly EUR 500 million (see Table 14). For Germany, Italy and Spain, about EUR 220 
million to EUR 250 million in turnover was generated by biotechnology-related applications 
                                                 
136 ETEPS (2006). Bio4EU Task 2 Main report. 
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in the agro-food sector, while France and the Netherlands showed the lowest biotechnology-
related turnover for the countries covered.  
 
These data provide a first estimate of the economic dimension and the importance of the 
adoption of modern biotechnology by the relevant agro-food industries. Biotechnology-
related turnover represents 17% of the total turnover of the agro-food subsectors that use 
modern biotechnology in the generation of products and services (relevant input sectors). 
Expressed in terms of the agro-food turnover and the EU GVA, the direct contribution of 
modern biotechnology is estimated to be 0.3% and 0.01%, respectively. In comparison, in the 
US the biotechnology-related turnover of the agro-food sector for 2003 (the most recent 
available year) was reported to be EUR 76 million, i.e. this equals 0.0007% of the respective 
US GVA.  
 
It should be noted, however, that these data are only estimates as the definitions used for 
biotechnology, biotechnology active company and the agro-food sector are not always clear 
and they may vary among the different countries. Therefore, the comparability among the 
different countries should be treated with caution.  
 
Table 15: Amount and share of biotechnology-related employment of biotechnology active firms out of 
total employment in the agro-food sector  
Source: ETEPS137, and IPTS calculations 
 
Country 
(year) 
Number of employees in 
biotechnology active 
agro-food firms1 
Number of employees 
in country 
Direct contribution to 
overall employment  
(in %) 
Belgium (2000) 1026 2, 5 4 195 000 8 0.024 
Ireland (2003) 277 3, 6 1 814 000 8 0.015 
Sweden (2003) 607 4, 7 4 329 000 8 0.014 
Total of listed 
EU countries 1910 10 338 000 
8 0.018 
1 In the statistics/reports it was not clearly mentioned if all employees working in biotechnology active firms in 
the agro-food sector are meant or all biotechnology active employees working in biotechnology active firms in 
the agro-food sector. Definitions of employees active in biotechnology companies given in the corresponding 
reports listed below in notes 5 to 8. 
2 Number of employees active in the ‘agro-bio sector’ (clear definition not available). 
3 Number of employees active in the ‘agro-food sector’ (clear definition not available). 
4 Number of employees active in the biotech applications ‘agro-biotech’ and ‘biotech food’ (clear definitions not 
available). 
5 LUC; ULG; Vlerick Management (2004): Report on the national Biopharma innovation system of Belgium. 
Report to the Federal Science Policy Office. 
6 Inter Trade Ireland (2003): Mapping the Bio-Island – A North/South study of the private biotechnology sector. 
7 Van Beuzekom, B.; Arundel, A. (2006): OECD Biotechnology Statistics – 2006. 
8 Eurostat (2003): http://epp.eurostat.ec.europa.eu.  
 
The same approach, applied to employment, is presented in Table 15. Unfortunately there are 
no data at a sufficiently disaggregated level for estimating the number of employees of the 
sectors that include companies using modern biotechnology techniques. However, the direct 
contribution to the EU employment is estimated at approximately 0.02% (see Table 15), based 
                                                 
137 ETEPS (2006). Bio4EU Task 2 Main report. 
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on a very limited number of countries. This is within the same order of magnitude as the 
relevant economic contribution presented above.  
 
In the following sections, an analysis of the contribution of modern biotechnology at a 
disaggregated level will be made, using a bottom-up approach, and the findings between the 
two sets of analyses will be compared. 
 
 
2.3.5 Analysis at a disaggregated level 
 
The analysis of the contribution of modern biotechnology to the agro-food sector at a 
disaggregated level follows a bottom-up approach, including the specific sectors in which 
modern biotechnology has been mostly applied. Modern biotechnology applications were 
broken down into the following application types by sector classification138 (see Table 16). 
 
Table 16: Structure of the bottom-up approach for assessing the contributions of modern biotechnology to 
the agro-food sector 
 
Marker assisted selection 
Micropropagation Plants 
Genetic modification 
Marker assisted selection 
Livestock 
Embryo technologies  
Marker assisted selection 
Breeding/propagation in 
primary production  
Fish/shellfish 
Sex/ploidy manipulation 
Food processing 
 Improved enzymes and fermentation processes 
(recombinant techniques and/or the use of molecular 
markers)  
Food/feed additives (vitamins, amino acids, enzymes, 
etc.) Other inputs to the agro-
food sector 
 
Veterinary products (recombinant vaccines, etc.) 
Animal/plant health monitoring  
Food safety monitoring (e.g. salmonella) Modern biotechnology-based diagnostics 
 
Traceability in the food chain (e.g. GMO traceability) 
 
Data from various sources were used in the analysis. Information that was publicly available 
was supplemented by targeted surveys and expert opinion139.  
 
Of importance in the development and adoption of modern biotechnology are the decision 
maker(s) that influence the adoption of a technology. The decision maker may vary for 
different applications including the biotechnology producer (e.g. the aim for adoption is to 
reduce costs), the farmer (e.g. demand for a higher quality input), the processor (e.g. requiring 
raw material of a specific quality), and the wholesaler or final retailer (e.g. by defining the 
product specifications). While all these stakeholders may be important in decision making for 
                                                 
138 Identified earlier as the main application areas of modern biotechnology (ETEPS (2006) Bio4EU Task 1). 
139 Mainly through the ETEPS consortium and IPTS surveys.  
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the adoption of specific technologies (and therefore for the resulting impacts), a recent trend is 
the increasing importance of decisions taken downstream in the supply chain (i.e. by the 
retailer).  
 
Because of the complexity in the structure of the agro-food sector, this impact assessment will 
mainly be followed to the first user level, i.e. to the farmgate or to the food manufacturing 
stage, depending on the application; qualitative descriptions of indirect impacts further 
downstream will be made when such information is available. 
 
2.3.5.1 Breeding and propagation in primary production  
 
The application of modern biotechnology in breeding and propagation in the primary sector is 
mostly relevant at the top of the breeding pyramid, the aim being to improve and accelerate 
genetic improvements in the population (plants or animals). Additionally, modern 
biotechnology may also be used throughout the breeding schemes, for example in parentage 
identification and lineage traceability. Therefore, the direct impacts of modern biotechnology 
in this area are expected to occur in the breeding companies or departments and other 
specialised biotechnology companies supporting the breeding or propagation of plants or 
animals, rather than at the production and farmer level. However, the use of these 
biotechnology-derived inputs (as seeds, mother plants, embryos, young animals, breeding 
animals, etc.) by the farmers will produce indirect impacts up to the farmgate. These impacts 
may also find their way further downstream, such as through the processing stage, to the 
wholesale and retail stage.  
 
 
2.3.5.1.1 Breeding and propagation – plants 
 
The currently used modern biotechnology applications in plant breeding and propagation are 
mainly related to the use of molecular markers, herein called marker assisted selection 
(MAS), and tissue culture/micropropagation. These techniques are applied either by 
breeding/seed companies, or by specialised laboratories involved in the supply of horticultural 
products and/or young plants. The direct impacts therefore relate to the turnover generated by 
these activities, whereas the indirect impacts cover the downstream effects to the farmgate. 
 
The EU seed sector provides EU as well as non-EU farmers with the most important input for 
the realisation of farming activities. Seeds (or any other type of propagating material) provide 
the germ plasm for the grow-out stage, which is the result of genetic selection over many 
years. According to the European Seed Association (ESA), the EU seed sector (field and 
vegetable crops combined) comprises more than 400 seed companies, and while the sector 
seems to have been following a trend of consolidation, there is still a large number of small 
and medium sized companies. In general, approximately 10% of the companies generate 40% 
of the turnover, indicating that a large share of seed production is provided by a smaller 
number of medium and large sized companies. Moreover, large multinational companies seem 
to have a lead in major crops (maize, soya, cotton, etc.) while in horticultural crops, small and 
medium enterprises (SMEs) are competing with larger companies.  
 
The global seed market has been estimated by the International Seed Association (ISA) at 
approximately EUR 24.4 billion, while the international trade in seeds accounts for 
approximately 15% of that. The EU turnover from seed sales has been estimated by the ESA 
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at EUR 6.1 billion. Eurostat provides data on the intermediate consumption of seeds and 
planting stock (1st generation and certified seeds, allocated to the input industries at about 
EUR 7.6 billion in 2003), as well as on the value of multiplied seeds (allocated to primary 
production at EUR 762 million). Data available from the ESA indicate exports of about EUR 
2.7 billion while the ISA provides estimates for EU imports at EUR 2.3 billion, which 
confirms the strong global position of the EU. Moreover, it has also been suggested that EU 
companies are important players in the US and hold a similar share of the Latin American 
market to US companies140, while they are not as strong in the remaining world markets. The 
ESA also estimates that field crops account for approximately 60% of the total, with 
horticultural crops making up the rest. According to ESA statistics, the EU seed industry is 
estimated to employ about 30 000 people. In general, seed breeding is most profitable, in 
particular for those crops for which farmers use little or no saved seed. This is especially the 
case for hybrid varieties, and particularly for maize.  
 
 
Marker Assisted Selection (MAS) 
 
Molecular markers (certain DNA regions linked directly or indirectly to specific traits) are 
used in several ways: MAS and related techniques make use of them to identify and help 
incorporate desirable traits into selection schemes. The desired traits may aim to improve 
agronomic traits (e.g. resistance to physical, chemical or biological stress) or product quality 
traits (e.g. difference in nutrient content). Molecular markers are also used indirectly to 
improve the breeding process, e.g. in the verification of pedigrees (through the use of 
microsatellites for lineage traceability in fish, for example). Overall, the use of molecular 
markers may simplify breeding procedures, improve the accuracy of selection and increase 
the rate of genetic progress (reducing the development time) by identifying organisms 
carrying desirable genetic variants for a given trait at an earlier age. MAS is applied to maize 
breeding for the production of feed, food and industrial grade maize. The current available 
information only allows an analysis to be carried out on MAS used in the broad sense (i.e. the 
direct and indirect use of molecular markers). MAS is applied on a research basis in almost all 
plant-related sectors, including crops, vegetables, fruits, and forestry. However, there is very 
limited information available on the commercial application of MAS.  
 
The maize seed companies surveyed (five companies in France and Germany141) suggest that 
the sector would not remain competitive without the use of molecular markers throughout the 
breeding process: medium and large sized companies claim that all current maize seed 
production uses MAS (i.e. adoption rate of 100%) while smaller companies show a smaller 
adoption rate (as low as 33%). Similar claims have been put forward by the ESA in their 
contribution submitted within the context of the Bio4EU study142. 
 
The share of maize in total EU seed production is estimated at EUR 405 million (6.6% of 
total), based on the maize area cultivated and seed cost information143. Using as the MAS 
adoption rate the expert estimate of 33 - 100% of maize seed turnover, provides an estimate of 
                                                 
140 Tait et al. (2001). PITA project: Policy influences on technology for agriculture: chemicals, biotechnology 
and seeds. Final report. Scottish Universities Policy Research and Advice Network (SUPRA), Edinburgh. 
http://www.supra.ed.ac.uk/Publications/paper22.pdf.  
141 (ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications). 
142 See http://bio4eu.jrc.ec.europa.eu/submissions.html.  
143 The estimate is based on the maize area cultivated (6 195 000 ha) and the cost of maize seeds (EUR 65.39 per 
ha), resulting in a EUR 405 million maize seed turnover. 
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the direct contribution of MAS at a range of EUR 133 - 405 million, which is 2.2 - 6.6% of 
the total seed-related turnover at EU level or 0.01 - 0.03% of the agro-food sector turnover. 
The real value is probably closer to the upper estimate as the market share of seeds produced 
by medium and large companies is likely to be larger.  
 
As molecular markers are claimed to be used throughout the breeding process of other plants, 
the direct contribution may be significantly larger. Unfortunately, the adoption rate of MAS in 
all seed and propagating material for crop and horticultural production is not known. A recent 
publication144 suggests that maize breeding is more amenable to the application of MAS (in 
the narrow sense) as compared to wheat, barley and rice, for biological as well as agronomic 
reasons. Therefore, it is likely that the adoption of MAS is relatively high for maize and lower 
for other crops/horticultural plants. An estimate of the potentially direct impacts of the 
adoption of MAS may be obtained by extrapolating the lower value suggested for maize 
(33%) to the total seed turnover as a high estimate, which results in a total contribution of 
EUR 2013 million or 0.17% of the total agro-food sector. It should be noted, however, that 
these estimates are only given to provide benchmarks on the adoption and potential impacts of 
MAS and should not be taken as robust calculations. 
 
The indirect impacts from MAS adoption relate to the value generated from growing the seeds 
up to the farmgate, as well as through the use of maize by the manufacturing, wholesale and 
retail sectors. These calculations add further complexity, due to the difficulty of tracing the 
biotechnology-derived products throughout the food chain, and due to the additional 
complexity added by extra-EU trade flows at each stage. While exact data of the share of 
maize produced in the EU from MAS-derived seeds are not available, it seems reasonable to 
apply the breeders’ adoption rate to maize production145. This would imply that a EUR 2429-
7360 million turnover from EU maize farming is MAS-derived, accounting for 0.2 - 0.6% of 
the total agro-food sector and 0.009 - 0.024% of the total EU GVA. When the 33% adoption 
rate is applied to all plant production, the indirect contributions rise to a turnover of EUR 55.6 
billion from crop production, which accounts for 4.7% of the total agro-food turnover and 
0.19% of the EU GVA. 
 
The estimates provided here on the economic contribution of MAS do not provide any 
information on the actual benefits accrued for the adoption of MAS compared to the 
alternative of non-adoption. However, the fact that the technology is adopted is already an 
indication of the benefits it provides. These benefits seem to be clear for the breeders, who 
claim that they would not remain competitive without the use of molecular markers in their 
development of improved varieties, and are likely to be passed on to the growers, who 
consciously adopt the improved varieties. It should be noted here that it is impossible to 
accurately report the share of MAS maize seeds or derived grains that have been marketed, as 
the companies do not keep separate accounts of conventional or MAS-derived products. This 
is further complicated by the fact that the introduction of a new variety in the market may take 
up to 10-15 years from the initial development phase. MAS-based breeding was reported146 to 
increase the costs for the breeding companies in the short term (mainly due to the high initial 
                                                 
144 Koebner, R (2004). MAS in cereals: green for maize, amber for rice, still red for wheat and barley. Paper for 
the workshop on: Marker assisted selection: a fast track to increase genetic gain in plant and animal breeding? 
Turin, http://www.fao.org/Biotech/docs/Koebner.pdf.  
145Assuming that all main seed providers (e.g. EU, US, etc.) have adopted the technology at similar rates (expert 
opinion, ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications). 
146 Expert opinion (ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food 
Applications). 
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investment cost, and the need for highly qualified employees), but to be profitable in the long 
term. The high costs may prove to be a challenge for small companies who may not be able to 
remain competitive. Supporting programmes, such as through R&D financing and research 
industry networking, were therefore mentioned as very valuable tools in giving SMEs a 
chance to benefit from MAS.  
 
The contribution of MAS to employment is less clear as such data are not available. Expert 
opinion146 indicates that the share of employees working in the field of MAS in maize 
breeding is approximately 30% for small companies, and as high as 100% in larger ones (as 
an indication, altogether the companies interviewed employ between 70 und 600 workers in 
the field of maize breeding). Moreover, between 4 - 70% of new employment created is said 
to be dedicated to MAS in maize breeding. These shares do not refer only to technical jobs 
but also include various supporting jobs (e.g. marketing and sales).  
 
The expectations for MAS use in the EU are in general positive, both because of the expected 
further developments in genomics research and because MAS may be an alternative to the use 
of the controversial genetic modification techniques. Furthermore, the interviewees stressed 
the likely increasing importance of using MAS in the development of varieties towards 
industrial applications (e.g. the production of plant biomass), and the potential implications 
this may have in the production of maize and other relevant crops. 
 
Crop breeding in general and maize breeding in particular, is a highly competitive field, the 
main competitors being the US and the EU, dominated by a small number of large private 
companies. While there is no information on the extent of the use of MAS in the EU versus 
the US, the technologies used are comparable. 
 
 
Genetic modification (GM) 
 
Genetic modification (GM), also known as genetic engineering or recombinant DNA 
techniques, is one of the newest methods to introduce novel traits to plants. The adoption of 
GM crops has been progressing at a faster pace than has been the case for other innovations in 
plant varieties, such as the introduction of hybrid maize decades ago. In the first year of 
introduction (1996) about 1.7 to 2.6 million hectares of GM crops were grown, almost 
exclusively in a single country (the US). Ten years later (2006) the area under GM crops had 
expanded to 100 million hectares in 22 countries of which 11 are high-income economies. 
More than 10 million farmers cultivated GM crops in 2006. During these first years of 
commercial GM crop cultivation (1996-2006)147, two agronomic traits were introduced by 
genetic engineering into a few major crops that dominated the market. These traits are 
herbicide tolerance and insect resistance (referred to as Bt crops since the gene conferring 
resistance comes from the soil bacterium Bacillus thuringiensis). Today GM varieties have a 
significant global share of the four major agricultural crops for which they are commercially 
available (maize, canola148, soya bean and cotton). The number of GM crops authorised for 
cultivation in the EU is small when compared with other world regions. The EU so far has 
authorised the cultivation of two Bt maize varieties. These are the transgenic event Bt-176 of 
the company Syngenta authorised in 1997 and the transgenic event MON-810 of the company 
Monsanto authorised in 2003. In practice, the only GM crop currently available to EU farmers 
                                                 
147 James, C. (2006). Global status of commercialised biotech/GM crops in 2006. ISAAA Brief No. 35 (Ithaca, 
N.Y.). http://www.isaaa.org/resources/publications/briefs/35/. 
148 Canola is a type of oilseed rape. 
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for cultivation is Bt maize. Within the EU, Spain is the only country growing significant 
quantities of Bt maize. Spain cultivated 53 667 hectares of Bt maize varieties in 2006149. 
France, Germany, Portugal and the Czech Republic also grew Bt maize in 2005 and 2006 but 
reporting very small areas in the order of one thousand hectares or fewer. Slovakia joined this 
group of EU Bt maize-growing countries in 2006 although the area cultivated is negligible. 
Before 2005, the adoption in these latter countries can be considered as non-existent. Table 17 
shows GM maize adoption rates in the EU and worldwide in 2005, for which figures are more 
definitive150.  
 
Table 17: GM maize adoption rates in the EU and worldwide in 2005 
 
Adoption rates (share of GM maize area/total grain maize area, in %) Source of data 
53 225 ha/421 724 ha in Spain  12.62 Spanish Ministry of Agriculture1 
500 ha /1 654 000 ha in France 0.03 
300-500 ha/443 000 ha in Germany  0.07 
150 ha/ 98 000 ha in Czech Republic 0.15 
750 ha/110 000 ha in Portugal  0.68 
54 925ha/6 059 000 ha in the EU  0.83 
Eurostat2 
Clive James3 
15 649 920 ha/30 096 000 ha in the US 52 USDA 20054; USDA 20065 
289 000ha/1 700 000 ha in South Africa 17 Clive James3 
21 200 000 ha/147 000 000 ha in the World 14 Clive James3 
Note: In the US GM maize can be either Bt maize, Herbicide Tolerant (HT) maize or HT/Bt maize while in the 
EU it is only Bt maize.  
1 Spanish Ministry of Agriculture (2006) Superficie en hectáreas de variedades de maíz GM, 
http://www.mapa.es/agricultura/pags/semillas/estadisticas/serie_maizgm98_06.pdf. 
2 EUROSTAT (2006) Agriculture and fisheries statistics http://epp.eurostat.ec.europa.eu/. 
3 James, C. (2005). Global Status of Commercialised Biotech/GM Crops in 2005. ISAAA Brief No. 34 (Ithaca, 
N.Y.). 
4 USDA (2005). Acreage in 2005, http://usda.mannlib.cornell.edu/reports/nassr/field/pcp-bba. 
5 USDA (2006). Adoption of genetically engineered crops in the US in 2005: corn varieties. 
http://www.ers.usda.gov/Data/BiotechCrops/ExtentofAdoptionTable1.htm. 
 
 
Focusing on Spain, GM seed turnover was estimated to be about EUR 4.1 million in 2002, 
EUR 6.7 million in 2003, and EUR 11.9 million in 2004151. These figures can be considered 
as the equivalent to the total EU GM seed turnover according to the zero adoption elsewhere 
in the EU. The annual evolution of the GM maize seed turnover is mainly a consequence of 
the annual increase of the GM maize area in Spain during the years 2002, 2003 and 2004 
(21 004, 32 244 and 58 219 hectares, respectively)149. As mentioned in the MAS section 
above, the EU turnover from seed sales was estimated by the ESA to EUR 6.1 billion in 2003. 
The EU turnover from GM seed sales had a share of 0.2% of the EU turnover from seed sales 
                                                 
149 Spanish Ministry of Agriculture (2006), Superficie en hectáreas de variedades de maíz GM, 
http://mapa.es/agricultura/pags/semillas/estadisticas/serie_maizgm98_06.pdf.  
150 Statistics for 2006 are not yet available for all crop/country combinations. 
151 Turnover figures are calculated as total Bt maize seed cost per hectare multiplied by the area of Bt maize in 
Spain in each respective year. Total Bt maize seeds cost per hectare are annual averages obtained from a survey 
of Spanish Bt maize farmers and conducted by IPTS. The average seed costs are available for years 2002, 2003 
and 2004 (EUR 197, EUR 209 and EUR 204 per hectare, respectively). More details are found in the Bio4EU 
GM crops case study (available at http://bio4eu.jrc.ec.europa.eu/documents.html). 
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in 2004. A more reasonable comparison can be made using the total EU market value of 
maize seeds as the reference. In this case, the EU turnover from GM maize seeds out of the 
total EU market value of maize seeds is about 2.9%. Based on these figures, it can be 
concluded that the direct impact is rather small as a consequence of the low adoption rate of 
GM crops in the EU (0.9% of GM maize area out of the total EU maize area in 2005).  
 
The indirect impact is defined as the turnover from GM maize grain sold by EU farmers. In 
2004 this turnover accounted for EUR 85 million152. This figure can also be considered as the 
equivalent to the indirect impact for the whole EU and represents 1.2% of the total EU maize 
turnover. Again this small share is a consequence of the small adoption of GM maize in the 
EU.  
 
A recent study153 analysed the agronomic and economic performance of Bt maize cultivated 
in Spain, compared to conventional maize. In 2002-2004, farmers using Bt maize obtained an 
average increase in their gross margin of EUR 85 per hectare and growing season compared 
with farmers growing conventional maize. This represents an increase of 12% over the 
average gross margin obtained by maize farmers in Spain. These benefits, however, vary 
widely in the three regions studied, ranging from EUR 125 per hectare to just EUR 7 per 
hectare. GM seed prices paid by farmers are higher than for conventional maize seeds. On 
average this price difference in seeds accounts for EUR 30 per hectare. The economic welfare 
resulting from the adoption of Bt maize in Spain is basically shared by farmers and seed 
companies. Bt maize belongs to the so-called ‘first generation of GM crops’ which aims to 
provide a higher production efficiency at farm level. Therefore, direct benefit for consumers 
could only come from a reduction of the market price. No differences in the price received by 
Spanish farmers for Bt maize or conventional maize crop were found in the study. In Spain, 
the Bt maize grain produced is used entirely for animal feed production. These findings match 
those of the Spanish feed industry that the introduction of Bt maize in Spain has not reduced 
the cost of their raw material. The largest share of welfare created by the introduction of Bt 
maize (74.4% on average) went to Bt maize farmers and the rest went to the seed companies 
(25.6% on average), taken to include seed developers, seed producers and seed distributors. 
 
The same study looked at factors which might have affected the adoption of Bt maize in 
Spain. One of the most relevant factors is farm size because it is frequently a surrogate for 
other factors such as farmers’ wealth. In contrast to other technologies such as machinery 
which requires extensive capital investments and many hectares over which the farmer can 
spread the costs of acquisition, the adoption of Bt maize in Spain has been farm size-neutral 
because the technology is linked to the seeds, which are completely divisible and can be used 
in any amounts. 
 
Some experts consider the potential economic impacts of GM crops not yet approved for 
commercial cultivation by EU farmers, but cultivated elsewhere in the world, to be an 
opportunity cost for the EU, in terms of forgone benefits. There is a small but growing 
number of ex ante studies addressing this potential economic impact154. Positive on-farm and 
                                                 
152 Average GM maize yields in Spain were 11430 kg per hectare during the three-year period 2002-2004. These 
yields multiplied by EUR 0.128 per kilogram received by farmers in 2004 yield a revenue of EUR 85 million. 
153 Gómez-Barbero, M., J. Berbel and Rodríguez-Cerezo E. (2008). Adoption and performance of the first GM 
crop introduced in EU agriculture: Bt maize in Spain. European Commission, IPTS, EUR 22778. 
http://www.jrc.es/publications/pub.cfm?id=1580.  
154 Gómez-Barbero, M. and Rodríguez-Cerezo E. (2006). Economic impact of dominant GM crops worldwide: a 
review. European Commission, IPTS, EUR 22547. http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1458. 
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aggregate economic benefits are predicted by these studies, derived from increased yields and 
reduced production costs for farmers. However, these analyses should also consider the novel 
regulatory framework on labelling and traceability of genetically modified organisms (GMOs) 
and derived products that became operative in 2004155. It introduces issues such as possible 
market segmentation, price differentials, and novel costs for identity preservation and 
labelling/traceability. Analyses of the economic impacts of introducing GM crops in 
agriculture in the EU should also now consider the novel concept of coexistence between GM 
and non-GM agriculture developed by the EU156. Member States have begun drafting rules 
requiring farmers cultivating GM crops to take measures (if necessary) to ensure coexistence 
and consequently to bear the resulting costs. A similar framework does not exist in other areas 
of the world where GM crops are cultivated; this raises new questions regarding the GM crop 
adoption process by EU farmers and its economic balance.  
 
As with molecular marker-supported breeding, no employment data are available for 
developing and marketing GM seeds. According to the ESA’s statistics, the EU seed industry 
is estimated to employ about 30 000 people. Calculations of how many of these workers are 
directly related to breeding, producing, conditioning, marketing and distributing GM seeds is 
rather difficult due to the lack of data. Additionally, GM seeds are mainly not produced in the 
EU but elsewhere (e.g. the US and Chile), and therefore the employment impact in the EU 
might be low. Considering an average maize plot area of 12 hectares per farm in Spain and 
58 219 hectares of Bt maize grown in 2004 in total, the population of users of the Bt 
technology is about 4800 farmers. At farm level, it seems that the adoption of Bt maize in 
comparison to conventional maize had no effect on the number of farm labourers157. 
 
 
Micropropagation158 
 
Micropropagation refers to the in vitro asexual propagation of plants based on cell and/or 
tissue culture. It therefore serves towards multiplying a desirable genotype rather than 
improving the breeding value of plants. Furthermore, micropropagation refers to a number of 
techniques that vary depending on the plant types and varieties. 
 
Micropropagation has been adopted where it is cost-effective, as it provides several 
advantages compared to alternative plant propagation methods (mainly seeds or cuttings-
based): rapid and space-saving propagation; uniformity of products; elimination of viral, 
bacterial or fungal pathogens. This technique also serves conventional, MAS or genetic 
engineering-based breeding techniques by providing sufficient and high quality starting stock. 
Therefore, micropropagation is mainly applied for the provision of young and mother plants.  
 
                                                 
155 Regulation (EC) No 1830/2003 of the European Parliament and of the Council of 22 September 2003 
concerning the traceability and labelling of genetically modified organisms and the traceability of food and feed 
products produced from genetically modified organisms and amending Directive 2001/18/EC; OJ L268, 
18.10.2003, p.24. 
156 European Commission (2003). Commission Recommendation of 23 July 2003 on guidelines for the 
development of national strategies and best practices to ensure the coexistence of genetically modified crops 
with conventional and organic farming. 
157 Gómez-Barbero, M., J. Berbel and Rodríguez-Cerezo E. (2008). Adoption and performance of the first GM 
crop introduced in EU agriculture: Bt maize in Spain. European Commission, IPTS, EUR 22778. 
http://www.jrc.es/publications/pub.cfm?id=1580. 
158 Non-referenced information is based on expert opinion (ETEPS (2006). Bio4EU Task 2 Case studies report – 
Primary Production and Agro-food Applications). 
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The main stakeholders involved in micropropagation are specialised commercial laboratories 
and laboratory units of companies producing young plants. The activity of a company may be 
limited to the production and sale of young and/or mother plants, or may also involve the 
grow-out phases (open land or in greenhouses) up to the final retail sale. Furthermore, some 
companies are simultaneously involved in micropropagation of several different plant types 
(ornamentals, vegetables, etc.) as well as in plant and seed breeding. As a result, the economic 
activity of micropropagation is dispersed in several different sectors, which results in a lack of 
relevant statistical information.  
 
Micropropagation has been applied with variable success to the different agricultural and 
horticultural fields. The commercial uptake of micropropagation has been highest in 
ornamental plants (of different types, such as flowers, foliage plants, woody ornamentals, 
etc.), followed by vegetable and fruit plants. Current production techniques for 
micropropagation have made a strong and continued growth within the micropropagation 
industry possible. Furthermore, where micropropagation is applied, demand for most of the 
ornamental plants exceeds the capability of the commercial laboratories to produce sufficient 
numbers of plants. 
 
A survey of European micropropagation laboratories conducted in 1996-1997 identified 193 
commercial laboratories active in this area159. The countries with the highest numbers of 
companies were the Netherlands (36), Germany (31), the United Kingdom (18), Belgium (14) 
and Italy (14). However, young plant companies having integrated micropropagation 
laboratories were not included in the survey, and as there has been build-up of such units 
recently, this number is likely to be an underestimate.   
 
The adoption of micropropagation depends on its cost-effectiveness compared to other 
alternatives and varies within the horticultural industry, and even within the ornamental plant 
industry. As data on the adoption and impact of micropropagation in the EU are not available, 
interviews were carried out in 11 horticultural breeding or propagation companies. These 
companies were selected for their activities on those plants where micropropagation plays an 
important role, namely orchids and pot plants and also strawberries and certain ornamental 
woods that show high production volumes in Europe160. Nine out of the 11 companies were 
commercial plant propagation laboratories, the other two being young plant companies. The 
interviewed companies were located in Germany, the Netherlands, Belgium, Austria and the 
United Kingdom. 
 
The survey revealed that three out of the 11 companies were active in conventional 
propagation, 10 were active in micropropagation, five were active in breeding and four were 
involved in R&D activities, which indicates that 91% of these companies are active in 
micropropagation. Moreover, the companies provided a breakdown of their activity fields as 
shown in Figure 17. 
 
                                                 
159 Ríordáin, F.O. (2000). COST 822 – The Directory of European Plant Tissue Culture — 1996. Acta Hort. 
(ISHS) 530:33-38. http://www.actahort.org/books/530/530_2.htm 
160 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
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Figure 17: Activity field shares of the interviewed companies  
Source: ETEPS161 
 
On average, 81% of the overall activity in the adopting companies is related to 
micropropagation, indicating the dependence of these companies on this technology. When 
this share is calculated over all 11 companies (including the single non-adopter) the 
micropropagation-related activity share falls to 74%. The 11 interviewed companies indicated 
total annual sales of 28 308 000 plants, which, multiplied by the 74% activity rate, provides 
an estimate of 20 947 920 plants produced through micropropagation. 60% of the plants 
produced were orchids, followed by fruit plants (16%, mainly small berries and fragaria), 
perennial herbaceous plants (8%), pot plants (8%), ornamental shrubs/trees (4%), cut flowers 
as mother stock (3%), the remaining being vegetables and forestry plants. The turnover of the 
interviewed companies ranged from between EUR 250 000 and EUR 2 million per year. 
Taking this turnover range and multiplying it with the estimated number of companies (193) 
described above and the estimated micropropagation-related share of the adopters (81%), 
provides an estimate of the range of the total turnover (direct impact) of specialised 
micropropagation laboratories in the EU, at EUR 39 - 313 million. This estimate should be 
treated with caution, as it merely intends to provide an idea of the order of magnitude of the 
economic contribution of micropropagation in the EU. Using as a benchmark the total value 
of nursery plants and flowers in the EU (EUR 6.4 billion162) provides an indication of the 
importance of micropropagation to the sector at 0.6 - 4.7%, which is likely to be conservative, 
as it does not include the turnover of young plant companies using micropropagation. The 
indirect impacts of micropropagation relate to the production of adult ornamental plants and 
flowers (EUR 8.3 billion) that are derived from micropropagated young plants and mother 
stock162. The adoption share for the biotechnology producers (0.6 - 4.7%) may be used as the 
best estimate, which results in EUR 50 - 389 million or 0.004 - 0.033% of the agro-food 
                                                 
161 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
162All sector information based on: European Commission, DG Agriculture and Rural Development (2006): 
Working Document of the Commission staff on the situation of the flowers and ornamental plants sector. 
http://ec.europa.eu/agriculture/markets/fruitveg/flowers/analysis.pdf.  
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sector163. This is probably an underestimate of the true contribution, as the propagation of 
superior mother stock will probably have a multiplier effect164.  
 
While the contribution benchmarked to the sector may seem low, certain plants can only be 
propagated profitably by means of micropropagation. Furthermore, the huge demand for some 
ornamental plants like orchids can only be fulfilled by applying micropropagation. Therefore, 
this technique is often described to be complementary to conventional young plant 
production. One of the first drivers for the adoption of micropropagation was the high demand 
for cut flowers (e.g. gerbera) in Europe in the eighties. Today the general demand for cut 
flowers is decreasing, whereas the production of orchids gains ever more significance. 
Therefore, the extent and success of micropropagation mainly relies on the market demand of 
end consumers and can change significantly within a few years. 
 
Labour is by far the largest cost item when producing micropropagated plants, which may 
even reach 60 - 85% of the total costs. For conventional propagation fewer employees are 
needed. Therefore labour costs have a lower share on the total expenditures than in 
micropropagating companies. However, the need of land and operating capital is higher in 
conventionally working firms. The high labour costs have been a driver in seeking low wage 
countries for the installation of micropropagation activities (both within and outside the EU, 
such as in Asia). 
 
From the interviewed companies, it was estimated that approximately 75% of the employees 
are related to micropropagation (a conservative estimate of the total number of employees in 
the interviewed companies is 400 people). Using a similar approach as the one used for 
turnover, it is estimated that the number of employees dedicated to micropropagation would 
fall in the range of 1563 - 15 630 (10 - 100 employees per company, multiplied by the 193 
companies and by 81%, the micropropagation-related activity of adopters).  
 
The production of ornamental flowers and plants is of particular importance to the agricultural 
economy of certain regions of the EU. Furthermore, the EU is a major player in global 
production with a 12% share by area and a 42% share by value. EU production is 
characterised for the highest production intensity achieved mainly through the use of modern 
technologies. The value of production is stable for ornamental flowers and plants but is 
increasing for nursery flowers and plants. Furthermore, the EU is a net exporter of nursery 
flowers and plants and a net importer of ornamental flowers and plants, while the total 
balance is positive. Meanwhile, EU domestic production is the main source of internal 
consumption. Overall, nursery and adult flower and plant production is a very competitive 
sector, the main advantages of EU producers compared to their competitors (mainly in 
developing countries) is capital availability linked to modern technology use, logistics and a 
home market. To this end, micropropagation seems to be one tool that enables some EU 
producers to remain competitive. 
 
 
 
 
                                                 
163 Complications in the calculation include the unknown share of imports and exports of total as well as of 
micropropagation plants and flowers at the appropriate level of dissagregation.  
164 It should also be noted that some micropropagation companies may have the grow-out phase integrated in 
their young plant activities, and therefore the direct and indirect impacts will be confounded.  
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2.3.5.1.2 Breeding and propagation – livestock 
 
Modern biotechnology used in livestock breeding and propagation refers to MAS and embryo 
technologies used in assisted reproduction. Similar to plants, the biotechnology producers are 
located upstream from the farmers, and they include livestock breeders and related 
biotechnology producers, that supply input to farming in the form of embryos, breeding 
animals, semen, etc. Therefore, the direct impacts relate to the turnover generated by these 
activities, whereas the indirect impacts cover the downstream effects to the farmgate, 
processing and final retail sale of the respective products. 
 
The EU animal breeding sector mainly serves the most important livestock species produced 
in the EU, namely cattle, pigs and poultry165. The structure of the respective breeding sectors 
differs significantly, especially that of poultry breeding, mostly due to differences among the 
reproductive biology of the different species. In general, animal breeders (as plant breeders) 
have two main activities: i) genetic selection for improving the desirable characteristics and ii) 
assisted reproduction for producing large numbers of the desirable genotypes. According to 
the Sustainable Farm Animal Breeding and Reproduction Technology Platform (FABRE)166, 
breeding efforts are responsible for an economic gain through improved production of EUR 
1.83 billion. Cattle accounts for 27% (EUR 500 million), similar to pigs, poultry for 33%, and 
fish for 4%.  
 
Many ruminant breeders are farmers’ cooperatives, with a modest turnover and a small 
number of employees (e.g. fewer than 250); these cooperatives target their activities to their 
own countries, reaching market shares of 75% or more, while no organisation has more than 
25% of the EU market share. In pig breeding, on the other hand, private companies account 
for approximately 50% of the activity, the rest being cooperatives. Some of the organisations 
may reach market shares at a national level of 75 - 100%, and in general a few organisations 
(i.e. three to six) serve each country. As in cattle breeding, no single organisation has more 
than 25% of the EU market. In contrast, poultry breeding in the EU and globally is 
characterised by a significant concentration of the market to a handful of private companies. 
As an example, in laying hens, just three companies serve 80 - 95% of the EU market and 
over 75% of the global market; while in broilers four breeding companies dominate with 35 - 
60% of the market. EU breeding organisations hold, therefore, a very strong position in the 
EU (accounting virtually for the vast majority of the market) and hold leading positions 
globally. The EU-wide annual turnover stemming from animal breeding activities was 
estimated at EUR 2 billion, 40% related to pig breeding, 30% to cattle breeding, 15% to 
poultry breeding with the remaining related to other livestock (mainly other ruminants, such 
as sheep and goats, and horses)167. 
 
 
                                                 
165Information on the structure of the animal breeding sectors is based on A.M. Neeteson and P. Robinson (2003) 
Farm animal breeding in Europe – 2003, SEFABAR. 
166 FABRE (2006). Sustainable farm animal breeding and reproduction: a vision for 2025. FABRE Technology 
Platform, Oosterbeek. http://www.fabretp.org/content/view/19/38/.  
167 IPTS estimate based on information from ETEPS (2006). Bio4EU Task 2 Case studies report – Primary 
Production and Agro-food Applications and expert opinion: EUR 1400 million from the reported activities of 
major breeding organisations in the surveys for pig (EUR 800 million) and cattle (EUR 600 million) breeding. 
The EU-wide shares in final animal output were then used to estimate the relevant turnover for poultry (EUR 
300 million) and other animal breeding (EUR 300 million).  
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Embryo technologies168 
 
Embryo technologies as part of modern biotechnology refer to a range of techniques, centred 
around embryo transfer but also including in vitro embryo production, embryo and semen 
sexing, etc. While these techniques have been used to a variable extent with several livestock 
species (cattle, pigs, equidae, etc.), commercial application at any significant level has only 
taken place in cattle breeding, and mainly in the dairy sector. Embryo transfer (ET) is used as 
a means to propagate selected animal genetics throughout the breeding process at a faster 
pace. Therefore, it does not have an effect on the breeding value of an animal per se, but it 
aids the faster dissemination of the desirable genetics. The main alternative method is 
artificial insemination (AI), which is also the main vehicle for propagation in livestock. AI 
has been used for approximately 60 years and is considerably cheaper than ET, which has 
limited the use of ET to the top of the breeding pyramid, although ET infers several 
advantages169. 
 
The EU cattle herd consists of approximately 40 million cows and heifers. The dairy segment 
accounts for the majority of gain achieved through genetic improvement in cattle. There is a 
large international trade in cattle semen and embryos meaning that livestock genetic 
evaluation can occur across countries. The International Bull Evaluation Service170 involves 
nearly 50 countries and is responsible for standardising the international genetic evaluation of 
bulls. The EU is an important player in the international cattle breeding sector as five out of 
the ten largest cattle breeding companies are based in the EU. There are a number of different 
companies/organisations involved in cattle breeding such as large privately owned companies 
(e.g. Genus in the UK, AltaGenetics in the Netherlands) and cooperatives (e.g. CRV in the 
Netherlands, Svensk Avel in Sweden) operating on an international scale, as well as 
significant national schemes (e.g. in Denmark, France and Italy) and numerous smaller 
organisations such as individual breed societies or AI associations (e.g. in Germany several of 
the AI associations have their own breeding programmes). ET services are provided either by 
veterinary specialists or specialist ET companies, but may also be part of the breeding 
companies themselves. It has been estimated that there are more than 100 such ET ‘teams’ in 
the EU171. 
 
The direct economic impacts of ET may be estimated based on the ET-related turnover 
realised by the above described companies. While appropriate statistical information is not 
available, information obtained through a survey of livestock breeding companies and from 
targeted interviews of cattle breeders and ET companies provide insights into the direct 
economic contribution of the use of ET. Furthermore, the European Embryo Transfer 
Association (AETE) provides annual updates on the number of ET globally, for which 2004 
data are presented in Table 18. 
 
The proportion of calves resulting from ET is very small (<0.5% of total calf production), as 
this technology is only meant to be used at the top of the breeding pyramid. The ET activity 
reported from the survey of nine companies (9000 ET representing a turnover of EUR 20 
million) represents around 10% of the ET activity reported for Europe (see Table 18), 
                                                 
168 Non-referenced information is based on expert opinion and data from (ETEPS (2006). Bio4EU Task 2 Case 
studies report – Primary Production and Agro-food Applications). 
169 It should be noted that these technologies may be applied in combination, e.g. AI and ET may be used 
simultaneously in a breeding programme. 
170 http://www-interbull.slu.se/.  
171 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
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although the share may be closer to 5% as the reported activity is probably an underestimate 
of the actual total. The total EU-wide revenue from this activity may therefore be estimated at 
least at EUR 200 million. Based on these data, the turnover per ET is estimated at EUR 2000, 
which falls within the range of publicly reported values.  
 
Results from the targeted interviews indicate that the share of ET-related turnover out of total 
turnover of the companies is very variable (depending on the type of company, e.g. specialist 
ET company vs. large breeding company) and can be up to 60% in very specialised 
companies.  
 
Table 18: Top European countries ranked according to total numbers of embryos transferred (in vivo plus 
in vitro) in 2004.  
Source: European Embryo Transfer Association (2005) via ETEPS (2006)172, IPTS calculation 
 
Country Number of embryos transferred 
Value in EUR million  
(IPTS estimate,  
number of embryos x EUR 2000) 
France 29 618 59.2 
Netherlands 16 466 32.9 
Germany 11 285 22.6 
Belgium 7190 14.4 
Italy 6755 13.5 
Czech Republic 6427 12.9 
United Kingdom 5000 10.0 
Denmark 3983 8.0 
Finland 2985 6.0 
Switzerland 1680 3.4 
Ireland 1444 2.9 
Spain 1329 2.7 
Sweden 1300 2.6 
Total 95 462 190.9 
 
The indirect contribution of ET relates to the use of ET derived products by the cattle farmers 
(beef and dairy). Expert opinion from the interviews indicated that the proportion of AI bulls 
themselves derived from ET is at least 75% in those countries with the largest numbers of 
cattle. Based on this estimate, it is assumed that 75% of farmgate products have been based on 
the use of ET, which accounts to EUR 55.2 billion or 4.6% of the agro-food sector. While it is 
clear that ET is neither the sole parameter and perhaps neither the most crucial one for 
ensuring the realisation of the economic activity and the farmgate output, its diffusion and 
application in livestock breeding is considered very important. 
 
                                                 
172 European Embryo Transfer Association AETE (2005) 21st Scientific Meeting, Keszthely. 
http://www.aete.eu/pdf_publication/17.pdf. In ETEPS (2006) Bio4EU Task 2 Case studies report – Primary 
Production and Agro-food Applications. 
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As noted by FABRE the strategic importance of animal breeding and reproduction is much 
greater than one might guess from the size and volume of the sector173. Based on the group's 
estimate of the economic gain achieved through cattle breeding (EUR 500 million) and the 
experts' estimate that at least 75% of AI bulls are derived from ET (in those countries with the 
largest numbers of cattle), it is assumed that 75% of the improvements (EUR 375 million 
annually) would not be feasible without the use of ET. The total ET-related return of genetic 
improvement assumed at 375 million represents 0.3% of the value of animal production (EUR 
127 billion) or 0.5% of the cattle share of animal production (EUR 73.6 billion). 
 
The allocation of 75% of the indirect economic impacts of breeding to ET should be treated 
with care as genetic improvement also depends on the concomitant application of other 
breeding techniques, including other biotechnology applications. However, at the same time, 
it may be argued that it would not have been feasible to disseminate 75% of this genetic 
improvement without ET. The benefit (indirect impacts) of ET adoption at the farmgate and 
through to final output is also illustrated by the following examples174: 
• the company Genus indicates that their ET breeding herd (which is at the top of the 
pyramid) in the UK averages 14 000 litres of milk per cow per year compared to a UK 
average of 7000 litres 
• the company Cogent illustrates the value of genetic improvement for beef indicating that 
the difference between the offspring of an average bull and a bull with an outstanding 
breeding value is EUR 45 as a calf and EUR 105 for the adult animal 
• in Denmark between 1984 and 2002, protein production in the first lactation period of 
dairy cattle increased by approximately 80 kg in 305 days with more than 50% of this 
increase due to genetic improvement (the rest being the result of management 
improvements)  
• in the Netherlands, the average production per lactation of recorded cows increased by 
62% in the 20 years from 1985 (from 5600 to 8900 kg milk). 
 
 
Marker assisted selection (MAS) 
 
MAS is applied in animals in the same way as in plants. Molecular markers are used to aid the 
breeding of all livestock species. However, no definitive data are available on the extent to 
which MAS is used in livestock breeding nor on the extent to which livestock products have 
been derived from livestock selected through MAS. 
 
As for plants, the impacts of the use of markers in livestock breeding and production are not 
quantifiable from the data available. The advantage of genetic markers is that they can be 
assimilated within a general breeding programme but the disadvantage of this is that their 
contribution cannot be disaggregated from the value of the programme as a whole. Usually, 
organisations do not distinguish and record their activities in MAS separately from their 
conventional breeding practices as the two are integrated.  
 
A survey conducted in 2005175to cover all major livestock producers provides some relevant 
insights. More information was also obtained from targeted interviews of major EU pig 
                                                 
173 FABRE (2006). Sustainable farm animal breeding and reproduction: a vision for 2025. FABRE Technology 
Platform, Oosterbeek. http://www.fabretp.org/content/view/19/38/.  
174 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
175 ETEPS (2006). Bio4EU Task 2 Main report. 
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breeders176, but focused on MAS in the narrow sense, i.e. excluding supporting uses of 
markers in breeding that are not directly involved in the selection of a particular trait.  
 
The MAS specific turnover realised by the 16 breeding companies/organisations that replied 
to the survey can be used as the minimum direct economic contribution of MAS in livestock 
breeding, while applying the MAS turnover share to the estimated total livestock breeding 
related turnover may provide a maximum estimate177. The total MAS specific turnover 
amounted to approximately EUR 207 million (a low estimate of direct economic contribution) 
which is 28% of the total turnover reported by these companies (EUR 740 million), and 10% 
of the total estimated turnover of EU livestock breeding (EUR 2 billion). Applying the 28% 
adoption rate to the total estimated turnover of EU livestock breeding of EUR 2 billion yields 
the maximum estimate of EUR 560 million178. More than half of the MAS turnover was 
realised from sales outside the EU, corroborating the strong position of EU livestock breeders. 
Regarding the use of MAS (in the narrow sense) in pig breeding in the EU, and based on very 
limited quantitative and descriptive data from interviews, the best estimate was that MAS has 
contributed to the breeding of around 40 - 80% of breeding females179 in that they or their 
parents or grandparents had been selected using MAS or testing had been used to ascertain 
that a specific marker was not useful in the population because a specific gene was not 
segregated in that population. While this estimate should be used with caution as it is based on 
a large number of assumptions (due to the lack of firm quantitative data on market share, sales 
volume or the extent to which markers are used for most of the organisations interviewed), it 
may be used as an indication for the adoption of MAS by the pig sector.   
 
The indirect contribution of MAS refers to the turnover realised by livestock producers from 
products that have been derived from livestock selected through MAS. A rough estimate of 
the indirect contribution is obtained by applying the estimates obtained for the breeding sector 
to the growing sectors (total animal output of EUR 127.4 billion), which yields EUR 12.74 - 
35.67 billion or 1.5 - 3% of the agro-food economy. 
 
Some impacts related to pig production have been described in the general literature and these 
are summarised in Table 19.  
 
As described in the ET analysis, the value of adopting MAS in the breeding process relates to 
the fact that breeding provides economic gains to the farmers. Using the estimates provided 
by FABRE as an illustration, 40 - 80% of the EUR 520 million annual economic gain related 
to pig production at the farmgate may be due, to some extent, to the use of MAS. The total 
MAS-related return of genetic improvements assumed to be EUR 208-416 million represents 
0.16 - 0.32% of the value of animal production (EUR 132 billion) or 0.8 - 1.6% of the pig 
share of animal production (EUR 26 billion). 
 
                                                 
176 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
177 Assuming that the share obtained from the surveyed companies is at the high end, as in general companies 
involved in biotechnology are more likely to reply to a biotechnology specific survey. 
178 This indicates that the companies replying to the survey covered approximately 50% of the total activity. 
179Assuming 15 million sows in the EU with 40% being replaced per year and hence a market of 6 million gilts 
per year. Assumptions were made about market shares of different organisations based on stated sales from 
organisations which are expected to be broadly similar in size and verbal indications of the use of MAS or 
indications from marketing literature. Where no data were available, the assumption, based on interviews, was 
that 25-80% of pigs were produced using MAS. Note that MAS may not be used to the same extent in the 
production of parent males and females (ETEPS (2006). Bio4EU Task 2 Case studies report – Primary 
Production and Agro-food Applications.). 
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Table 19: Impacts of MAS on pig breeding and production 
Source: ETEPS180 
 
Genetic marker Impact Value Reference 
Halothane1 Reduced mortality of between 4-16 per 
1000 to zero and improved meat quality 
Improved public perception 
and better economic 
performance 
McLaren & 
Rohl2, based 
on PIC data 
Halothane Carriers show 43% more drip loss in 
meat after two days 
Better economic performance 
and consumer acceptability 
Otto et al. 
20063 
ESR  
(trait affected: litter 
size) 
Increased rate of genetic response in 
litter size by 30% 
Economic performance Short et al.4 
MC4R 
(trait affected: 
appetite – 
production 
efficiency) 
Increased lean by 1.4% and reduced 
backfat by 1.1 mm 
Economic performance Plastow 20065 
Combination 
(unspecified) 
Reduced drip loss from meat over 7 days 
from 5% to 3% 
Economic performance and 
consumer acceptability 
Primetiva et 
al. 20066 
FUT1 
(trait affected: 
resistance to E. coli 
F18 – disease 
resistance) 
Resistance to infection by E. coli F18, 
reducing mortality to zero and 
improving growth of surviving pigs 
Improved public perception 
and better economic 
performance 
Van der Steen 
et al. 20057 
IGF2 
(trait affected: 
higher muscle 
mass8) 
EUR 2.8/head advantage to positive 
genotypes in US trial 
Improved economic 
performance 
Interview data 
1 RYR1/CRC1 ryanodine receptor gene, trait affected: sudden deaths/meat quality (causal mutation known). 
2 McLaren and Rohl, personal communication quoted in 
http://db.genome.iastate.edu/%7Emax/Reviews/1998_review/. 
3 Otto, R. et al. quoted in Primetiva, L., R. Klont, O. Southwood and Plastow G. (2006). The influence of 
ultimate pH on meat quality and the role of marker assisted selection. In: Rehout, V. (ed.) Biotechnology 2006. 
Scientific Pedagogical Publishing, Cˇ. Budeˇjovice, p. 41-44. 
4 Unpublished results of Short, Wilson, McLaren and Plastow, quoted in: Rothschild, M.F. and Plastow G.S. 
(1998). Current advances in pig genomics and industry applications. Department of Animal Science, Iowa State 
University, Ames, I.A. http://db.genome.iastate.edu/%7Emax/Reviews/1998_review/. 
5 Plastow, G. (2006). Proceedings of the British Society of Animal Science 2006: 204. 
http://www.bsas.org.uk/Publications/Annual_Conference_Proceedings/. 
6 Primetiva, L., R. Klont, O. Southwood and Plastow G. (2006). The influence of ultimate pH on meat quality 
and the role of marker assisted selection. In: Rehout, V. (ed.) Biotechnology 2006. Scientific Pedagogical 
Publishing, Č. Budějovice, p. 41-44. 
7 van der Steen, H.A.M. et al. (2005). Journal of Animal Science 83: E1-E8. 
http://jas.fass.org/cgi/content/abstract/83/13_suppl/E1. 
8 This marker may also improve uniformity of slaughter animals as only the gene from the male parent is 
expressed (causal mutation known). 
 
 
The additional benefits of MAS adoption through to final output may also be illustrated in the 
following publicly reported example where a pig breeding organisation collaborates with a 
meat marketing organisation to use genetic markers to identify pigs with improved meat 
quality. The example is from Germany where a retailer, EDEKA Südwest, and a pig breeding 
                                                 
180 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
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company, PIC Deutschland, have an agreement to use markers in a pig meat quality 
programme to supply branded meat181. A group of boars selected on the basis of a package of 
seven meat quality genetic markers derived from PIC has been established in (AI) stations for 
use in the "Gutfleisch-Programm". The EDEKA group is part of the largest food marketing 
association in Europe. Boars for this programme are not necessarily of PIC origin. Producers 
are being offered around EUR 0.02 per kg premium if they use boars selected for the 
programme (interview data). EDEKA requires a supply of around 7000 – 10 000 pigs per 
week for this programme, at a carcass weight of around 92 - 95 kg. 
 
 
2.3.5.1.3 Breeding and propagation – fish 
 
Modern biotechnology currently used in fish production is mainly applied in fish farming. 
Fish breeders have been applying techniques for ploidy and sex manipulation for several 
years, and are using molecular markers more and more to optimise breeding strategies. As in 
the other primary production sectors, direct economic impacts refer to the activity of 
companies in the breeding sector, whereas indirect impacts consist of downstream effects to 
the farmgate. Molecular markers in fisheries management (harvest fisheries) is still at a rather 
experimental/pilot phase.  
 
In general, fish breeding resembles poultry breeding in structure, as fish are characterised by a 
high fecundity and as there are only a small number of dominant companies. For example, 
only five companies are involved in salmon selection. On the other hand, fish breeding 
activities are often integrated with other activities in the primary or processing sectors; from 
the statistical standpoint (Eurostat), hatcheries and breeding activities form part of the primary 
sector activities specific to fish farming, without separating between the breeding and grow-
out stages. 
 
While there are no data on the total turnover realised by the EU fish breeding sector, the best 
estimate that can be used for illustrative purposes is 8% of the final farmgate output182 (final 
farmgate output was EUR 2.77 billion for 2003), and take species specific farmgate output (in 
value terms) to estimate the species specific relative shares of breeding output. A survey of 
salmon, trout and oyster breeders and national experts gives an estimate of the adoption of 
modern biotechnology in aquaculture183. The use of markers in the wide sense has been 
mainly applied in salmon breeding (i.e. mainly used as a tool for genetic selection via 
fingerprinting and not for assisting in the selection of traits) and based on a conservative 
estimate seems to contribute to 30% of the salmon’s and trout’s annual production of eggs 
(EUR 10 million and 11 million, respectively), and 10% for oyster’s annual spat production 
(EUR 2 million). Sex and ploidy manipulation techniques have been applied since the 70s, 
mainly in trout and oyster breeding, and based on a conservative estimate contribute 50% 
(EUR 18 million) and 20% (EUR 4 million) to the total EU turnovers, respectively. Therefore, 
and based on the species included in the analysis, it can be estimated that approximately 15% 
of the EU-wide fish farming turnover was produced through the use of seed fish produced 
                                                 
181 The Pig Site (2005). EDEKA Südwest and PIC Deutschland sign technology contract for meat quality, 28 
June. 5M Enterprises Ltd., Sheffield. http://www.thepigsite.com/swinenews/9611/. And: expert opinion (ETEPS 
(2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
182 Conservative expert opinion based on the share of the hatchery costs in the total production costs for different 
fish species. The shares of the three different species were calculated based on Eurostat data for 2003 at: trout 
18%, salmon 16%, and oysters 10%. 
183ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
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with the aid of modern biotechnology184 (modern biotechnology-related turnover of EUR 45 
million over a total breeding-related turnover of EUR 277 million). While these adoption rates 
should be treated with care as indications on the representativeness of these values over the 
whole industry are not available, they do fall within the range of values reported in the 
literature and obtained from expert opinion. For a rough estimate of the potential significance 
of modern biotechnology to the sector, the adoption rates reported above can be used over the 
total estimated turnover from fish breeding (direct impacts) and fish growing to the farmgate 
(indirect impacts). On the whole, available information indicates that modern biotechnology is 
used widely in particular sectors, namely sex and ploidy manipulation in trout and oyster 
production and MAS fingerprinting for salmon and trout, as a relatively large share of seed 
fish are produced using these technologies. As the overall sector is relatively small, the 
significance to the whole EU agro-food sector and the EU economy is, however, relatively 
small. Applying the 15% adoption rate to the EU-wide fish farmgate turnover provides an 
estimate of the indirect contributions of biotechnology at EUR 432 million, representing 
0.04% of overall agro-food turnover. 
 
Moreover, expert opinion indicates that sex and ploidy manipulation may have reached the 
limits of potential benefits where applied (i.e. trout and oysters) and therefore, its adoption is 
not likely to increase any further. Nevertheless, these techniques have not been adopted at the 
same rate in all EU Member States, and therefore the EU-wide adoption is likely to increase 
in the future. The highest growth rate in adoption is, however, expected to occur with the use 
of MAS in the breeding of all species involved. Overall, the outlook is an increase in the use 
and importance of modern biotechnology in fish farming. 
 
 
2.3.5.2 Diagnostics 
 
Modern biotechnology-based diagnostics refer here mainly to DNA-based tests and 
immunoassays. However, modern biotechnology-based diagnostics may involve a wide range 
of other techniques, the common thread being the detection at the molecular level in 
combination with rapidity, usually referred to as rapid methods.  
 
Modern biotechnology-based diagnostics have found several applications, the vast majority of 
which are in the human health sector. However, an important share of diagnostics are 
developed for the primary production and food sectors, namely in animal, fish and plant 
health monitoring and in food safety monitoring. Economic information on the diagnostics 
sector is scarce and, where available, is of a complex nature. 
 
While diagnostics in farm animal health monitoring are used by the farmers themselves in 
cases of emergency, the major use is for monitoring purposes, especially within the context of 
notifiable diseases, such as bovine spongiform encephalopathy (BSE), brucellosis, bovine 
tuberculosis, etc. In the majority of cases, the monitoring is carried out by state and public 
institutions. Modern biotechnology-based diagnostics in general provide novel or improved 
diagnostic tools. The improvements may be in terms of accuracy and precision or, most 
frequently, in terms of the time needed to provide results. 
 
                                                 
184 Conservative estimate, as for trout and oysters only the highest turnover estimate was used (i.e. related to 
sex/ploidy manipulation) in order to avoid double-counting where both sex/ploidy manipulation and MAS are 
applied together. 
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The world market for animal health diagnostics has been estimated at EUR 400 million for 
2003185, which is much smaller than for the therapeutics sector and the human health 
diagnostics sector. However, this estimate mainly considers rapid tests or kits, which in the 
scope of this study falls in modern biotechnology diagnostics. As approximately half of the 
largest companies are based in the EU, a simplified estimate is that the EU annual modern 
biotechnology diagnostics turnover amounts to EUR 200 million186. Diagnostics for food 
safety in the EU have been reported to be EUR 500 million187, approximately 20% of which is 
from rapid methods. Therefore, a rough estimate of the size of the direct contribution of 
modern biotechnology-based diagnostics is provided at EUR 300 million which represents 
0.03% of the total EU agro-food sector (also covering diagnostics used in plant health or other 
agricultural activities). 
 
The indirect contribution of diagnostics to the EU economy relates to the turnover realised by 
laboratories carrying out the tests as well as downstream impacts such as helping in the 
assurance of consumer confidence, in the maintenance of trade, and in the avoidance of 
negative impacts through disease or contamination. 
 
The laboratory related turnover for modern biotechnology-based diagnostics applied in food 
safety and veterinary health may be conservatively estimated at EUR 1500 million188, 
accounting for 0.13% of the EU agro-food economy. 
 
The indirect impacts related to ensuring the continuous functioning of the food chain (food 
chain actors, regulators, consumers) are very complex to calculate. Farm animal disease 
outbreaks can have serious economic consequences, with a fast and accurate diagnosis being 
an important tool in their avoidance and/or monitoring. There are a number of examples 
where modern biotechnology has been used for the provision of diagnostics in animal health 
and food safety. Some illustrative examples are provided in the following sections. 
 
 
Foot and mouth disease (FMD) diagnostics189 
 
FMD is one of the most important livestock diseases and is listed in the A list of diseases by 
the World Organisation for Animal Health (OIE). FMD is difficult to differentiate clinically 
from several other diseases and so accurate laboratory diagnosis of any suspected case is a 
matter of urgency. Following the FMD epidemic of 2001, there has been much interest in the 
development of biotechnological tests for improving the collection of information for use in 
                                                 
185 BCC (2004). Animal therapeutics and diagnostics. Report HLC034A. BCC Research, Wellesley, M.A. 
http://www.bccresearch.com/hlc/HLC034A.asp (abstract available online). 
186 BSE tests alone, a large share of which are immunoassays, would account for approximately EUR 100 
million annually for the period 2001-2005, assuming a conservative price of EUR 10 per test. 
187 No data are available at sector level, so the best estimate was taken from the data provided by Blankenfeld-
Enkvist, G. and Brännback M. (2002), Technological trends and needs in food diagnostics, Technology Review 
132/2002, National Technology Agency, Helsinki. http://www.tekes.fi/julkaisut/Food_diagnostics.pdf. The 
report covers the food chain from the raw material to the end product (turnover of EUR 491 million). 
Furthermore, GMO diagnostics were included (estimated at EUR 3 million for 1999 with predicted annual 
growth rates of 100%; and a more conservative estimate was taken). 
188 DNA-based tests and immunoassays for GMO detection cost EUR 6-150 per test while the laboratory 
analysis cost EUR 100-570 (ETEPS (2006). Bio4EU Task 2 case studies report – primary production and the 
agro-food applications.). For BSE testing (immunoassay), a laboratory analysis was estimated at EUR 40 - 50. 
Therefore a five-fold higher laboratory turnover over the turnover of the test-kits is a conservative estimate.  
189 Non-referenced information is based on expert opinion and data from (ETEPS (2006). Bio4EU Task 2 Case 
studies report – Primary Production and Agro-food Applications). 
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the epidemiology of the disease, in differentiating between the many strains and species 
which cause confusion in diagnosis and in the early diagnosis of an outbreak. There are at 
least eleven modern biotechnology firms actively involved in the development and 
commercialisation of FMD diagnostic tests, four of which are located in the EU. Expert 
opinion indicates that jobs in inspection and surveillance have already been increasing, in the 
EU and globally, post 2001.  
 
The indirect impact of the availability of modern biotechnology-based diagnostics for FMD is 
related to its instrumental role in the avoidance of an outbreak. Following the 2001 outbreaks, 
Member States have increased their surveillance activities and this may be contributing to the 
fact that no new cases of FMD have been reported since 2001. However, it is not possible to 
attribute this fall in incidences to new biotechnological approaches for early diagnosis of 
FMD. Currently, all EU countries are recognised by the OIE as disease-free without prior 
vaccination. 
 
The costs incurred following the 2001 outbreak can be used as an example of the potential 
costs that may be avoided through the use of improved biotechnology-based FMD 
diagnostics. The UK government alone is estimated to have lost GBP 2.4 billion over two 
years (mainly from compensation payments and reduced tax returns) without the inclusion of 
the heavy losses incurred by agricultural export, transport, tourism, hotels and restaurants in 
the UK. Moreover, the European Commission had also made provisions for EUR 400 million 
in 2001, and had earmarked a further EUR 400 million towards FMD. Modern biotechnology 
companies are active in the EU and the US for developing improved diagnostics for FMD, 
although the most significant impact is expected in the creation of ‘pen-side’ tests that will be 
simple for farmers to use, and in the development of marker vaccines, for enabling 
surveillance rather than post-facto detection. A major challenge to modern biotechnology-
based FMD diagnostics relates to the difficulties encountered by the relatively small 
biotechnology companies to provide the product in adequate numbers. To this end, some 
argue that the state should not only play an important role in funding relevant R&D but also in 
the necessary stockpiling of these products for future use.  
 
 
Bovine spongiform encephalopathy (BSE) diagnostics190 
 
Modern biotechnology has enabled the provision of the only rapid tests (immunoassays) 
available for the detection of BSE. These are postmortem diagnostic kits that allow samples to 
be taken at the abattoir to give results which can be reported back the next day, allowing the 
carcass to enter the food chain in case of a BSE-negative result. Prior to the development of 
these kits, testing for BSE took three to five days. The new diagnostic kit allows many more 
samples to be tested, enabling the level of surveillance as required by Regulation (EC) 
999/2001191. Thirteen tests produced by ten companies have been approved for use in the EU. 
Of these companies, six are based in the EU (in the UK, Germany, France, Ireland and the 
Netherlands), two in the US and one each in Japan and Switzerland. The EU market is 
dominated by two of the six EU companies, with a third being a major competitor in the field 
due to its production and use of small ruminant tests alongside its BSE tests. The other 
                                                 
190 Non-referenced information is based on expert opinion and data from (ETEPS (2006). Bio4EU Task 2 Case 
studies report – Primary Production and Agro-food Applications). 
191 Regulation (EC) No 999/2001 of the European Parliament and of the Council of 22 May 2001 laying down 
rules for the prevention, control and eradication of certain transmissible spongiform encephalopathies, OJ L 
147, 31.5.2001, p. 1–40. http://ec.europa.eu/food/fs/afs/marktlab/marktlab14_en.pdf.   
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companies hold very little, and in some cases no share of the EU market at all. Globally, three 
of the companies producing kits used in the EU, are located outside of the EU – Prionics 
(Switzerland), Idexx (US) and Fujirebio (Japan). Of these, Prionics and Idexx have major 
shares of the global market in rapid diagnostic tests (the worldwide market is dominated by 
Prionics, Enfer Scientific (Ireland), Bio-Rad (US) and Idexx), with the Fujirebio product 
being more recently released and approved. The surveillance programme tests over 10 000 
animals annually, a number which could not be achieved without the use of the rapid test kits. 
The rapid diagnostic kits are mainly used in the appointed veterinary laboratories in Member 
States, as part of required surveillance for BSE with the approved kits. Taking as a 
conservative cost of a BSE diagnostic at EUR 10 (cost of immunoassay) and of a laboratory 
analysis at EUR 45 (range reported is EUR 40 - 50), the annual turnover of test kit producers 
and laboratory analysis is estimated at EUR 100 000 and EUR 450 000, respectively 
(assuming that most of the testing is done through the use of the modern biotechnology-based 
test kits). The implementation of BSE surveillance has had a positive impact on employment. 
The impact on employment in the EU is estimated to be similar for diagnostics producers as 
well as for the agencies conducting the analyses, with at least a 200 - 300% expansion for 
coping with the demands of the passive surveillance programme. This has led to the creation 
of regional laboratories, as well as outsourcing contracts to other laboratories to handle the 
increased throughput.  
 
However, the surveillance comes at a cost: about EUR 1.56 million were spent per 
identification of a BSE case in healthy animal stocks, and EUR 0.07 million per BSE case in 
(at risk) animal stocks. These costs are mainly borne by individual Member States, with some 
state aid from the EU. Moreover, additional costs, such as related to fallen stock and 
emergency slaughter of farm animals, are covered by the Member States with some support 
from the EU, but also indirectly, by the cattle industry and the consumers. 
 
Besides the direct impacts of the production and use of the test kits, enabling the EU-wide 
surveillance programme has had an indirect economic impact through the reopening of market 
borders. For example, beef was recently re-approved for export from the UK to EU Member 
States. This was achieved through the continued surveillance for BSE, which proved that the 
incidence of the disease was below the agreed threshold, and that there was compliance with 
the introduced measures designed to eradicate the disease. Moreover, the modern 
biotechnology-based diagnostics may also be seen as aiding in the avoidance of a new 
outbreak, and thereby preventing the effects experienced after previous outbreaks: in the UK, 
sales of beef fell by 40%, the price of beef fell by more than 25%, export markets were lost 
(trade estimated at about GBP 520 million), and there were effects on employment, as 
abattoirs temporarily closed or reduced their working hours. Moreover, it was estimated that, 
in the year following the start of the BSE crisis, the total economic loss to the UK was 
between GBP 740 million and 980 million (0.1 - 0.2% of the UK GDP). This pattern (a fall in 
consumer confidence and its follow-on economic effect) was mirrored in some other EU 
countries where BSE was discovered. The cost of the epidemic to the EU has been calculated 
at 10% of the annual value of the EU beef sector, while the discounted present value has been 
estimated at EUR 92 billion192. In the EU, BSE surveillance is likely to decline over time, as 
the number of cases detected decreases, and therefore the current surveillance programme 
may be less cost-effective in the long-term. Looking into the future, modern biotechnology 
companies are currently working on the development of live animal tests, as well as on prion-
                                                 
192 Cunningham, E.P. (ed.) (2003). After BSE: a future for the European livestock sector. EAAP Series no. 108, 
Wageningen Academic Publishers, Wageningen. 
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specific diagnostic tests for humans. In addition, some companies have started branching out 
to other areas of surveillance of animal diseases.  
 
 
Salmonella diagnostics193 
 
Salmonella causes food poisoning and is the second most prevalent food pathogen after 
Campylobacter194. The mere frequency of the occurrence of salmonellosis is a sufficient 
indication of the significant public health costs it incurs. For example, a cost assessment made 
in the US in 2005, provides an estimate of the annualised cost of salmonellosis at about USD 
2.4 billion with an average cost of USD 1709 per case, of which 89% relates to premature 
deaths, 8% to direct medical costs and 3% to productivity loss195. A new generation of 
modern biotechnology diagnostic methods, both DNA- and immunoassay-based, enables a 
faster detection of the food pathogen Salmonella bacterium. Faster detection is considered 
crucial in avoiding salmonella outbreaks, and thereby preventing the associated costs. 
Conventional analysis for salmonella, dominantly used, requires 4-7 days for presumptive 
evidence of salmonella in foodstuffs. This is often too long a time from public health 
perspectives when an outbreak can get expensive and serious in this timeframe. Overall, it is 
expected that rapid tests reduce testing times by 1 - 5 days. 
 
Over 75 companies are currently providing salmonella diagnostic products, kits or services in 
the EU. In a few cases, the parent firm is US based but has considerable EU presence; all the 
other firms are based in EU Member States. The costs related to the surveillance for 
salmonella is borne mainly by the food industry (farmers, retailers, processors) for ensuring 
salmonella control and safety, while the costs in the case of human salmonellosis outbreaks 
are borne by the patients and the public health budgets. Nevertheless, it is difficult to attribute 
changes in reported disease incidences to modern biotechnology for pathogen detection. In 
several cases better enforcement by an EU Member State and ‘therapeutic’ or ‘preventative’ 
techniques such as heat-treatment of eggs or vaccination of poultry are identified by the 
respective Member State’s regulatory agencies as the key cause of the falling incidence of 
human zoonotic cases. 
 
Many US firms have recently acquired smaller EU firms, as illustrated by Neogen’s 
acquisition of a Scottish base for serving the European and worldwide market better and 
Neogen’s plans to add more R&D staff in Ayr, Scotland. This shows an increased interest in 
the EU market for salmonella detection as well as in EU research, by non-EU firms. The 
latter, in combination with the high level of activity in the development of improved 
diagnostics, illustrate the promise of emerging biotechnologies in salmonella detection and 
wider food safety issues, indirectly indicating expectations for growth in revenue and 
employment by firms that develop or provide these new biotechnology applications. 
 
 
 
                                                 
193 Non-referenced information is based on expert opinion and data from (ETEPS (2006). Bio4EU Task 2 Case 
studies report – Primary Production and Agro-food Applications). 
194 The EFSA Journal (2006), 94, The Community Summary Report on Trends and Sources of Zoonoses, 
Zoonotic Agents, Antimicrobial Resistance and Foodborne Outbreaks in the European Union in 2005. 
195 Economic Research Service (2006). Foodborne illness cost calculator: salmonella. Economic Research 
Service, US Department of Agriculture, Washington, D.C. 
http://www.ers.usda.gov/Data/FoodborneIllness/salm_Intro.asp.  
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Diagnostics for GMO traceability196  
 
Modern biotechnology provides the only means for the identification and quantification of 
GMOs in the food chain, through the availability of specific DNA-based and antibody-based 
assays. The availability of these diagnostics has several implications for the EU: firstly, it 
ensures freedom of choice for EU consumers and users of GM and non-GM products; 
secondly, it enables the implementation of the EU regulations dealing with the approval, 
labelling and traceability of GMOs197; and thirdly, it provides the tool towards long-term 
monitoring of GMOs for the control of potential risks (e.g. related to the environment or 
human health).  
 
There are about 50 diagnostic laboratories in the EU which deal with GMO analyses, and 
most of them are located in France, Germany and Austria. Information was largely gathered 
based on interviews with company representatives. In Germany, 15% to 20% of all diagnostic 
laboratories carry out GMO testing. The largest share of the products is DNA-based due to 
their higher accuracy for quantitative analyses, which are particularly used for checking 
against the obligatory thresholds. GMO tests are usually an additional service offered by 
diagnostics providers, and the share of revenues specific to GMO testing ranged between 9% 
and 13% of the total annual revenues of the interviewed companies. Moreover, the 
interviewees suggested that GMO test-kit production and laboratory analysis is non-profitable 
per se, as it is a small part of their overall activities and is accompanied by higher costs 
compared to other tests. These costs result particularly from the need to update the test kits 
(due to new GMO varieties) and to adjust the test kits to adhere to certain standards. 
According to the interviewees, on the one hand, it is difficult for private suppliers of GMO 
test kits to compete with national laboratories, while on the other hand, firms which produce 
test kits for the identification of GMOs are not yet exposed to much competition. 
 
The impact on employment seems to have been relatively small, as the companies producing 
test kits and providing the analyses were already well structured for the provision of similar 
services, and as the GMO related activities account for only a small part of their overall 
activities.  
 
Nevertheless, the tests are necessary for the food and feed industries concerned: results of a 
survey conducted in Germany revealed that the majority of the oil mills (75%) carry out 
analytical tests for the identification of GMOs, compared to 28% of companies from the dairy 
industry, 37% for the bakery industry, 44% from the confectionary industry and 43% from the 
feed industry. The relative proportions are highly correlated to the existence of raw materials 
or products for which GMOs are used. Overall, only a limited number of the German food 
and feed industry companies carry out analytical GMO tests internally, 94 - 100% of the 
respondents indicated that they assign external diagnostic laboratories for this task.  
 
                                                 
196 Non-referenced information is based on expert opinion and data from (ETEPS (2006). Bio4EU Task 2 Case 
studies report – Primary Production and Agro-food Applications). 
197 For example: Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 
2003 on genetically modified food and feed, OJ L 268, 18.10.2003, p. 1–23. http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:268:0001:0023:EN:PDF; Regulation (EC) No 
1830/2003 (22 Sept. 2003) of the European Parliament and of the Council concerning the traceability and 
labelling of genetically modified organisms and the traceability of food and feed products produced from 
genetically modified organisms and amending Directive 2001/18/EC, OJ L 268, 18.10.2003, p. 24-8. http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:268:0024:0028:EN:PDF.  
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As in all traceability programmes, ensuring GMO traceability comes at a cost, which  is 
mainly borne by the food industry: approximately 40% of the German food and feed 
producers reported additional costs due to GMO analyses; nevertheless, current indications 
show that these costs are small in relation to the total revenues of the companies. 
 
The market developments related to GMO detection in the coming five years will be mainly 
dependent on the commercialisation of new GM varieties in the EU and on the regulatory 
framework in the EU. This is likely to have an impact on costs and revenues as well as on the 
number and qualification of the employees. However, as the demand for test kits for the 
identification of GMOs will presumably increase, the higher costs may be overcompensated 
by the growth in revenues thus leading to decreasing costs per unit due to economies of scale. 
In addition, the interviewed companies expected that they will create a limited number of new 
jobs in the future, in particular for highly qualified staff, due to an increase in the production 
of test kits. 
 
 
2.3.5.3 Food and feed additives, and veterinary products 
 
Modern biotechnology is used in a number of processes for the production of various inputs to 
primary production and the food chain, such as animal and plant health related products (e.g. 
vaccines, therapeutics, pesticides), as well as food and feed additives and fertilisers. These 
products are provided by companies falling into several manufacturing subsectors (mainly 
under NACE DG 24), but statistics are not available at a level of disaggregation that would 
allow a complete analysis. 
 
Within these input sectors, modern biotechnology has been mainly applied in the production 
of livestock pharmaceuticals, particularly vaccines, and in the industrial production process of 
some therapeutics (such as antibiotics), and of food and feed additives, particularly food/feed 
enzymes (e.g. phytases, amylases), amino acids (e.g. lysine, threonine, tryptophane) and 
vitamins (e.g. riboflavin). All these products are produced by the manufacturing sector (where 
the direct contributions to the economy will be reflected), and are used by the primary 
production and/or the food and feed processing sectors (reflecting the indirect contributions). 
Plant protection products and fertilisers are not included in this analysis as they do not involve 
modern biotechnology in their production process to a significant extent198. 
 
Modern biotechnology-based products can be categorised according to product groups in 
chemicals (including enzymes) and vaccines. Vaccines will be treated separately in the 
section on animal health products, as they form a rather different product category.  Modern 
biotechnology-based chemicals, however, while comprising diverse products, share some 
common features. These products are relevant in their use as food and feed additives 
(including therapeutics such as antibiotics), and are produced mainly through fermentation 
and/or through enzymatic production processes. According to a market study199, the major 
                                                 
198 Biofertilisers and biopesticides are still emerging applications, and may, in some cases, involve biotechnology 
steps. 
199 Leuchtenberger, W., Huthmacher K. and Drauz, K. (2005). Biotechnological production of amino acids and 
derivatives: current status and prospects. Applied Microbiology and Biotechnology, 69:1-8. 
http://dx.doi.org/10.1007/s00253-005-0155-y. And Maertz, U. (2005). World markets for fermentation 
ingredients. 
http://www.bccresearch.com/RepTemplate.cfm?ReportID=221&cat=fod&RepDet=HLT&target=repdetail.cfm 
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product groups are enzymes, amino acids and derivatives, crude antibiotics, organic acids, 
vitamins and other products, such as xanthan. The global market for fermentation products 
(excluding ethanol) was estimated to be approximately EUR 11 billion in 2004, accounting 
for EUR 3.9 billion of crude antibiotics, EUR 2.7 billion of amino acids, EUR 1.8 billion of 
organic acids, EUR 1.5 billion of enzymes, EUR 800 million of vitamins, and EUR 300 
million of xanthan.  
 
The global market of amino acids has been estimated to be EUR 3.5 billion200, which leaves 
EUR 800 million derived mainly through enzymatic catalysis (also modern biotechnology-
based) and to a minor extent through chemical synthesis. It has been estimated that food and 
feed amino acids account for about 56% and 32% of the global amino acid market, 
respectively, which corresponds to approximately EUR 3.1 billion, nearly all produced 
through modern biotechnology. Assuming an EU share in production of 20%201 provides an 
estimated turnover of EUR 620 million (of which EUR 400 million are for feed additives and 
EUR 220 million are for food additives).  
 
Regarding vitamins, the 2002 global market had been estimated to be EUR 1.7 billion202, all 
of which can be allocated to food and feed use203, the latter having a larger share. The share of 
modern biotechnology-based products (the turnover estimated above to be about EUR 800 
million) accounts for approximately 50% of the total. As EU companies reportedly have an 
important share in global vitamin production (50%204), the modern biotechnology-based, EU-
related turnover is estimated to be EUR 400 million. 
 
As far as biotechnology-based crude antibiotics are concerned, the agro-food relevance is 
relatively low: while the exact share of the veterinary or EU-related turnover is not known, a 
best estimate can be taken as 1.8%205 and 30%, respectively, which accounts for 
approximately EUR 20 million. Organic acids (the main product being citric acid) are used in 
a variety of applications, with food and feed uses having a major share. For illustrative 
purposes, assuming that food and feed accounts for 50% of the total consumption and an EU 
share similar to that for the amino acid market (20%) yields an estimated turnover of EUR 
180 million. Xanthan represents the smallest group of fermentation products globally, of 
which approximately 70% is used in food applications206. Using as a best estimate an EU 
share of 20%207, yields an estimated turnover of EUR 40 million.  
                                                 
200 Leuchtenberger, W., Huthmacher K. and Drauz, K. (2005). Biotechnological production of amino acids and 
derivatives: current status and prospects. Applied Microbiology and Biotechnology, 69:1-8. 
http://dx.doi.org/10.1007/s00253-005-0155-y. 
201 IPTS conservative estimate based on data provided by ETEPS (2006). Bio4EU Task 2 Case studies report – 
Industrial Biotechnology Applications: Lysine (which represents approximately 26% of the feed additives 
market): EU companies produce 40% of total production, while 14% of the total production takes place in the 
EU. 
202 BCC Research (2003). The global market for vitamins in food, feed, pharma and cosmetics.  
203 A minor share also targets the pharmaceutical and cosmetics markets. 
204 From Prepared Foods (2003) Taking vitamins - in the know, accessed online at 
http://findarticles.com/p/articles/ mi_m3289/is_9_172/ai_108051736 (Original Source. BCC Inc): DSM/Roche 
and BASF/Takeda hold 27% and 21% of the global vitamin business, respectively. 
2051.8% is the estimated share of farm animal-related pharmaceuticals over the total (3% of veterinary 
pharmaceuticals of which 60% is farm animal-related; see ETEPS (2006). Bio4EU Task 2 Main report) 
206 J.L. Flores Candia and W.D. (1999). Xanthan Gum in Encyclopedia of Bioprocess Technology: Fermentation, 
Biocatalysis, and Bioseparation. John Wiley & Sons, Inc. Accessed online at: Deckwer 
http://www.mrw.interscience.wiley.com/ebt/articles/ebt222/abstract-fs.html. 
207 It is reported that the larger producer is the US company CP Kelco which is part of Huber, while the Chinese 
are also very strong. The main EU player is Danisco. 
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Enzyme production itself, presented in more detail in Section 2.4, has been estimated as 
having a global value of EUR 1.8 billion, the EU having a share of 75% (turnover of EUR 1.3 
billion) of which up to 48% is food and feed related (EUR 650 million208). 
 
In total, the modern biotechnology-based food and feed additive production (direct 
contribution to the economy) is calculated from the above estimates to be EUR 1.91 billion. In 
the following sections, the various product groups will be described in more detail from a 
sectorial viewpoint. 
 
 
Feed additives 
 
Feed additives are estimated to be EUR 4.8 billion globally209 including amino acids, 
vitamins, minerals, antibiotics, enzymes and acidifiers. While the exact shares for the EU are 
not available, a conservative estimate of 20%210 has been used, which corresponds to EUR 
960 million. As the majority of feed additives (mainly amino acids and enzymes, but also 
organic acids, antibiotics, etc.) are produced through modern biotechnology a large share of 
the figure estimated above will correspond to the direct contribution of modern biotechnology 
for feed additives. Assuming, as a best estimate, that 90% of the feed additives are modern 
biotechnology derived, results in a turnover of EUR 864 million211, which is approximately 
50% of the turnover estimated for both food and feed additives of the respective categories212. 
 
Feed additives have been gaining importance globally as animal production is gaining 
importance to consumers. The European Feed Manufacturers Federation (FEFAC) estimates 
that approximately 3% of feed material consumption is related to feed additives (out of the 
approximately 143 million tonnes European feed production in 2005)213. It has been estimated 
that 65% of poultry and 10% of swine feed already contains enzymes such as carbohydrases 
or phytases214, the feed enzyme market amounting to approximately EUR 120 million. 
Moreover, the EU and the US are currently the global leaders of compound feed production, 
at 143 millions tonnes (24% share) and 150 millions tonnes (25% share), respectively, while 
                                                 
208 From DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische 
Technik und Biotechnologie, Frankfurt a.M., p.33; 46% of enzymes production was allocated to food, and 2% to 
silage and feed; In Section 2.4, a rounded-up range of 30-45% is provided corresponding to food-related 
enzymes (information from two different sources). 
209 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications. 
210 IPTS conservative estimate based on shares from three different case studies provided by ETEPS (2006). 
Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications.: i) Lysine (which represents 
approximately 26% of the feed additives market): EU companies produce 40% of total production, while 14% of 
the total production takes place in the EU; ii) Riboflavin: EU companies hold 30% of total production; iii) 
Cephalosporin intermediates: about 35% of 7-ACA and 50% of 7-ADCA are produced in the EU.  
211 IPTS estimate based on ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology 
Applications. And DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für 
Chemische Technik und Biotechnologie, Frankfurt a.M.: Amino acids represent about 33% of all feed additives, 
while expert opinion indicates that nearly all amino acids used as feed additives are produced via modern 
biotechnology. Moreover, all enzymes used as feed additives may be considered modern biotechnology, while a 
number of important vitamins (e.g. vitamins C, B12, B2), antibiotics (e.g. cephalosporin intermediates) and 
organic acids (e.g. citric acid) are mainly modern biotechnology-based.  
212 As feed-related amino acids account for EUR 400 million, it is implied that feed has a 36% share of the 
remaining product categories.  
213 FEFAC (2006) From Farm to Table: key figures 2005. http://www.fefac.org/file.pdf?FileID=3669. 
214 J.B. van Beilen and Li Z. (2002). Current Opinion in Biotechnology 13: 338-344. 
http://dx.doi.org/10.1016/S0958-1669(02)00334-8.  
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the annual turnover of the EU compound feed industry was estimated to be approximately 
EUR 36 billion in 2004.  
 
The role of feed additives is mainly to complement the nutritional profile215 of feeds in several 
ways. Feed enzymes mainly function as digestibility enhancers, whereas vitamins, amino 
acids and minerals mainly directly complement the lacking nutrients. Modern biotechnology 
has been applied in the production of a large number of feed additives, but mainly in feed 
enzymes (e.g. phytases, carbohydrases, enhancing the digestibility of phosphorus and 
carbohydrates), amino acids (e.g. lysine) and vitamins (e.g. riboflavin). The production of 
enzymes in general is described in greater detail in Section 2.4. The use of enzymes in feeds 
(at an estimated value of EUR 30 million216) may induce a variety of changes, mainly related 
to feed formulation and ingredient composition. Feed formulation has been traditionally 
driven by least-cost objectives, but now it increasingly accommodates environmental and 
food quality objectives. Therefore the indirect economic impacts of the use of modern 
biotechnology derived enzymes relate to the induced changes in ingredient selection. For 
example, the use of phytase may accommodate more plant ingredients (or more types of plant 
ingredients used) in the feeds for monogastric animals (such as pigs, poultry and some fish) 
and less use of inorganic mineral supplements. The indirect impacts may take place at the 
level of the feed ingredient producers (which may impact back to the raw material provider, 
farmer, etc.), the feed manufacturer, all the way to the animal producer.  
 
Amino acids and vitamins are supplements that provide the essential nutrients lacking in the 
macro-ingredients used in the feeds. As with enzymes, the direct impacts relate to the 
turnover realised at the industrial production step (a more detailed analysis can be found in 
Section 2.4). The indirect impacts are similar to those of enzymes, as modern biotechnology 
has enabled the cost-effective use of such additives. Amino acids, almost all of which are 
produced using modern biotechnology, represent about 36% of the feed additives market. An 
illustrative example is the case of lysine: modern biotechnology enabled the cost-effective 
production of lysine which, in turn, facilitated its use in a large share of prepared animal 
feeds, mainly for monogastric animals (particularly pigs, but also poultry and farmed 
carnivorous fish). This change brings about several effects, such as the partial substitution of 
soya-derived ingredients by wheat- and corn-derived ingredients (which have a lower lysine 
content compared to soya) in pig feeds. This substitution may also have impacts on the EU 
crop-growing sector and trade dependence, as among the various protein-rich feed materials, 
soya bean meal has one of the lowest levels of self-sufficiency in the EU217.  
 
Another example is the biotechnological production of riboflavin, with direct impacts found 
in the turnover realised from its production by the manufacturing industry, and indirect 
impacts related to its various uses, such as in prepared animal feeds, in food supplements, and 
as a colouring agent. 70% of the global production of riboflavin is used for animal feed. The 
production of riboflavin using modern biotechnology seems to have resulted in cost 
                                                 
215 Another role is to increase the physical performance of the feed, but as this is not relevant for biotechnology-
based feed additives, it is not developed any further here. 
216 From DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische 
Technik und Biotechnologie, Frankfurt a.M., p.33; 46% of enzymes production was allocated to food, and 2% to 
silage and feed; In Section 2.4, a rounded-up range of 30-45% is provided corresponding to food-related 
enzymes (information from two different sources). 
217 FEFAC (2006). Feed and Food – Statistical Yearbook 2005. http://www.fefac.org/file.pdf?FileID=5071. 
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reductions of 40 - 50% compared to the conventional, chemical production process218 thus 
potentially facilitating its use as a feed additive.  
 
In general, modern biotechnology enables the production of feed additives at lower costs, 
making their use by the feed industry (and the livestock producers) more attractive. The most 
simplistic approach to providing some estimate to the indirect contribution of feed additives 
would include the estimate of the turnover share of prepared farm animal feeds that contain 
such products (approximately EUR 38 billion for 2004219). Similarly, the share of livestock 
produced from feeds containing these products could also be included. However, as explained 
earlier, these kinds of estimates include many shortcomings. 
 
 
Food additives 
 
Food processing using enzymes is described in detail in Section 2.4. The direct impacts of 
modern biotechnology concern the turnover realised by the enzyme producers relevant to food 
applications (approximately EUR 390 million) as well as the turnover specific to the 
biotechnology-based production of chemicals (e.g. related to some vitamins and amino acids), 
whereas the indirect impacts refer to the shares of food and beverage manufacturing turnover 
using enzymes (estimated to about EUR 304 billion; Section 2.4) and other food additives. 
While there are no comprehensive estimates on the total and modern biotechnology-based 
turnover related to chemicals used as food additives (of the chemical groups considered 
herein), a conservative estimate can be made as the difference between the total figure of 
EUR 1.9 billion calculated for food and feed additives together, the figure estimated for feed 
additives of EUR 860 million, and the figure estimated for food enzymes,  which results in a 
turnover of approximately EUR 455 - 650 million. The indirect implications of the use of 
these products are related to their downstream use in the various food and beverage products 
and the food chain in general. 
 
 
Animal health products 
 
The emphasis in the livestock sector is put more and more on prevention rather than 
treatment, especially on environmental (microbial resistance) and human health grounds. 
Therefore, vaccines (along with diagnostics) are gaining importance in the farm animal health 
sector. Modern biotechnology has been applied to a greater extent in vaccine production in the 
animal health sector when compared with the human health sector. In the therapeutics area, 
we find mainly anti-parasitic, anti-inflammatory and analgesic products, the latter two being 
mainly used in companion animals. Modern biotechnology approaches in the anti-parasitic 
field are focusing on the development of vaccines for parasite species rather than on chemical 
treatments. In general, there is no major demand for products focusing on treatment, and 
therefore little developmental activity.  
 
The global market for animal health products was estimated to be approximately EUR 13 
billion220 in 2004. Five out of the ten largest veterinary pharmaceutical companies (in terms of 
                                                 
218 OECD (2001). The application of biotechnology to industrial biotechnology. OECD, Paris. And EuropaBio 
(2003). White biotechnology: gateway to a more sustainable future. EuropaBio, Brussels. http://www.europa-
bio.be/documents/100403/press_release_en-1.pdf. 
219 Eurostat data, accessed online at http://epp.eurostat.ec.europa.eu. 
220 ETEPS (2006). Bio4EU Task 2 Main report. 
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turnover) are based in the EU220, and therefore a reasonable estimate of the EU-share of the 
global market can be given as EUR 6.5 billion (including diagnostics, estimated above as 
being approximately EUR 700 million), which is similar to the veterinary product 
consumption by EU livestock producers of about EUR 5.2 billion221. The veterinary vaccines 
sector accounted for 20% of global animal health product revenues in 2004 with revenues of 
EUR 2.52 billion, and is expected to grow in excess of EUR 3.1 billion by 2009. In the 
absence of specific information, an estimate of the biotechnology-related turnover for 
vaccines can be given as follows: assuming that 50% of the global vaccine turnover is EU-
derived (this share is based on the number of the largest veterinary pharmaceutical companies 
and their turnover) and considering that 24 out of the 33 vaccines approved by EMEA (73%) 
are based on modern biotechnology222, the direct contribution of modern biotechnology-based 
vaccines in the EU is estimated to be approximately EUR 920 million (0.08% of the agro-
food sector turnover). 
 
The vaccine market for farm animals is highly dependent on official vaccination programmes 
and the respective disease status in the EU Member States. Additionally, as vaccines are used 
for prevention, and as their further use is prohibited in the EU when eradication is achieved 
(for disease monitoring purposes), it is reasonable to assume that the largest share of the 
turnover is provided by newly developed (and therefore mainly modern biotechnology-based) 
vaccines. The indirect impacts of vaccines are to be found in the turnover realised by animal 
producers, as their use ensures the avoidance of economic losses due to disease outbreaks, as 
well as the assurance of animal trade between different Member States. 
 
An analysis of the modern biotechnology vaccine for Aujeszky’s disease (pseudorabies), the 
first example of the so-called DIVA (Differentiating Infected from Vaccinated Animals) or 
marker vaccines provides some insights into the indirect impacts that may be expected223. 
Marker vaccines in the eradication process, although not essential, make it possible to 
differentiate between vaccinated and infected animals and this greatly shortens the time 
needed to complete the eradication. Furthermore, because of the DIVA characteristic of the 
modern biotechnology-based vaccine, it is the only authorised product in the EU for 
Aujeszky’s disease. In addition, all authorised products are sourced from European 
companies, except for products from Fort Dodge (US), which is, however, partly located in 
the Netherlands (serving the EU market). Based on the information gathered, there are 
approximately six companies offering several products each, of which only one has received 
EU-wide authorisation. A large majority of the companies’ revenues come from the EU, 
although at least one company reported some activity in South East Asia.  
 
As there are no alternative non-modern biotechnology products available, a comparison of the 
significance of the vaccine can only be made to alternative eradication methodologies or to 
non-eradication. Compared to non-eradication, the benefits are clear as the disease was 
responsible for substantial economic losses to the pig sector. Before the development of the 
vaccine, animal culling was the only approach for containment. Information on the 
effectiveness of eradication programmes was available for seven countries, namely Belgium, 
                                                 
221 EUROSTAT, European Agricultural Accounts, Agricultural Information System - Key indicators 
(2003)(accessed online at 
http://epp.eurostat.ec.europa.eu/portal/page?_pageid=0,1136206,0_45570467&_dad=portal&_schema=PORTAL
). 
222 They use recombinant strains or antigens produced using recombinant technology; six are sub-unit vaccines 
as described above, while two others use other biotechnology-based approaches; from ETEPS (2006). Bio4EU 
Task 2 Main report. 
223 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
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the Netherlands, the Czech Republic, Denmark, France, the UK, and Germany. Figures show 
that in the long-term it has proved to be more cost-effective to attempt a full programme of 
eradication rather than to treat the disease or allow it to remain endemic in the pig population. 
Economic benefit is much greater when taking into account the full savings made through 
eradicating the disease, especially in light of the trade and livestock movement restrictions 
introduced by Decision 93/24/EEC224. Moreover, it may be argued that the EU followed a 
more successful path compared to the US, by taking a centralised decision and by pursuing 
and using specifically the Glycoprotein E (gE)-negative marker vaccine. Currently, from 13 
EU Member States from which information was available, ten are disease-free with or without 
continuing vaccination and three are currently vaccinating the endemically affected pig 
population. 
 
In the therapeutics area, the adoption of modern biotechnology is limited to its use in specific 
steps of the industrial production process, such as in the production of the antimicrobial 
cephalosporins (covered in more detail in Section 2.4.2.4). While the use of antimicrobials 
will have an impact on the turnover realised by livestock producers, specific information is 
not available. Furthermore, and as mentioned earlier, antimicrobials are used less and less in 
the farm animal sector. 
 
 
2.3.5.4 Summary 
 
A summary of the economic contribution of modern biotechnology to the agro-food sector is 
provided in Table 20. The total direct impacts from the application of modern biotechnology 
to the agro-food sector have been estimated in a range of approximately EUR 3 - 5.6 billion. 
This represents 13 - 23% of the total turnover realised by the input sectors using modern 
biotechnology, 0.26 - 0.47% of the agro-food sector, and 0.01 - 0.02% of the total EU 
GVA225. It is interesting to note that these estimates fall within the range of the aggregated 
estimate (0.3% and 0.01%, respectively; see Section 2.3.4). Overall, the largest share of the 
direct contribution relates to modern biotechnology applied in the agro-food related 
manufacturing sectors (e.g. food enzymes, chemicals and veterinary products) followed by the 
breeding sectors. The relatively large variation between the low and high estimates is mainly 
due to the large uncertainty of the use of MAS in plants (see Figure 18 and Figure 19). 
 
The indirect contributions to the economy have been estimated to a value of about EUR 380-
450 billion, which accounts to 32 - 38% of the agro-food sector, or 1.3 - 1.55% of the total EU 
GVA225. The indirect implications are therefore approximately two orders of magnitude larger 
than the direct ones, indicating the important diffusion of modern biotechnology-derived 
products to the user sectors. The largest share of the indirect impacts relates to the use of 
modern biotechnology by the food processing sector, followed by the livestock sector and the 
plant sector. The range in the estimate is also mainly due to the uncertainty in the use of MAS 
in the various sectors (see Figure 20 and Figure 21). 
 
                                                 
224 Commission of the European Communities  93/24/EEC: Commission Decision of 11 December 1992 
concerning additional guarantees relating to Aujeszky's disease for pigs destined to Member States or regions 
free of the disease OJ L 016 , 25/01/1993 p. 0018 – 0021. 
225The turnover values were multiplied by 0.3 to estimate the GVA (0.3 is the average GVA:turnover ratio of the 
primary production and agro-food industry), see Annex 3 – Agro-Food ).  
The Bio4EU Analysis report 93 
Table 20: Summary of the economic contribution of modern biotechnology in the agro-food sector 
 
EU turnover, EUR 
million (input sectors) 
EU turnover, EUR million 
(downstream users) Biotechnology application 
Biotechnology Total 
Share 
(in %)1 
Biotechnology Total 
Share 
(in %)1 
Maize 133-405 405 33-100 2429-7360 7360 33-100 Molecular 
markers All crops 2013 6100 33 55 583 168 432 33 
Micropropagation All plants 
flowers 
39-313 6400 0.6-5 50-389 8268 0.6-5 
Maize 12 405 3 85 7360 1.2 
Pl
an
ts
 
Genetic 
modification All crops 12 6100 0.2 85 168 432 0.05 
Molecular 
markers 
All 
livestock 
207-560 2000 10-30 12 737-35 664 127 374 10-30 
Cattle 190 600 32 55 170 73 560 75 
Li
ve
st
oc
k 
Embryo transfer 
All 
livestock 
190 2000 10 55 170 127 374 43 
Salmon 10 34 30 133 443 30 
Trout 11 38 30 149 498 30 
Oysters 2 21 10 28 277 10 
Molecular 
markers 
All fish 23 210 11 310 2769 11 
Trout 18 38 50 249 498 50 
Oysters 4 21 20 55 277 20 
Ploidy/sex 
manipulation 
All fish 23 210 11 304 2769 11 
Fi
sh
 
Both technologies All fish 32-462 210 15 437-614 2769 15 
Vaccines 920 1260 73 - - - Veterinary 
products All 
products 
920 5200 18 - - - 
Diagnostics All 300 7003 43 1500 35003 43 
A
gr
o-
fo
od
 c
ha
in
 
Other inputs 
(chemicals and 
biologicals) 
Food and 
feed 
additives 
12504 23005 75 304 0306 797 069 38 
  Total   3083-5604 22910 13-23 376 439-453 035 1 193 763
7 32-38 
1 Rounded figures 
2 The low estimate assumes that both technologies are applied simultaneously and therefore only the highest 
value per technology per species is counted in order to avoid double counting; the high is the sum of the two 
technologies assuming no overlap. 
3 The totals are not comprehensive, so the calculated share of the modern biotechnology-based diagnostics may 
be overestimated. 
4 Feed additives estimated at EUR 860 million and enzymes related to food processing estimated at EUR 390 
million. 
5 The totals are not comprehensive as they only include specific product categories (food and feed related amino 
acids, vitamins, organic acids, antibiotics and xanthan, see Section 2.3.5.3), so the calculated share of the modern 
biotechnology-based food and feed additives may be overestimated. 
6 Only refers to the use of food enzymes in food manufacturing. 
7 The total refers to the total turnover of the agro-food sector (see Table 12). 
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Figure 18: Shares of the different biotechnology applications to the direct contribution to the economy: 
Low estimate 
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Figure 19: Shares of the different biotechnology applications to the direct contribution to the economy: 
High estimate 
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Figure 20: Shares of the different biotechnology applications to the indirect contribution to the economy: 
Low estimate 
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Figure 21: Shares of the different biotechnology applications to the indirect contribution to the economy: 
High estimate 
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2.4 Industrial biotechnology 
 
Of growing importance within the broad area of biotechnology are industrial biotechnology 
applications. Apart from the actual producers of biotechnological goods and services (mainly 
enzyme producers), this includes a broad spectrum of applications from bioenergy (including 
biofuels) to biotechnological industrial processes and decontaminating environmental media. 
The full range of modern biotechnology is applied in industrial biotechnology, mainly for the 
identification, adaptation and large scale production of enzymes as catalysts and their 
adaptation to extreme production process conditions, which are then applied in the different 
application areas. 
 
2.4.1 The contribution of the manufacturing sector to the EU economy 
 
Modern biotechnology in industrial biotechnology applications is mainly used in the 
manufacturing sector. The manufacturing sector, although losing importance over the past 
decades in relation to the different services sectors, plays an important role in achieving the 
objectives of the Lisbon Strategy. Manufacturing is the second biggest employer and 
contributor to gross value-added (GVA) in the EU (after category NACE K ‘Real estate, 
renting, business’).  
 
Overall GVA in the EU was EUR 9484 billion in 2004, generated by about 200 million 
employees226. In the same year, the manufacturing sector contributed a share of 17.4% or 
EUR 1528 billion to the overall GVA (see Figure 22), generated by 33 million employees, 
16.5% of all employees.227. 
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Figure 22: Share of manufacturing to the EU’s gross value-added 2004 
Source: Data from Eurostat228 
                                                 
226 Eurostat (2006). European business - facts and figures, p.17-18. 
http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-BW-05-001/EN/KS-BW-05-001-EN.PDF. 
227 Eurostat (2005). Europe in figures: Eurostat yearbook 2005. European Commission, Eurostat, Luxembourg, 
p. 234. http://bookshop.europa.eu/uri?target=EUB:NOTICE:KSCD05001:EN. 
228 Eurostat database. http://epp.eurostat.ec.europa.eu/. 
17,4% 
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The manufacturing sector in itself is heterogeneous. It consists of 14 subsectors, which are 
classified in the European NACE categories NACE DA-DN. In 2002229, the largest 
manufacturing sectors regarding their contribution to the EU’s GVA were metal, food, 
electrical/optical equipment, machinery, transport equipment and chemicals, all with a 
contribution of roughly 2% to the overall GVA of the EU, respectively 10 - 12% to EU 
manufacturing (see Table 21).  
 
Table 21: Contribution of manufacturing sectors to the EU's GVA (2002) 
Source: Data from Eurostat 230 
 
 Share of the 
EU’s GVA (in 
%) 
Share of 
manufacturing
GVA (in %) 
EU GVA (All economic activity) 100.00  
NACE D Manufacturing (total) 17.41 100.00 
DA 15, 16 Manufacture of food products; beverages and tobacco 
products 
2.19 12.56 
DB 17, 18 Manufacture of textiles and textile products, and 
apparel, dressing and dying of fur 
0.77 4.44 
DC 19 Manufacture of leather and leather products 0.18 1.01 
DD 20 Manufacture of wood and wood products 0.41 2.35 
DE 21, 22 Manufacture of pulp, paper and paper products; 
publishing and printing 
1.70 9.77 
DF 23 Manufacture of coke, refined petroleum products and 
nuclear fuel 
0.28 1.63 
DG 24 Manufacture of chemicals, chemical products and man-
made fibres 
1.95 11.21 
DH 25 Manufacture of rubber and plastic products 0.86 4.92 
DI 26 Manufacture of other non-metallic mineral products 0.83 4.76 
DJ 27, 28 Manufacture of basic metals and fabricated metal 
products 
2.35 13.50 
DK 29 Manufacture of machinery and equipment n.e.c. 1.96 11.24 
DL 30-33 Manufacture of electrical and optical equipment 2.09 11.99 
DM 34, 35 Manufacture of transport equipment 1.95 11.20 
DN 36, 37 Manufacturing not classified, including recycling 0.74 4.22 
n.e.c.: not elsewhere classified 
 
The manufacturing sector and its subsectors are not static. As mentioned above, the share of 
manufacturing to the EU’s GVA has been decreasing slightly over the last decades, whereas 
service related business is gaining importance. Also the internal structure of the sector is 
changing, the relative weight of textiles production, for example, has been decreasing for 
                                                 
229 2002 is taken as the reference year for the analysis, as it is the most recent year with rather complete data sets 
in Eurostat. The main conclusions are not affected when combining these data with more recent figures from 
IPTS research, as the relation between the sectors has been relatively stable over time. 
230 Eurostat database. http://epp.eurostat.ec.europa.eu/. 
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several years231. 
 
Biotechnology does not appear as a separate category amongst the NACE categories. 
However, industrial biotechnology as a horizontal enabling technology is applied in different 
manufacturing subsectors. Industrial biotechnology applications can be assigned to NACE 
categories as follows: 
 
Enzyme producers which provide the manufacturing sector with modern biotechnology 
products (direct impacts of modern biotechnology):  
• NACE DG 24: Manufacture of chemicals, chemical products and man-made fibres  
This sector includes the enzyme producers in the area of fine chemicals. Also chemical 
intermediate producers using biotechnological processes fall in this category. 
 
Biotechnology users, i.e. sectors which use modern biotechnology products (indirect impacts 
of modern biotechnology) by application area: 
• NACE DA 15: Manufacture of food products, beverages 
Modern biotechnology is used in practically the entire category 15. It represents an 
important and long established production factor. 
• NACE DB 17: Manufacture of textile and textile products  
In this category, enzymes are applied in the finishing of several different textiles (cotton, 
wool, silk), as well as in processes such as polishing, desizing, etc.  
• NACE DB 18: Manufacture of apparel; dressing and dyeing of fur  
This category includes the processing of leather clothes, which uses enzymes in several 
production steps (soaking, liming, bating, etc.). 
• NACE DC 19: Manufacture of leather and leather products  
This category includes all other non-clothing leather products (saddlery, luggage, 
footwear, etc.), which apply similar enzymatic treatment in production as in NACE  
DB 18. 
• NACE DE 21: Manufacture of pulp, paper and paper products  
Pulp and paper uses enzymatic processes at different stages of the value chain (raw 
material treatment, bleaching, de-inking, etc.). 
• NACE DF 23: Manufacture of coke, refined petroleum products and nuclear fuel  
This category includes the petrol fuel sector, which is the reference when describing the 
economic impact of biofuels. 
• NACE DG 24: Manufacture of chemicals, chemical products and man-made fibres  
This category not only contains the enzyme and chemical producers, but also some of the 
most important users of enzymes (detergents, polymers, pharmaceuticals, etc.). 
 
This list is not exhaustive. Enzymes are used in other industrial sectors as well, such as 
mining (bioleaching), but these applications are applied to such a limited extent that they are 
not relevant when analysing the economic impact of industrial biotechnology in the EU. 
 
The application of biotechnology in end-of-pipe technologies such as the treatment of 
contaminated air, soil, water and waste are not counted as manufacturing activities (except: 
recycling). Efforts are under way to collect information on environmental goods and services 
for statistical use, but currently the information is rather scattered and appears in different 
NACE categories: 
                                                 
231 According to the Eurostat database the contribution of textile production to manufacturing decreased by 35% 
between 1995 and 2005. http://epp.eurostat.ec.europa.eu/. 
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• NACE DN 37: Recycling  
This category includes the recycling of non-metal waste and scrap (DN 37.2) as relevant 
category for biotechnology. 
• NACE E 41: Collection, purification and distribution of water  
This category includes waste water treatment, a traditional application area for 
biotechnology. 
• NACE O 90: Sewage and refuse disposal, sanitation and similar activities  
This category includes the treatment of contaminated soil, e.g. by micro-organisms 
(bioremediation). 
 
An overview of the sectors of relevance for industrial biotechnology, including the respective 
GVA as well as their share to the EU’s GVA and to the manufacturing sector's GVA, is 
presented in Table 22. 
 
Table 22: Contribution to the EU’s GVA by the industrial biotechnology relevant sectors 
Source: Data from Eurostat232 
 
Year 2002 GVA 
(EUR 
million) 
Share of 
EU GVA 
(in %) 
Share of 
manufacturing
GVA (in %) 
EU GVA (all economic activity) 8 782 816 100.00  
NACE D Manufacturing (total) 1 528 982 17.41 100.00 
DA 
15 
Manufacture of food products; beverages  181 220 2.06 11.85 
DB  
17, 18 
Manufacture of textiles and textile products 67 894 0.77 4.44 
DC 
19 
Manufacture of leather and leather products 15 418 0.18 1.01 
DE  
21, 22 
Manufacture of pulp, paper and paper products; publishing 
and printing 
149 367 1.70 9.77 
DF 23 Manufacture of coke, refined petroleum products and nuclear 
fuel 
24 866 0.28 1.63 
DG 
24 
Manufacture of chemicals, chemical products and man-made 
fibres 
171 361 1.95 11.21 
DN  
36, 37 
Manufacturing not classified, including recycling 64 590 0.74 4.22 
E 41 Collection, purification and distribution of water 19 705 0.22 Not 
manufacturing 
O 90 Sewage and refuse disposal, sanitation and similar activities No data 
available 
No data 
available 
No data 
available 
Total 705 278 7.91 44.13 
 
Table 22 summarises those sectors in which modern biotechnology applications are used. For 
NACE O 90 no data were available from the Eurostat database. Altogether, the sectors in 
question contributed around EUR 700 billion or 8% to EUs GVA in 2002, or 44% to the 
manufacturing GVA (water treatment is excluded as it is not including manufacturing). 
                                                 
232 Eurostat database. http://epp.eurostat.ec.europa.eu/. 
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However, a further disaggregation of the NACE categories reveals a much smaller share: For 
example in E 41, biotechnology is applied only to water purification, not to collection and 
distribution. This means that the overall share of the sectors in which industrial 
biotechnology can be applied contributes most probably less than 5% to the EU’s overall 
GVA. This further disaggregation will be carried out in the following sections dealing with 
individual industrial sectors. 
 
 
2.4.2 The contribution of industrial biotechnology 
2.4.2.1 Enzyme production 
 
The substitution of chemical catalysts in production processes through biological systems 
achieving the same effect in a more efficient manner, i.e. biocatalysts, represents the classical 
application area for industrial biotechnology. Biocatalysts are, in some applications, entire 
organisms, which are referred to as whole cell conversions. In most cases enzymes are used 
as catalysts. The advantages as compared to chemical catalysts are the increased efficiency, 
improving often up to several orders of magnitude, and the reduced energy consumption, as 
enzymes often work at room temperature. Enzymes are derived from micro-organisms, in 
some cases from extremophiles – organisms which live under ‘extreme’ conditions. These 
enzymes can also be applied under high pressure and temperature conditions. Table 23 shows 
the main enzyme groups together with the reaction catalysed by them, as well as the applying 
industries. 
 
Table 23: Different groups of enzymes and reactions 
Source: Lievonen 1999233 
 
Type of enzyme Substrate Reaction catalysed by the enzyme Industry 
Proteases 
(proteolytic 
enzymes) 
Proteins 
Proteins are broken into shorter 
fragments, peptides and eventually 
into amino acids 
Detergents, food, 
pharmaceuticals, chemical 
synthesis 
Carbohydrases Carbohydrates Hydrolysis of carbohydrates into sugar 
Food, feed, pulp and paper, 
textiles, detergents 
Lipases Fats (triglycerides) 
Hydrolysis of fats into fatty acid 
and glycerol molecules 
Food, effluent treatment, 
detergents 
Pectinases Pectins Clarification of fruit juices Food, beverage 
Cellulases Cellulose Hydrolysis of cellulose Pulp, textile, feed, detergents 
Amylases Polysaccharides 
Hydrolysis of starch into smaller 
carbohydrate molecules such as 
glucose and maltose 
Food 
 
                                                 
233 Lievonen, J. (1999). Technological opportunities in biotechnology. Working Paper 43. VTT Group of 
Technological studies, Espoo, p. 24. http://www.vtt.fi/inf/julkaisut/muut/1990s/wp43.pdf.  
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Table 23 illustrates the multipurpose character of different enzyme classes, which makes it 
particularly difficult to assign capital and labour costs at the level of enzyme producer to 
enzyme induced costs and benefits down the value chain.  
 
Currently, 117 enzyme producers can be identified globally234. The majority of them are 
located in Europe, where 80 enzyme producing companies are active (including five 
companies in Switzerland). Almost 20% of them are located in France. The leading world 
market companies are located in Denmark. 21 companies can be found in the US, the rest is 
distributed in other regions (see Figure 23). 
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Figure 23: Global and European distribution of companies producing enzymes 
  
The most important companies in terms of production volumes are Novozymes (Denmark), 
Danisco/Genencor (Denmark), DSM (the Netherlands), AB Enzymes (Finland), Chr. Hansen 
(Denmark) and DIREVO Biotech AG (Germany). The world production volume for enzymes 
was estimated to be 53 000 tonnes in 2001, with Europe (including Switzerland) having a 
share of 79%. With an estimated 5% growth of the enzyme market, a production volume of 
around 65 000 tonnes for 2005 can be assumed235.  
 
The value of the global enzyme market is currently estimated to be around EUR 1.6 - 1.8 
billion236. Under the assumption of an EU share of 75% in enzyme production and an even 
distribution of enzyme price levels, it can be concluded that in 2005, EUR 1.2 billion worth 
of enzymes were sold. A comparison with the 2005 business report of Novozymes shows that 
their sales of technical, food and feed enzymes amount to EUR 770 million in 2004. That 
would result in a share of around EUR 540 million for the other EU producers, which falls 
into a plausible range. 
 
                                                 
234 ETEPS (2006). Bio4EU Task 2 Main report. 
235 DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik 
und Biotechnologie, Frankfurt a.M., p.29. http://biotech.dechema.de/img/biotech_/brennpunkt/041110.htm. 
And: Gavrilescu, M. and Y. Chisti (2005). Biotechnology Advances 23: 471-499. 
http://dx.doi.org/10.1016/j.biotechadv.2005.03.004. 
236 DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik 
und Biotechnologie, Frankfurt a.M., p.43. http://biotech.dechema.de/img/biotech_/brennpunkt/041110.htm. 
And: Novozymes (2005). The Novozymes report 2005. Novozymes, Bagsværd, p. 11. 
http://www.report2005.novozymes.com/Services/Download+report (conversion: 1 DKK = EUR 0.135).  
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What is the contribution of enzyme production to the EU economy? Enzymes can be 
classified as fine chemicals or specialities. For a first approximation, the production volume 
and sales are compared against the relevant subsector in the NACE classification, which is 
DG 24.66 – manufacture of other chemical products (see Table 24)237.  
 
Table 24: Enzyme production compared to NACE sector DG 24  
Source: Data from Eurostat238, IPTS calculations 
 
Year: 2002 GVA 
(EUR million) 
Share of 
EU GVA  
(in %) 
Share of 
manufacturing GVA 
(in %) 
EU GVA (All economic activity) 8 782 816 100.00  
NACE D Manufacturing (total) 1 528 982 17.41 100.00 
DG 24 Manufacture of chemicals and 
chemical products 170 555 1.94 10.64 
DG 24.6 Manufacture of other chemical 
products 14 857 0.17 0.93 
DG 24.66 Manufacture of other chemical 
products (2003) 7906 0.09 0.49 
Enzyme production* 741 0.0084 0.05 
*Estimate 
 
In 2003 the total sales of subsector DG 24.66 amounted to EUR 30.5 billion, with a value-
added of EUR 7906 million, corresponding to a relation in sales and value added of around 
25% (see Table 24). Compared to that, the biggest enzyme producer, Novozymes, declares 
their GVA to be 57% of the turnover239. This indicates that within the area of fine chemicals, 
which can be characterised as low volume/high value products, enzyme production is in the 
area of very high value products.  
 
If the turnover and value-added relation of 57% is applied to the total enzyme sales of EUR 
1.3 billion of all EU producers, a value-added of around EUR 741 million can be estimated 
(see Table 24). These figures reflect a small contribution of enzyme production to the EU 
economy (0.0084% to the EU’s overall GVA, or 0.05% to EU manufacturing). Based on 
these figures, enzyme producers can be characterised as profitable enterprises producing high 
technology intermediate products, which unfold their impact on the EU economy in the 
application areas down the supply chain, as will be seen in the analysis of industrial 
applications (see Section 2.4.2.2). 
 
 
Employment effects 
 
Although no precise data are available, employment effects in terms of jobs being created in 
the industry producing enzymes can be roughly calculated. An expert estimate for the fruit 
                                                 
237 NACE DG 24.66 includes amongst other items: protein substances, materials used in the finishing of textiles 
and leather, catalysts and other chemical products for industrial use. 
238 Eurostat data from on-line database. http://epp.eurostat.ec.europa.eu/. 
239 Novozymes (2005). The Novozymes report 2005. Novozymes, Bagsværd, p. 22. 
http://www.report2005.novozymes.com/Services/Download+report (turnover DKK 6024 million, GVA DKK 
3424 million). 
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juice enzyme business counts a total of 200 employees for this area from R&D down to 
marketing and sales operations240. As this segment represents half of ‘fruit utilisation and 
wine’, i.e. 3.5% of all enzyme production241, the extrapolation to all enzyme production 
results in approximately 6000 employees in EU enzyme production, assuming that the 
production of enzymes for different application areas requires a similar input of capital and 
labour. This corresponds to about 0.003% of EU employees, or 0.02% of the employees in 
EU manufacturing. Again Novozymes serves as the benchmark. It states its employees 
number at 4000, which corresponds to Novozymes' 66% of EU enzymes production. Half of 
these work outside the EU. In total, it can therefore be assumed that in EU enzyme 
production between 4000 and 6000 people are employed, representing 0.015 – 0.02% of the 
manufacturing employment (see Table 25). 
 
Table 25: Employment in enzyme production  
 
Year: 2002 Employment 
Share of EU 
employment  
(in %) 
Share of 
manufacturing 
employment 
(in %) 
EU employment (all economic activity) 200 000 000 100.00  
NACE D Manufacturing (total) 33 000 000 16.50 100.00 
DG 24 Manufacture of chemicals and 
chemical products (2001) 1 928 800 0.96 5.84 
DG 24.6 Manufacture of other chemical 
products 208 400 0.10 0.63 
DG 24.66 Manufacture of other chemical 
products (2003) 117 200 0.06 0.36 
Enzyme production* 4000 - 6000 0.002 - 0.003 0.015 - 0.02 
*Estimate 
 
As can be seen from Table 26, the relation between employment and value-added – the 
labour productivity – reveals that the chemical sector with a value of 2.0 is generating double 
the GVA per employment unit than the EU average. Subsectors DG 24.6 and DG 24.66 also 
show high values with 1.6 and 1.5, respectively. Enzyme production with 2.8 - 4.2 has a very 
high labour productivity, indicating a mature large scale industry with a high degree of 
automatisation.  
 
 
 
 
 
 
 
 
 
 
 
                                                 
240 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications 
241 DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik 
und Biotechnologie, Frankfurt a.M., p.30. http://biotech.dechema.de/img/biotech_/brennpunkt/041110.htm. 
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Table 26: Labour productivity in enzyme production 
 
Year: 2002 
Share of EU 
GVA  
(in %) 
Share of EU 
employment  
(in %) 
Labour 
productivity 
EU (All economic activity) 100.00 100.00 1.0 
NACE D Manufacturing (total) 17.41 16.50 1.1 
DG 24 Manufacture of chemicals and chemical 
products (2001) 
1.94 0.96 2.0 
DG 24.6 Manufacture of other chemical 
products 
0.17 0.10 1.6 
DG 24.66 Manufacture of other chemical 
products (2003) 
0.09 0.06 1.5 
Enzyme production* 0.0084 0.002 - 0.003 2.8 - 4.2 
*Estimate 
 
 
Outlook 
 
The future development of enzyme production depends on the future demand in user markets. 
These are mainly detergents and food/feed, whereas pulp and paper, textiles and leather 
processing only account for a smaller share in enzyme production. Some general factors will 
influence the market penetration of enzymes in all of these segments, such as the increasing 
need to reduce energy consumption and greenhouse gas emissions. These targets are 
supported by the energy efficiency of enzymatic processes in general. Besides that, the 
outlook differs when looking at the characteristics of the specific markets. 
 
 
2.4.2.2 Downstream users in industry: detergents, pulp and paper, textiles, and food 
 
In addition to the direct impacts of modern biotechnology generated by enzyme producers, 
indirect impacts are generated by the use of enzymes in the main application areas in industry 
– production of detergents, pulp and paper processing, textile finishing, and food processing. 
These sectors are analysed in the following sections.  
 
 
2.4.2.2.1 Detergents containing enzymes 
 
The world’s leading detergent enzyme producing companies are European, with Novozymes 
holding 50% of the world market and Danisco/Genencor 20%. Total sales in 2005 amounted 
to EUR 592 million (see Table 27), which corresponds to 33% of the overall enzyme market 
volume (EUR 1.8 billion in 2005242). As can be derived from Table 27, the market for 
detergent enzymes grew in the EU and Japan by approximately 4.5% per year, and in the US 
                                                 
242 DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik 
und Biotechnologie, Frankfurt a.M., p.43. http://biotech.dechema.de/img/biotech_/brennpunkt/041110.htm. 
And: Novozymes (2005). The Novozymes report 2005. Novozymes, Bagsværd, p. 11. 
http://www.report2005.novozymes.com/Services/Download+report (conversion: 1 DKK = EUR 0.135). 
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by 5.5% per year. Two thirds of all enzymes for detergents are sold in the EU, US and Japan. 
Global market growth therefore exceeds the growth of the EU economy, which was between 
1% and 2% in recent years. The main reasons for this are the growing demand to lower 
energy consumption, the increasing dishwasher market and the uptake of enzymatic 
processes in the production of liquid detergents. 
 
Table 27: Annual sales for detergent enzymes by region (EUR million) 
Source: ETEPS 2006243 
 
Region/year 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
EU 160 168 175 181 192 200 206 214 224 232 
US 110 117 123 130 138 147 153 162 171 180 
Japan 50 53 54 57 59 61 64 67 70 73 
World total  491 517 537 557 592 619 641 669 700 731 
 
The high share of enzymes for detergents out of the total enzymes market as well as the 
continuous market growth indicate a well established market. In fact, this segment is the most 
important one for most of the enzyme companies. For Novozymes, one third of sales stem 
from detergent enzymes, for Genencor this is 50%244. 
 
The development of the enzyme market for detergents depends on the market for cleaning 
products. The corresponding EU industry sector is NACE DG 24.51 – manufacture of soap, 
detergents, cleaning and polishing. The growth rate of this sector was 1.5% in 2001, 0% in 
2002 and 2% in 2003. The growth rate of detergent enzymes of 4.5% per year in the same 
period indicates a growing share of detergents containing enzymes. In terms of turnover, the 
share of detergents containing enzymes out of total detergents was between 30% and 50% in 
2005. 
 
Table 28: Contribution of detergents containing enzymes to the EU’s GVA 
 
Year: 2002 GVA (EUR million) 
Share of EU 
GVA  
(in %) 
Share of 
manufacturing  
(in %) 
EU GVA (all economic activity) 8 782 816 100.00  
NACE D Manufacturing (total) 1 528 982 17.41 100.00 
DG 24 Manufacture of chemicals and 
chemical products 170 555 1.94 11.15 
DG 24.51 Manufacture of soap, detergents, 
cleaning and polishing (2003) 7807 0.09 0.51 
Detergents containing enzymes * 2500 – 4000 0.03 – 0.05 0.16 – 0.25 
*Estimate 
 
                                                 
243 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications; original figures in 
US Dollar (conversion: 1 USD = EUR 0.7765; 22 November 2006). http://www.profound.com/research/. 
244 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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The overall sales of soap, detergents and maintenance products totalled around EUR 30 
billion in 2005, according to AISE245. According to Eurostat, the equivalent NACE sub-
category DG 24.51 (Manufacture of soap, detergents, cleaning and polishing) showed a 
turnover of EUR 32 billion in 2003, which confirms the order of magnitude. In order to 
calculate the contribution of detergents containing enzymes to the EU’s GVA, their share of 
turnover in all detergents (30 - 50%) is applied to the value-added of the category NACE DG 
24.51, which results in a contribution of EUR 2.5 - 4 billion, or 0.03% - 0.05% of the EU’s 
GVA (see Table 28). 
 
The use of enzymes in the production of detergents does not lower the production cost246. 
The incentive to use enzymes seems to be therefore in the savings on the end-user side 
through lower washing temperatures, which gives detergents containing enzymes a 
competitive advantage.  
 
 
Employment effects and labour productivity in detergent production 
 
Indirect employment effects through the application of modern biotechnology, i.e. enzymatic 
processes, in detergent production can be roughly estimated. According to Eurostat, in 
category NACE DG 24.51 the number of employees amounted to 120 000 in 2003. Applying 
the share in turnover of enzymatic detergents from all detergents (30 - 50%), it can be 
assumed that between 36 000 and 60 000 jobs can be assigned to detergent production 
processes which include the application of modern biotechnology (see Table 29). 
 
Table 29: Employment in detergents production using enzymes 
 
Year: 2002 Number of employees 
Share of EU 
employment  
(in %) 
Share of manufacturing 
employment  
(in %) 
EU employment (all economic 
activity) 200 000 000 100.00  
NACE D Manufacturing (total) 33 000 000 16.50 100.00 
DG 24 Manufacture of chemicals 
and chemical products (2001) 1 928 800 0.96 5.84 
DG 24.51 Manufacture of soap, 
detergents, cleaning and polishing 
(2003) 
119 100 0.06 0.36 
Detergents containing enzymes * 36 000 – 60 000 0.02 – 0.03 0.11 – 0.18 
*Estimate 
 
As can be seen from Table 29, the absolute contribution to overall EU employment as well as 
to the manufacturing sector is marginal with a share of 0.02 - 0.03% or 0.11 - 0.18%, 
respectively. The look at labour productivity reveals that the value-added of enzymatic 
detergent production is almost the same as in conventional production. With a relation of 1.5 
both are relatively efficient when compared to overall manufacturing labour productivity 1.1 
(see Table 30). 
                                                 
245 International Association for Soaps, Detergents and Maintenance Products. http://www.aise-net.org/.  
246 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications.  
The Bio4EU Analysis report 107
 
Table 30: Labour productivity in detergent production using enzymes 
 
Year: 2002 Share of EU 
GVA (in %) 
Share of EU 
employment (in %) 
Labour 
productivity 
EU (all economic activity) 100.00 100.00 1.0 
NACE D Manufacturing (total) 17.41 16.50 1.1 
DG 24 Manufacture of chemicals and 
chemical products (2001) 
1.94 0.96 2.0 
DG 24.51 Manufacture of soap, detergents, 
cleaning and polishing (2003) 
0.09 0.06 1.5 
Detergents containing enzymes * 0.03 – 0.05 0.02 – 0.03 1.5 – 1.6 
*Estimate 
 
 
Outlook 
 
The large enzyme market for detergents is expected to grow in the range of around 5% after a 
phase of stagnation247. The main reasons for this are the already mentioned need to lower the 
washing temperature as an energy saving measure, the growing sales of automatic 
dishwashers and the growing liquid detergent market. Due to technological progress it can 
also be expected that enzymes are developed for specialised detergent applications, such as 
the removal of specific stains, or the cleaning of utensils in hospitals or of delicate 
surfaces247.  
 
 
2.4.2.2.2 Enzymes in pulp and paper processing 
 
Enzymes are applied at different stages during the production of pulp and paper. The most 
important processes in terms of sold enzymes is the bleaching of chemical pulp (see Table 
31).  
 
Table 31: Share of enzymes for different pulp and paper process steps 
Source: ETEPS 2006247 
 
Process Enzyme applied Share in total pulp and paper enzyme sales (in %) 
Bleaching of chemical pulp Xylanase 67 
Stickies control Lipase 8 
Deinking, fibre modification Cellulase 8 
Others (e.g. slime control) Others (e.g. pectinase, polysaccharidase) 17 
 
The most important enzyme producers for the pulp and paper industry are AB Enzymes 
(Finland), Novozymes (Denmark), Iogen (Canada), Buckman (US) and Danisco/Genencor 
                                                 
247 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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(Denmark). Market shares amongst these companies are not known, as they have strengths in 
different types of enzymes, which compete on different markets. However, it seems that AB 
Enzymes and Iogen have the highest share in xylanase production. Xylanase for bleaching is 
used in around 20 mills in North America, Scandinavia, and Russia, and to a lesser extent in 
Asia. Overall it is estimated that 10% of all pulping is done with enzymatic processes248.  
 
Table 32: World market for enzymes used in pulp and paper processing (in EUR million) 
Source: ETEPS 2006248 
 
Enzyme 2002 2003 2004 2009 
Xylanase 29.6 30.5 31 38.3 
Lipase 3.7 3.8 3.9 4.5 
Cellulase 3.7 3.8 3.9 4.5 
Others* 7.5 7.7 7.8 8.9 
Total 44.5 45.8 46.6 56.2 
* Others include pectinases and other polysaccharidases 
 
Table 32 shows that the share between the different enzyme groups used in the processing of 
pulp and paper, as shown in Table 31, has been stable over the past years. Growth of the 
world market slowed down from 3% in 2003 to 1.7% in 2004. Nevertheless, it is expected 
that the growth rate will accelerate to a 3.5% yearly average until 2009248. When looking at 
the sales of enzymes for the pulp and paper industry in different global regions, a similar 
picture emerges. Sales in North America, Western Europe and the rest of the world show 
limited but constant growth rates (about 2.5% globally) (see Table 33). 
 
Table 33: Regional sales of enzymes for the pulp and paper industry (EUR million) 
Source: ETEPS 2006248 
 
Region 2002 2003 2004 2009 
North America 16 16.4 16.9 20.2 
Western Europe 14.7 15.2 15.5 18 
Rest of the world 14 14.2 14.5 18 
Total 44.7 45.8 46.9 56.2 
 
The GVA of overall pulp manufacturing, with and without enzymes can be estimated to be 
around EUR 2 billion in 2002 (see Table 34)249. On the basis of the 10% share estimated for 
enzymatic pulping, a rough approximation results in a GVA of EUR 200 million for this 
process in the EU. However, in reality the value will be higher, as the share of enzymatic 
pulping is higher in the EU, North America and Russia, than in other global regions, in 
particular in Asia248. Furthermore, xylanase in pulp bleaching represents two thirds of 
enzymatic processes in pulp and paper production, so that the overall GVA with some 
plausibility is in the range of EUR 300 million.  
                                                 
248 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
249 For DE 21.11 (manufacture of pulp) only the turnover of around EUR 6.8 billion (2003) is known. It was 
assumed that the relation between turnover and value-added is like in the next higher NACE category DE 21.1 
(29% for manufacture of pulp, paper and paperboard), and was calculated accordingly. 
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Table 34: Contribution of pulp produced with enzymes to the EU’s GVA 
 
Year: 2002 GVA (EUR million) 
Share of EU GVA  
(in %) 
Share of 
manufacturing 
GVA (in%) 
EU GVA (All economic activity) 8 782 816 100.00  
NACE D Manufacturing (total) 1 528 982 17.41 100.00 
DE 21 Manufacture of pulp, paper and 
paper products (2003) 46 160 0.53 3.02 
DE 21.1 Manufacture of pulp, paper and 
paperboard 22 173 0.25 1.45 
DE 21.11 Manufacture of pulp* 2000 0.02 0.13 
Manufacture of pulp using enzymes* 300 0.0034 0.02 
*Estimate 
 
On average, the production cost in pulp bleaching is lowered by 5 - 6% because of the use of 
xylanase250. As this cost-saving emerges on the capital input side and not on the labour input 
side, savings will probably be higher in global regions where labour is cheaper, i.e. in Russia 
and Asia (except Japan). 
 
 
Employment effects and labour productivity in pulp and paper processing 
 
When only looking at the most important application of modern biotechnology in pulp and 
paper processing, the bleaching of pulp with xylanases, it is reasonable to apply the 10% 
diffusion rate of this process to industry also to employment. No data are available on 
employment in pulp processing, but an approximation can be made based on Eurostat data. In 
the NACE category DE 21.1 (Manufacture of pulp, paper and paperboard), a turnover of 
EUR 75 billion was generated by 246 500 employees in 2002. Applying this relation to 
subcategory DE 21.11 (Manufacture of pulp), a turnover of EUR 6.8 billion (2003) results 
which was generated by roughly 22 000 employees.  
 
As 10% of pulp is manufactured with enzymatic bleaching, it can be assumed that the 
indirect impact on employment, i.e. jobs created though manufacturing processes which rely, 
at least partly, on modern biotechnology, can be assigned to around 2200 employees. Taking 
into account that, on the one hand, the share of enzymatic pulp bleaching in the EU is 
probably a bit higher than in other global regions, and on the other hand, that the application 
of xylanase accounts for only around two thirds of all enzymatic processes in the pulp and 
paper sector, employment figures in modern biotechnology-related production can be 
estimated to be around 3000 (see Table 35). 
 
 
 
 
 
                                                 
250 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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Table 35: Employment in pulp and paper processing using enzymes 
 
Year: 2002 Number of employees 
Share of EU 
employment (in %) 
Share of 
manufacturing 
employment (in %) 
EU Employment (all economic 
activity) 200 000 000 100.00  
NACE D Manufacturing (total) 33 000 000 16.50 100.00 
DE 21 Manufacture of pulp, paper and 
paper products (2003) 738 600 0.37 2.24 
DE 21.1 Manufacture of pulp, paper 
and paperboard 243 500 0.12 0.74 
DE 21.11 Manufacture of pulp*  22 000 0.011 0.07 
Manufacture of pulp using enzymes* 3000 0.0015 0.01 
*Estimate 
 
Similar to the case of detergents containing enzymes, the contribution of enzymatic pulp and 
paper processing to EU employment of 0.0015% is marginal. In terms of labour productivity, 
the enzymatic process is with a labour productivity of 2.3 more efficient than the 
conventional one with 2.1 (see Table 36). Both processes are far above the EU manufacturing 
average, which indicates well established technology in this sector. 
 
Table 36: Labour productivity in pulp and paper processing using enzymes 
 
Year: 2002 Share of EU GVA (in %) 
Share of EU 
employment (in %) 
Labour 
productivity 
EU (All economic activity) 100.00 100.00 1.0 
NACE D Manufacturing (total) 17.41 16.50 1.1 
DE 21 Manufacture of pulp, paper and 
paper products (2003) 0.53 0.37 1.4 
DE 21.1 Manufacture of pulp, paper and 
paperboard 0.25 0.12 2.1 
DE 21.11 Manufacture of pulp* 0.0227 0.011 2.1 
Manufacture of pulp using enzymes* 0.0034 0.0015 2.3 
*Estimate; **2003 data 
 
 
Outlook 
 
In the pulp and paper sector, enzymatic processes have not diffused into industrial use as was 
expected some 20 years ago. However, some processes are now established, and the maturity 
of the enzyme markets for pulp and paper processing is very well reflected in the slow but 
steady growth, which has been predicted to continue by around 3.5% per year until 2009251.  
 
                                                 
251 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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2.4.2.2.3 Enzymes in textile processing 
 
Enzymes are applied at several stages in the production and processing of textiles. The use of 
cellulase for denim finishing and biopolishing is the largest application, with around two 
thirds of global enzyme sales for textile processing. Other processes include desizing of 
starch from textile fibres with amylases, scouring of textiles with pectinases (bioscouring), 
the degradation of residual hydrogen peroxide with catalases (post bleaching) and proteases 
for the treatment of silk (removal of natural fibrin).  
 
The uptake of enzymatic processes into EU textile finishing applications is as follows: 
• desizing with amylases: 100% 
• post bleaching with catalases: 40 - 50% 
• denim finishing with cellulases: 80 - 90%. 
 
For bioscouring and biofinishing the degree of diffusion into the industry is not known, 
although 25% of sold textile enzymes are used for biofinishing processes.  
 
The world market volume of enzymes for textiles is estimated to be around EUR 140 million, 
which corresponds to 8% of all enzyme sales (EUR 1.8 billion). 32% of textile enzymes are 
sold to China, 15% to India and 25% to South and Central America, which indicates the 
concentration of parts of textile manufacturing in these countries252. The remaining 28% are 
sold to Europe, Africa and Far East. According to Novozymes, the growth in textile enzyme 
sales was mainly based in the development of the Chinese and Far East markets. 
 
 
Figure 24 shows a model of a textile finishing process for cotton. According to this simplified 
structure, the finishing process consists of six steps. In four of those, enzymes can be applied. 
For Step 1 ‘desizing’, 100% diffusion is estimated, for Step 4 ‘bleach clean-up’, 40 - 50%252 
(45% will be used hereafter). For the two steps in which the degree of diffusion is not known 
(Step 2 scouring, Step 6 rinsing), a 50% application is assumed. In total, this sums up to two 
production steps with no enzymatic processes, one step with 45%, two steps with 50%, and 
one step with 100% application. If all production steps are given the same weight in terms of 
cost, resource use etc., an average diffusion of enzymatic processes into textile finishing of 
around 40% results.  
 
The textile sector in the EU has been shrinking continuously throughout the last years and 
contributed 0.41% to the EU’s GVA in 2002. According to Eurostat, the contribution of the 
textile sector to the EU’s GVA decreased by 35% between 1995 and 2005253. Within the 
sector, the initial production process steps, like weaving, decreased more than textile 
finishing, which contributed 0.05% to the EU’s GVA in 2002, or 0.28% to EU manufacturing 
(see Table 37).  
 
                                                 
252 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
253 Eurostat http://epp.eurostat.ec.europa.eu/. 
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Figure 24: Model process for cotton manufacturing 
Source: Kvistgaard and Wolf 2002254 
 
A model calculation results in a cost reduction of approximately 80% for both the scouring 
and the bleach clean-up process steps254. For desizing, a price increase in direct material cost 
was calculated for the enzymatic process, in other words, the input enzymes per unit are more 
expensive than the input chemicals. However, as the enzymatic process is applied 100%, it 
can be assumed that the additional cost is more than offset through savings in energy and 
water cost. Under the assumption that the application of peroxidases as well as the desizing 
step with amylases are cost neutral, and the two non-enzymatic production steps in the model 
application remain unchanged, an overall average cost reduction of around 25% can be 
estimated through the application of enzymes in textile finishing. This results in a higher 
value-added figure per unit, as less capital costs occur.  
 
 
 
                                                 
254 Kvistgaard, M. and Wolf O. (eds.) (2002). The assessment of future environmental and economic impacts of 
process integrated biocatalysts. European Commission, IPTS, EUR 20407, p.44. 
http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1022.  
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Table 37: Contribution of textile finishing using enzymes to the EU’s GVA 
Source: Data from Eurostat255, IPTS calculations 
 
Year: 2002 GVA  (EUR million) 
Share of EU 
GVA (in %) 
Share of 
manufacturing  
(in %) 
EU GVA (all economic activity) 8 782 816 100.00  
NACE D Manufacturing (total) 1 528 982 17.41 100.00 
DB 17 Manufacture of textiles 35 795 0.41 2.34 
DB 17.3 Finishing of textiles 4307 0.05 0.28 
Textile finishing with enzymes* 2000 0.02 0.13 
*Estimate 
 
Under the assumption that 40% of textile finishing uses enzymatic processes, it is plausible to 
say that of the EUR 4.3 billion GVA contributed by textile finishing, EUR 2 billion are 
generated through enzymatic processes (see Table 37). This corresponds to a 0.02% 
contribution of enzymatic textile finishing to the EU’s GVA (0.11% to EU manufacturing).  
 
 
Employment effects and labour productivity in textile production 
 
No data are available with respect to employment shares for enzymatic processes in textile 
finishing. According to Eurostat, 121 200 people were employed in textile finishing in 2002 
(see Table 38). The simple application of the estimated 40% share of enzymatic processes to 
this figure results in 48 480 employees in textile finishing with enzymatic processes. This is a 
very rough approximation, as in reality no clear-cut distinction between staff working in 
enzymatic processing and non-enzymatic processing can be made. 
 
Table 38: Employment in textile finishing using enzymes 
Source: Data from Eurostat255, IPTS calculations 
 
Year: 2002 Number of employees 
Share of EU 
employment (in %) 
Share of manufacturing 
employment (in %) 
EU employment (all economic 
activity) 200 000 000 100.00  
NACE D Manufacturing (total) 33 000 000 16.50 100.00 
DB 17 Manufacture of textiles 1 157 700 0.58 3.51 
DB 17.3 Finishing of textiles 121 200 0.06 0.37 
Textile finishing with enzymes* 48 480 0.02 0.15 
*Estimate 
 
If the contribution of textile manufacturing and textile finishing – with and without enzymes 
– is compared to the respective contributions to EU GVA, a mixed picture emerges. Overall 
labour productivity in textile manufacturing is 0.7, i.e. 30% below the EU average or almost 
                                                 
255 Eurostat database. http://epp.eurostat.ec.europa.eu. 
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40% below the manufacturing overage. This indicates that more staff are needed to generate 
value-added than in other manufacturing sectors. Labour productivity in textile finishing is 
0.8, which is still less than the overall EU economy and manufacturing values, but 15% 
higher than textile manufacturing. This confirms that textile finishing is a more capital 
intensive kind of manufacturing. The use of enzymes in textile finishing, based on rough 
estimates, leads to a labour productivity of 0.9 (see Table 39). This is still below the EU 
economy and manufacturing values, but points to technological optimisation of the capital 
input through the application of enzymes. 
 
Table 39: Labour productivity in textile finishing using enzymes 
 
Year: 2002 Share of EU GVA (in %) 
Share of EU 
employment (in %) 
Labour 
productivity 
EU (all economic activity) 100.00 100.00 1.0 
NACE D Manufacturing (total) 17.41 16.50 1.1 
DB17 Manufacture of textiles 0.41 0.58 0.7 
DB17.3 Finishing of textiles 0.05 0.06 0.8 
Textile finishing with enzymes* 0.0227 0.024 0.9 
*Estimate 
 
 
Outlook 
 
In the case of enzymes for textile finishing, the situation is different to other enzyme markets 
due to the development of the textile sector itself. On the one hand, the sector has been 
shrinking over the years. On the other hand, the internal structure of the sector moves away 
from textile producing activities, such as weaving, towards textile finishing processes, which 
are more enzyme intensive. These, which are usually combined with enzymes when using 
washing processes, allowed a slow growth of 2.7% for the enzyme market for textiles in the 
EU. The non-EU markets for textile enzymes, which are also dominated by EU producers, 
are growing at a faster pace: 3.3% in the US and 3.9% in Asia256. 
 
 
2.4.2.2.4 Enzymes in food processing 
 
Biotechnology has been used in food production for several thousand years. Classical 
techniques like fermentation have been applied to beverages, food and feed. Today, modern 
biotechnology is established in almost all areas of food production. This is reflected in the 
importance of food and feed enzymes in the overall enzyme market. The overall share of food 
and feed enzymes in global enzyme sales ranges between 30% and 45%257. A few examples 
illustrate the diversity of enzymatic reactions and the targeted processes and products. Since 
the early 1960s, all glucose production is done by enzymatic hydrolysis instead of acid 
hydrolysis. This process cuts steam costs by 30%, ash by 50% and by-products by 90%258. 
                                                 
256 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
257 DECHEMA (2004). Weiße Biotechnologie: Chancen für Deutschland. Gesellschaft für Chemische Technik 
und Biotechnologie, Frankfurt a.M., p.30. http://biotech.dechema.de/img/biotech_/brennpunkt/041110.htm. 
And: ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
258 Olsen, H.S. (2004). Enzymes at work. Novozymes, Bagsværd, p. 27. 
http://www.novozymes.com/en/MainStructure/PressAndPublications/Brochures/Brochures+about+enzymes/.  
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Laccases, as another example, are used in the clarification of juice as well as in baking in the 
treatment of dough259. Also amylases, proteases and xylanases play important roles in baking, 
cheese production, sweetener production and other food production processes.  
 
The examples show the ‘multi-target’ character of many enzymes, which are applied in a 
variety of completely different processes and products260. This makes it difficult to assign the 
economic impact of modern biotechnology to individual enzymes and to avoid double 
counting at the same time. An economic analysis is furthermore hampered by the fact that 
most of the enzymatic food production processes have been adopted by the whole industry, 
i.e. the alternative non-enzymatic process as an efficiency benchmark is not available. This 
challenge is very well illustrated by the case of fruit juice production, which will be discussed 
below.  
 
Table 40: Share of enzyme sales per application area in the food sector 
Source: ETEPS 2006261 
 
Food application area Enzyme sales in 2006 (in %) 
Dairy 26 
Starch and sugar 25 
Bakery processing 24 
Fruit juice 7 
Wine making 7 
Brewing 6 
Nutrition and dietary supplements 5 
Total 100 
 
Nevertheless, different food production subsectors use enzymes to a different extent. Table 
40 shows the EU food enzymes market disaggregated to application areas. Only the food 
subsectors mentioned in Table 40 are dealt with in the analysis as users of modern 
biotechnology, i.e. enzyme users. It has to be kept in mind that enzymes are used in 
practically all food manufacturing, however, applications other than the ones mentioned in 
Table 40 play such a minor role that their impact on the EU economy and employment is 
negligible. From this perspective, the food production subsectors analysed for the indirect 
impact of modern biotechnology are as shown in Table 41. Around 50% of the food 
manufacturing sector uses larger quantities of enzymes in production. The contribution to EU 
GVA is 1%. The contribution of these food production processes to the overall 
manufacturing sector’s GVA is 5.76%.  
 
 
 
                                                 
259 Rodríguez Couto, S. and Toca Herrera J.L. (2006). Biotechnology Advances 24: 500-513. 
http://dx.doi.org/10.1016/j.biotechadv.2006.04.003.  
260 The company websites of enzyme producers provide a good overview: information of AB Enzymes on 
speciality products (http://www.abenzymes.com/?page=page&view=27), Direvo’s information on industrial 
enzymes (http://www.direvo.com/industrial-enzymes/), and Novozymes' report "Enzymes at work" (see 
footnote 258). 
261 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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Table 41: Share of food production using enzymes in overall food production, manufacturing and the 
EU's GVA 
Source: Data from Eurostat, IPTS calculations262 
 
Year: 2002 
GVA 
(EUR 
million) 
Share of  
EU GVA  
(in %) 
Share of 
manufactu-
ring GVA 
(in %) 
Share of 
food 
products 
GVA  
(in %) 
EU GVA (all economic activity) 8 782 816 100.00   
NACE D Manufacturing (total) 1 528 982 17.41 100.00  
DA 15 Manufacture of food products (2003) 181 220 2.06 11.85 100.00 
DA 15.3 Fruit and vegetables 10 758 0.12 0.70 5.94 
DA 15.4 Vegetable and animal oils and fats 
(2003) 5011 0.06 0.33 2.77 
DA 15.5 Dairy products (2001) 17 505 0.20 1.14 9.66 
DA 15.62 Starch and starch products (2003) 797 0.01 0.05 0.44 
DA 15.7 Prepared animal feed 6916 0.08 0.45 3.82 
DA 15.81 Bread, pastry, cakes (2003) 26645 0.30 1.74 14.70 
DA 15.83 Manufacture of sugar* 1946 0.02 0.13 1.07 
DA 15.93 Wine making (2003) 4413 0.05 0.29 2.44 
DA 15.94 Cider and fruit wines 590 0.01 0.04 0.33 
DA 15.96 Manufacture of beer 13 464 0.15 0.88 7.43 
Food production subsectors using enzymes  88 046 1.00 5.76 48.59 
*Estimate 
 
 
Example: Juice production 
 
Enzymatic preparations have been used for 60 years in fruit juice processing263. The enzymes 
used are pectinases, hemicellulases, amylases and proteases. They are used for clarification of 
the juice, degrading of carbohydrates, and breaking down cell walls. As in other food 
production areas, the share of enzymatic processes in the particular production steps is 100%, 
i.e. no non-enzymatic fruit juice production exists which could be used as a comparison to 
benchmark efficiency gains. For process comparisons, the production of naturally cloudy 
apple juice, which does not need enzymatic treatment for clarification could be taken into 
account264. However, enzymes may be used even in this case for peeling the fruit and 
conserving the final product. Furthermore, naturally cloudy apple juice is to be treated as a 
different product with different end consumer markets. Production price comparisons would 
not be meaningful. This illustrates the basic challenge in assessing the impact of modern 
biotechnology in food production. Enzymes are the state-of-the-art technology and cannot be 
compared to a non-biotechnology production technology. Therefore it is reasonable to 
account the entire output of fruit and vegetable juice as an indirect impact of modern 
                                                 
262 Eurostat database. http://epp.eurostat.ec.europa.eu. 
263 Olsen, H.S. (2004). Enzymes at work. Novozymes, Bagsværd, p. 42. 
http://www.novozymes.com/en/MainStructure/PressAndPublications/Brochures/Brochures+about+enzymes/. 
264 Bates, R.P et al. (2001). Principles and practices of small and medium scale fruit juices processing. FAO 
Agricultural Service Bulletin 146, p.162. ftp://ftp.fao.org/docrep/fao/004/y2515e/Y2515E05.pdf.  
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biotechnology. The same assumption is made for the other food production processes listed 
above in Table 41. 
 
Table 42 shows the contribution of NACE category DA 15.32 (fruit and vegetable juice) to 
the food sector’s GVA, to manufacturing sector’s and to the EU’s GVA in total. It can be 
seen that the food sector is one of the largest subsectors in manufacturing, with a contribution 
of around 12% (2% to the EU’s GVA). Within that, NACE DA 15.3 is amongst the smaller 
segments, and juice production contributes 0.12% to EU manufacturing GVA (0.02% to the 
EU’s GVA).  
 
Table 42: Share of juice production in food production, manufacturing and the EU’s GVA 
Source: Eurostat265 
 
Year: 2002 
GVA 
(EUR 
million) 
Share of  
EU GVA  
(in %) 
Share of 
manufacturing 
GVA (in %) 
Share of food 
production 
GVA (in %) 
EU GVA (all economic activity) 8 782 816 100.00   
NACE D Manufacturing (total) 1 528 982 17.41 100.00  
DA 15 Manufacture of food products 181 220 2.06 11.85 100.00 
DA 15.32 Fruit and vegetable juice 1894 0.02 0.12 1.05 
 
As Table 42 also shows, fruit and vegetable juice have a share of around 1% in overall EU 
food processing. At the same time, the share of enzymes for fruit and vegetable juice out of 
total food enzymes sales in the EU is 7%266. This shows that within food processing, this is a 
rather enzyme-intensive production process. These 7% correspond to a value of EUR 12.8 
million, out of the total EU food enzymes market with a value of EUR 184.9 million266. In 
the US, the market for food enzymes in total is around EUR 110.5 million, out of which fruit 
juice enzymes with EUR 3.9 million have a share of around 3.5%266. On a global scale, fruit 
juice enzymes have a share of around 5.75% (ca. EUR 23 million) out of the entire food 
enzymes market (ca. EUR 400 million)267. 
 
Development of fruit juice consumption since 2000 in Europe shows a growing market (see 
Figure 25). In four years, consumption grew in Eastern Europe by around 90%, in Western 
Europe by 10%, and in total by 25% (which corresponds to a yearly growth of approximately 
6%). As enzymatic production processes are the rule in this industry, it shows that this 
application area of modern biotechnology is growing several times faster than the EU 
economy in general.  
 
                                                 
265 Eurostat database. http://epp.eurostat.ec.europa.eu/  
266 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
267 ETEPS (2006). Bio4EU Task 2, main report (conversion: 1 USD = EUR 0.7765). 
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Figure 25: Consumption of fruit juice and nectar in Europe  
Source: Doehler Group268 
 
This growth is similar to that of the direct competitors in the market for non-alcoholic 
beverages (water, carbonated drinks, still drinks)268. Price competitiveness through optimised 
production processes plays a crucial role in maintaining a strong position in this market. 
Enzymatic processes are one important element in process optimisation for fruit juice 
production, as this is a rather enzyme-intensive manufacturing subsector, as discussed above. 
 
 
Employment effects in juice production 
 
The strong reliance on enzymatic processes in fruit juice production is also underlined by the 
fact that fruit juice producers maintain staff with enzyme expertise in laboratories269. 
However, the direct impact on labour markets is rather small in absolute terms: Around 200 
persons in the EU are employed in fruit juice enzyme production. Of more interest is the 
indirect effect. Following the line of argumentation that the entire fruit juice production 
represents an indirect impact of modern biotechnology, as all fruit juice is produced with 
enzymatic processes, the entire workforce can also be counted in the same manner. No data 
are available in the Eurostat database on that issue, but an approximation can be made. In the 
NACE category DA 15.3 (Processing and preserving of fruit and vegetables), 265 600 
employees generated a value-added of EUR 10.75 billion in 2002. The value-added generated 
in the NACE sub-category DA 15.32 (fruit and vegetable juice), was EUR 1.89 billion in 
2003. Assuming the same relation between value-added and employment, a workforce 
estimate of roughly 47 000 employees in the EU can be calculated (see Table 43). This 
figure, corresponding to 0.02% of overall EU employment (0.12% of EU manufacturing 
employment) is most likely to increase, as the above shown market development of fruit juice 
in Europe indicates. 
 
                                                 
268 Doehler Group, http://www.doehler.de/en/markets_and_trends/.  
269 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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Table 43: Employment in fruit and vegetable juice production 
 
Year: 2002 Number of 
employees 
Share of EU 
employment (in %) 
Share of manufacturing 
employment (in %) 
EU employees (all economic activity) 200 000 000 100.00   
NACE D Manufacturing (total) 33 000 000 16.50 100.00 
DA 15 Manufacture of food products 4 434 100 2.22 13.44 
DA 15.32 Fruit and vegetable juice* 47 000 0.02 0.12 
*Estimate 
 
In terms of labour productivity, the production of fruit and vegetable juice shows an 
employment:value-added ratio of 0.9, which corresponds precisely to the average of food 
production (see Table 44). The average of 0.9, which is below the EU average, implies that 
food processing (excluding agriculture) is a labour-intensive manufacturing sector. 
 
Table 44: Labour productivity in fruit and vegetable juice production 
 
Year: 2002 Share of EU GVA (in %) 
Share of EU 
employment (in %) 
Labour 
productivity 
EU (all economic activity) 100.00 100.00 1.0 
NACE D Manufacturing (total) 17.41 16.50 1.1 
DA15 Manufacture of food products 2.06 2.22 0.9 
DA15.32 Fruit and vegetable juice* 0.02 0.02 0.9 
*Estimate 
 
 
The food sector in the EU 
 
As discussed above, the assessment of the impact of modern biotechnology on the EU food 
sector is shaped by some special characteristics of both the enzymes in use and the food 
sector itself. Most importantly, it is the long tradition of enzymatic processes in the food 
industry, which led to a wide diffusion of this technology in basically all subsectors of food 
processing. Additionally, most of the enzymes are used for several different purposes, which 
makes it very difficult to assign economic impacts to individual enzymes. Furthermore, 
enzymatic processes, where applied, have in most cases become the state-of-the-art process 
which can hardly be benchmarked against a conventional process.  
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Table 45: Employment in food manufacturing sectors using large quantities of enzymes 
 
Year: 2002 Number of employees 
Share of EU 
employment (in %) 
Share of 
manufacturing 
employment (in %) 
EU employment (all economic activity) 200 000 000 100.00  
NACE D Manufacturing (total)  33 000 000 16.50 100.00 
DA 15 Manufacture of food products 
(2003) 4 434 100 2.22 13.44 
DA 15.3 Fruit and vegetables 265 600 0.13 0.80 
DA 15.4 Vegetable and animal oils and 
fats (2003) 59 100 0.03 0.18 
DA 15.5 Dairy products 396 200 0.20 1.20 
DA 15.62 Starch and starch products 
(2003) 17 300 0.01 0.05 
DA 15.7 Prepared animal feed 130 900 0.07 0.40 
DA 15.81 Bread, pastry, cakes (2003) 1 226 000 0.61 3.72 
DA 15.81 Bread, pastry, cakes (2003) 
(adjusted to industrial bread production) 224 682 0.11 0.68 
DA 15.83 Manufacture of sugar* 55 800 0.03 0.17 
DA 15.93 Wine making (2003) 77 200 0.04 0.23 
DA 15.94 Cider and fruit wines 7900 0.00 0.02 
DA 15.96 Manufacture of beer 140 400 0.07 0.43 
Share of food production subsectors using 
enzymes  2 376 400 1.19 7.20 
Share of food production subsectors 
using enzymes  
(adjusted to industrial bread production) 
1 375 082 0.69 4.17 
*Estimate 
 
However, the share of enzyme sales in the food sector (see Table 40) makes it possible to 
concentrate on a number of selected food production processes, which use enzymes in large 
quantities. Table 41 shows the different manufacturing sub-categories, which apply modern 
biotechnology at different stages of the production process. Their GVA amounts to EUR 88 
billion, generated by 2.376 million employees in 2003 in the EU, which is regarded as an 
indirect impact of modern biotechnology in the EU (see Table 45). The contribution to the 
EU’s GVA is 1% and to EU employment it is 1.2% (agriculture is not included in this 
calculation). 
 
However, for the assessment of the labour productivity of the food manufacturing sector 
using enzymes one important adjustment has to be made with regards to NACE category DA 
15.81 (bread, pastry and cakes). This category represents a statistical outlier in two respects. 
On the one hand, with around 1.2 million employees it has the highest number of employees 
amongst all industrial biotechnology sectors discussed in this study; on the other hand, it has 
the lowest labour productivity (0.5). These two facts are directly linked to each other: this 
subcategory is particularly labour intensive, because in EU countries with the highest bread 
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consumption, the structure of the bakeries market is dominated by small family owned shops. 
This leads to a rather strong distortion in the overall results of this study. The aim is, 
therefore, to separate the share of bread which is industrially produced on a large scale from 
bread that is crafted in micro-enterprises. Based on this for industrially produced bread the 
following figures can be estimated: 224 000 employees in NACE category DA 15.81 
generated a value-added of EUR 8.5 billion270. These adjusted figures are taken for the 
calculation of the overall EU employment in food manufacturing and the corresponding 
labour productivity (see Table 46). As a result it appears that the food manufacturing 
subsectors using large quantities of enzymes, have a weighted average labour productivity of 
1.2, which is 30% higher than the average value of 0.9 for the entire food manufacturing 
sector. 
 
Table 46: Labour productivity in overall food manufacturing 
 
Year: 2002 Share of EU GVA (in %) 
Share of EU 
employment (in %) 
Labour 
productivity 
EU employment (all economic activity) 100.00 100.00  
NACE D Manufacturing (total) 17.41 16.50 1.1 
DA 15 Manufacture of food products 
(2003) 2.06 2.22 0.9 
DA 15.3 Fruit and vegetables 0.12 0.13 0.9 
DA 15.4 Vegetable and animal oils and 
fats (2003) 0.06 0.03 1.9 
DA 15.5 Dairy products 0.20 0.20 1.0 
DA 15.62 Starch and starch products 
(2003) 0.01 0.01 1.0 
DA 15.7 Prepared animal feed 0.08 0.07 1.2 
DA 15.81 Bread, pastry, cakes (2003) 
(adjusted to industrial bread production) 0.10 0.11 0.9 
DA 15.83 Manufacture of sugar* 0.02 0.03 0.8 
DA 15.93 Wine making (2003) 0.05 0.04 1.3 
DA 15.94 Cider and fruit wines 0.01 0.00 1.7 
DA 15.96 Manufacture of beer 0.15 0.07 2.2 
Share of food production subsectors 
using enzymes 0.80 0.69 1.2 
*Estimate 
 
 
Outlook 
 
As discussed above, enzyme applications used in food manufacturing are manifold, and it 
may well be that different subsectors develop at different paces. On average, this market has 
                                                 
270 This calculation is based on the information that out of 25 million tonnes of bread sold in the EU in 2005, 8 
million were produced industrially. A large bread producer generates a turnover of EUR 89 544.33 per 
employee (http://www.bimbo.com). These figures, combined with EUR 60 billion turnover/EUR 27 billion 
value-added for all bread in the EU, resulted in the adjusted figures. 
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shown continuing growth in the past, and for the coming five years a growth rate of 2 - 3% in 
the EU has been estimated271. Since EU food enzyme producers are world market leaders, 
market developments in other regions are relevant as well. Growth in the US, with enzymes 
for starch and sugar processing as the largest segment, grew by 3.4% in recent years. The 
modest but linear growth (past and predicted) shows that food enzymes represent a mature 
market with limited volatility. High technical entry barriers for future competitors, and 
regulations in the EU which restrict the use of new types of enzymes in food manufacturing 
are further stabilising factors for the market272. 
 
 
2.4.2.3 Modern biotechnology in bioethanol production 
 
The production of bioethanol is the only application area of modern biotechnology in the 
field of biomass energy supply which has been taken into account in the context of this study. 
The majority of ethanol production processes are dedicated to its use as a transport fuel. 
Therefore it makes sense to describe the economic dimensions in relation to the fossil fuel 
production sector. A look at NACE DF 23.2 (manufacture of refined petroleum products) 
shows the size of the sector. The sector includes more than just transport fuel, as refineries 
also provide intermediate chemical products. In 2003, refinery products included the 
following273:  
• gas/diesel oil    36.0% 
• gasoline     20.9% 
• residual fuel oils   15.6% 
• naphtha     5.9% 
• kerosene/jet fuels   6.1% 
• refinery gas    3.3% 
• liquefied petroleum gases (LPG) 2.9% 
• various other petroleum products 9.4% 
 
This list shows that 78.6% of refinery products go into fuel production (see list items in 
bold). Therefore it is estimated that 80% of the GVA of NACE sector DF 23.2 accounts for 
petrol fuel products (see Table 47). 
 
NACE category DF 23 employs around 175 000 people in the EU and contributes 0.28% to 
the EU’s GVA (respectively 1.63% to EU manufacturing GVA). NACE category DF 23.2 
(manufacture of refined petroleum products) is the largest subsector, employing 135 000 
people and contributing 0.25% to the EU’s GVA (or 1.44% to EU manufacturing GVA). As 
discussed above, it is assumed that 80% of NACE DF 23.2’s output (at the refinery gate) are 
transport fuels, whereas the remaining 20% are chemicals and other products. Consequently 
it is assumed that transport fuel contributes with 0.2% to the EU’s GVA, (or 1.15% to EU 
manufacturing GVA) and employs around 100 000 staff, as shown in Table 48. These 
relations have been more or less stable over the past years, and it can be assumed that the 
share remains roughly similar, although the workforce is decreasing by about 0.5% per year. 
                                                 
271 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
272 For example, in the fruit enzyme market, EU regulations only permit pectases, amylases and proteases 
(ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications). 
273 Eurostat (2006). European business - facts and figures, p.56. 
http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-BW-05-001/EN/KS-BW-05-001-EN.PDF. 
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The transport fuel production is a mature sector with large scale production facilities. The 
production volume per average oil refinery amounted to roughly 6 million tonnes fuel in 
2005. The resulting turnover per employee sums up to EUR 5.3 million (see Table 48). 
 
Table 47: Share of fuel production in manufacturing of refined petroleum products, manufacturing and 
the EU's GVA  
Source: Eurostat274 
 
Year: 2002 GVA (EUR million) 
Share of EU 
GVA (in %) 
Share of 
manufacturing GVA 
(in %) 
EU GVA (all economic activity) 8 782 816 100.00  
NACE D Manufacturing (total) 1 528 982 17.41 100.00 
DF 23 Manufacture of coke, refined petroleum 
products and nuclear fuel 24 866 0.28 1.63 
DF 23.2 Manufacture of refined petroleum 
products* 21 974 0.25 1.44 
Fuel share in DF 23.2* 17 579 0.20 1.15 
*Estimate 
 
In contrast to the production of fossil fuel, bioethanol production is a young industry, which 
still undergoes rapid economic and, in particular, technological development. Table 48 shows 
basic figures of the economic impact of bioethanol production in comparison to fossil fuel 
production. For 2005 there is a share of 0.21% of bioethanol in the GDP fraction of total 
liquid fuels. This results in a share of 0.0005% of bioethanol production in overall GDP 
(2005)275. In 2005, 525 people were employed directly, and around 5000 indirectly in 
bioethanol production, which corresponds to 0.3% of NACE DF 23.2 employment, or around 
0.015% of overall EU employment in manufacturing.  
 
Table 48 also shows that the average production cost of bioethanol still exceeds the cost of 
fossil fuel production by far. Whereas in 2005 one litre fossil fuel production cost EUR 0.33, 
a litre of bioethanol cost EUR 0.53 (i.e. it was 60% more expensive)276. If the energy contents 
are to be compared, it cost EUR 0.76 in 2005 to produce the energy equivalent of fossil fuel 
with bioethanol (130% more expensive). In 2004, production costs were still twice as high: 
the production of one litre bioethanol was 150% more expensive, and the production of the 
fossil fuel energy equivalent was 270% more expensive. The comparison of the average 
yearly production volumes per production plant (fossil fuel: 6 000 000 tonnes, bioethanol: 
100 000 tonnes) shows that oil refineries produce on a larger scale, and that there is still room 
for development in the bioethanol production figures to lower the production cost per unit. 
Nevertheless, a prediction of future cost development for biofuels on the basis of past 
experience can only be done within certain limitations. The growth of production volume of 
individual plants is limited due to geographic dependence on raw material supply (biomass). 
                                                 
274 For DF 23, the GVA at basic and at factor prices was available on the Eurostat database, for DF 23.2 the 
GVA was available at factory prices only. The estimation made in Table 49 is based on extrapolating the known 
relation DF23/DF23.2 at factory prices to the unknown relation DF23/DF23.2 at basic prices. 
275 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
276 The price/unit relation for biofuel is indicative and is slightly different depending on the raw material used 
and the different production pathways. The cost comparison to fossil fuel, however, should reflect the 
approximate range. 
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And, related to that, the large scale production of biofuels has repercussions for the raw 
material price itself, which might compensate cost reductions through efficiency gains. 
 
Table 48: Comparison of fossil fuel and bioethanol contributions to the EU economy 
 
 Fossil fuel in the EU Bioethanol in the EU 
Contribution to EU economy 0.25% GVA share (2002) 0.0005% GDP share (2005) 
Contribution to EU manufacturing 1.15% (Share NACE D in 2002) 
0.0023% (Share NACE D in 
2005) 
Employment (2005)  Direct: 40 000  Direct: 525  
 Total: ca. 100 000 * Total: ca. 5500  
Contribution to employment in the EU 0.05% (2002) 0.0003% (2005) 
Turnover per employee (2005) EUR 5 300 000  EUR 800 000  
Production cost (2005) EUR 0.33/litre  EUR 0.53/litre  
Production cost (petrol energy eq.) EUR 0.33/litre EUR 0.76/equivalent petrol litre 
Overall production (2005) 600 000 000 tonnes * 750 000 tonnes  
Output average production plant (2005) 6 000 000 tonnes/year  100 000 tonnes/year ** 
Number of factories 104 refineries (2005) 16 (2005), 23 (2006) 
Sales (2004) EUR 139 billion  EUR 192 million  
Trade (2004) Not available 13% imports  
* 0.8 x DF 23.2 employment; ** Estimate 
 
 
Altogether, empirical evidence reflected in Table 48 shows a modest contribution of 
bioethanol to EU economic performance. A look at bioethanol development over time reveals 
a picture of an industry with high growth rates (see Table 49). Bioethanol production in the 
EU shows large differences in output from year to year, but overall a strong growth of more 
than 100% between 2002 and 2005. The development from 2004 to 2005 reflects strong 
growth rates for all bioethanol economic indicators (see Table 49). This has several reasons, 
such as technological progress, recent changes in the crude oil market price and, as a knock 
on effect from this, a changing legal framework at national and EU level. The EU set a target 
of 5.75% for biofuel’s share in overall EU road transport fuel, which was recently increased 
to 10% by 2020277. Some Member States already design their national policies accordingly, 
such as The Netherlands and Germany, which recently announced a 10% obligatory biofuel 
share until 2014278. 
 
 
 
 
 
 
                                                 
277 Brussels European Council, 8 and 9 March 2007, Presidency conclusions (7224/1/07). 
http://www.consilium.europa.eu/ueDocs/cms_Data/docs/pressData/en/ec/93135.pdf.  
278 FTD (2006). Koalition zwingt Ölkonzernen zehn Prozent Biosprit auf. Financial Times Deutschland 
(Hamburg), online version 24 October 2006. http://ftd.de/unternehmen/industrie/124573.html.  
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Table 49: Bioethanol’s key parameter development over the past years in the EU 
 
Bioethanol 2002 2003 2004 2005 2006 
Total production volume (1000 tonnes) 346 446 419 750 --- 
Change to previous year --- +29% -6.1% +79% --- 
Bioethanol share out of total liquid fuel --- 0.077% 0.071% 0.12% --- 
Change to previous year --- --- -7.8% +70% --- 
Share of European bioethanol production 
out of world production 
--- 1.7% 2.1% 2.6% --- 
Change to previous year --- --- +23.5% +23.8% --- 
Sales (EUR million) --- 204 192 427 --- 
Change to previous year --- --- -5.9% +122% --- 
Employment --- 312 413 525 --- 
Change to previous year --- --- +32.4% +27.1% --- 
Number of factories --- --- --- 16 23* 
Change to previous year --- --- --- --- +43.7% 
*Additionally the construction of 8 more bioethanol factories has been approved, which therefore could be 
counted as 31 new factories or an increase of 94% 
 
 
International comparison 
 
As Table 49 shows, bioethanol as a transport fuel only plays a minor role for EU transport 
and the overall economy at the moment. Outside the EU, bioethanol as a fuel plays a similar 
role although at different scales. Of particular interest is the EU comparison with the US, 
Brazil and Japan. 
 
As Figure 26 shows, the world fuel bioethanol production has been increasing since the mid 
1970s at high growth rates, with an accelerating trend in the last five years. The distribution 
of the 29 million tonnes of bioethanol fuel production shows the dominating position of the 
US and Brazil (see Table 50).  
 
Historically this development is related to a series of events on the oil market. So it is no 
coincidence that the start of this development took place shortly after the first oil price crisis 
in the early 1970s. At that time, Brazil was the only country which decided to cover its 
national fuel demand with bioethanol, favoured by the national large scale sugar cane 
production. The US only showed interest in bioethanol as a large scale product more recently, 
because the price of oil rose rapidly in the early 2000s. Since then, bioethanol production is a 
policy priority in the US. 
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Figure 26: Global production of bioethanol for fuel in thousand tonnes 
Source: Worldwatch Institute279  
 
Growth rates in fuel bioethanol production have been very high in all the major bioethanol 
producing countries and regions. In the EU and the US bioethanol production doubled 
between 2002 and 2005, in Brazil the increase seemed to be less with 30% because 
production had already been at a high level before, and in contrast, Chinese production 
increase was very high, because production levels were very low in 2002. India just entered 
the picture in 2005. A production volume of 240 000 tonnes indicates that production there 
had also passed the pilot phase. In 2004 and 2005 Japan did not produce bioethanol as a 
transport fuel, but imported around 400 000 tonnes.  
 
Table 50: Global bioethanol production volumes 
Source: Worldwatch Institute280 
 
 Production (1000 tonnes)
in 2002 
Production (1000 tonnes)
in 2005 
Growth between 2002 
and 2005 (in %) 
Brazil 10 000 13 000 30 
US and Canada 6700 13 000 91 
China 230 1600 592 
EU 346 750 117 
India --- 240 --- 
Japan --- --- --- 
                                                 
279 Worldwatch Institute (2006). Biofuels for Transportation, p.5.  
http://www.worldwatch.org/system/files/EBF038.pdf.  
280 Worldwatch Institute (2006). Biofuels for Transportation.  
http://www.worldwatch.org/system/files/EBF038.pdf; And: IEA (2004). Biofuels for transport. International 
Energy Agency, Paris. http://www.iea.org/Textbase/publications/free_new_Desc.asp?PUBS_ID=1262.  
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Bioethanol is not competitive as is fossil fuel (except in Brazil). Therefore it is pushed into 
the market through legal measures. Table 51 shows the bioethanol share of all liquid fuels for 
different countries, thereby revealing its political importance in different global areas. 
 
Table 51: Bioethanol volume development in different global areas 
Source: ETEPS, Worldwatch Institute, IEA281  
 
Bioethanol 1999 2000 2001 2002 2003 2004 2005 
Global production volume  
(1000 tonnes) 
14 600 13 800 15 000 18 200 22 100 23 000 29 000 
US - Bioethanol share in national 
liquid transport fuel 
    1.20% 1.50% 1.90% 
Brazil - Bioethanol share in 
national liquid transport fuel 
    14% 14% 14% 
EU - Bioethanol share in national 
liquid transport fuel 
    0.15% 0.14% 0.21% 
US - Share in world production ~30% 35% 35% 35% 38% 44% 45% 
Brazil - Share in world production ~70% 63% 58% 52% 48% 48% 45% 
EU - Share in world production 0.80% 1.40% 1.40% 1.80% 1.70% 2.10% 2.60% 
Others - Share in world 
production 
0% 0.60% 6.60% 10.20% 12.30% 5.90% 6.30% 
 
The global production volume has more than doubled since 1999 (see Table 51). The main 
contributor to this growth has been the US, which increased their world market share from 
about one third in 1999 to approximately 45% in 2005. At the same time, the Brazilian share 
in global bioethanol production decreased from 70% in 1999 to around 45% in 2005, due to 
production increases in other global regions. The EU showed an increasing share in world 
bioethanol production, which has more than tripled since 1999, although starting from a low 
level. 
 
Table 51 also shows that the share of bioethanol in the national transport fuel supply has 
remained stable in Brazil over the years, which indicates that a desired level has been reached 
and no additional incentives have been set. The numbers indicate a different background for 
the US and the EU. The share of bioethanol in the national transport fuel supply is increasing, 
which indicates regulatory measures such as tax exemptions in order to push non-competitive 
bioethanol into the market. 
 
 
Outlook 
 
A prediction of bioethanol production volumes over the coming five years is very difficult to 
make. The short-term trend indicates an increase: several new large bioethanol plants in 
Germany, Spain and France have been built since 2004. Whereas 16 plants producing 
bioethanol existed in 2005, there were 23 in 2006, which corresponds to an increase of 50%. 
Plans have been made in several other EU Member States to construct bioethanol plants (e.g. 
                                                 
281 ETEPS (2006). Bio4EU Task 2, main report And: Worldwatch Institute (2006). Biofuels for Transportation. 
http://www.worldwatch.org/system/files/EBF038.pdf; And: IEA (2004). Biofuels for transport. International 
Energy Agency, Paris. http://www.iea.org/Textbase/publications/free_new_Desc.asp?PUBS_ID=1262. 
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Belgium and The Netherlands). According to experts, the amount of bioethanol produced in 
the EU may triple or even quadruple in the coming five years. The EU production of fossil 
fuels is growing by 2% each year, but may level off because of a lower demand caused by 
price increases. Therefore, the share of bioethanol in liquid fuel may grow beyond 1% in the 
near future.  
 
As mentioned before, regulatory initiatives and fixed targets for the share of bioethanol in 
transport fuel at EU level (5.75% and recently 10%) as well as at Member State level (e.g. 
10% in Germany) are likely to support the increase in production volumes. The US have 
announced that they will cover national fuel supply with 30% biofuels by 2030282. 
 
This growth could be accelerated through current attempts to lower the production cost for 
second generation bioethanol. Modern biotechnological processes already exist to make 
organic raw material, such as wood, waste and other organic material (cellulosic biomass), 
available for bioethanol production, which would lead to a lowering of raw material price and 
therefore an increase in the competitiveness of bioethanol. Pilot plants are running, for 
example, in Sweden, but information on production cost is not available. The availability of 
this second generation cellulosic ethanol is the pre-condition for reaching the US 30% target, 
accordingly research funds and other subsidies are being made available particularly for this. 
Overall subsidies for bioethanol in the US reached the level of USD 5.1 - 6.8 billion/year, and 
are expected to reach USD 6.3 - 8.7 billion/year during the coming five years283. As a result, 
companies such as Novozymes (enzyme development) and Broin (the largest dry mill ethanol 
producer in the US) announced their collaboration for the accelerated development of 
cellulosic ethanol284. 
 
 
2.4.2.4 Biotechnology-based polymers and other biotechnology-based chemicals 
 
2.4.2.4.1 Biotechnology-based polymers 
 
A number of different technologies for the production of biotechnology-based polymers are 
already established. The most prominent amongst these is the starch-based poly-lactic acid 
(PLA). However, the large scale production of PLA is concentrated in the US and Japan, 
although a number of PLA plants have now been established in the EU as well. Currently, 
their contribution to EU economic growth and employment is rather modest. There are also 
other biotechnology-based polymers produced in the EU. In total, eight companies could be 
identified (see Table 52). 
 
 
 
 
                                                 
282 DOE (2006). DOE published roadmap for developing cleaner fuels. Press release, 7 July. US Department of 
Energy, Washington, D.C. http://www.doe.gov/news/3804.htm.  
283 Koplow, D. (2006). Biofuels – at what cost? Government support for ethanol and biodiesel in the United 
States. The Global Subsidies Initiative, International Institute for Sustainable Development, Geneva. 
http://www.globalsubsidies.org/article.php3?id_article=6. 
284 Novozymes (2006). Broin and Novozymes to collaborate on the development of ethanol from cellulosic 
biomass. Press release, 26 October. Novozymes, Bagsværd. 
http://www.novozymes.com/en/MainStructure/PressAndPublications/PressRelease/2006/NzBroinBiomass.htm. 
The Bio4EU Analysis report 129
 
Table 52: Companies producing biotechnology-based polymers in the EU 
 
Company  Product Production volume 
Rodenburg BioPolymers, 
The Netherlands 
Solanyl® (lactic acid-based 
polymer) 40 000 tonnes/year 
Tate & Lyle, UK  1,3 Propanediol 
Joint venture with DuPont, USA; 
planned production in the USA 
23 000 to 450 000 tonnes/year 
Hycail (taken over by Tate & Lyle 
in 2006), The Netherlands/UK Poly-lactic acid  Pilot plant 
Uhde Inventa-Fisher, Germany Poly-lactic acid Pilot plant 
PURAC, Netherlands Poly-lactic acid 80 000 tonnes/year 
Galactic, Belgium Poly-lactic acid 25 000 tonnes/year 
Biomer, Germany Biomer ®  (Poly-hydroxy-butyrate)   
Boehringer Ingelheim, Germany Poly-lactic acid (Resomer®)  
 
Production volumes of biotechnology-based polymers has been estimated to be around 
148 000 tonnes per year in the EU. Compared to 32.5 million tonnes of oil-based polymers, 
this is a marginal share of 0.4%285.  
 
Table 53: Contribution of production of biotechnology-based polymers to the EU's GVA 
Source: Data from Eurostat286, IPTS calculation 
 
Year: 2002 GVA (EUR million) 
Share of EU 
GVA (in %) 
Share of 
manufacturing 
GVA (in %) 
EU GVA (all economic activity) 8 782 816 100.00  
NACE D Manufacturing (total) 1 528 982 17.41 100.00 
DG 24 Manufacture of chemicals and 
chemical products 170 555 1.94 11.15 
DG 24.16 Manufacture of plastic in primary 
form (2003) 16 153 0.18 1.06 
Biotechnology-based polymers* 33.7 0.0003 0.0021 
  *Estimate 
 
Cost-efficiency is currently not the overriding motivation for the production of 
biotechnology-based polymers. This manufacturing subsector is in the technological start-up 
phase, with a steep learning curve. The situation is comparable to that of bioethanol 
producers, being at an even earlier stage. The most competitive biotechnology-based polymer 
is currently solanyl, with a production price of around EUR 1.13/kg. The price per kilo is 
currently estimated to be EUR 2.2 - 3.4 for PLA and EUR 20 for polyhydroxyalkanoates 
                                                 
285 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
286 Eurostat database. http://epp.eurostat.ec.europa.eu. 
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(PHA)287. In summary, biotechnology-based polymers are between 4 and 26 times more 
expensive than the oil-based competing products. The meaningfulness of these figures is 
limited. Different conventional polymers have different technical characteristics and therefore 
different end-user markets. Accordingly, biotechnology-based polymers are developed to 
meet different technical criteria. Some of them might be applied in specialised medical uses, 
others in bulk applications like plastic bags. This has, in turn, a direct impact on the 
competitiveness threshold in each individual case.  
 
As no evidence is available on employment created through the production of biotechnology-
based polymers, and cost-efficiency assessments do not lead to meaningful results, the impact 
of biotechnology-based polymers in the EU currently can be regarded as negligible. In the US 
and Japan, the situation is somewhat different. In 2002, the then largest PLA production site 
(140 000 tonnes/year) was up and running in the US. Cost figures are not available for this 
plant. However, it is obvious that in comparison to oil-based polymers, the threshold for 
competitiveness has still not been reached. Global production capacities for PLA are 
growing, in the US as well as in Japan and the EU. This indicates that the product is expected 
to become competitive in the near future.  
 
In Japan, Mitsubishi Rayon is the world’s largest producer of acrylamide, another 
biotechnology-based polymer, producing 20 000 tonnes per year of the 100 000 tonnes yearly 
global production. This process has a long tradition and has developed into a competitive 
production process over time. 
 
 
Outlook 
 
Price reductions are expected for all biotechnology-based polymers in the near and mid-term 
future. The average cost for PLA production is expected to decrease to EUR 1.35/kg, the 
price for PHA might even decrease to EUR 3-5/kg by 2010288. The average price of different 
oil-based polymers today is around EUR 0.75/kg. It can be concluded that the 
competitiveness gap is shrinking, but that in the coming five years biotechnology-based 
polymers will not break substantially into the market for primary plastics, apart from highly 
specialised application areas. 
 
 
2.4.2.4.2 Other biotechnology-based chemicals 
 
One of the key strengths of enzymes is their ability to replace chemical catalysts. Enzymatic 
reactions therefore have been taken up in the chemicals industry. The variety of processes in 
use is large, and well-known examples include the large scale production of acrylamide, the 
production of lactic acid as an intermediate chemical product (see above section on 
biotechnology-based polymers), or the production of the cephalosporins (a group of 
antibiotics, see below). Other prominent examples are the applications of enzymatic 
processes in the production of (bio)pharmaceuticals, vitamin B2 and bioethanol. 
Nevertheless, aggregated data for this group of biotechnology-based chemicals are practically 
not available. The contribution of this sector to the EU economy will therefore have to be 
carried out qualitatively. 
                                                 
287 Crank, M. et al. (2005). Techno-economic feasibility of large-scale production of bio-based polymers in 
Europe. European Commission, IPTS, EUR 22103. http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1343. 
288 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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About 305 companies in the EU could be identified as developers and producers of 
biotechnology-based chemicals. This includes a very heterogeneous group of processes and 
products (including service providers), as well as large companies and SMEs. If only the 
known producers of chemical substances (33) as well as bioethanol (16) and biotechnology-
based polymers (7) producing companies are taken into account, this figure narrows down to 
56289. Compared to the 60 000 chemical companies in the EU this is a small fraction (0.1%). 
In the US, this relation is significantly higher: 1.7% of all chemical companies (16 000) are 
developers or producers of biotechnology-based chemicals (266). In Japan, 2.5% of all 
chemical companies are producers of biotechnology-based chemicals (127 out of 5000).  
 
The contribution of chemicals, which are produced through the application of modern 
biotechnology, represents only an insignificant share to the EU economy. Due to this, and 
because of the absence of reasonable data on employment, cost-efficiency and future market 
developments, this application area is not included in the overall assessment of industrial 
biotechnology impacts on the EU economy. 
 
 
Example: Cephalosporins 
 
For individual products, data coverage is better, as for example for the manufacturing of  
7-ACA/7-ACDA290 (building blocks for cephalosporins), but the range of biotechnology-
based chemicals is too heterogeneous to extrapolate figures from this case to the entire sector.  
 
The antibiotic cephalosporin falls in the category of pharmaceuticals which are produced 
through the application of modern biotechnology. Some cephalosporins are produced on the 
basis of 7-ACA, which is derived from cephalosporin C. Other cephalosporins are produced 
on the basis of 7-ADCA, which is derived from penicillin G291. The production route for both 
7-ACA and 7-ADCA includes several steps, starting with fermentation. The following steps, 
initially chemical, have recently been carried out partially by biotechnological processes.  
 
The market volume for 7-ACA was 5000 tonnes in 2006, 35% of which was produced in the 
EU. World production is manufactured to 85% by 10 companies291. In the EU the largest 
producers are Antibioticos (Italy) with a capacity of 600 tonnes/year and Sandoz 
(Switzerland, but with its production facilities in Frankfurt, Germany) with 400 tonnes/year.  
 
20% of 7-ACA’s production is manufactured biotechnologically. As all Sandoz’s production 
is biotechnological, and Antibioticos is known to produce 50% of its output 
biotechnologically, it can be estimated that with 900 tonnes the EU contributes 75% of all 
biotechnologically produced 7-ACA291. The world market value for 7-ACA was EUR 300 
million in 2006. Cost-efficiency gains cannot be calculated. However, due to legal 
requirements Sandoz changed the production in Frankfurt from chemical to biotechnological 
manufacture. Due to this change Sandoz managed to produce 99.3% less undesired by-
products that need to be incinerated291. This indicates that the biotechnological route is at 
least as cost-efficient as the chemical synthesis. Employment in the EU production of 7-ACA 
is estimated to be 1200 staff. 
 
                                                 
289 ETEPS (2006). Bio4EU Task 2, annex report data tables. 
290 7-ACA: 7-aminocephalosporanic acid; 7-ADCA: 7-aminodeacetoxycephalosporanic acid 
291 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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The case is similar for the production of 7-ADCA. The Dutch company DSM is the world’s 
largest producer with several hundred tonnes production capacity. The value of the world 
market lies currently at EUR 200 million. The EU share in production and sales is around 
50%. The change from chemical to biotechnological synthesis led to savings in energy use of 
40% and in input materials of 35%. The use of solvents in the process was reduced by 
91%292.  
 
In international comparison, the EU has a competitive position in the production of 7-ACA 
and 7-ADCA. This is indicated through the high world market shares in production volumes. 
Worldwide only a few producers are active and actually form a global oligopoly. The 
uncertain factor in this situation is, like in other areas of industrial biotechnology, the rapid 
development of production capacity in China. The North China Pharmaceutical Corporation 
NCPC and the Harbin Pharmaceutical Group, which alone employs more than 8000 staff, 
produce several thousand tonnes of antibiotics, including 7-ACA and 7-ADCA. It is known 
that NCPC is developing biotechnological production routes for future production processes. 
It cannot be predicted how this will influence the current world market structure. 
 
 
2.4.2.5 Modern biotechnology in bioremediation 
 
Bioremediation is the collective term for the treatment of contaminated water, soil, air and 
solid waste with living organisms, mostly micro-organisms, to degrade or transform 
hazardous organic contaminants. These end-of-pipe applications of biotechnology were 
developed from the 1970s and 1980s onwards. 
 
Among the different applications, biotechnological waste water treatment has the longest 
tradition, whereas biotechnological air filters and specific waste treatments are more recent. 
The mechanism is similar in all these applications, in that micro-organisms adapted to 
degrade specific pollutants are used to decontaminate environmental media. This can be done 
on-site, which is usually the more economic solution, or off-site, which entails transporting 
contaminated material to a decontamination site. Often the most suitable micro-organisms are 
found in the direct environment of the contaminated material. 
 
Bioremediation has been thoroughly reviewed by the OECD, which collected a number of 
examples293. For air and off-gases, micro-organisms in peat and compost beds are able to 
break down simple volatile organic compounds and reduce odours; at the same time these 
processes are often simpler and cheaper than the alternative chemical approach. 
Contaminated soils can be treated ‘in situ’ by injecting nutrient solutions and/or air to support 
microbial activity (‘biostimulation’). Bioaugmentation – the introduction of specific strains or 
consortia of micro-organisms on the contaminated site to improve the capacity for pollutant 
degradation – is at a comparatively early stage of development294. Another biological soil 
remediation method is ‘ex situ’, which ranges from simple composting to soil-flushing 
techniques. Solid waste treatment is similar to soil clean-up techniques. Solid organic waste 
can be degraded in the presence of oxygen in landfills and during composting. Degradation in 
                                                 
292 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
293 OECD (1994). Biotechnology for a clean environment. OECD, Paris. 
http://www.oecd.org/dataoecd/47/50/2370637.pdf.  
294 El Fantroussi, S. and Agathos S.N. (2005). Current Opinion in Microbiology 8: 268-275. 
http://dx.doi.org/10.1016/j.mib.2005.04.011.  
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an oxygen-depleted environment produces usable methane. Waste water treatment has the 
longest record of applying micro-organisms for clean-up purposes with several different 
technologies295. 
 
Currently, limited use is made of modern biotechnology in bioremediation. It is used, for 
example, to support the efficient production of enzymes296, which are employed, inter alia, to 
clean up pesticide residues. In this case, the enzyme is isolated from bacteria in the 
environment of the pollutants, cloned into a common bacterium, produced by industrial-scale 
fermentation and then applied during decontamination297. 
 
The fact that micro-organisms are able to adapt to the degradation of a wide range of 
problematic pollutants, such as chlorinated solvents, sparked expectations in the 1980s that 
modern biotechnology would enhance possibilities of bioremediation through the 
modification of micro-organisms. Modification aimed at increasing the degradation capacity, 
both by improving the degradation rate, i.e. enabling the micro-organisms to clean material 
faster, and also by enlarging the applicability to a greater variety of pollutants. Steps have 
been taken in that direction, resulting in the first-ever patenting of a living organism, a 
Pseudomonas strain able to degrade a series of recalcitrant compounds298. 
 
The use of modified micro-organisms in bioremediation, however, faced several challenges. 
With the exception of a few cases, modified micro-organisms have performed poorly in 
degrading pollutants compared with their naturally occurring counterparts. One exception is 
the use of transgenic plants for the decontamination of soil, for example modified tobacco 
plants for phytodetoxification of explosives (TNT) in soil299. However, this application is not 
actually being used to remove explosive residues from soil. In addition, the interaction of 
modified micro-organisms with the natural environment is difficult to predict, and newly 
introduced micro-organisms have often turned out not to be as fit than their competitors and 
have been eliminated298. The potential risks associated with uncontrolled growth and 
proliferation of the genetically modified organisms (GMOs) in the environment, and with the 
possibility of gene transfer to other organisms have limited the applications of GMOs in 
bioremediation up to now.  
 
Another example of the use of modern biotechnology in environmental applications is the 
development of biosensors. Biosensors are analytical devices incorporating biological 
material, such as micro-organisms, enzymes, antibodies, etc., which are associated with, or 
integrated into, a physicochemical transducer system, which may be e.g. optical or 
electrochemical300. The system is introduced into environmental media, e.g. water, and gives 
a signal once it detects a specific pollutant. However, no evidence could be found that true 
biosensor systems (which do not need additional, external physical translation of signals) are 
currently on the market. 
 
                                                 
295 Gaugitsch H. and Schneider M. (1997). Einleitung, Zusammenfassung und Bewertung. In: 
Umweltbiotechnologie in Österreich, Schwerpunkt: Nachsorge, Monographien Band 85B, Bundesministerium 
für Umwelt, Jugend und Familie, Vienna, p. 501-510. 
296 Alcalde, M. et al. (2006). Trends in Biotechnology 24(6): 281-287. 
http://dx.doi.org/10.1016/j.tibtech.2006.04.002.  
297 Sutherland, T. et al. (2002). Pesticide Outlook 13: 149-151. http://dx.doi.org/10.1039/b206783h.  
298 Cases I. and de Lorenzo V. (2005). International Microbiology 8: 213-222. 
http://www.im.microbios.org/0803/0803213.pdf.  
299 Hannink, N. et al. (2001). Nature Biotechnology 19: 1168-1172. http://dx.doi.org/10.1038/nbt1201-1168.  
300 ETEPS (2006). Bio4EU Task 2 Case studies report – Industrial Biotechnology Applications. 
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2.4.3 Summary 
 
Indirect effects of modern biotechnology are several magnitudes higher than direct effects (if 
looking at enzyme producers and users). In this study only the sectorial analysis has been 
carried out, looking at immediate users of enzymes. A macroeconomic perspective has not 
been taken. 
 
Enzyme producers can be characterised as profitable enterprises, producing highly 
technological intermediate products, which unfold their impact on the EU economy in the 
application areas down the supply chain. In comparison with other manufacturing sectors 
such as detergents production or pulp and paper processing, contributions of food production 
seem to be quite large. This picture reflects the actual situation rather well. Food production 
is the manufacturing sector with the longest tradition in the use of enzymes, and it is the one 
which currently exploits the potential of modern biotechnology to optimize production 
processes with the largest degree of uptake into production processes. 
 
The large scale production of biotechnology-based polymers is dominated by the US and by 
Japan, although EU producers have increased the production volume, currently to the level 
the US production achieved 5 years ago. The US embarked later on working on technology 
for the production of bioethanol, but through policy support gained a large share of world 
production a few years later. Both, the markets for bioethanol and biotechnology-based 
polymers indicate a general willingness in the US to embark on large-scale production of 
products which are expected to become competitive only in the future.  
 
Due to the lack of quantifiable information, the development of industrial biotechnology in 
India, and in particular in China, has not been incorporated into this analysis. One of the few 
evident facts is the build-up of very large bioethanol production capacities in China during 
the past three years, representing today more than twice the capacity of the EU’s production. 
For the near future one single production site with a capacity of 600 000 tonnes is planned (as 
a comparison: the EU’s production in 2005 was 750 000 tonnes), indicating that China will 
outpace the EU both in growth rates and market volumes very soon. Information from other 
industrial biotechnology applications (e.g. cephalosporin production) has indicated a similar 
behaviour when entering into the market: Once a decision to embark on this technology has 
been taken, very large production capacities are developed.  
 
Labour productivity is the relation between ‘share of the EU’s GVA (in %)’ and ‘share of the 
EU’s employment’, which is used in this study as a very basic parameter to compare 
manufacturing using enzymes with manufacturing not using enzymes. If the total GVA is 
considered, it can be seen that 2.4% of EU employees generate 2.47% of the EU’s GVA. This 
indicates that, in summary, over all the manufacturing sectors, labour productivity is close to 
1, i.e. one per cent of the labour input factor generates one per cent of value-added.  
 
The look at modern biotechnology applications shows a surprising difference: 1.06% of EU 
GVA is generated by 1.23% of EU employees. This indicates a labour productivity of 0.86, 
i.e. those manufacturing sectors work less efficiently when modern biotechnology is applied. 
 
Disaggregation makes things clearer. Enzyme production is a high tech sector: 0.0078% of 
the EU’s GVA is generated by 0.003% of EU employees, i.e. labour productivity is very high 
(2.6). In the comparative sector of fine chemicals, labour productivity is around 1.5, i.e. 
substantially lower.  
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The results are similar for industrial applications: In pulp and paper as well as in detergents 
manufacturing using enzymes the labour productivity of the production processes using 
enzymes can be 2 or even more. This is much above the EU average, and in all cases equal or 
more to conventional production. Even in the traditional and labour intensive food sector, 
which has an average labour productivity of 0.9, those subsectors which use large quantities 
of enzymes have a labour productivity of 1.2, i.e. they are more efficient. 
 
The important outlier is the production of bioethanol, and with a labour productivity of 0.7, 
shows only 70% of the EU average. This value, however, indicates that this technology is at a 
very early stage in its life cycle, and still has a steep learning curve. The lowering of 
production costs from year to year shows that efficiency gains can be achieved. 
 
As a general conclusion it can be said that the contribution of modern biotechnology to EU 
economic growth and employment is modest in absolute terms, but a new technology, which 
is superior to conventional processes in economic terms, can find its way into the EU 
economy. With the exception of bioethanol, which has attracted a lot of attention as a 
potential substitute for fossil fuels, data availability for industrial biotechnology is poor.  
 
Table 54 summarises the key figures. 
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Table 54: Economic and employment figures for modern industrial biotechnology in the EU  
 
 Year: 2002 
G
V
A
 
(E
U
R
 m
ill
io
n)
 
Sh
ar
e 
of
 E
U
 
G
V
A
 (i
n 
%
) 
Sh
ar
e 
of
 
m
an
uf
ac
tu
ri
ng
 
G
V
A
 (i
n 
%
) 
E
m
pl
oy
m
en
t 
Sh
ar
e 
of
 E
U
 
em
pl
oy
m
en
t 
Sh
ar
e 
of
 
m
an
uf
ac
tu
ri
ng
 
em
pl
oy
m
en
t 
La
bo
ur
 
pr
od
uc
tiv
ity
 
EU GVA (all economic activity) 8 782 816 100.00  200 000 000 100.00  1.0 
NACE D Manufacturing (total) 1 528 982 17.41 100.00 33 000 000 16.50 100.00 1.1 
Direct impacts 
Enzymes 
DG 24.66 
Manufacture of 
other chemical 
products** 
7906 0.09 0.49 117 200 0.06 0.36 1.5 
 Enzyme production* 741 0.0084 0.05 4000 - 6000 
0.002 – 
0.003 
0.015 
– 0.02 
2.8 – 
4.2 
Indirect impacts 
Detergents 
DG 24.51 
Manufacture of 
soap, detergents, 
cleaning and 
polishing** 
7807 0.09 0.51 119 100 0.06 0.36 1.5 
 
Detergents 
containing enzyme 
*** 
4000 0.045 0.26 60 000 0.03 0.18 1.5 
Textiles DB 17.3 Textile finishing 4307 0.05 0.28 121 200 0.06 0.37 0.8 
 Textile finishing using enzymes 2000 0.0227 0.13 48 480 0.024 0.15 0.9 
Pulp and 
Paper 
DE 21.11 
Manufacture of 
pulp* 
2000 0.0227 0.13 22 000 0.011 0.07 2.1 
 
Manufacture of 
pulp using 
enzymes 
300 0.0034 0.02 3000 0.0015 0.01 2.3 
Fuel 
DF 23.2 Refined 
petroleum products 
(calculated with 0.8 
ratio to focus on 
fuel) 
17 579 0.20 1.15 108 000 0.05 0.33 3.7 
 Bioethanol**** 16 0.0002 0.0011 525 0.0003 0.0016 0.7 
Food/Feed DA 15 Manufacture of food products** 181 220 2.06 11.85 4 434 100 2.22 13.44 0.9 
 
Food 
manufactured 
using large enzyme 
quantities 
69 927 0.8 4.57 1 375 400 0.69 4.17 1.2 
 Total sectors 212 914 2.42 13.93 4 804 400 2.40 14.56 1.0 
 Total indirect impacts 76 243 0.87 4.98 1 487 405 0.74 4.51 1.2 
Total sectors 220 819 2.51 14.42 4 921 600 2.46 14.91 1.0 
Total modern biotechnology 
contribution 76 984 0.88 5.03 1 493 405 0.75 4.53 1.2 
*Estimate; **2003 data; ***Detergents calculated with enzymes share = 50%; ****2005 data, only direct employment 
counted 
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3 Contribution of modern biotechnology to environment and energy 
3.1 General outline and overall contribution of modern biotechnology 
 
Regarding ‘environment and energy’, relevant EU policies are described in the following 
documents: the Sustainable Development Strategy301, the 6th Environmental Action 
Programme302, the Environmental Technology Action Plan303, the Green Paper on energy 
supply304, and are considered in the Common Agricultural Policy as well as the Common 
Fisheries Policy305. 
 
The policy objectives that were derived from these sources are: i) improved resource 
productivity, ii) better waste prevention, iii) improved air, soil and water quality, iv) better 
preservation of biodiversity, v) reduction of greenhouse gas emissions and vi) improved 
energy supply security (see Annex 1 – Methodology).  
 
The contributions of modern biotechnology to these policy objectives differ widely between 
the individual application areas. The more obvious contributions of modern biotechnology 
relate to improvements in resource productivity and reductions of greenhouse gas emissions: 
increasing production efficiency and reducing input use has been a main objective of technical 
innovations both in primary and in industrial production, and replacing fossil fuels by bio-
ethanol can also reduce the emission of greenhouse gas in the EU. At the same time, 
diversifying the energy portfolio with the help of renewable energy sources such as 
bioethanol could also improve energy supply security. In primary production, improvements 
in resource productivity assisted by modern biotechnology are also linked to improvements in 
nutrient or other harmful substance emissions, mainly by lowering the relevant emissions per 
unit output. Moreover, direct impacts have been realised, such as the replacement of drug and 
antibiotic treatments, with the use of vaccines in animal production, many of which are 
produced using modern biotechnology. Furthermore, modern biotechnology supported the 
reduction of harmful emissions due to the use of improved crop varieties or biotechnology-
based feed additives. In industrial production, modern biotechnology also leads to reduced 
waste generation and less water usage. Together with reduced emissions, this can be expected 
to improve air, soil and water quality. Regarding the preservation of biodiversity, concerns 
have been raised about potential risks from the cultivation of genetically modified organisms 
(GMO), which requires a case-by-case evaluation. To this end, the EU has put in place 
                                                 
301 European Commission COM (2001) 264 final: Communication from the Commission  A Sustainable Europe 
for a Better World: A European Union Strategy for Sustainable Development. http://europa.eu/eur-
lex/en/com/cnc/2001/com2001_0264en01.pdf; AND: Council of the European Union (2006) DOC 10917/06: 
Renewed EU Sustainable Development Strategy.  
http://register.consilium.europa.eu/pdf/en/06/st10/st10917.en06.pdf.  
302 European Commission COM (2001) 31 final. Communication from the Commission to the Council, the 
European Parliament, the Economic and Social Committee and the Committee of the Regions on the sixth 
environment action programme of the European Community 'Environment 2010: Our future, Our choice' - The 
Sixth Environment Action Programme.  
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2001:0031:FIN:EN:PDF 
303 European Commission COM (2004) 38: Communication from the Commission to the Council and the 
European Parliament - Stimulating Technologies for Sustainable Development: An Environmental Technologies 
Action Plan for the European Union. http://ec.europa.eu/environment/etap/pdfs/com_2004_etap_en.pdf 
304 European Commission COM (2006) 105: Green Paper A European Strategy for Sustainable, Competitive and 
Secure Energy. http://ec.europa.eu/energy/green-paper-energy/doc/2006_03_08_gp_document_en.pdf.  
305 European Commission (2007). Common Agricultural Policy: http://ec.europa.eu/agriculture/index_en.htm; 
About the Common Fisheries Policy. http://ec.europa.eu/fisheries/.  
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specific legislation making obligatory the carrying out of comprehensive risk assessments 
before placing such products on the EU market.  
 
While the overall contribution of modern biotechnology to the different environmental 
objectives is impossible to quantify in absolute terms, the fact that modern biotechnology 
applications lead, in general, to improvements in the eco-efficiency of production processes, 
while being themselves a new source of economic activity, strengthen its role in assisting in 
the decoupling between economic growth and environmental pressures. 
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3.2 Human and animal health biotechnology 
 
Biotechnology-based products used for the treatment (or diagnosis) of humans or animals 
may have a potential impact on the environment as a result of their use and/or manufacturing. 
Although direct evidence for this has been scarce, it is often thought that the production of 
medicinal products using biotechnological approaches (e.g. recombinant DNA technology) 
might have fewer negative consequences on the environment than previous methods. One 
example to this end could be the production of recombinant human insulin, which replaced 
the extraction of insulin from animal pancreases. Although there are no specific data on the 
environmental consequences of the animal pancreas extraction process, it is likely to have had 
significant environmental impacts as it involved extraction of insulin from large quantities of 
imported animal pancreases and required the disposal of a large residue of biological matter.  
 
The potential environmental impact of biotechnology-based products has been recognised by 
regulatory authorities. In the EU, Directive 2001/83/EC306 relating to medicinal products for 
human use first introduced a requirement for the assessment of the environmental impact of 
such products on a case-by-case basis, prior to being given marketing authorisation. The 
Directive also requires that specific arrangements to limit impacts are considered. In this 
context, the European Medicines Agency (EMEA) has recently published guidelines on the 
environmental risk assessment of medicinal products for human use307 which focus on the 
potential risks arising from the use of the products and not from their manufacturing. Another 
EMEA guideline also addresses the environmental risk assessment of products containing or 
consisting of genetically modified organisms308, based on the requirement of pharmaceutical 
legislation (Regulation EC/726/2004309) that human medicinal products respect the 
environmental safety requirements foreseen in Directive 2001/18/EC310 on the deliberate 
release into the environment of genetically modified organisms. At the same time ERAPharm, 
a programme funded by the EU Research Framework Programme 6 and aiming at improving 
the scientific basis and the methods for evaluating potential risks that pharmaceuticals pose to 
the environment, is expected to finalise its results and provide relevant recommendations in 
2007311.  
 
In addition to biopharmaceuticals, biotechnology is applied to the development of non-
biotechnology drugs, e.g. small molecules or fine chemicals. The share of biotechnology 
processes related to chemical processes is estimated to be between 10% and 15%. Their 
                                                 
306 Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community 
code relating to medicinal products for human use. OJ L 311, 28/11/2004, p. 67-128. 
http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/consol_2004/human_code.pdf. 
307 Committee for Medicinal Products for Human Use (2006). Guideline on the environmental risk assessment of 
medicinal products for human use. EMEA/CHMP/SWP/4447/00. European Medicines Agency, London. 
http://emea.europa.eu/pdfs/human/swp/444700en.pdf.  
308 Committee for Medicinal Products for Human Use (2005). Environmental risk assessments for medicinal 
products containing, or consisting of, genetically modified organisms (GMOs). European Medicines Agency, 
London. http://emea.europa.eu/pdfs/human/bwp/13514804en.pdf. 
309 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for human and veterinary use 
and establishing a European Medicines Agency. OJ L 136, 30.4.2004, p. 1. 
http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf. 
310 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate 
release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ 
L 106, 17.4.2001, p. 1. http://europa.eu.int/eur-lex/pri/en/oj/dat/2001/l_106/l_10620010417en00010038.pdf. 
311 Internet: http://www.erapharm.org/. 
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application in the manufacturing of health related products, such as antibiotics, might have a 
positive impact on the environment by improving resource and energy use, reducing 
emissions of other pollutants to water, air and soil, and reducing waste generation. One 
example illustrating this point is the production of cephalosporin, discussed in Section 3.4.3.5.  
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3.3 Agro-food biotechnology 
3.3.1 The relevance of primary production and agro-food to environment and energy 
 
The agro-food sector interacts in a variety of ways with the environment. Section 2.3.3 
provides a detailed description of the sector as well as of the use of modern biotechnology 
within the sector. Therefore, this section will only address the energy and environment 
relevant issues.  
 
The agro-food sector, in life cycle terms, has been identified as being one of the major 
contributors to environmental pressures in the EU, of which animal products account for a 
significant share312,313. For a comprehensive evaluation of the environmental implications of 
the agro-food sector, the complete life cycle of the supply chain needs to be taken into 
account (see Figure 27). Previously conducted life cycle assessments in agro-food have 
indicated that the largest share of environmental pressure is associated with the primary 
production phase. Moreover, as indicated in Section 2.3, modern biotechnology is mainly 
relevant in two phases of the agro-food supply chain: 
• the primary production stage, which includes agriculture and fisheries activities 
• the industrial manufacturing stage, which includes the production of inputs as well as 
the downstream processing of products from the primary production sector.  
 
The environmental issues of the agro-food related manufacturing activities (i.e. enzyme 
production and use, e.g. for feed additive production and food processing) are common to 
those covered in Section 3.4 on industrial biotechnology and will be presented there.  
 
At the primary production phase, the agricultural sector (including animal production) is a 
major source of environmental pressure as farmers manage more than half of the EU land 
area314. Agricultural activities are relevant for a range of environmental concerns315, the main 
ones being the pollution of surface waters and seas by nutrients and pathogens, the pollution 
of groundwater by nitrate and pesticides, the loss of biodiversity through habitat degradation 
and ultimately the loss of species, the pollution of air through greenhouse gases and other air 
pollutants that contribute to climate change and acidification, and the over-abstraction of 
water for irrigation. Agriculture (at the farm stage) is a major contributor to all of the above 
environmental pressures, but to a lesser extent for the emission of greenhouse gases and the 
use of energy and the emission of tropospheric ozone precursors: it is responsible for about 
10% of greenhouse gas emissions and less than 5% for use of energy and ozone precursors.  
 
 
                                                 
312A. Tukker, G. Huppes, J. Guinée, R. Heijungs, A. de Koning, L. van Oers, S. Suh, T. Geerken, M. Van 
Holderbeke, B. Jansen, P. Nielsen. Editors: P. Eder and Delgado L. (2006). Environmental Impact of Products 
(EIPRO) - Analysis of the life cycle environmental impacts related to the final consumption of the EU-25. 
European Commission, IPTS, EUR 22284. http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1429. 
313 Steinfeld, H. et al. (2006). Livestock’s long shadow: environmental issues and options. Food and Agriculture 
Organisation, Rome. http://www.virtualcentre.org/en/library/key_pub/longshad/A0701E00.pdf.  
314 EEA (2006), Land accounts for Europe 1990 – 2000: Towards integrated land and ecosystem accounting, 
EEA Report No 11/2006. http://reports.eea.europa.eu/eea_report_2006_11/en/eea_report_11_2006.pdf. 
315 EEA (2006), Integration of environment into EU agriculture policy — the IRENA indicator-based assessment 
report. EEA Report No 2/2006. http://reports.eea.europa.eu/eea_report_2006_2/en/IRENA-assess-final-web-
060306.pdf. 
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Figure 27: The life cycle of the agro-food supply chain 
 
As far as the fishery sector is concerned for harvest fisheries, the main environmental issue is 
related to biodiversity loss through overfishing, while for aquaculture, the concerns are 
similar to those encountered in agriculture, but to a lesser extent in absolute terms, as the 
sector itself is considerably smaller. Fish farming may, however, be an important contributor 
to environmental pressure at a local scale, such as regarding nutrient emissions to the aquatic 
environment. Moreover, fish farming has some additional environmental concerns that are 
specific to the sector, such as the transfer of pathogens and potential genetic impacts to wild 
fish populations.  
 
The likely developments of environmental pressure from economic activities of the primary 
sector depend on two main factors: 1) the level of activity and 2) its eco-efficiency (i.e. the 
environmental impact per unit output). It is, therefore, the interaction between these two 
factors that will determine the final outcome. For the agricultural sector, data from the 
European Environment Agency (EEA) for the period 1990 - 1998 indicate that while the 
GVA increased by 5%, so did the eco-efficiency of agriculture, resulting in absolute 
decoupling between acidifying substances and ozone precursors316. While there was also an 
improvement in the eco-efficiency for energy use and related greenhouse gas emissions, the 
use of energy, water and irrigated land, as well as of fertilisers and pesticides was 
comparatively stable in absolute terms (see Figure 28). Overall, in the 1990s there was a 
                                                 
316EEA (2005). The European environment - state and outlook 2005. EEA Report No 1/2005. 
http://reports.eea.europa.eu/ state_of_environment_report_2005_1/en/SOER2005_all.pdf. 
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limited improvement in the eco-efficiency of the agricultural sector, when compared with the 
energy and industry sectors. 
 
 
 
Figure 28: Eco-efficiency of agriculture in the EU  
Source EEA316 
 
Recent trends and forecasts show some decoupling of the agricultural economic activity from 
some environmental pressures (see Figure 29). 
 
Of interest in primary production is the discussion surrounding the levels of intensity of 
different production systems. Nevertheless, improvements in eco-efficiency may take place in 
both intensive and extensive (such as the so-called High Nature Value farmland, HNV) 
systems, and may involve improvements in all environmental issues, such as in resource use 
as well as in emissions of harmful substances. While biodiversity of wild fauna and flora is, in 
general, higher in HNV farmland when compared with the intensive system type, and several 
national livestock breeds are better fit to specific HNV farmlands, they are in general not 
competitive in the global market, and therefore, specific targets have been set towards the 
conservation of HNV farmland through agri-environmental measures under the EU’s 
Common Agricultural Policy.  
 
In general, R&D has been important for the introduction of technological innovations that 
have improved resource productivity, and environmental pressure. Other factors, such as 
sector structural changes, have however also been important. 
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Figure 29: Decoupling in the agriculture sectors 2000 and 2010 - outlook for key environmental resources 
and pressures  
Source EEA317 
 
Besides the core generic environmental indicators that are used in global comparisons, there 
are other issues of a more specific nature, which may have important environmental 
implications because e.g. being related to higher and/or more immediate potential risks, of 
high uncertainties regarding potential risks, of a high local relevance. These issues may be 
relevant only in specific sectors/applications/environments which renders their full coverage 
and analysis in this study difficult. Such issues will be mentioned, however, wherever they are 
of relevance to modern biotechnology in the following sections. 
 
 
3.3.2 The contribution of agro-food biotechnology  
 
The application of modern biotechnology may have diverse effects on the environmental 
performance of the agro-food sector. This analysis follows the same structure as in Section 
2.3, in the sense that it looks at both direct and indirect impacts. Direct impacts relate to the 
activities using modern biotechnology whereas indirect impacts relate to the activities using 
biotechnology-derived products. As described in Section 2.3, the first are to be found almost 
exclusively with the providers of inputs to primary production and food processing, which 
mainly comprise manufacturing and breeding activities. Therefore, the direct environmental 
impacts are relevant for the activities of these subsectors, while the indirect environmental 
impacts are related to the activities of biotechnology product users, mainly in the farming and 
food processing sectors. 
 
 
3.3.2.1 Breeding and propagation  
 
The environmental effects of modern biotechnology applications in breeding and propagation 
are relevant almost entirely at the level of farming (i.e. indirect impacts). Firstly, the 
                                                 
317 EEA (2005). The European environment - state and outlook 2005. EEA Report No 1/2005. http://reports. 
eea.europa.eu/state_of_environment_report_2005_1/en/SOER2005_all.pdf. 
The Bio4EU Analysis report 145
production of biotechnology products, e.g. seeds and other propagating material, embryos, 
eggs and fry, breeders, does not really involve major qualitative differences in environmental 
terms compared to the grow-out phases; and secondly, the environmental exchanges during 
the production of biotechnology products, take place on a much smaller scale compared to the 
grow-out phases (i.e. in number of inputs used, output produced, etc.). 
 
This analysis will, therefore, concentrate on environmental implications at the farm-level. As 
potential changes in the environmental effects depend more and more on the specific 
technology rather than the sector to which it is applied, the analysis is structured by 
technology. Where additional issues specific to different users arise, these are discussed 
accordingly. 
 
The major breeding and propagation goals is to drive genetic selection, which has been 
traditionally aimed at improving agronomic traits, such as yield, efficiency, and resistance to 
various stress factors, and is now more and more aimed at more complex traits, such as 
product quality traits and disease resistance. While it is not possible to provide an exhaustive 
analysis of the change in the environmental performance of all production systems for all 
selection schemes, in general, genetic improvements have led, directly or indirectly, to 
improvements in productivity and/or efficiency over the years for all species of agricultural 
relevance (plants, animals and fish).  
 
As a general rule, and as discussed above, technical change and innovation has had either a 
neutral or a positive effect on eco-efficiency while the level of economic activity in the 
various subsectors has been stable or increasing. Genetic selection has been considered an 
important driver of productivity improvements, but it is not the sole factor. Nevertheless, an 
important share of the improvements in resource productivity is also ascribed to genetic 
selection.  
 
 
3.3.2.1.1 Marker assisted selection (MAS) 
 
MAS is applied in a similar way to plants, livestock and fish, i.e. with the aim to aid in the 
selection of desirable traits, either directly or indirectly. When MAS is applied successfully, it 
results in improving the selection and introgression of desirable traits to the commercial 
populations, facilitating therefore conventional breeding schemes. Qualitatively, the impacts 
to be expected are similar to the ones taking place through conventional selection; an 
exception to this rule concerns the selection for traits that, until now, were not amenable to 
conventional techniques, such as disease resistance and product quality related traits (mainly 
multigene determined traits). The environmental implications of MAS will vary qualitatively, 
depending on the trait that is being targeted, and quantitatively, depending on the obtained 
difference in the targeted trait and the level of adoption of the technology. Currently, there is 
no comprehensive information on the specific traits that have been targeted through the use of 
MAS, but it is reasonable to assume that MAS has been used for a few important single 
nucleotide polymorphism (SNP) determined traits and, to a lesser extent, for the more 
complex approach through quantitative trait loci. In addition, molecular markers have been 
used more extensively in all types of breeding schemes for the determination of kinship, 
indirectly supporting breeding schemes, etc. (see Section 2.3.5.1) 
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For example, the case study on MAS in pigs318 provided an overview of the major known 
traits targeted through MAS, none of which were of a direct environmental relevance. In 
general, there are no examples of the use of MAS providing direct benefits or harms to the 
environment, but the indirect impact may be considerable. An example is the improvement of 
the growth rate and food conversion ratio (using both traditional genetics or those supported 
through MAS), which reduces the amount of feed required to produce one kg of meat as well 
as the amount of emissions per unit output. In another example318, the use of MAS to support 
genetic selection for improving the reproductive rate may reduce the amount of pollution 
arising from maintaining the breeding animals, through reducing the number of breeding 
animals that are required to be maintained in order to produce a slaughter generation animal. 
 
As with plants and livestock, the environmental implications of using MAS in fish breeding 
have not been recorded. Nevertheless, the basic principles behind the potential environmental 
relevance of this technology are the same in all applications. In absolute terms, however, the 
impacts are likely to be smaller, as the technology has, until now, been used to a lesser extent 
in fish farming compared to the other sectors. As far as ploidy and sex manipulation are 
concerned, expert opinion suggested positive implications due to the adoption of the 
technology, related to improved production efficiencies, and the reduced need for chemical 
treatment following a decrease of secondary infections caused by aggressiveness and stress318. 
 
The use of modern biotechnology in genetic selection schemes has been criticised to 
negatively affect the genetic diversity of the farmed populations (mainly through reducing the 
available gene pool); however, this is rather a general feature of mainstream agricultural 
practices, whose main goal has been the optimisation of the gene pool in terms of production 
objectives. Modern biotechnology also provides the tools for optimising the impacts on 
genetic diversity, e.g. through supporting the proper design of breeding schemes, as well as 
for mapping genetic diversity and aiding plans for breed/variety conservation and monitoring. 
In this context, the use of molecular information is also fundamental for improving the 
germplasm resources and therefore for the maintenance of the EU’s biodiversity. Modern 
biotechnology provides several tools, while it is the proper use and management of the tool, in 
combination with other factors that determine what the impacts will be. 
 
From the above, a qualitative estimate can be made that MAS, where applied, has mainly 
either a neutral or a beneficial impact on the eco-efficiency of the primary sector. While a 
negative effect cannot be ruled out, such as in situations where the selection of an important 
trait indirectly affects the resource efficiency, it is highly unlikely as resource efficiency also 
has important economic considerations.  
 
 
3.3.2.1.2 Genetically modified crops  
 
Any innovation that results in changing crop management may have an impact on the 
environment. There is scientific consensus that the impact of the introduction of genetically 
modified (GM) varieties has to be analysed case-by-case depending on the nature of the 
genetic modification and the changes in field management prompted by the new 
characteristics of the variety (herbicide tolerance, insect resistance, etc.)319.  
 
                                                 
318 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
319 FAO (2004). The State of Food and Agriculture, 2003 - 2004. Food and Agriculture Organisation, Rome. 
http://www.fao.org/docrep/006/Y5160E/Y5160E00.HTM.  
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In particular, Bt crops can potentially reduce the environmental pressure of intensive 
agriculture (through less spraying of insecticides) but could also have an impact on non-target 
insect species (since the GM plant produces its own insecticide) that must be evaluated. Data 
from Spain on changes in the use of insecticides due to Bt maize cultivation320 show that 42% 
of conventional maize growers versus 70% of Bt maize growers do not use insecticides at all 
for controlling corn borers. Moreover, 21% of conventional maize farmers versus 2% of Bt 
maize growers give two or more treatments per year. On average, conventional maize growers 
applied 0.86 insecticide treatments/year compared with 0.32 treatments/year of Bt maize 
growers. This reduction is modest in absolute terms, because the conventional way of maize 
borer control (replaced through Bt maize) is not based on heavy insecticide use due to its 
limited efficacy.  
 
Regarding the impacts on non-target organisms and the development of resistant pest 
populations, no detrimental effect of farm scale Bt maize cultivation in Spain has been 
observed on the activity and abundance of non-target arthropods, according to research 
commissioned by the Spanish Ministry for the Environment and performed by public 
institutions321. Data released after five years of commercial Bt maize plantings (1998 - 2003 
period) did not show an increase in Bt-toxin resistance for corn borer populations sampled in 
Spain. However, the researchers argue for the need to maintain the systematic monitoring 
activity for longer periods. It should also be mentioned that any GM product currently 
available for growing in the EU needs to go through an obligatory risk assessment, including 
an environmental risk assessment. 
 
 
3.3.2.1.3 Micropropagation 
 
Micropropagation has rather marginal environmental implications compared to MAS and 
genetic modification as it does not affect the breeding value of the crop in question; it is 
merely involved in the multiplication step of the breeding process. Nevertheless, the 
following environmental implications may be considered, even if, in absolute terms, the 
impacts are likely to be small322: i) micropropagation will indirectly improve the efficiency of 
the breeding process through the multiplication of desirable genotypes, and therefore it will 
have some share in the change that the related breeding scheme induces; ii) the field growing 
periods are shortened compared to conventional seed-based propagation which implies a 
reduction of water, fertiliser and pesticides used; iii) micropropagation techniques can ensure 
that propagating material is disease-free, reducing pathogen transfer. 
 
 
3.3.2.1.4 Embryo transfer (ET) 
 
As ET is not directly involved in altering breeding value but only in the propagation (and 
therefore faster dissemination) of desired genotypes, the main environmental impact is based 
on assisting the rapid and cost-effective dissemination of improved resource productivity 
based on genetic improvements. For example, the number of cattle in the EU is declining 
whilst output is steady or increasing. This is particularly obvious for milk production, which 
                                                 
320 Gómez-Barbero, M., J. Berbel and Rodríguez-Cerezo E. (2007). Adoption and socioeconomic impacts of the 
first genetically modified crop introduced in EU agriculture: Bt maize in Spain. European Commission, Seville. 
(Publication in preparation.) 
321 De la Poza, M., et al. (2005). Crop Protection, 24: 677-684. http://dx.doi.org/10.1016/j.cropro.2004.12.003.  
322 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
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has been the focus of selection for the last fifty years. In the EU-15, cattle numbers decreased 
from 1994 to 2001 (with the exception of Sweden) by approximately 11%. In the same period 
the average milk yield per head increased by 17%323. Embryo transfer combined with embryo 
freezing provides a very effective means of conserving biodiversity where breeds are under 
threat (it is more efficient for the recovery of a breed than frozen semen as semen only 
provides a hybrid in the first instance and it is then necessary to go through rounds of 
backcrossing to recover the lost breed) or for salvaging a population, for example, when 
eradication is required for disease control purposes (e.g. to control foot and mouth disease 
outbreaks)324. 
 
 
3.3.2.2 Feed additives and veterinary products325  
 
Feed additives (whether biotechnology-based or not) in general optimise nutrient utilisation, 
thereby resulting in improvements of the environmental performance of animal production. 
Some feed additives have a direct environmental objective, such as some of the feed enzymes. 
Phytase addition, for example, is aimed towards the reduction of phosphorus emissions in pig 
and poultry production. On the other hand, many feed additives induce indirect environmental 
benefits by optimising nutrient metabolism and utilisation, such as the case of the amino acid 
lysine, which by optimising nitrogen metabolism, results in the reduction of nitrogen 
excretion in pig production326. Moreover, as the addition of lysine to pig feeds is associated 
with a concomitant replacement of soya beans by wheat or maize, and as the area needed to 
grow soya beans is larger than the respective area for maize or wheat, the use of lysine may 
also result in a considerable reduction of the agricultural area needed per unit output327. In 
general, as low protein and low phosphorus diets are increasingly used in animal production, 
partly due to stricter restrictions in environmental regulations, the use of such feed additives is 
gaining in importance. 
 
The environmental implications of modern biotechnology applied in the production of animal 
health products are in general positive: firstly, there is a general trend towards prevention 
(vaccination and other immuno-stimulation methods, most of which are increasingly 
biotechnology-based) which leads to a decrease in the use of chemical treatments (e.g. 
antibiotics). A decrease in the use of antibiotics will reduce the occurrence of microbial 
resistance to antibiotics, while marker-vaccines are more effective in eradication programmes 
therefore reducing the number of animals that need to be culled. Moreover, the prevention of 
disease and the subsequent disease eradication inherently implies improvements in production 
efficiency associated with a healthy stock.  
                                                 
323 Table 4.1 in: Liinamo, A.-E. and Neeteson-van Nieuwenhoven A. (2003). Economic value of livestock 
production in the EU – 2003. Farm Animal Industrial Platform, Oosterbeek. 
http://www.effab.org/publications/effab-publications/doc_details/55-economic-value-of-livestock-production-in-
the-eu-2003.  
324 ETEPS (2006). Bio4EU Task 2 Case studies report – Primary Production and Agro-food Applications. 
325 The environmental implications at the manufacturing stage can be found in Section 3.4. 
326 Gâtel, F. and Porcheron E. (2003). The role of cereals in the European protein supply. In: Protein 
requirements and supply for a competitive European pig production in 2010: protein supply for European pigs 
2010. Proceedings of a European Workshop, March 18, Brussels. Fefana, Brussels, p. 23-27. 
http://www.fefana.org/Publications.aspx.  
327 Toride, Y. (2002). Lysine and other amino acids for feed: production and contribution to protein utilisation in 
animal feeding. In: Protein sources for the animal feed industry: FAO Expert Consultation and Workshop, 29 
April - 3 May, Bangkok. Food and Agriculture Organisation, Rome, p. 161-166. 
http://www.fao.org/docrep/007/y5019e/y5019e00.htm.  
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3.3.2.3 Modern biotechnology-based diagnostics 
 
In environmental terms, the adoption of modern biotechnology-based diagnostics brings about 
improvements (efficiency and/or accuracy) in avoiding potential environmental contamination 
(e.g. Salmonella) and/or animal culling in the case of outbreaks (e.g. BSE, FMD). Moreover, 
modern biotechnology-based diagnostics for tracing GMOs in the food chain also permit the 
long-term monitoring of GMOs in the environment, which is crucial for the post-marketing 
environmental monitoring and general surveillance that supplement the environmental risk 
assessments of GMOs under current EU legislation. 
 
 
3.3.3 Summary 
 
Food consumption is an important driver of major environmental pressures. Agro-food related 
modern biotechnology has environmental implications mainly for two stages of the agro-food 
chain, namely the primary production and manufacturing of input and food processing. The 
use of modern biotechnology in the manufacturing stage is, in general, beneficial for the 
environment as it is characterised by improvements in resource efficiency and related 
emissions (for more details see Section 3.4). However, it is the primary production stage that 
is considered to be the most important contributor for most of the relevant environmental 
pressures. Generally speaking, the adoption of modern biotechnology indirectly has positive 
environmental implications in primary production, as increased production efficiency has 
been a main target of technical innovations, and as a decoupling between economic growth 
and environmental pressures has been, at least partially, demonstrated. More direct impacts 
have also been realised, such as the reduction of drug and antibiotic treatments in animal 
production, partially enabled through the use of (recombinant) vaccines, or the reduction of 
harmful emissions through the use of modern biotechnology derived feed additives.  
 
It should be stressed, however, that some modern biotechnology applications may also raise 
new challenges, requiring a case-by-case evaluation of specific aspects or potential risks. To 
this end, the EU has put in place specific legislation making obligatory the carrying out of 
comprehensive risk assessments before placing such products on the EU market.   
 
In terms of overall environmental pressure, the EU primary production sector has been 
witnessing a relative stabilisation and/or decrease of farm-level economic activities in recent 
years, while technical efficiency has been improving328. Moreover, for some specific sectors, 
growth rates are still positive or are expected to increase even further in the near future (e.g. 
for the production of energy crops). The challenge for modern biotechnology will therefore be 
to provide the tools towards further improving resource productivity and aiding in the 
decoupling of economic growth from environmental pressures.  
 
                                                 
328 Scenar 2020 – Scenario study on agriculture and the rural world. European Commission, DG Agriculture and 
Rural Development, http://ec.europa.eu/agriculture/publi/reports/scenar2020/indextech_en.htm. 
150   The Bio4EU Analysis report 
3.4 Industrial biotechnology 
 
Industrial biotechnology has impacts on resource and energy use, greenhouse gas (GHG) 
emissions, emissions of other pollutants to water, air and soil, and on the generation of waste. 
In the analysis of environmental impacts of industrial biotechnology, those sectors in the 
manufacturing sector (according to NACE) are looked at in which industrial biotechnology is 
applied. The key parameter in the analysis is the contribution to GHG emissions, and, related 
to that, the impact on energy use. In the majority of cases analysed here, the main part of 
carbon dioxide (CO2) emissions stems from the energy used for industrial processes. 
Therefore a replacement of chemical processes with biotechnological ones usually reduces 
emissions directly in the process and through the reduced energy demand. Furthermore, the 
impact on water use and emission of pollutants to different environmental media is analysed. 
Where possible, the environmental impact of manufacturing using enzymes will be compared 
with the respective benchmark sector which does not use enzymes.  
 
 
3.4.1 Overview of anthropogenic greenhouse gas emissions 
 
When looking at the environmental impact of modern biotechnology in industrial 
manufacturing processes, the effect on GHG emissions is one of the key elements in the 
analysis for various reasons: climate change is amongst the environmental challenges with a 
high priority, GHG emissions are a EU-wide problem (with global repercussions), and the 
emissions are produced directly through industrial processes and indirectly through industrial 
fuel combustion, i.e. the energy generated for these industrial processes. From the opposite 
perspective this means that an alternative (biotechnological) production process can 
potentially affect GHG emissions at the source in industrial processes and through a changed 
industrial energy demand. 
 
Figure 30 shows the distribution of anthropogenic GHG emissions in the EU for 2004. CO2, 
methane (CH4) and nitrous oxide (N2O) are the three most important GHGs. CO2 with 83% is 
by far the largest contributor; CH4 and N2O contribute with 7.5% and 8% respectively. The 
remaining 1.5% is generated by hydrofluorocarbons (HFCs), perfluorocarbons (PFCs) and 
sulphur hexafluoride (SF6). Overall, industrial processes generate directly 8% of GHG 
emissions, and another 13% through industrial combustion. Transport contributes with 21% to 
overall GHG emissions in the EU. More than 90% of transport related emissions are 
generated by the combustion of road transport fuels (two thirds diesel and one third petrol 
combustion). 
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Figure 30: Anthropogenic greenhouse gas emissions by sectors in the EU (2004)329 
CO2, CH4, N2O, HFC, PFC, SF6; all measured in CO2 equivalent; HFC, PFC, SF6 together contribute around 
1.5% to overall GHG emissions, not shown. 
 
A look at the individual GHG emissions shows that the major contributors to CO2 emissions 
are transport, energy generation and industry (see Figure 30). CH4 is generated mainly by 
agriculture, waste treatment and energy generation. The main N2O emission contributors are 
agriculture and industrial processes. The remaining 1.5%, composed of HFCs, PFCs and SF6 
are generated mainly by industry. 
 
 
                                                 
329 Calculated on the basis of the progress report of the EU to the IPCC, submission 2006, in: EEA (2006). The 
European Community’s initial report under the Climate Change Protocol, Annex 2. European Environment 
Agency, Copenhagen. http://reports.eea.europa.eu/technical_report_2006_10/en/index_html.  
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3.4.2 Greenhouse gas emissions of the manufacturing sector 
 
In Section 2.4 on economic impacts of industrial biotechnology, NACE categories have been 
identified, in which industrial biotechnology is applied. NACE categories are used for 
consistency and comparability, but the actual Eurostat information, which served as a 
framework for the economic analysis, provides no information on environmental impacts. The 
main industrial biotechnology applications can be found in the following sectors (for details 
see Section 2.4.1): 
 
• NACE DA 15: Manufacture of food products, beverages 
• NACE DB 17 Manufacture of textile and textile products 
• NACE DB 18: Manufacture of apparel; dressing and dyeing of fur 
• NACE DC 19: Manufacture of leather and leather products 
• NACE DE 21: Manufacture of pulp, paper and paper products 
• NACE DG 24: Manufacture of chemicals, chemical products and man-made fibres 
 
This list is not exhaustive. Enzymes are used in other industrial sectors as well, such as 
mining (bioleaching), but these applications are applied to such a limited extent that they are 
not relevant when analysing the environmental impact of industrial biotechnology in the EU. 
 
In the context of this analysis it is of interest to know which of the above listed manufacturing 
sectors are the strongest contributors to CO2, CH4 and N2O emissions. Eurostat provides very 
scattered data on GHG emissions by industrial sector. The GHG emission contributions of the 
individual NACE categories can only be derived on the basis of 2001 data for four countries 
(Denmark, Germany, Italy and the UK)330 (see below).  
 
 
Carbon dioxide 
As can be seen in Figure 30, industrial processes directly contribute 6% to CO2 emissions, 
and indirectly an additional 16% through industrial fuel combustion, i.e. the generation of 
energy used for these processes. Together this represents a share of 22%. The contribution of 
the individual industrial sectors to these emissions is shown in Figure 31.  
 
The following sectors are the manufacturing sectors which emit the most CO2 and apply 
industrial biotechnology: 
• chemicals:12% 
• food, beverages, tobacco: 7% 
• pulp and paper: 6% 
• textiles: 2% 
• leather: < 1% 
 
Together these sectors emit about 27% of the CO2 emissions of the manufacturing sector, i.e. 
emissions on which industrial biotechnology might impact. These figures only relate to 
immobile emission sources. The mobile sources have to be included, i.e. transport fuels, 
which make 25% of all CO2 emissions and thereby represent one of the largest contributors. 
                                                 
330 Data from Eurostat (http://epp.eurostat.ec.europa.eu/). For detailed values, see Annex 4. It is assumed that the 
GHG emission distribution of these four countries can be extrapolated to the EU as a whole. 
The Bio4EU Analysis report 153
The transport sector’s impact on CO2 emissions is affected by industrial biotechnology 
because of the application of bioethanol.  
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Figure 31: Contribution of NACE manufacturing sectors to CO2 emissions 
Source: data from Eurostat331, IPTS calculations; n.e.c.: not elsewhere classified 
 
As can be seen in Figure 30, industrial processes directly account for 6% of CO2 emissions. 
Under the assumption that modern biotechnology is applied in sectors responsible for 27% of 
CO2 emissions of the manufacturing sector, it shows that modern biotechnology could 
influence about 1.6% of CO2 emissions332. As one central characteristic of enzymatic 
processes in industry is the reduction of energy use, the CO2 emissions from industrial fuel 
combustion could be reduced as well, although this effect is difficult to quantify, as the main 
industrial sectors demanding energy (metal and steel, non-metallic mineral products) do not 
apply industrial biotechnology.  
 
 
Methane 
In the case of CH4 emissions, the contributions of those manufacturing sectors in which 
industrial biotechnology is applied are: 
 
• food, beverages, tobacco: 34% 
• chemicals: 30% 
• textiles: 4% 
• pulp and paper: 2% 
                                                 
331 Eurostat data from the online database. http://epp.eurostat.ec.europa.eu/. 
332 Considering the share of CO2 emissions of the manufacturing sector out of the overall GHG emissions (5%) 
and based on the 27% share that modern biotechnology applying sectors have in these CO2 emissions, modern 
biotechnology could influence about 1.3% of the overall GHG emissions. 
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Figure 32: Contribution of NACE manufacturing sectors to methane emissions 
Source: Data from Eurostat333, IPTS calculations; n.e.c.: not elsewhere classified 
 
This totals 70% of the CH4 emissions of the manufacturing sector. However, as can be seen in 
Figure 30, industrial processes have a negligible contribution to methane emissions. Most of 
the emissions are caused by agriculture and waste disposal. Therefore CH4 emissions will not 
be taken into further account in this analysis.  
 
 
Nitrous oxide  
Figure 30 shows that N2O emissions account for 8% of total GHG emissions. Most of this is 
generated by agriculture, industrial processes contribute 14%. This share is mainly generated 
by chemicals, representing a share of 87% of manufacturing N2O emissions (Figure 33). 
 
                                                 
333 Eurostat data from the online database. http://epp.eurostat.ec.europa.eu/. 
The Bio4EU Analysis report 155
 
87%
4%
3%
1%
1%
1%
1%
1%
1%
Food, beverages, tobacco
Textiles
Leather
Wood
Pulp and paper
Chemicals
Rubber, plastic
Other non-metallic mineral products
Basic metals, fabricated metal
products
Machinery and equipment
Electrical and optical equipment
Transport equipment
Manufacturing n.e.c.
 
Figure 33: Contribution of NACE Manufacturing sectors to nitrous oxide emissions 
Source: Data from Eurostat334, IPTS calculation; n.e.c.: not elsewhere classified 
 
 
 
Summarising the above information, it can be concluded that industrial processes in general 
(with and without enzymatic processes) only contribute to a limited extent to overall GHG 
emissions (8%, see Figure 30). These emissions consist of CO2 emissions (5%), N2O 
emissions (1.1%), and HFCs, PFCs and SF6 (together 1.5%). The industrial fuel combustion 
to generate the energy for all industrial processes contributes with 13.3% to GHG emissions, 
which is more than the industrial processes themselves (see Figure 34). 
 
The manufacturing sectors in which industrial biotechnology can be applied generate around 
2.1% of overall GHG emissions (1.1% CO2 and 1% N2O, other GHG not taken into account). 
As the industrial N2O emissions are almost exclusively generated by the production of two 
chemical substances (nitric acid and apidic acid), and these are not produced 
biotechnologically, the following analysis of industrial emissions concentrates exclusively on 
CO2 emissions. 
 
                                                 
334 Eurostat data from the online database. http://epp.eurostat.ec.europa.eu/. 
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Figure 34: Contribution of manufacturing with and without biotechnological processes to GHG emissions 
in the EU (all values in %) 
 
The transport sector contributes 21.4% to overall GHG emissions (20.8% CO2, 0.1% CH4 and 
0.5% N2O). 37% of GHG emissions from transport are generated through petrol combustion, 
which corresponds to a share of 7.9% to overall GHG emissions. As the application of 
modern biotechnology in the transport fuel sector is limited to bioethanol, these 7.9% 
represent the emissions which can be addressed through the substitution of petrol. As in the 
case of industrial GHG emissions, the analysis of environmental impacts of biofuel will 
concentrate exclusively on CO2 emissions. 
 
 
3.4.3 The contribution of industrial biotechnology 
3.4.3.1 Enzyme production 
 
The production of enzymes as an intermediate chemical product has environmental impacts 
itself in terms of energy use, process related GHG emissions and pollution to different 
environmental media. However, the actual impact is difficult to measure. The production of 
enzymes is targeted at a heterogeneous variety of applications in industry, partly replacing 
existing processes, and partly being used for new products. It is not possible to collect 
information on all the different ‘conventional’ chemical production processes and to 
benchmark enzyme production against them; however, fragmented information exists. Two 
issues are of interest in the context of this analysis: the replacement of chemical catalysts with 
enzymes, and the replacement of conventionally produced enzymes with enzymes produced 
with genetically modified organisms. 
 
 
Example animal feed additive 
 
Most environmental impact studies in the area of industrial biotechnology focus on 
environmental effects in the production process, in which an enzyme is applied, e.g. 
enzymatic processes in the textile industry (see below Section 3.4.3.2). Little information is 
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available analysing the environmental impacts of enzyme production itself. One example of 
comparing the actual production process of enzymes with the chemical it replaces has been 
provided by industry.  
 
The enzyme Ronozyme, a phytase, serves to replace the animal feed additive monocalcium 
phosphate (MCP). Novozymes carried out a comparative life cycle assessment (LCA) which 
did not only look at the environmental savings from the application of the end product in pig 
feed, but also considered the production process itself335. The production of the enzyme is 
superior in all analysed environmental categories. Most notably, it takes 26 MJ to produce one 
kg of Ronozyme, while it takes 400 MJ to produce 29 kg of MCP (1 kg Ronozyme replaces 
29 kg MCP). The difference in the impact on global warming is similar, as most of the CO2 
emissions are produced by the energy generation for the production processes. The overall 
environmental savings, including the production process and application, are shown in Table 
55. 
 
Table 55: Comparative LCA for ronozyme phytase (1 kg) and monocalcium phosphate (MCP, 29 kg) 
Source: Nielsen and Wenzel 2006335 
 
Impact category Ronozyme phytase MCP Relation MCP/Ronozyme 
Global warming, g CO2 eq 1900 32000 17 
Acidification, g SO2 eq 4.8 530 110 
Nutrient enrichment, g PO4 eq 2.2 1500 700 
Photochemical ozone formation, g C2H4 
eq 1.5 12 8 
Phosphate rock, g <0.1 24000 >240000 
Primary energy, MJ 26 400 15 
Agricultural land, m2/year 0.15 0 0 
 
This is one isolated example, which does not allow drawing general conclusions with regard 
to environmental superiority of enzyme production. However, the replacement of large 
quantities of chemical catalysts (or other chemical intermediates) with comparably low 
quantities of enzymes seems to be the rule (see below in Section 3.4.3.2 examples for the pulp 
and paper and the textiles sector). Against this background it can be concluded that generally 
less energy is used in the production of enzymes than in the production of those substances 
they replace, and that accordingly CO2 emissions are reduced, and thus the climate change 
impact (although this cannot be quantified). 
 
 
Example enzyme production by genetically modified organisms 
 
The environmental impact from the production of enzymes seems to be generally favourable 
when compared with the production of chemical substances they replace. However there are 
also different ways to produce enzymes. A study analysed the production of five different 
enzymes in a cradle to gate environmental assessment, i.e. focusing on the company’s internal 
                                                 
335 Nielsen, P.H. and Wenzel H. (2006). International Journal of Life Cycle Assessment, (Online-First), 7, 
http://www.novozymes.com/NR/rdonlyres/B79EB435-1C16-47EE-9BF4-1A9C749E40A5/0/lca2006082652.pdf 
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production process (here: Novozymes)336. The following environmental impact categories 
were analysed: global warming, acidification, nutrient enrichment, photochemical ozone 
enrichment, primary energy consumption, and use of agricultural land. Differences in the 
various environmental impact categories could be identified for all analysed enzymes, 
indicating that not all processes producing enzymes have the same environmental impact. 
Results show that the fermentation process stage was the main process responsible for global 
warming impacts. The environmental impact of enzyme production can differ when shifting 
from conventional production strains to genetically modified production strains (see Figure 
35).  
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Figure 35: Comparative LCA for enzymes produced with and without GM product strains  
Source: Nielsen et al. 2006336; Figures are normalised to the GMM produced enzyme; GMM: Genetically 
modified micro-organism 
 
As can be seen in Figure 35, the environmental impacts from the production of enzymes with 
genetically modified organisms are lower in all impact categories. However, this has been 
demonstrated on the basis of an individual production process, so it is not possible to derive 
general conclusions from this. 
 
 
3.4.3.2 Downstream use of enzymes 
 
Enzymatic processes in pulp and paper production 
 
The pulp and paper industry produces emissions to air and water, as well as solid waste as a 
by-product. Different processes with different environmental impacts are applied in pulp and 
paper production. Some of them, for example mechanical pulping, are resource intensive in 
terms of energy and water usage. The main pollutants are NOx, SO2, CO337, CO2 and 
particulate matters. Waste water contains adsorbable organic halogen compounds (AOX) and 
                                                 
336 Nielsen, P.H. et al. (2006). International Journal of Life Cycle Assessment, (Online-First), 7,  
http://dx.doi.org/10.1065/lca2006.08.265.1  
337 NOx: nirous gases; SO2: sulphur dioxide; CO: carbon monoxide 
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is characterised by high biological and chemical oxygen demand (BOD and COD)338. 
Chlorine emissions have been reduced over the past decades. Today, most pulp and paper 
production uses elementary chlorine free (ECF) or totally chlorine free (TCF) processes. 
 
A model production process has been developed in order to analyse the environmental and 
economic effects of the application of enzymes in the pulp and paper industry. It shows the 
different application areas in mechanical as well as in chemical pulping (see Figure 36 and 
Figure 37). The application of xylanase in the chemical pulping process reduces chlorine (Cl2) 
use by 90%. This, in turn, leads to AOX reductions in waste water of between 15% and 
20%339. 
 
 
 
Figure 36: Model of chemical pulping 
Source: Kvistgaard and Wolf 2002338 
 
The application of cellulases in mechanical pulping, together with the application of the 
fungus Ceriporiopsis subvermispora leads to reductions in energy use of around 32%. 
However, the investment costs for the application of the fungal process step are high, and the 
actual acceptance by industry is not known. Energy reduction through enzymatic processes, in 
particular in mechanical pulping, leads to additional GHG emission savings. The direct 
average GHG emission savings through enzymatic processes in mechanical pulping are 
around 5%340.  
 
Laboratory scale tests have shown that enzymatic treatment of raw material before entering 
into the pulping process leads to energy savings of between 15% and 20%340. This is 
particularly interesting in the case of mechanical pulping, which uses energy up to 2.5 - 3.5 
MWh/t. However, these processes are not yet applied in industry. 
 
 
                                                 
338 Kvistgaard, M. and Wolf O. (eds) (2002). The assessment of future environmental and economic impacts of 
process integrated biocatalysts. European Commission, IPTS, EUR 20407, p. 24. 
http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1022. 
339 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. And: Kvistgaard, 
M. and Wolf O. (eds.) (2002). The assessment of future environmental and economic impacts of process 
integrated biocatalysts. European Commission, IPTS, EUR 20407, p. 30. 
http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1022. 
340 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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Figure 37: Model of mechanical pulping 
Source: Kvistgaard and Wolf 2002341 
 
Apart from the application of xylanases in chemical pulping, and cellulases in mechanical 
pulping, enzymatic processes are also applied in other production steps. In deposit control, 
proteases are used for controlling microbial activity in paper machines, leading to a reduction 
of chemical input.  
 
In case of stickies control, esterases (lipases) are used to hydrolyse triglycerides to glycerol 
and free fatty acids in mechanical pulp. This leads to savings in the consumption of additives 
and surface active chemicals. Additionally, the fibre properties are improved. Cellulases are 
used for the deinking of recycled paper as raw material. This leads to reduced use of hydrogen 
peroxide and sodium hydroxide. For the reduced input of chemicals in deposit control, 
stickies control and deinking, no quantitative data are available. 
 
In summary, it can be concluded that enzyme applications in pulp and paper manufacturing 
lead to reductions in CO2 emissions directly and indirectly through reduced energy use. The 
main environmental impact is, however, the reduction of chemical input in several process 
steps, leading to a reduced load of pollutants in waste water streams.  
 
 
Enzymatic processes in textile finishing 
 
The textile industry shows a high usage of energy and water. In textile wetting, 100 litres of 
water are used for one kilogram of textiles. For further textile finishing (washing, dyeing, 
bleaching and other treatment), 15 - 20 kWh/kg are consumed342. In addition, textile 
processing steps such as the removal of contaminants, bleaching, application of dyes and 
other finishing processes generate a variety of pollutants. As most of these steps are carried 
out in wet processes, the main environmental impact occurs in the form of aqueous effluents. 
                                                 
341 Kvistgaard, M. and Wolf O. (eds.) (2002). The assessment of future environmental and economic impacts of 
process integrated biocatalysts. European Commission, IPTS, EUR 20407, p. 30. 
http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1022. 
342 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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The following list provides an overview of effluents generated on an average textile 
production site343: 
 
• Salts  
• Natural fibre contaminants  
• Sizes (mainly starch derivatives, but also polyacrylates and polyvinyl alcohol) 
• Preparation agents (mainly mineral oils, but also ester oils) 
• Surfactants (dispersing agents, emulsifiers, detergents) 
• Carboxylic acids (mainly acetic acid) 
• Thickeners (starch derivatives) 
• Urea 
• Complexing agents  
• Organic solvents 
• Special auxiliaries with more or less ecotoxicological properties 
 
Enzymatic processes are applied at several stages in textile finishing. Amylases are applied in 
desizing, i.e. the removal of starch size. As this process has been widely taken up by industry, 
the use of chemicals is, in this specific case, reduced to zero.  
 
The application of lyases in the scouring of textiles (bioscouring) reduces the input of alkaline 
chemicals as well as overall water usage. BOD and COD as well as the salt load of waste 
water are diminished. Energy use is reduced through lowering the process temperature from 
100oC to around 60oC. Additionally, the process time is decreased344.  
 
The application of catalases in the post bleaching process to remove bleaching residues such 
as hydrogen peroxide (H2O2), reduces the chemical load by 80%. Additionally, water usage is 
reduced by 50% and energy usage by 20%. The process time is shortened by 33%344. 
 
The use of laccases in denim bleaching leads to reductions in energy use by 9 - 14%, together 
with 17 - 18% less water usage. The process time is shortened by 9 - 10%. 
 
In summary, it can be concluded that the environmental impacts of enzymatic processes in the 
textile industry are, as a rule, positive in the sense of reduced water and energy usage and 
reduced pollutants emitted mainly to water, as a consequence of reduced chemicals input. The 
secondary impact of the energy reduction is a reduced emission of GHG. 
 
 
Detergents containing enzymes 
 
The analysis of the environmental impacts of enzyme-based detergents is different from the 
discussion of other industrial applications such as pulp and paper processing. The main 
environmental impact occurs at the level of the detergent end-user and not in the actual 
detergent production process. The reason for this is that enzymes are not used to produce 
detergents, but are incorporated as part of the end product. Consequently, the desired effect 
emerges in the washing process at industrial or household level. 
                                                 
343 Kvistgaard, M. and Wolf O. (eds.) (2002). The assessment of future environmental and economic impacts of 
process integrated biocatalysts. European Commission, IPTS, EUR 20407, p. 41. 
http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1022. 
344 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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Washing needs water and energy to process the washing at the desired temperature. The main 
effect of enzymes in detergents is to remove stains at lower washing temperatures with the 
same efficiency. The washing temperature can be lowered in a lot of washing processes from 
60oC to 40oC, leading to a reduction of CO2 emissions which is around 75 g per kg of 
laundry345. When reducing the washing temperature from 95oC to 40oC, energy consumption 
is reduced by 70%346. Quantitatively, this effect cannot be measured, as the overall energy use 
for washing processes is not known. 
 
Other environmental impacts of the application of enzymes in detergents are reduced water 
consumption and a shorter duration of the washing process, which in turn leads to a longer 
life of washing machines. Despite these advantages, large scale laundries are not applying 
detergents containing enzymes, while most household detergents are enzyme-based346. 
 
In addition to this, a number of toxic substances in detergents has been reduced by between 
5% and 60%, such as benzoapyrene, lead, cadmium, sulphur oxide, etc. At the same time, 
exposure to enzymes can lead to allergic reactions. For this reason, enzyme-based detergents 
have so far not been used for open surface cleaning either in households or in industry346. 
 
 
Enzymatic processes in food processing 
 
The analysis of environmental impacts of modern industrial biotechnological processes in 
food manufacturing meets similar challenges as the measurement of economic impacts. As 
most enzymatic processes in the food industry have been totally accepted, no benchmark 
sector is available for comparison. Therefore these processes cannot be analysed with regards 
to their environmental performance compared to traditional processes. 
 
The case of fruit juice illustrates this well. Cell walls of fruits are broken down enzymatically, 
which subsequently leads to reduced energy use in pressing the fruit pulp compared to the 
hypothetical case of a non-enzymatic process. One reported example is the introduction of 
enzymes for clarification of lemon juice. This reduced the process time from several weeks to 
6 hours compared to the conventional process using the fruits natural enzymes and calcium. A 
reduced use of chemicals is reported since no preservative needs to be added to avoid 
microbial spoilage and no calcium346. Enzymatic peeling of fruit as a relatively new 
technology replaces steam-based peeling, leading again to savings in energy. 
 
In the heterogeneous area of food manufacturing, these examples do not allow for any 
generalisation. As for the environmental impacts of enzymatic processes in the food 
manufacturing sector, it can only be concluded that around 50% of food manufacturing 
subsectors use enzymes in large quantities (see Section 2.4.2.2), and that the contribution of 
food and feed manufacturing to CO2 emissions is around 7% (excluding agriculture), 
respectively 0.89% of overall GHG emissions. The further introduction of enzymatic 
processes and the optimisation of existing ones will reduce negative environmental impacts in 
a similar way to other industrial applications (less usage of water and energy, reduction of 
input chemicals). These developments will, however, have a limited effect as enzymatic 
processes are already widely accepted in this manufacturing sector. 
                                                 
345 Nielsen, P.H. and Nielsen J.D. (2005). Environmental assessment of low temperature washing. Submission by 
Novozymes in the context of this study’s stakeholders dialogue 
(http://bio4eu.jrc.ec.europa.eu/stakeholders.html).  
346 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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3.4.3.3 Modern biotechnology in bioethanol production  
 
The production of bioethanol has impacts on several environmental dimensions. These are 
mainly a reduced depletion of non-renewable fossil fuel resources and a reduction of GHG 
emissions. The environmental impacts differ, depending on the chosen production path. 
Further factors influencing environmental impacts are the share of imports from non-EU 
regions, the mix between diesel and petrol, the share of blending, and the (future) shift from 
first-generation to second-generation fuel, i.e. the shift to cellulosic biomass as a feedstock for 
bioethanol production. Impacts on GHG emissions have been estimated as presented in Table 
56. 
 
Table 56 shows for diesel as well as for petrol that the substitution through biofuels could lead 
to reduced GHG emissions. In the case of bioethanol produced from wheat, these could be 
reduced from 3.62 tCO2eq/toe to 1.85 tCO2eq/toe, which corresponds to around 50% 
reduction. Wheat is the main raw material used for bioethanol production in the EU. Table 56 
also shows that the biofuel production from cellulosic biomass (straw or wood) could lead to 
a reduction of up to 90% GHG emissions. 
 
Table 56: Estimated GHG emissions from different biofuels 
Source: European Commission 2006347 
 
 Greenhouse gas emissions (tCO2eq/toe) 
Savings (%) 
Diesel (3.65)   
Biodiesel from rape* 1.79  51 
Biodiesel from soya* 2.60  29 
Biodiesel from palm* 1.73  53 
BTL from straw n.a.  n.a. 
BTL from farmed wood 0.27  93 
Petrol (3.62)   
Ethanol from sugar beet 2.17  40 
Ethanol from wheat 1.85  49 
Ethanol from sugar cane 0.41  89 
Cellulosic ethanol from straw 0.333  91 
*chemical transformation; BTL: biomass to liquid; toe: tonne of oil equivalent; n.a.: not available. 
 
Against the background of a 7.9% share of petrol in GHG emissions, a hypothetical petrol 
substitution with bioethanol from wheat of 100% would lead to a 4% reduction of all GHG 
emissions (under the assumption of unchanged transport fuel demand). Achieving the 5.75% 
target of the EU348 in 2010 would lead to a GHG reduction of around 0.23%. This calculation 
                                                 
347 European Commission (2006). Accompanying document to the EC Biofuels Progress Report. SEC (2006) 
1721/2, p. 20. http://ec.europa.eu/energy/energy_policy/doc/08_annexe_to_biofuels_progress_report_en.pdf. 
348 Directive 2003/30/EC of the European Parliament and of the Council of 8 May 2003 on the promotion of the 
use of biofuels or other renewable fuels for transport. OJ L 123/42, 17.5.2003. http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:123:0042:0046:EN:PDF. 
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takes into account the whole lifecyle. In absolute terms, real CO2 savings in the EU through 
bioethanol was 0.7 MtCO2eq in 2005349. 
 
In the biofuels progress report published by the European Commission at the beginning of 
2007, different shares of biofuels in transport fuels are estimated up to the year 2020350. In the 
case of a 7% biofuels blend in road transport fuel in 2020, a saving of 48 MtCO2eq is 
estimated when compared with the situation without biofuels. In the case of a 14% blend, 
savings of 101 or 103 MtCO2eq are estimated351. The difference stems from assumptions on 
how much of the biofuel is imported and how much is produced domestically.  
 
In a report published by the European Commission in 2006, the overall potential for a 
reduction in CO2 emissions in the EU has been simulated for different scenarios. The most 
favourable scenario would be a combination of a high share of renewables in energy 
generation together with progress made in energy efficiency, leading to CO2 emissions 
remaining well below the 1990 level over the whole projection period (-6.7% in 2010, -21.4% 
in 2020 and -29.3% in 2030), whereas the Kyoto protocol requests a reduction of 5% below 
1990 levels. In absolute terms this means that in 2020 around 960 MtCO2eq would be saved 
when compared with a baseline scenario, and also that biofuels could contribute between 5% 
and 10% to this development352. The baseline scenario predicts an increase of CO2 emissions 
from 3674 MtCO2eq in 2000 to 3928 MtCO2eq in 2020353. 
 
When discussing the environmental impacts of increased biofuel shares in EU transport fuel, 
the focus on GHG emissions has to be widened. Savings of CO2 emissions as discussed above 
can be compensated if inappropriate land, for example wetland, is chosen to grow raw 
material for biofuels. The CO2 balance could be neutralised or even reversed to negative. 
Large scale growth of raw material for biofuels might also impact on biodiversity. However, 
according to the European Environment Agency (EEA) enough biomass can be produced in 
the EU to cover even high demands for biofuels production354. So the challenge is not a 
bottleneck in land availability, but to identify appropriate land for growing raw material for 
biofuels. 
 
An experiment has been carried out by Nielsen & Wenzel in order to compare environmental 
impacts of bioethanol as a substitute for petrol: The effect from driving one mile with a petrol 
car was compared to a flexifuel car running on E85 (the 15% share of bioethanol was 
produced from corn)355. A reduction of emissions of slightly more than 30% could be 
                                                 
349 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
350 European Commission COM (2006) 845 final: Communication from the Commission to the Council and the 
European Parliament - Biofuels Progress Report.  
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2006:0845:FIN:EN:PDF.  
351 These estimates refer to accumulated saving through bioethanol and biodiesel. 
352 Mantzos, L. and Capros P. (2006). European energy and transport: scenarios on energy efficiency and 
renewables. European Communities, Luxembourg, p. 46.  
http://ec.europa.eu/dgs/energy_transport/figures/scenarios/energy_efficiency_en.htm.  
353 Mantzos, L. and Capros P. (2006). European energy and transport: trends to 2030 – update 2005. European 
Communities, Luxembourg, p. 37.  
http://ec.europa.eu/dgs/energy_transport/figures/trends_2030_update_2005/energy_transport_trends_2030_updat
e_2005_en.pdf.  
354 EEA (2005). How much biomass can Europe use without harming the environment? Briefing, European 
Environment Agency, Copenhagen. http://reports.eea.europa.eu/briefing_2005_2.  
355 Nielsen, P.H. and Wenzel H. (2005). Environmental assessment of ethanol produced from corn starch and 
used as an alternative to conventional petrol for car driving. The Institute for Product Development, Technical 
University of Denmark, Lyngby. http://www.ipu.dk/upload/publikationer/bio-ethanol-report.pdf. 
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measured. Emissions of sulphur dioxide and phosphate increased, whereas emissions causing 
photochemical ozone formation were reduced. In other words, a changing from petrol to E85 
reduces global warming and photochemical ozone formation, while acidification and soil 
nutrient enrichment will increase.  
 
 
3.4.3.4 Production of biotechnology-based polymers  
 
The production of oil-based polymers has environmental impacts in terms of energy use, 
GHG emissions and waste streams. Polymer production processes are large scale processes, 
which have been improved over the last decades in terms of reducing negative environmental 
impacts. The production of biotechnology-based polymers, however, has the potential to 
further reduce negative environmental impacts from the production and consumption of 
polymers. As there are a variety of different biotechnology-based polymers with different 
characteristics (see Section 2.4.2.4), the difference in environmental impact depends on the 
comparison with the oil-based polymer to be replaced. In Table 57 the impacts in terms of 
energy usage and GHG emissions are shown. 
 
Table 57: Energy consumption and CO2 emissions of biotechnology-based polymers production  
Source: ETEPS 2006356 
 
Polymer Energy consumption Direct CO2 emissions 
Production of Solanyl® compared to 
conventional oil-based plastics 
40 % less than bulk plastics such as 
polyethylene (PE) No data available 
Production of NatureWorks® compared to 
conventional oil-based plastics 
20%-50 % less than other plastics 
(PET, HDPE, Nylon-6) 50%-70 % less 
Production of Bio-PDO-based 
polytrimethylene terephthalate compared 
to conventional oil-based plastics 
16 % less than polyethylene 
terephthalate (PET) 
No difference (indirect 
effects not included)  
 
The production of Solanyl® needs 40% less energy than polyethylene (PE) production356. 
These energy savings lead to indirect savings of GHG emissions. Data on GHG emissions 
reduction in direct process comparison between polyethylene and Solanyl® are not available.  
 
Poly-lactic acid (PLA) can be used as a substitute for different oil-based polymers. According 
to the polymer replaced the comparative savings in energy use as well as in GHG emission 
vary. The range of saved energy for the production of PLA is between 20% and 50%. The 
range of GHG emission reductions is between 50% and 67%.  
 
Bio-PDO-based polytrimethylene terephthalate (PTT) is suitable to substitute polyethylene 
terephthalate (PET). A comparison between the production of these polymers shows energy 
savings of 16% for the production of the biotechnology-based polymers, also leading to 
indirect GHG emission reductions. Information for direct GHG emission savings from the 
production processes is not available. 
 
                                                 
356 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
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In the case of polyhydroxyalkanoates (PHA), LCAs show no clear results, probably due to 
different system boundaries. Different LCAs show GHG emission changes varying between 
savings in one case (27 - 48%) and increased emissions in another case (200%).  
 
Polymers produced with modern biotechnology are at an early stage of development. This is 
illustrated by the fact that the first commercial PLA plant consumed much higher amounts of 
energy per polymer output unit than the conventional equivalent357.  
 
Ongoing process developments indicate changing environmental impacts in future (large 
scale) production processes. The US company Metabolix is investigating the modification of 
switchgrass for the direct production of PHA, which would eliminate the fermentation step 
and consequently reduce energy use and GHG emissions. The US producer Cargill started 
research on making lignocellulose biomass accessible for the production of PLA. This would 
lower the fossil energy used for the production of PLA by 80%358. 
 
A further aspect with regard to the environmental impacts of biotechnology-based polymers is 
that they differ from oil-based polymer waste streams. PLA can be composted, incinerated, or 
it can go to pre-consumer recycling and to post-consumer recycling/recovery. In the case of 
composting, tests have shown that PLA polymers can be composted in full compliance with 
DIN, ISO, CEN and ASTM359 regulations. When incinerated, PLA produces fewer by-
products than traditional polymers, having also a comparable lower energy content. Pre-
consumer recycling studies show that PLA can be used in thermoforming like any other 
polymer. In post-consumer recycling, a separate collection system needs to be put in place358.  
 
The latter issue points to a negative environmental impact of biotechnology-based polymers. 
Ideally the difference to oil-based polymers is not recognisable for end consumers, which 
prevents them to collect biotechnology-based polymers separately. As a result, oil- and 
biotechnology-based polymers enter the same waste streams. Biotechnology-based polymers 
are not compatible with the existing oil-based polymer recycling system and could negatively 
impact on the product quality of recycled polymers. 
 
 
3.4.3.5 Production of other biotechnology-based chemicals 
 
Chemical production in the EU is resource intensive in terms of energy and water, and leads 
to emissions of CO2, CH4 and N2O. Additionally, the production of chemicals leads to by-
products and pollutants which need special treatment. Today, a large number of chemicals are 
produced through biotechnological processes. These processes are so heterogeneous and data 
are so scattered that a consistent picture of the environmental impacts of the application of 
modern industrial biotechnology in the production of chemicals cannot be drawn. 
 
One well documented example is the production of acrylamide, which is one of the few 
biotechnologically produced bulk chemicals in the several 100 000 tonnes range. A 
comparison of the energy consumption and CO2 emissions is presented in Table 58 and Table 
                                                 
357 ETEPS (2006). Bio4EU Task 2, case studies report: industrial biotechnology applications. 
358 OECD (2001). The application of biotechnology to industrial sustainability. OECD, Paris, p. 88. 
http://www.oecd.org/bookshop?pub=932001061P1.  
359 DIN: Deutsches Institut für Normung, Germany; ISO: International Organization for Standardization; CEN: 
European Committee for Standardisation; ASTM: American Society for Testing and Materials. 
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59. The comparison shows a 30% lower energy consumption, and CO2 emissions are reduced 
by 25%.  
 
Table 58: Comparison of energy consumption in the production of acrylamide (MJ/kg acrylamide) 
Source: OECD 2001360 
 
 Catalytic process Enzymatic process 
Steam 1.6 0.3 
Electric power 0.3 0.1 
Raw materials 3.1 3.1 
Total 5.0 3.5 
 
 
Table 59: Comparison of GHG emissions in the production of acrylamide (kg CO2/kg acrylamide) 
Source: OECD 2001360 
 
 Catalytic process Enzymatic process 
Steam 1.25 0.2 
Electric power 0.25 0.1 
Raw materials 2.3 2.3 
Total 3.8 2.6 
 
 
Another example for which some data is available is the production of cephalosporins (see 
also Section 2.4.2.4). Concerning the 7-ACA process, no information concerning the changes 
in energy use and GHG emissions compared to the chemical synthesis is available. The input 
of solvents is reduced by almost 100%. The waste streams from the 7-ACA production 
process are reduced by 10% in the case of waste water, which additionally does not contain 
heavy metals or hazardous chemicals. Incineration material is reduced by almost 100%. In the 
case of 7-ADCA production, waste water generation is reduced by 90%. The CO2 emissions 
from the energy production as well as from the fermentation process decrease by 75%. 
Energy consumption is reduced by 37% (electricity) respectively 92% (steam production)361. 
 
In the context of the Bio4EU study, industry provided information on the biotechnological 
production of a number of other substances, such as amino acids. For these amino acids, used 
as animal feed additives for pig feed replacing inorganic feed supplements, a number of 
environmental impact categories have been analysed: global warming, acidification, nutrient 
enrichment and photochemical ozone formation. It turned out that the biotechnology-based 
amino acids were superior in all analysed categories, with the reduction in nutrient enrichment 
being the most significant difference due to a reduced phosphate content in pig manure. 
However, environmental benefits were not only achieved indirectly through changes in pig 
feed, but also through the production process of the supplement. As a small quantity of the 
amino acids replaced a large quantity of the inorganic supplement, environmental impacts 
                                                 
360 OECD (2001). The application of biotechnology to industrial sustainability. OECD, Paris, p. 74. 
http://www.oecd.org/bookshop?pub=932001061P1. 
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from the respective production processes differed widely. Studies carried out analysing the 
environmental impact of amino acids in poultry feed came to similar conclusions. 
 
These examples show similarities to the application of modern biotechnology in other 
industrial processes as discussed above in the sense that generally the use of energy in the 
process and the emission of GHG is reduced. It can be assumed that in other biotechnological 
production processes in the chemical industry the impacts are similar.  
 
 
3.4.4 Summary 
 
Industrial biotechnology is mainly applied in the manufacturing sector. It impacts on the 
environment through changes in GHG emissions, energy use, waste generation and reduction 
of other non-renewable resources. The share of manufacturing sectors using enzymatic 
processes in GHG emissions is around 2.1%. This share consists of a 1.1% contribution to 
CO2 emissions and a 1% contribution to N2O emissions. The latter are almost exclusively 
produced by the chemicals industry (production of nitric and adipic acid). For both 
substances, no large scale biotechnological production is in use, so that the impact of modern 
biotechnology in industrial applications on N2O emissions can be assumed to be zero. 
 
The transport sector is one of the largest GHG contributors with 21% of total emissions. 37% 
of this share is generated by petrol combustion, which corresponds to 7.9% of total GHG 
emissions. The blending of transport fuels with bioethanol could help to improve the 
environmental impact of this sector. The environmental impacts of bioethanol compared to 
fossil fuel depend on a variety of factors, such as import share (and origin of imports), chosen 
biomass and production pathway. First-generation biofuels, produced in the EU using the 
most economically attractive production method, have been estimated to result in GHG 
emissions of 35 - 50% lower than the conventional fuels they replace. Applied to the 7.9% 
share of petrol in overall GHG emissions this means that a 100% replacement of petrol with 
bioethanol would lower GHG emissions by around 4%. Accordingly, compliance with the 
5.75% replacement target of the EU362 will lead to a GHG emissions reduction of around 
0.23%. Recently the replacement target was increased to 10% by 2020363. Calculations for a 
higher share in 2020 show that with a 7% contribution (petrol and diesel) 48 MtCO2eq can be 
saved, and with a 14% target, around 100 MtCO2eq can be saved364. 
 
Power generation is the largest GHG emitting sector: 29% of all GHG are generated in energy 
generation industries themselves, 17% in fuel combustion in other sectors (non energy and 
non industrial, e.g. residential, agriculture), and 13% in industrial fuel combustion, i.e. energy 
generated for industrial processes. The GHG emissions from industrial fuel combustion are 
more than 50% higher than the GHG emissions from industrial processes themselves (8%). 
Power generation experiences two environmental impacts through the application of modern 
                                                 
362 Directive 2003/30/EC of the European Parliament and of the Council of 8 May 2003 on the promotion of the 
use of biofuels or other renewable fuels for transport. OJ L 123/42, 17.5.2003. http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:123:0042:0046:EN:PDF. 
363 Brussels European Council, 8 and 9 March 2007, Presidency conclusions. 
http://www.consilium.europa.eu/ueDocs/cms_Data/docs/pressData/en/ec/93135.pdf. 
364 European Commission SEC (2006) 1721: Commission staff working document. Review of economic and 
environmental data for the biofuels progress report.  
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biotechnology. A direct impact through a switch from non-renewable resources such as oil to 
renewable resources such as biomass as the input material, and an indirect impact through 
reduced energy demand from industrial processes. This indirect effect, which cannot be 
quantified, emerges because the application of enzymatic processes in industrial production 
leads, as a general rule, to reduced energy consumption in the respective processes. 
 
In addition to reductions in energy consumption (and thus GHG emissions, mostly CO2), the 
application of modern biotechnology in industrial processes (detergents, pulp and paper, 
textiles) lead, as a general rule, to savings in water consumption, and chemicals input. Also 
usually the process time is reduced.  
 
In the case of biotechnology-based polymers, three environmental impacts can be observed. 
In most of the cases, the energy usage and related GHG emissions are reduced. The same is 
true for process related GHG emissions. However, the values differ depending on the oil-
based polymer taken as a benchmark. For PHA, environmental indicators show negative 
environmental impacts compared to oil-based polymers. 
 
Other biotechnology-based chemicals cannot be depicted in the entirety of their 
environmental impacts, as information for a lot of processes is not available or accessible. 
Information concerning known examples indicates environmental impacts which are similar 
to those of the application of modern biotechnology in other industrial sectors, i.e. reductions 
in energy use, GHG emissions and waste generation. 
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4 Contribution of modern biotechnology to public health 
4.1 General outline and the overall contribution of modern biotechnology 
 
The programme of Community action in the field of public health describes the respective EU 
policy objectives365. This programme goes hand in hand with the Lisbon Strategy as good 
health is considered crucial to economic growth and sustainable development. Moreover, in 
the context of ‘health and food safety’ the general principles and requirements of food law 
must also be considered366, as far as the provision of safe and high quality food is concerned 
and taking into account the protection of animal health and welfare, as well as the European 
Environment and Health Strategy367.  
 
The assessment of the contribution of modern biotechnology to public health was based on 
relevant case studies and was structured along the following guiding policy objectives: 
improved warning, monitoring and control of communicable diseases, reduction of (major) 
non-communicable disease incidence, reduction of disease burden, and reduction of 
healthcare and social costs.  
 
The case study analysis presented in this section shows that modern biotechnology 
applications in the human health sector have a direct impact on the overarching public health 
policy objective of reducing the disease burden. This is achieved through the provision of 
effective treatments, unique solutions for treatment and diagnosis (e.g. enzyme replacement 
therapy for Gaucher’s disease or HIV/AIDS diagnostic tests), potentially safer treatments or 
unlimited supplies of pharmaceuticals (e.g. human recombinant insulin or recombinant 
hepatitis B vaccine). Additionally, modern biotechnology enables further development of 
drugs with the aim of increasing the quality of patients’ lives (e.g. human insulin analogues). 
Similarly to modern health biotechnology, the public health effects of modern biotechnology 
applications in the agro-food sector build on the availability of new and better diagnostics and 
vaccines. Especially the monitoring and control of some of the most important zoonoses and 
food safety concerns (e.g. salmonellosis and BSE) help in safeguarding EU-wide food safety 
but also in assuring consumer confidence in the food chain and facilitating the continuity of 
related trade activities. Hence, modern biotechnology directly contributes to the control and 
monitoring of diseases, thus improving quality of life and potentially reducing burden of 
disease.  
 
The contribution of modern health biotechnology applications for reducing healthcare and 
social costs is less clear. Whereas in some cases these applications increase efficiency in the 
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healthcare sector, thus contributing to the objective of reducing healthcare costs, in other 
cases a new treatment puts an over-proportional strain on healthcare resources. While the 
latter case is not specific to biotechnology-based therapies but applies also to conventional 
approaches, it nevertheless emphasises the ethical question of how to allocate scarce resources 
in healthcare, when efficiency considerations could prevent patients’ access to potentially life-
improving or even life-saving therapies. However, a more general assessment of the cost-
effectiveness of health biotechnology applications is still pending, given that in many cases 
results of pertinent studies are only preliminary and further studies need to be carried out. The 
cost-effectiveness of modern biotechnology applications is also relevant for applications in 
the agro-food sector which may impact public health indirectly. It has been reported, for 
example, that the use of the modern biotechnology-based vaccines for Aujeszky’s disease in 
pigs is the most cost-effective option for the eradication of the disease. Similarly, modern 
biotechnology-based diagnostics are crucial for the surveillance of several of the major 
communicable livestock diseases in the EU, which, however, may be achieved at a high 
monetary cost. Yet, like with health applications, a general assessment is not feasible, 
especially if social and ethical costs are taken into account. 
 
Ensuring optimal animal health and welfare is important both from a social and an economic 
perspective and it is relevant for several of the policy objectives identified in this study, such 
as the reduction of disease burden and the reduction of social costs. Modern biotechnology 
may have several and contrasting implications for animal health and welfare. On the one hand 
some modern biotechnology applications may present new issues in terms of animal welfare, 
potentially necessitating a case-by-case assessment. On the other hand, modern biotechnology 
provides solutions that improve animal health and welfare in a variety of ways, such as 
through replacing the use of animals as tools in chemical safety testing or through the 
provision of novel animal health management tools that decrease animal suffering. 
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4.2 Human health biotechnology 
 
Probably the most important – but difficult to measure – impact of a new technology in the 
health sector is its contribution to people living healthier, better, longer and more productive 
lives, thus increasing social welfare and individual well-being as well as economic growth. 
Another impact of a new technology in the health sector is the potentially improved efficiency 
within the healthcare system. Thus, these two potential impacts of health technologies are 
directly linked to EU public health policy objectives, namely "Improved warning, monitoring 
and control of communicable diseases (including medical product safety)" and "Reduction of 
(major) non-communicable disease incidences (e.g. mental illnesses, cancer, cardio-vascular 
diseases, diabetes)", which principally relates to the effectiveness of health interventions, and 
the "Reduction of healthcare and social costs and the reduction of disease burden", which 
principally refers to the efficiency of these interventions. 
 
For modern health biotechnology applications to have an impact, it is obviously necessary 
that the related products (therapeutics, vaccines and diagnostics) have achieved a certain level 
of diffusion, on their respective markets and in the clinics. The analysis of the underlying 
economic indicators and of their economic performance has been carried out in Section 2.2. 
 
The impact of modern biotechnology on the incidence of zoonoses will be discussed in the 
section on agro-food (Section 4.3).  
 
In the following sections, the health policy objectives and related aspects will be discussed 
and the impact of modern biotechnology will be illustrated by means of eight case studies 
describing modern health biotechnology applications including biopharmaceuticals, 
diagnostics and preventives. The case studies are presented and the effectiveness of the 
respective biotechnology applications is examined, including their potential impact on the 
burden of disease within the EU and on the quality of life of its citizens. Likewise, the cost-
effectiveness of these applications is evaluated, and some ethical implications of cost-
effectiveness analysed are highlighted. 
 
The following Section 4.2.1 looks at the impact of health biotechnology in the field of 
therapeutics, while Section 4.2.2 evaluates its impact in the field of diagnostics and Section 
4.2.3 considers preventives; Section 4.2.5 extrapolates some more general tendencies from the 
case studies.  
 
 
4.2.1 Therapeutics 
 
The following case studies regarding biopharmaceuticals have been analysed and will be 
discussed below: recombinant human insulin for diabetes, interferon-beta for multiple 
sclerosis, genetically engineered glucocerebrosidase enzyme for Gaucher’s disease and CD20 
monoclonal antibodies for Non-Hodgkin’s lymphoma. 
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4.2.1.1 Recombinant human insulin for diabetes 
 
Diabetes is a chronic disease for which there is currently no cure; the disease is caused by a 
loss of the insulin regulatory process, which is vital for the regulation of glucose levels in the 
blood. Over time, diabetes can damage the heart, blood vessels, eyes, kidneys, and nerves, in 
some cases leading to blindness, limb amputation, kidney failure, stroke and overall increased 
mortality. There are two main types of diabetes: type 1 diabetes is characterised by a lack of 
insulin production; without daily administration of insulin, type 1 diabetes is fatal. Type 2 
diabetes results from the body’s ineffective use of insulin. Type 2 diabetes comprises 90% of 
patients with diabetes around the world, and is largely the result of excess body weight and 
physical inactivity368.  
 
The World health Organisation (WHO) estimates that currently more than 180 million people 
worldwide have diabetes and that this number is likely to exceed 360 million by 2030368; the 
International Diabetes Federation (IDF) reports similar figures, with 194 million cases of 
diabetes in 2003 and projected 333 million cases for 2025. For Europe (including all the 
countries of the former Soviet Union, Turkey and Israel) the IDF reports 48.4 million people 
with diabetes in 2003 and projects that 58.6 million people will have diabetes in 2025369. 
Another study estimates that in the year 2000 in the same region (without Israel) 5% of all 
deaths, i.e. 602 800 deaths, were attributable to diabetes370. Within the EU, diabetes is 
responsible for about 5 - 10% of total healthcare spending; a share that is projected to rise 
significantly because the average age of the EU population is expected to increase and so is 
the prevalence of obesity. To these direct costs, further indirect costs need to be added, like 
loss of productivity due to sickness, disability, premature retirement or premature mortality; 
intangible costs include inconvenience, pain, loss of leisure time or loss of mobility371. 
 
The existence and role of insulin, which is essential for the treatment of diabetes, was 
discovered in 1921. This discovery found an immediate use when insulin was extracted from 
animal pancreases to treat diabetes. Although changes in lifestyle and proper diet 
management can help to alleviate the consequences of the disease, type 1 diabetic patients 
generally require insulin throughout their lives, while also some patients with type 2 diabetes 
may need insulin at more severe stages or when dietary approaches and weight reduction 
attempts fail.  
 
To circumvent issues of potential contamination and of immune reaction against animal 
insulin with prolonged use, a genetic engineering approach was used to produce recombinant 
human insulin, which was the first genetically engineered product on the market (launched in 
1982). According to a survey of the IDF in 2002 on the access to, and availability of, insulin 
in its member countries, 70% of the insulin that is currently available in the world is 
recombinant human insulin, followed by porcine insulin with 17%, bovine insulin with 8% 
and porcine-bovine mixtures with 5%, with most of the animal insulin used outside the 
industrialised countries. However, this survey also finds that despite its spread, recombinant 
human insulin is considerably more expensive in most countries where both human and 
animal insulin are commercially available, e.g. within European countries, the average price 
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of human insulin was twice as high as the price of porcine insulin372. Yet, in its position 
statement the IDF writes that ‘there is no overwhelming evidence to prefer one species of 
insulin over another’ and ‘[modern highly purified] animal insulins remain a perfectly 
acceptable alternative’373. Similarly, a recent review article finds ‘no relevant differences in 
efficacy and adverse effects between human and purified animal (mainly porcine) insulin. [...] 
In our systematic review we could not identify substantial differences in the safety and 
efficacy between insulin species’ 374. Therefore, on the face of it, human insulin is more 
widely used than animal insulins even though it is equally effective but more expensive.  
 
An explanation for this situation could be that human insulin is preferred by clinicians 
because they perceive that it avoids the risk of immune reactions and of contamination – a 
view that has been confirmed in selected interviews with health professionals375. Moreover, 
according to a study for the US, the actual cost of insulin (and delivery supplies) only 
amounts to 7.6% of total diabetes-related healthcare expenditures376. Hence, in the eyes of 
physicians who decide on which insulin species to give to their patients, the perceived safety 
of human insulin may come at a small cost. Also, while there are diabetic patients who prefer 
animal insulins, other patient groups may – for ethical reasons – prefer not to consume animal 
products. Yet, many such patient-oriented outcomes relating to quality of life, as well as 
effects on diabetic complications were never investigated scientifically377. Regarding the costs 
of recombinant human insulin vs. animal insulins, a further question would be to what extent 
the production of animal insulin could be limited by the availability of appropriate pancreases 
and at what point such a limitation would drive up the price of animal insulins if less 
recombinant human insulin would be consumed.  
 
However, the development of recombinant human insulin opened the way for the engineering 
of another form of insulin: insulin analogues. While the first generation of recombinant 
insulins was designed to be identical to human insulin, insulin analogues were designed to 
improve the control of insulin requirements. Today there are several analogue products 
available, like fast-acting insulins that may take effect within five minutes of injection and 
last up to 3-4 hours, or slow-acting insulins that help prevent the building-up of blood glucose 
over the longer term. Hence, these products help diabetic patients manage their insulin 
requirements in different situations (like before mealtimes or at night-time). While the 
advantages of insulin analogues to patients – e.g. for the less constrained timing of their meals 
– is obvious, the generally higher prices of these products may reduce their cost-effectiveness, 
especially when used in the therapy of type 2 diabetic patients. Apart from their cost-
effectiveness, also the long-term effects of insulin analogues need to be investigated in more 
detail378.  
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While recombinant human insulin and insulin analogues are effective in the treatment of 
diabetes, these products do not seem to add to the efficacy of conventional animal insulins. 
Hence, the contribution of biotechnology-derived insulin products to the reduction of the 
burden of diabetes may need to be considered marginal. However, especially insulin 
analogues may improve the quality of life of diabetes patients, which could be seen as the 
major contribution of recombinant insulins. The effectiveness and quality aspect of 
recombinant insulins also needs to be contrasted with their price. While more detailed studies 
are lacking, the generally higher price of recombinant human insulin vs. animal insulins 
seems not to be reflected in greater clinical efficacy. Because of the marginal impact on the 
burden of diabetes, substantial productivity gains due to more healthy and active patients 
cannot be expected.  
 
Judging such qualitative improvements requires more specific cost-utility analyses and more 
fundamental ethical decisions; any current assessment cannot come to a conclusive 
evaluation. It should also be noted that, in early 2007 it was announced that plant-produced 
recombinant human insulin (compared to recombinant human insulin from yeast) has been 
demonstrated to be equivalent to human insulin. The company that developed this new 
process believes it can help to accommodate the rising demand for insulin, which may be 
further increased through the commercialisation of alternative delivery technologies that 
require several times more insulin per dose than administration through injection; it also 
believes product costs may be reduced by 40% or more379. 
 
 
4.2.1.2 Interferon-beta for multiple sclerosis 
 
Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system. Its 
onset occurs primarily in young adults and it affects women more often than men. The exact 
cause of the disease is unknown, but a genetic predisposition is suspected. The disorder can 
manifest in a remitting or progressive development, and is characterised by lesions that occur 
throughout the brain and spinal cord. These lesions cause alterations in the transmission of 
messages by the nervous system, which has severe consequences like loss of memory or the 
loss of balance and muscle coordination (which makes walking difficult); other symptoms 
include slurred speech, tremors, stiffness or bladder problems. MS is categorised by one of 
five disease subtypes: benign, monosymptomatic, relapsing-remitting (RRMS), secondary-
progressive (SPMS) or primary progressive (PPMS). However, about 75% of all MS patients 
suffer from either the relapsing-remitting or the secondary-progressive form of the disease380. 
 
Because there are no national registries for the disease, there is uncertainty regarding the 
number of MS patients and estimates can vary substantially380. According to the WHO, in 
2002 there were 454 400 people who suffered from MS in Europe, 256 500 of which lived in 
Western Europe381,382. However, according to the Multiple Sclerosis International Federation, 
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there are currently over 563 400 cases of MS within the EU alone383. Given the number of 
people who suffer from MS and the fact that it primarily affects young adults who may not 
only be building their families but who are also generally at an economically very productive 
stage of their lives, the individual consequences of this disease are severe and the economic 
and social costs are substantial384. This is also reflected in the high share of indirect costs, i.e. 
of costs that occur outside the healthcare system, such as productivity losses, costs for 
informal healthcare or estimates of intangible costs. Economic analyses of the costs of MS 
estimate that indirect costs usually make up more than half of total costs385. Annual total costs 
are, for instance, estimated to reach several billion euros in some bigger EU countries and in 
the US, and still hundreds of millions of euros in other European countries with smaller 
populations386. 
 
Prior to 1993, when the US Food and Drug Administration (FDA) licensed interferon-beta-1b 
for the treatment of certain patients with MS in the US387, the only MS therapy was a 
treatment with corticoids to accelerate recovery388. Even though interferon-beta is not a cure 
for MS, it may slow down the development of some disabling effects and decrease the 
number of relapses of the disease. The mechanism by which interferon-beta acts on MS is not 
fully understood389, but it is explained by the repression of inflammatory processes in the 
body. In the meantime more drugs for MS were developed, but most are still only at 
development or clinical trial stage; altogether worldwide there are 172 products available or 
under development for the therapy of MS388.  
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However, the use of interferon-beta in the treatment of MS is not without controversy. In 
2002 the UK’s National Institute for Health and Clinical Excellence (NICE) issued the 
guidance that ‘on the balance of their clinical and cost-effectiveness neither interferon-beta 
nor glatiramer acetate is recommended for the treatment of MS’, but that patients currently 
receiving either drug could suffer loss of well-being if their treatment is discontinued and that 
they, therefore, should have the option to continue treatment390. As a result of this guidance, 
the UK government has reached an agreement with the manufacturers of the drugs on a risk-
sharing scheme for the supply of interferon-beta (and glatiramer acetate) to its National 
Health Service (NHS)391. Nevertheless, the guidance has still effects: the prescription rate of 
interferon-beta in the UK, at around 2 - 3% of MS patients, is far lower than the rate in other 
EU countries, where it is about 12 - 15%392. Pending data from the risk-sharing scheme, a 
planned review of the original guidance was deferred from 2004 until November 2006393. Yet, 
more recent evaluations of the cost-effectiveness of interferon-beta that have been carried out 
in the meantime do not (yet) show a very different picture: the impact of interferon-beta on 
the progression of MS seems to be rather limited, at least in the short to medium term for 
which there are factual data of treatment successes, and for the modest benefits the drug is 
considered too costly394. 
 
 
4.2.1.3 Genetically engineered glucocerebrosidase enzyme for Gaucher’s disease  
 
Gaucher’s disease is an inherited metabolic disorder caused by one or more genetic defects 
that result in functional deficiency of an enzyme called glucocerebrosidase (or 
glucosylceramidase). This deficiency causes a lipid to accumulate in the spleen, liver, lungs, 
bone marrow and sometimes in the brain, where it causes functional abnormalities of these 
organ systems. The resulting course of the disease can be quite variable, ranging from no 
outward symptoms to severe disability and death. The accumulation of the lipid 
(glucocerebroside) in some of the body’s cells and tissues is putting this disease into the 
family of lipid-storage disorders. The genetic predisposition for the disease needs to be 
inherited from both parents for the disease to manifest itself. There are three types of 
Gaucher’s disease, according to when in life the symptoms appear and how severe the course 
of the disease is. Patients who have the most common type 1 Gaucher’s disease usually bruise 
easily and experience fatigue due to anaemia. However, while they have enlarged livers and 
spleens and suffer from skeletal disorders and sometimes from lung and kidney impairment, 
their brains are not affected; type 2 and 3 are more severe and usually lethal395. Type 1 
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Gaucher’s disease affects one in about 50 000 individuals in the general population, while 
type 2 and 3 each affect even less, namely fewer than one in 100 000 individuals396. For 
instance, the prevalence of all types of Gaucher’s disease combined is one in 57 000 in 
Australia and only one in 86 000 in the Netherlands397. Given these prevalence rates, for a EU 
population of 458 973 024 in 2004398, there could be around 5000 to 18 000 individuals who 
suffer from Gaucher’s disease in the EU.  
 
Historically, Gaucher’s disease has been treated by the removal of part of the spleen, which 
can however accelerate bone disease and is not done any more except in extreme cases. 
Another option was bone marrow transplantation, which however required matching donors 
and carried a high mortality rate. Given these alternatives, the current treatment of choice is 
enzyme replacement therapy399. This therapy compensates the deficiency in the respective 
enzyme by its administration at an appropriate rate and dosage. While the involvement of 
glucocerebrosidase in Gaucher’s disease had been established by the 1970s, the breakthrough 
in a corresponding therapy came with the modification of the glucocerebrosidase enzyme. 
This was first done by modifying a placenta extract. However, 22 000 human placentas are 
required to supply this product (Ceredase) to one patient for one year The subsequent product 
was a recombinant enzyme (Cerezyme, an analogue of the human enzyme (beta)-
glucocerebrosidase), which proved to be as effective as Ceredase in treating Gaucher’s 
disease, but was more easily available and free of potential contamination400. This drug was 
launched in the US in 1994 and authorised in the EU in 1997401. A more recent alternative 
intervention to enzyme replacement therapy is substrate reduction, i.e. a reduction of the 
creation of cerebroside, whose accumulation is the clinical cause of Gaucher’s disease. The 
respective enzyme inhibitor (miglustat; product name Zavesca) was approved in the EU in 
2002 and in the US in 2003402. It is currently being marketed for patients ‘for whom enzyme 
replacement therapy is not an option’403, because the drug is less effective and can have 
undesirable side-effects400. 
 
Enzyme replacement therapy in Gaucher’s disease has proven to be efficacious from a clinical 
point of view, with only few mild adverse reaction, and it also improves the quality of life 
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from the patients’ perspective404. Estimates of the simple costs of procuring the quantities of 
the drug for one patient per year range from about EUR 100 000 to several times that 
amount405. Gaining one ‘quality-adjusted life year’ (QALY the weighted equivalent of one 
healthy life year) with the enzyme replacement therapy may cost anything between EUR 
150 000 and 2 million, beyond any usually applied cost-effectiveness thresholds406. This 
highlights the specific ethical questions surrounding ‘orphan drugs’ 407, namely whether 
scarce public money in the healthcare sector should be spent according to equity (all 
individuals are entitled to the same minimum quality of healthcare) or efficiency 
considerations (limited resources should be used to treat a large number of people who suffer 
from a disease that can be treated at a relatively low cost)408.  
 
 
4.2.1.4 CD20 monoclonal antibodies for non-Hodgkin’s lymphoma 
 
Non-Hodgkin’s lymphoma (NHL) is a type of cancer in which malignant cells form in the 
lymph system. The latter is part of the immune system and consists of the tissues and organs 
that produce, store and carry white blood cells to fight infections and other diseases. Because 
lymph tissue is found throughout the body, NHL can begin in almost any part of the body and 
spread to the liver and many other organs and tissues. This spreading of the cancer is divided 
into four stages (I-IV), depending on where the cancer is found and how it has spread409. NHL 
is more common in men and older age groups than in women and younger age groups (see 
Figure 38). Over the last three decades, the incidence of NHL in western industrialised 
countries has been consistently on the rise, and it now ranks amongst the most frequent 
malignant diseases410. In 2001 there were over 30 000 deaths within the EU due to NHL411. 
                                                 
404 Whittington, R. and Goa K.L. (1992). Drugs 44: 72-93. Abstract at 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1379912. And: 
Whittington, R. and Goa K.L. (1995). Pharmacoeconomics 7: 63-90. Abstract at  
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db =PubMed&list_uids=10155294. And: 
Damiano1, A.M. et al. (1998). Quality of Life Research 7: 373-386.  
http://dx.doi.org/10.1023/A:1008814105603.  
405 Whittington, R. and Goa K.L. (1995). Pharmacoeconomics 7: 63-90. Abstract at 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10155294. And: Clarke, 
J.T.R. et al. (2001). Canadian Medical Association Journal 165: 595-596. 
http://www.cmaj.ca/cgi/content/full/165/5/595. And: Connock, M. et al. (2006). Health Technology Assessment 
10 (24). http://www.hta.ac.uk/ProjectData/ 3_project_record_published.asp?PjtId=1414. 
406 Whittington, R. and K.L. Goa (1995). Pharmacoeconomics 7: 63-90. Abstract at  
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10155294. And: 
Connock, M. et al. (2006). Health Technology Assessment 10 (24).  
http://www.hta.ac.uk/ProjectData/3_project_record_published.asp? PjtId=1414. 
407 Orphan drugs are medicinal products to diagnose, prevent or treat a life-threatening, seriously debilitating or 
serious and chronic condition affecting less than five in 10 000 persons (in the EU). Because these conditions 
occur so infrequently that the cost of developing and bringing to the market a corresponding drug would not be 
recovered by the expected sales of the product, the pharmaceutical industry would be unwilling to develop the 
medicinal product under normal market conditions. See also Regulation (EC) No 141/2000 of the Euroepan 
Parliament and of the Council of 16 December 19999 on orphan medical products. OJ L 18/1 22.1.2000. 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:EN:PDF.  
408 ETEPS (2006). Bio4EU Task2, case studies report: human health applications. 
409 NCI (2006). Non-Hodgkin’s’s Lymphoma. Cancer Topics. National Cancer Institute, Bethesda, MD. 
http://www.cancer.gov/cancertopics/types/non-hodgkin’ss-lymphoma. 
410 Trümper, L. et al. (2004). Maligne Lymphome. In: Hiddemann, W. et al. (eds.) (2004). Die Onkologie, Teil 2. 
Springer Verlag, Berlin, pp. 1709-1774. http://www.springer.com/3-540-64648-5. And: Morgan, G. et al. (1997). 
Annals of Oncology 8: S49-S54. http://www.springerlink.com/content/r07442h1n6225553/. 
The Bio4EU Analysis report 181
Lymphomas were classically treated with radiotherapy and systemic chemotherapy (like 
‘CHOP’, a specific combination of anti-cancer drugs). Over the last years these treatments 
have been supplemented by autologous and allogeneic stem cell transplantation and by 
immunotherapy with monoclonal antibodies. This increase in available therapies makes it 
possible to better differentiate therapeutic strategies and aim for curative treatment412. The 
various therapies can also be combined, e.g. existing systemic chemotherapy regimes can be 
delivered with monoclonal antibodies, or monoclonal antibodies can be used for the delivery 
of targeted radiotherapy to tumour tissue413. 
 
 
 
Figure 38: Incidence of non-Hodgkin’s lymphoma in the EU by age (2001) 
Source: IARC 2006414.  
Note: Does not include Belgium and Cyprus.  
In immunotherapy, the immune system is put on a higher level of alertness with respect to 
cancer cells; in the treatment of NHL, genetically engineered CD20 antibodies have proven to 
be effective. The success of these antibodies relies on the fact that approximately 90% of the 
malignant B-cells in NHL express a CD20 antigen at their surface. This antigen is recognised 
by the corresponding CD20 antibody, which triggers the immune system to attack the 
malignant cells while sparing most normal tissue. Hence, such antibodies are ‘targeted’ drugs. 
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The need for engineering these antibodies arises from the fact that patients generally do not 
produce effective antibodies against the relevant antigens415. 
 
To date, studies on the effectiveness and cost-effectiveness of CD20 antibodies (rituximab) 
are scarce; the drug was approved in the US for the treatment of NHL in 1997 and in the EU 
in 1998416. A systematic review that was carried out in the UK could identify only one 
randomised controlled trial, which however confirmed the effectiveness of rituximab in the 
treatment of aggressive NHL (in combination with CHOP) in certain patient groups. In the 
same review, a cost-effectiveness analysis was carried out. This analysis showed that the 
addition of rituximab to the CHOP treatment regime may extend the patients’ lives by about 
one QALY at a cost of about GBP 10 000 (about EUR 15 000), which qualifies as a cost-
effective intervention. These results also confirm the data provided by industry417. Given this 
scarcity of information, for instance NICE has recommended the (general) use of rituximab 
only in some cases of NHL418. Another recent literature review of economic studies of 
currently available NHL treatment options also found (preliminary) evidence for the cost-
effectiveness of rituximab in the treatment of various forms of NHL. However, this study also 
concluded that more and better economic evaluations are needed to come to a more 
comprehensive assessment of the various effective treatments, including CD20 antibodies, 
that have been developed for NHL419. 
 
 
4.2.2 Diagnostics 
 
Diagnostics are gaining increasing importance for healthcare, constituting an invaluable set of 
tools for diagnosis, but in the recent years even more so for prognosis and prevention. As they 
are often a central part of first-line clinical decisions, diagnostics are a critical component of 
healthcare with growing social implications in terms of their impact on health outcomes but 
also healthcare delivery and costs420.  
Recent advances in biotechnology, and in particular genomic technologies, have greatly 
improved the understanding of disease mechanisms, and have, as a result, contributed to the 
development of new and improved diagnostics. These can be applied to early detection (e.g. 
for infectious diseases such as HIV/AIDS, SARS421), predisposition testing (e.g. breast 
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cancer) and prevention (e.g. early diagnosis of phenylketonuria to prevent mental retardation), 
but also in disease management and personalised ‘real time’ treatment (e.g. therapeutic drug 
monitoring tests to select drugs for resistant HIV strains), an important emerging trend in 
healthcare.  
 
Diagnostics based on modern biotechnology fall in two main categories. Nucleic acid-based 
tests are used to identify alterations in the genetic make-up of an individual correlating with a 
disease or a higher risk for developing a disease. Protein-based tests on the other hand can be 
used to identify changes in the levels of proteins during disease (e.g. hepatitis, cancer, etc.) or 
an infection (e.g. HIV). In general, this involves the detection of a protein by a specific 
antibody (e.g. immunoassays).  
 
In an era of increasing healthcare expenditures, the use of sophisticated diagnostics based on 
biotechnology is costly and may therefore pose a further economic strain on healthcare 
systems in spite of their potential positive role in improving public health through earlier 
diagnosis and prevention. In this context, assessing their impact on quality of life but also on 
healthcare delivery and costs is essential. This impact is evaluated based on three case studies, 
covering a broad spectrum of important communicable and non-communicable conditions. 
These include HIV testing, cardiac diagnostic assays and genetic testing.  
 
 
4.2.2.1 Biotechnology-based HIV testing 
 
The first case of an HIV infection was reported more than 20 years ago and by the end of 
2005, HIV was estimated to have affected 38.6 million people worldwide (Sub-Saharan 
Africa is the most affected region; however, the prevalence is high in other regions as 
well)422. In 2005 an estimated 4.1 million people became newly infected with HIV and 
between 2.4 million and 3.3 million people lost their lives to HIV/AIDS. Overall, the 
proportion of people who have become infected with HIV is believed to have peaked in the 
late 1990s and to have stabilised subsequently. However, recent projections confirm that the 
number of HIV/AIDS infections will continue to increase in the coming years although the 
magnitude will depend on how many people will have access to therapy and, more 
importantly, on the extent to which prevention strategies are efficiently applied423.  
 
According to UNAIDS, about 1.2 million people in the US were living with HIV at the end of 
2005, and approximately 40 000 new infections occur each year. In 52 countries of the 
WHO’s European region424, it has been estimated that 2.2 million people were living with the 
                                                 
422 UNAIDS (2006). Report on the global AIDS epidemic 2006. UNAIDS, Geneva. 
http://www.unaids.org/en/HIV_data/2006GlobalReport/. 
423 Mathers, C.D. and Loncar D. (2006). PLoS Medicine 3: 2011-2029. 
http://dx.doi.org/10.1371/journal.pmed.0030442.  
424 WHO European Region: Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and 
Herzegovina, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Georgia, 
Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, 
Luxembourg, Malta, Monaco, the Netherlands, Norway, Poland, Portugal, Republic of Moldova, Romania, 
Russian Federation, San Marino, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, 
Tajikistan, The former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Ukraine, the United Kingdom 
and Uzbekistan. 
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virus425 in 2005. The majority of these are in Eastern Europe and central Asia, where the 
overall rates of newly diagnosed HIV infections has increased significantly since 1998. In the 
same report, it is predicted that 100 000 - 580 000 people will need antiretroviral therapy by 
2010, indicating the growing implications of HIV/AIDS for healthcare.  
 
HIV belongs to the group of retroviruses, which are typically characterised by the long 
interval between infection and symptom development (patients may be asymptomatic for 
years after infection, although acute onset occurs within days). Individuals infected by the 
virus suffer from gradual but severe deterioration of their immune system, mainly as a result 
of the destruction of a subset of immune cells (known as CD4+ lymphocytes). Antiretroviral 
therapy was launched a decade ago and has made an important contribution to patient 
survival. However, the high mutability of the virus which in turn leads to drug resistance 
remains the pivotal challenge for the efficiency of available therapies used for the treatment of 
chronic patients and of the efficacy of post-exposure prophylaxis. A recent study indicates 
that in Europe drug-resistant HIV variants are frequently present in patients who have been 
recently infected or in patients suffering from a chronic infection and who have never been 
exposed to therapy before (baseline drug resistance)426. The early identification of such 
mutations is critical for monitoring the progression of the disease but more importantly for 
adjusting therapy accordingly427.  
 
The main types of HIV tests used currently for diagnosis, evaluation, monitoring and 
treatment of disease are based on modern biotechnology. These tests fall largely into two 
categories: i) protein-based (immunoassays) and ii) nucleic acid-based tests (NATs). The first 
category detects the presence of HIV (antibody or antigen) in a patient’s blood sample and is 
typically applied for the diagnosis of an infection or screening of blood donations. Some 
immunoassays have been designed to give rapid results in a non-laboratory setting.  
 
NATs detect DNA (or RNA) sequences which are highly specific to the virus. These tests can 
detect genetic HIV material from very small quantities and with a quick turnaround, which 
makes them a critical tool for the early detection of an infection and in identifying mutated 
strains (genotyping). This application is crucial for monitoring drug resistance and disease 
management (e.g. applying appropriate therapy, monitoring of transmissions, etc.) and is 
widely applied. NATs display additional advantages over phenotypic assays in the context of 
HIV testing and drug resistance427. For example, their ability to identify emerging mutations 
before the phenotypic onset of drug resistance is another crucial advantage for a timely 
change in therapeutic strategy.  
 
 
 
 
 
 
 
 
 
                                                 
425 WHO (2005). HIV/AIDS in Europe: overview. Fact sheet EUR/14/05. WHO Regional Office for Europe, 
Copenhagen. http://www.euro.who.int/Document/Mediacentre/fs1405e.pdf.  
426 Wensing, A.M.J et al. (2005). The Journal of Infectious Diseases 192: 958-966. 
http://www.journals.uchicago.edu/JID/journal/issues/v192n6/34030/brief/34030.abstract.html.  
427 Blum, R.A. et al. (2005). Pharmacogenomics 6: 169-179. http://dx.doi.org/10.1517/14622416.6.2.169.  
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Table 60: Cost-effectiveness of drug resistance testing – a comparison of US studies 
 
Reference Type of study Target population Main Results 
Weinstein 
et al. 
20011 
Modelling 
cost-
effectiveness 
HIV-infected patients in 
the US with a defined 
baseline of CD4 cell 
counts 
Primary resistance testing for guiding initial 
therapy was cost-effective at USD 22 300 per 
QALY gained with 20% prevalence, but at 
USD 69 000 per QALY gained if the 
prevalence of resistant variants is lower (4%) 
Sanders et 
al. 20052 
Modelling 
cost-
effectiveness 
Symptomatic patients who 
started treatment when 
CD4 cell counts dropped 
below a defined number 
With a 1% prevalence of unidentified HIV 
infection, testing was cost-effective at a ratio of 
USD15 078 per QALY. But the ratio increased 
in populations with lower prevalence 
Paltiel et 
al. 20063 
Modelling 
cost-
effectiveness 
US patients, low to 
moderate prevalence 
(0.05% to 1.0%) 
Routine HIV screening was cost-effective at 
USD 30 800 per QALY (one-time screening) or 
USD 32 300 per QALY (screening every five 
years), in a population with 1.0% prevalence 
and 0.12% annual incidence 
Cost-effectiveness is not observed if prevalence 
of undiagnosed HIV infection is below 0.2% 
and thus routine HIV testing is not 
recommended 
Main limitation: determining prevalence and 
incidence of undetected HIV infection 
1 Weinstein, M.C. et al. (2001). Annals of Internal Medicine 134: 440-450.  
http://www.annals.org/cgi/content/short/134/6/440. 
2 Sanders, G.D. et al. (2005). The New England Journal of Medicine 352: 570-585.  
http://content.nejm.org/cgi/content/abstract/352/6/570. 
3 Paltiel, A.D. et al. (2006). Annals of Internal Medicine 145: 797-806.  
http://www.annals.org/cgi/content/abstract/145/11/797. 
 
The likelihood of early detection of mutated HIV strains is greatly enhanced if genotyping is 
applied at the onset of care. Further to this, the chance to detect mutations in patients before 
they revert to normal (wild-type) is also increased. Thus, resistance testing is now 
recommended for treatment-naive patients, and for patients who are not responding to therapy 
or during pregnancy (guidelines have been published by the US Department of Health and 
Human Services Panel on Clinical Practices for Treatment of HIV Infection, the 
EuroGuidelines Group, and the British HIV Association)428. However, as these tests are 
relatively expensive, their widespread application is debated. Several studies have 
investigated the cost-effectiveness of routine use of genotyping for drug resistance in different 
scenarios (e.g. treatment failure or treatment-naive patients, prevalence, etc.). In the studies 
reviewed, genotyping was proven cost-effective although at different ratios (see Table 60), 
and still more cost-effective than, e.g. screening for colon cancer429 or prophylaxis against 
other infections430. Moreover, cost-effectiveness persisted even when the prevalence was low. 
Although most of the studies reviewed investigated the situation in the US (testing is already 
reimbursed in all but two states of the US) one European study reports a similar result, i.e. 
that the routine use of genotypic antiretroviral resistance testing (GART) after each treatment 
                                                 
428 Blum, R.A. et al. (2005). Pharmacogenomics 6: 169-179. http://dx.doi.org/10.1517/14622416.6.2.169.  
429 CEVR (2002). Cost-utility ratios 1976-2001. Center for the Evaluation of Value and Risk in Health, Boston. 
http://www.tufts-nemc.org/cearegistry/data/.  
430 Saag, M.S. (2001). Annals of Internal Medicine 134: 475-477. 
http://www.annals.org/cgi/content/short/134/6/475.  
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failure increases both life expectancy and healthcare costs per patient431. The use of GART 
after treatment failures is considered cost-effective and GART before the first treatment with 
Highly Active Anti-Retroviral Therapy (HAART) would also be cost-effective if it could 
lower the failure probability by a third. The cost-effectiveness of immunoassays is not clear.  
 
The uptake of HIV genotyping in routine clinical practice is considered to have been 
influenced by the wide availability of such testing by reference laboratories and patient 
awareness, but is predicted to be further driven by the high costs of new drugs. As monitoring 
drug resistance is essential for the effective management of HIV-infected patients, the 
application of these biotechnology tests may have a significant impact on the epidemic 
(projections suggest that by 2015 in the 60 countries most affected by HIV/AIDS, the total 
population will be diminished by 115 million because of HIV/AIDS). In addition, studies 
support the fact that routine testing (mainly using NATs) would be cost-effective considering 
the costs that can be saved through early diagnosis of HIV carriers.  
 
 
4.2.2.2 Cardiac diagnostic assays 
 
Cardiovascular disease (CVD) was estimated to have contributed to a third of global deaths in 
1999 and it is predicted to become the leading cause of death in developing countries by 
2010432. In the EU, CVD causes more than 1.5 million deaths and is the main cause of years 
of life lost due to premature deaths433. The overall cost of CVD in the EU was recently 
estimated to be EUR 169 billion annually434.  
 
The term CVD collectively refers to a class of diseases affecting the heart or the blood 
vessels. Theses include, for example, arteriosclerosis, heart failure, endocarditis, hypertension 
and congenital heart disease. Individuals suffering from CVD, particularly arteriosclerosis, 
are at high risk for an Acute Myocardial Infarction (AMI, heart attack)435, which currently 
represents the leading cause of death in the adult population in the US (one out of every five 
deaths436). The rapid diagnosis of an AMI episode (and its distinction from other non-critical 
conditions with similar symptoms) is critical for the effective management of the disease437.  
 
Tests for the diagnosis of AMI are based primarily on the detection of a defined set of 
biomarkers associated with this condition. Troponin, a protein found in the heart muscle, is a 
                                                 
431 Corzillius, M. et al. (2004). Antiviral Therapy 9: 27-36. 
http://www.intmedpress.com/general/contents.cfm?JournalTypeID=1&SectionID=2&SectionSubID=1&Section
SubSubID=1.  
432 WHO (2007). Strategic priorities of the WHO Cardiovascular Disease programme. World Health 
Organisation, Geneva. http://www.who.int/cardiovascular_diseases/priorities/.  
433 Petersen, S. et al. (2005). "European cardiovascular disease statistics." British Heart Foundation, London. 
http://www.heartstats.org/1570/.  
434 Leal, J. et al. (2006). European Heart Journal 27: 1610-1619. 
http://eurheartj.oxfordjournals.org/cgi/content/abstract/27/13/1610.  
435 A heart attack is caused by blocking the supply of blood and oxygen to the heart. This is typically a result of a 
clot in the coronary artery.  
436 AHA (2007). Heart attack and angina statistics. American Heart Association, Dallas, T.X. 
http://www.americanheart.org/presenter.jhtml?identifier=4591.  
437 AHA (2003). Heart and stroke facts. American Heart Association, Dallas, T.X. 
http://www.americanheart.org/presenter.jhtml?identifier=3000333.  
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very common biomarker with high prognostic and diagnostic value438. These assays are based 
on the use of monoclonal antibodies and can be grouped in two major categories: rapid tests 
which are used in the emergency care (point of care) and more quantitative tests used in a 
laboratory setting for a more detailed analysis. Their use in the clinic has allowed the rapid 
identification of patients suffering an AMI episode, as well as for the distinction of patients 
who display similar symptoms but are not actually in danger of an AMI (e.g. chest pains as a 
result of chronic indigestion). Additionally, these assays can be applied in monitoring disease 
progression in response to specific therapies.  
 
The economic benefit for healthcare systems resulting from the clinical application of cardiac 
diagnostics is not entirely clear, although it is estimated that a positive impact may be made 
by saving, for example, the costs of the treatment of patients who are not in danger (it is 
estimated that only 15% of people admitted to hospitals with chest pains are actually 
experiencing a heart attack)439. Certain studies support this estimation. For instance, one 
investigation explored the cost-effectiveness of various diagnostic strategies for patients 
suffering from chest pains (one of the main symptoms of AMI but also of other non-life 
threatening conditions). These strategies included either cardiac enzyme testing alone or in 
combination with admission to the hospital for observation over a few hours or overnight. The 
study showed that immediate cardiac enzyme testing alone has incremental cost-effectiveness 
compared to enzyme testing combined with overnight hospital admission for further 
observation440. In further support of the potential cost-effectiveness of cardiac enzyme testing, 
certain hospitals have reported savings from the use of troponin assays (mainly as a result of 
minimising the number of days a patient might spend in the hospital just for observation), in 
spite of the high cost of the test439,441.  
 
 
4.2.2.3 Genetic testing 
 
Modern biotechnology and genomic technologies have led to a wealth of genetic information, 
especially in correlation to specific diseases. This has, in turn, facilitated the rapid 
development of tests that may predict disease (or risk thereof) through the analysis of a 
person's genetic make-up. Genetic testing has been defined by the OECD442 as ‘testing for 
variations in germline DNA sequences, or for products/effects arising from changes in 
heritable sequences, which are predictive of significant health effects’. This definition 
indicates that the analysis of genetic information may be made through varying methods 
including cytogenetic and biochemical testing. However, as the association of specific DNA 
sequences with a disease phenotype has greatly improved, particularly following the 
completion of the human genome project, DNA testing has expanded to be considered the 
main type of genetic testing. In this context, it is estimated that DNA testing is currently 
available for over 1000 genetic disorders and the methods rely mainly on detecting specific 
mutations (often at the single nucleotide level) through polymerase chain reaction (PCR) and 
                                                 
438 Eggers, K.M. et al. (2004). American Heart Journal 148: 574-581. 
http://pt.wkhealth.com/pt/re/amhj/abstract.00000406-200410000-00004.htm.  
439 ETEPS (2006). Bio4EU Task2 Case studie report – Human Health Applications. 
440 Goodacre, S. and N. Calvert (2003). Emergency Medicine Journal 20: 429-433. 
http://emj.bmj.com/cgi/content/abstract/20/5/429.  
441 Polanczyk, C.A. et al. (1999). Annals of Internal Medicine 131: 909-918. 
http://www.annals.org/cgi/content/bstract/131/12/909.  
442 OECD (2000) Workshop on Genetic Testing: Policy Issues for the New Millennium, Vienna 
http://www.oecd.org/document/16/0,2340,en_2649_37407_1895632_1_1_1_37407,00.html. 
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DNA sequencing443. Another recent report estimates that about 700 000 tests per year are 
performed in the EU, whereas information regarding the US points to a 30% increase in the 
number of genetic tests carried out between 1995 and 1996444, although more recent data are 
scarce.  
 
Genetic tests may be classified based on the purpose for which they are performed. The most 
common application is diagnostic testing typically carried out to complement the clinical 
diagnosis of a patient with symptoms that have a suspected genetic cause (e.g. the test for 
fragile X syndrome in children with learning difficulties). In this case, the test is used either 
for confirmation or exclusion of the diagnosis already made in the clinic. Predictive testing is 
the second most common application of genetic testing and comes in two varieties: 
presymptomatic testing, which is performed on healthy individuals who have a condition of 
delayed onset (e.g. Huntington’s disease) and predisposition testing which informs medical 
staff of the increased or decreased risk of developing a certain condition. One such example is 
testing for mutations in the BRCA1 and BRCA2 genes, which confer susceptibility to breast 
cancer, although it is important to note that a positive result does not translate to 100% risk of 
developing cancer.  
 
Genetic testing may also be utilised in reproductive decision-making and is usually pertinent 
when parents are at high risk or who have previous experience of a family member with a 
serious genetic disorder. This application includes carrier testing, prenatal testing and 
preimplantation genetic diagnosis (done in conjunction with in vitro fertilisation). The latter is 
only an emerging application which has expanded considerably in the recent years. Genetic 
screening is an extended application of predictive testing (i.e. prenatal or carrier testing) 
carried out for a specific population. This type of testing is organised and implemented by 
national or regional health authorities.  
 
Pharmacogenetics is a newer application of genetic testing referring to the study of varied 
drug responses as a result of the differences in the genetic makeup of different patient 
populations. In 2002, the OECD estimated that pharmacogenetic tests represented about 5% 
of all testing carried out in laboratories in five EU countries (Italy, Austria, Finland, Portugal 
and the UK), the US and Canada. However, the availability of such tests has increased since 
then. Examples of currently marketed tests include tests for hereditary colon cancer, 
periodontitis, breast cancer (HER2), warfarin and 6-mercaptopurine poor metabolisers445. The 
ultimate aim of pharmacogenetic tests is to facilitate tailored therapy according to an 
individual patient’s needs, thus reducing potential adverse drug reactions which represent a 
considerable burden on healthcare expenditure. Consequently, the application of 
pharmacogenetics is predicted to have a major impact on cost-savings. However, the overall 
potential contribution of pharmacogenetics to improving the efficiency of the healthcare 
systems requires further investigation.  
 
Perhaps less visible, but quite common applications of genetic testing include paternity testing 
and forensics. Additionally, it is applied in disease stratification. Other applications, which are 
                                                 
443 McPherson, E. (2006). Clinical Medicine and Research 2: 123-129. 
http://www.clinmedres.org/cgi/content/abstract/4/2/123.  
444 Ibarreta, D. et al. (2003). Towards quality assurance and harmonisation of genetic testing services in the EU. 
European Commission, IPTS, EUR 20977. http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1124. 
445 Higashi, M.K. and Veenstra D.L. (2003). The American Journal of Managed Care 9: 493-500. 
http://www.ajmc.com/article.cfm?ID=2.  
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only indirectly related to human health, include testing for animal diseases and food testing. 
The potential impacts of the latter are discussed in Section 4.3.3.  
 
The most common diseases for which genetic testing is performed are those with a higher 
frequency in a population. These include cystic fibrosis, Duchenne muscular dystrophy, 
haemophilia A and B, familial breast cancer, fragile X syndrome, myotonic dystrophy, 
haemochromatosis, and hereditary non-polyposis coli. The association of specific mutations 
with these diseases are well established which potentially contributes to the increased use of 
the respective tests. In certain cases, genetic testing has replaced other diagnostic methods. 
For instance, the genetic test for myotonic dystrophy is widely used in clinical practice as it is 
less invasive and more accurate than the previously applied electromyography which failed to 
distinguish between this condition and other less severe types of myotonia446.  
 
However, a broader clinical implementation of genetic testing is still largely missing. For 
instance, the case study on phenylketonuria (PKU), a genetically inherited metabolic disease, 
indicates that testing is carried out primarily through biochemical methods, rather than DNA 
testing per se, partly because the biochemical tests are very efficient and not as costly, but 
also because the association of specific mutations with the disease phenotype is not yet 
entirely clear447. Genetic testing based on DNA analysis is also not widespread for 
haemochromatosis, another common metabolic disorder characterised by iron overload, in 
spite of the clear knowledge of the causing disease mutations (two specific mutations have 
been identified with strong correlation)448. As only a few carriers actually require treatment, 
testing can be performed efficiently with biochemical techniques, although genetic testing 
may be applied e.g. to confirm an unclear biochemical diagnosis.  
 
Table 61: Examples of marketed genetic tests and their approximate cost 
Source: Higashi et al. 2003449, adapted by IPTS 
 
Gene Clinical outcome Test provider and approximate cost 
Pathogenomics 
Mismatch 
repair genes 
Prediction of risk for colon cancer (hereditary 
non-polyposis colorectal cancer HNPCC) 
Available from multiple testing 
facilities: cost includes patient 
counselling  
USD 1300 - 3600 
BRCA1 Prediction for risk of breast cancer Myriad Genetic Laboratories, Inc  USD 2760 
Pharmacogenomics 
CYP2C9 Avoidance of major bleeding events Genelex USD 135 
TPMT Reduced haematopoietic toxicity DNA Sciences, Inc. USD 395 
 
                                                 
446 McPherson, E. (2006). Clinical Medicine and Research 2: 123-129. 
http://www.clinmedres.org/cgi/content/abstract/4/2/123. 
447 ETEPS (2006). Bio4EU Task2, case studies report: human health applications. 
448 Pietrangelo, A. (2004). New England Journal of Medicine 350: 2383-2397. 
http://content.nejm.org/cgi/content/extract/350/23/2383.  
449 Higashi, M.K. and Veenstra D.L. (2003). The American Journal of Managed Care 9: 493-500. 
http://www.ajmc.com/article.cfm?ID=2 
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The frequent lack of clear genotype-phenotype associations results primarily from the 
complex nature of the human genome but also from the fact that several gene-based diseases 
may be influenced by the environment, which makes it difficult to design highly specific and 
sensitive DNA tests (this is less likely to affect monogenic disorders where one specific gene 
is linked to a certain condition). However, the limited application of genetic testing in the 
clinic may be a result of several other factors, including the lack of proven utility and 
associated costs (both direct and indirect, e.g. for genetic counselling)450. For instance, 
BRCA1 and BRCA2 testing and counselling for breast cancer was estimated to cost more than 
USD 2000 per test in 2001451. However, in another case, the test may be relatively 
inexpensive but the accompanying therapy very costly, as is observed for HER2 testing452. A 
list of examples of marketed genetic tests and their approximate cost is provided in Table 61.  
 
The cost-effectiveness of genetic testing depends on many factors such as the prevalence of 
the genetic mutation and the disease in the population and the penetrance452. However, only 
few economic analyses of genetic testing exist, and those available have covered a limited 
number of diseases. One study reports that screening of high-risk (Ashkenazi Jewish) women 
for BRCA1/2 is cost-effective only when all women who test positive undergo prophylactic 
surgery453. However, the overall scarcity of cost-effectiveness studies for genetic testing 
impedes the evaluation of their potential impact on the efficiency of healthcare systems. An 
economic evaluation is further complicated by the unclear reimbursement situation and the 
limited information on patients' views related to these diagnostic technologies (e.g. are 
patients willing to pay for these tests even if their benefit is not clear). More research would 
be required to clarify these aspects influencing the wider clinical use of genetic testing in the 
future.  
 
One important implication of genetic testing relates to the development of systematic 
collections of human biological samples and associated data, known as biobanks. These have 
become an important research tool, particularly in the context of genetic association 
studies454. While the importance of biobanks in improving the understanding of disease is 
accepted, ethical concerns may be raised with regard to the use and protection of the collected 
data and/or samples. At the EU level, the regulatory framework for protecting personal data is 
provided by Directive 95/46/EC455.  
 
The social, legal and ethical implications of genetic testing must be taken into account when 
considering the overall benefit of technological advances in the area of diagnostics. DNA-
based testing and genotyping are being increasingly applied to the prediction of drug response 
and risk for diseases such as breast cancer (facilitated by the continuous identification of 
relevant biomarkers). Thus genetic testing offers a unique opportunity for improved and early 
diagnosis of monogenic and complex disorders facilitating prevention and (more 
                                                 
450 Higashi, M.K. and D.L. Veenstra (2003). The American Journal of Managed Care 9: 493-500. 
http://www.ajmc.com/article.cfm?ID=2. 
451 Lawrence, W.F. et al. (2001). Cancer Epidemiology Biomarkers & Prevention 10: 475-481. 
http://cebp.aacrjournals.org/cgi/content/abstract/10/5/475.  
452 Phillips, K.A. et al. (2004). The American Journal of Managed Care 10: 425-432. 
http://www.ajmc.com/Article.cfm?Menu=1&ID=2651.  
453 Grann, V.R. et al. (2004). Journal of Clinical Oncology 22: 494-500. 
http://jco.ascopubs.org/cgi/content/abstract/17/2/494.  
454 Smith, G.D. et al. (2005). The Lancet 366: 1484-1498. http://dx.doi.org/10.1016/S0140-6736(05)67601-5.  
455 Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of 
individuals with regard to the processing of personal data and on the free movement of such data. OJ L281/31 
23.11.1995. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31995L0046:EN:HTML.  
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personalised) therapy. However, the increasing collection of individual genetic information 
raises several concerns related to patient privacy, the potential misuse of a patient’s genetic 
data and access to healthcare. The incidence of genetic discrimination as a result of such data 
misuse (e.g. in the form of employment termination or limitation/refusal of health insurance 
provision) is being increasingly addressed by regulators and policy-makers456. In this context, 
the European Group on Ethics in Science and New Technologies published an opinion 
regarding the ethical aspects of genetic testing in the workplace457, based on which initiatives 
to protect employees’ personal data have been announced by the Euroepan Commission458. 
The issue of preferential treatment of a specific subgroup of patients based on a genotypic test 
merits serious attention, as it may lead to racial discrimination459. This is particularly 
important for medical practice and healthcare management as, in certain cases, the predictive 
value of some genetic tests is not clearly demonstrated.  
 
Additional ethical concerns are raised in the context of reproductive medicine. In this respect, 
the application of prenatal or preimplantation genetic diagnosis for establishing an unaffected 
pregnancy or identifying a genetic defect in the case of high-risk families, and the decisions 
connected to such diagnoses naturally raise questions related to the status of the embryo and 
the potential for eugenics460,461, as the technology could be potentially applied for the 
selection of desirable traits in an embryo. However, there are other dimensions to this issue, in 
that the same technology can be utilised for the identification of an embryo that could serve as 
a donor of stem cells for the treatment of an existing person462. In such cases, immune 
rejection of the cells by the recipient is a critical factor for the success of the therapy, and 
genetic diagnosis for the identification of appropriate donors (HLA typing) is becoming 
increasingly important and is gaining support (through regulation).  
 
 
In summary, it appears that diagnostics based on modern biotechnology are gaining 
importance in all aspects of clinical practice, including disease diagnosis, monitoring and 
prevention. However, their actual implementation in the clinic is widely varied ranging from 
routine (e.g. HIV testing for monitoring drug resistance) to limited use (e.g. genetic testing for 
PKU). Moreover, although these diagnostic tools may offer clinical benefits they also 
potentially pose economic strains to healthcare systems mainly due to their direct and indirect 
costs. Further cost-effectiveness studies would help elucidate their actual overall benefit. In 
                                                 
456 The Lewin Group (2005). The value of diagnostics, innovation, adoption & diffusion into healthcare. 
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this context, it is important to note that some experts highlight the use of these diagnostic 
tools to complement, rather than to replace, clinical medicine463.  
 
 
4.2.3 Preventives 
 
Recombinant hepatitis B vaccine, the first modern biotechnology vaccine authorised for 
humans, was selected as a case study for the assessment of the effectiveness of biotechnology 
in preventives. The results of this case study are discussed in the following.  
 
4.2.3.1 Recombinant hepatitis B vaccine 
 
Hepatitis is an inflammation of the liver that is caused by a virus, and while there are five 
different hepatitis viruses, the hepatitis B virus (HBV) is the most serious type: HBV can 
cause an acute disease with symptoms lasting several weeks including the yellowing of skin 
and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. It can 
take several months to a year to recover, but HBV can also cause chronic infection and many 
years later this can develop into cirrhosis of the liver or liver cancer – diseases that kill about 
one million persons each year worldwide and can hardly be treated. HBV is transmitted by 
contact with blood or body fluids of an infected person; the main ways of getting infected 
with HBV are from mother to child at birth (perinatal), from child to child contact in 
household settings, from unsafe injections or transfusions and from sexual contacts. But while 
the former ways of infection are more frequent in developing countries, in industrialised 
countries the majority of infections are acquired during young adulthood by sexual activity, 
and injecting drugs; HBV is also the major infectious occupational hazard of health 
workers464.  
 
According to the WHO, currently more than 350 million people worldwide are infected with 
HBV and have to live with chronic infections, i.e. about 6% of the global population carries 
the virus. For Europe in 2004 (including the countries of the former Soviet Union, Turkey and 
Israel), the WHO reports an incidence rate of 5.95 new cases of hepatitis B per population of 
100 000 (down from an incidence rate of 19.20 in 1995), while for the EU the reported 
incidence rate for 2004 was only 3.49 (down from 6.55 in 1996), even though for the EU this 
amounts to a small increase over 2003 when the incidence rate was only 3.43465. Given that 
the EU had a population of 458 973 024 in 2004466, this corresponds to 16 018 new hepatitis 
B cases in 2004. However, half of all hepatitis B infections may go unreported and two-thirds 
of the infections are asymptomatic467. Under this premise, there may have been almost 
100 000 new infections in 2004. Furthermore, given the high prevalence of HBV carriers in 
the rest of the world, HBV infections remain a risk.  
                                                 
463 McPherson, E. (2006). Clinical Medicine and Research 2: 123-129. 
http://www.clinmedres.org/cgi/content/abstract/4/2/123. 
464 WHO (2000). Hepatitis B. Fact sheet 204. World Health Organisation, Geneva. 
http://www.who.int/mediacentre/factsheets/fs204/. 
465 WHO (2006). European Health for All Database (HFA-DB), June 2006. WHO Regional Office for Europe, 
Copenhagen. http://data.euro.who.int/hfadb/.  
466 Eurostat (2006). Population by sex and age on 1 January of each year. Theme: Population and Social 
Conditions. European Commission, Eurostat, Luxembourg. http://epp.eurostat.ec.europa.eu/.  
467 Van Damme, P. et al. (1995). Vaccine 13: S54-S57. http://dx.doi.org/10.1016/0264-410X(95)80053-G. 
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The first vaccine against HBV became available in 1982. The agent for vaccination against 
hepatitis B contains a surface protein of the virus that triggers the development of antibodies 
and, thus, neutralises the infectivity of HBV. This protein is produced in the liver of 
chronically infected persons from where it spills into the blood. Consequently, for the first 
generation of vaccines, these agents were extracted from the plasma of infected persons, 
purified and inactivated. These plasma vaccines are still used in those parts of the world 
where biotechnological know-how is missing and where the incidence of hepatitis B is high 
(so that chronically infected donors of plasma are readily available). However, plasma 
vaccines have been largely replaced in the industrialised countries since 1986 when 
recombinant vaccines became available. These vaccines are produced in recombinant yeast 
and, therefore, are free from human plasma particles and potential contamination of the 
vaccine with infectious material. In the EU, the last plasma vaccine was taken off the market 
in 1991. Factors fuelling the transition from plasma to recombinant hepatitis B vaccines were 
not only the availability of the technological know-how, but – following the experience with 
HIV contaminated blood products in the 1980s – the fears of new safety hazards468.  
 
Either way, hepatitis B vaccines have an outstanding record of safety and effectiveness. Only 
about 1 - 6% of those who receive the vaccine develop a mild fever that lasts one or two days 
after injection of the vaccine, and more severe reactions and complications due to the vaccine 
are rare: allergic reactions occur about once every 600 000 doses and no fatal allergic reaction 
has been reported so far469. Since 1982, over one billion doses of hepatitis B vaccine have 
been used worldwide, and studies have shown that the vaccine is 95% effective in preventing 
chronic infection if the patients have not yet been infected470.  
 
Because plasma vaccines have by and large been replaced by recombinant vaccines in the 
industrialised world in the early 1990s, there is little comparative information on the 
production of plasma vaccines available (in the context of industrialised countries). The 
plasma vaccines were relatively expensive and testing was time-consuming because of the 
routine testing of the vaccine’s safety (innocuity) in chimpanzees, and because the availability 
of plasma from chronically infected persons was limited in low-endemicity industrialised 
countries471. In contrast, in these countries the biotechnological know-how and the genetically 
modified yeast strains were readily available and, therefore, the production of recombinant 
hepatitis B vaccines was relatively easy. Still, because of the need to demonstrate the safety 
and efficacy of the new vaccines in clinical studies, these new vaccines were initially 
substantially more expensive than the traditional products, also because the companies 
carrying out the underlying research had to protect their economic interests through the 
application of patents for their discoveries472.  
 
Nevertheless, after the introductory period of the new vaccine, i.e. by the mid-1990s, the 
sterile production of the agents from plasma in the EU had probably already become more 
expensive than the production of the antigen in recombinant yeast, and (in Germany) about 
half the end price of the vaccine could be attributed to sales and distribution costs and not to 
                                                 
468 ETEPS (2006). Bio4EU Task2, case studies report: human health applications. 
469 WHO (2006). Hepatitis B: the vaccine. IVB Topics. World Health Organisation, Geneva. 
http://www.who.int/immunization/topics/hepatitis_b/. 
470 WHO (2000). Hepatitis B. Fact sheet 204. World Health Organisation, Geneva. 
http://www.who.int/mediacentre/factsheets/fs204/. 
471 Stephenne, J. (1988). Vaccine 6: 299-303. http://dx.doi.org/10.1016/0264-410X(88)90173-9. (Information 
quoted in ETEPS (2006). Bio4EU Task2, case studies report: human health applications.)  
472 Poirot, P. and Martin J.F. (1994). Cahiers Santé 4: 183-187. http://www.john-libbey-
eurotext.fr/fr/revues/sante_pub/san/e-docs/00/04/1F/9A/resume.md?type=text.html.  
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the actual production of the vaccine473. While easier production and more competition may 
have driven down factory prices over time, nominal list prices for the hepatitis B vaccine in 
Germany have not changed much since 1983 and are still at a level of about EUR 60. 
However, available price information is inconsistent and some sources report considerably 
lower vaccine costs474. For example, the UNICEF Supply Division procures a dose of 
hepatitis B vaccine at the price of about EUR 0.20, excluding transportation and distribution 
costs475. The cost of a recombinant hepatitis B vaccine from producers of generic drugs in 
developing countries may be as little as one per cent of the price of a corresponding vaccine 
from multinationals in industrialised countries (e.g. the Indian company Shantha Biotechnics 
charges about EUR 0.95 for one course of the vaccine, while elsewhere international 
pharmaceutical companies may charge as much as about EUR 95)476. Yet, part of these 
differences may also be due to the fact that the production and use of vaccines is not only 
influenced by technical and economic factors, but also by changes in healthcare systems and 
vaccination strategies, or by national pricing and reimbursement policies.  
 
It seems to be plausible that, apart from the clinical benefits in terms of higher (perceived) 
safety, there may also have been a production-based advantage of recombinant hepatitis B 
vaccines over the corresponding plasma vaccines. One may also suspect that the improved 
supply of hepatitis B vaccines has had a share in the above-mentioned decline in the incidence 
rates of hepatitis B. Therefore, hepatitis B vaccines have not only improved efficiency in the 
healthcare system, they have also contributed to more effective disease prevention and, thus, 
generated more widespread social benefits in terms of safeguarded work capacities and 
general well-being. Yet, given the lack of an appropriate counterfactual situation in which 
plasma vaccines have been used, it is difficult to judge how many of these benefits have to be 
attributed to recombinant hepatitis B vaccines in contrast to hepatitis B vaccines as such.  
 
There have been several specific studies on the cost-effectiveness of various hepatitis B 
vaccination strategies – irrespective of whether the vaccines used are plasma or recombinant 
vaccines. The studies considered only cover industrialised countries to ensure comparability, 
because the social and economic effects of vaccination programmes depend on the underlying 
prevalence of the disease: the higher the prevalence is, the cheaper it is to avoid a new case. 
However, these studies give a mixed picture. While no study doubts the effectiveness of 
hepatitis B vaccines, sometimes the studies seem to be biased in favour of one particular 
vaccination strategy or the study's scientific quality seems questionable. The studies generally 
support the cost-effectiveness of one vaccination strategy or the other, i.e. the question is less 
whether hepatitis B vaccine as such can contribute to more efficiency in the healthcare 
system, but which vaccination strategy to choose477. 
 
                                                 
473 Caspari, G. and Gerlich H.W. (1997). Deutsches Ärzteblatt 94(26): A-1768. 
http://www.aerzteblatt.de/v4/archiv/artikel.asp?src=suche&id=6882.  
474 ETEPS (2006). Bio4EU Task2, case studies report: human health applications. 
475 Blanchet, S. (2006). Personal communication. Communication Officer, UNICEF Supply Division, 
Copenhagen (e-mail on 7 December 2006).  
476 DNM (2007). New Hep C drug means treatment for the masses. In-PharmaTechnologist Newsletter, 
Materials & Formulation, 04/01/2007. Decision News Media, Montpellier. http://www.in-
pharmatechnologist.com/news/ng.asp?n=73091. And: Shantha (2007). Shanvac-B. Products. Shantha 
Biotechnics, Hyderabad. http://www.shanthabiotech.com/shanvac_b.htm. 
477 Miller, M.A. and McCann L. (2000). Health Economics 9: 19-35. http://www3.interscience.wiley.com/cgi-
bin/abstract/69502209/. And: Diel, R. (2003). Evaluation aktueller Impfstrategien gegen Hepatitis A und B. 
Heinrich-Heine-Universität, Düsseldorf. http://deposit.ddb.de/cgi-bin/dokserv?idn=974297135. 
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Given the available information discussed so far, it is difficult to assess the impact of 
recombinant vs. plasma hepatitis B vaccines. Mainly due to safety concerns (whether 
substantiated or not) within the EU, recombinant hepatitis B vaccines have now been used 
exclusively for 15 years. During the same period the incidence rates of hepatitis B within the 
entire EU have experienced a substantial decline. Although the contributing factors cannot be 
disentangled easily, the trust in the vaccine and its ease of availability may have had their 
share in this success. Moreover, the quick adoption of recombinant hepatitis B vaccines could 
also indicate their economic profitability over plasma vaccines. While the end-price of 
hepatitis B vaccines has not fallen considerably in the EU countries for which such 
information is available, this may have been due to other costs (like the sales and distribution 
cost of the product and national regulations).  
 
 
4.2.4 The use of animals in research 
 
Animals are being increasingly employed in scientific research and drug development for 
purposes ranging from gene function studies to drug target validation and toxicity testing. 
Recent estimates indicate that a range of 75-100 million vertebrates are used worldwide per 
year in research, mainly related to drug development, the testing of vaccines and cancer 
research478. Most commonly, animals are used as research models for the study of a specific 
biological/molecular process associated with a disease or a genetic condition in humans, with 
the ultimate aim of developing a new therapy or of improving existing treatments479. The use 
of animal models has been particularly enhanced by the similarity of important molecular 
pathways between human and non-human species as uncovered by sequencing and comparing 
their genomes. For instance, mice and rats have a high homology to the human genome which 
may at least partly contribute to their frequent use as research models478.  
 
The contribution of animal models in medical advances may be illustrated by several 
examples, including their use in the development of the polio vaccine or techniques 
improving kidney transplantation, and the development of potential therapies for genetic 
conditions such as cystic fibrosis479. Additionally, animals may be used in compound 
screening and toxicity testing, as part of the drug development process. In spite of this, the use 
of animals in research has also raised concerns regarding the suitability of animals as models 
for human disease as it is argued that the differences that exist between humans and animals 
compromise the validity of these models in the study of disease or drug safety. At the same 
time, it is also recognised that careful design of the model could play a critical role in the 
outcome of the research. One illuminating example for this notion is that of thalidomide, a 
drug having been prescribed to pregnant women as an antiemetic (now withdrawn). The drug 
induced foetal malformations, which were not predicted by the mouse model used to test this 
drug initially. However, these side effects were later demonstrated when the drug was retested 
in pregnant mice.  
 
Additional concerns relate to the welfare of the animals themselves (additional animal welfare 
issues are discussed in the previous section). Some reports indicate that experimental animals 
may experience discomfort ranging from minor (e.g. due to a procedure such as single blood 
                                                 
478 Baumans, V. (2005). Scientific and Technical Review 24: 503-514. 
http://www.oie.int/eng/publicat/RT/2402/A_R2402_BAUMANS.htm.  
479 Bateson, P. et al. (2004). The use of non-human animals in research: a guide for scientists. The Royal Society, 
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sampling) to moderate and severe (resulting, for example, from recovery from anaesthesia or 
toxicity testing). The latter two categories represent a respective share of 30% and 20% of all 
laboratory animals480. Specific animal models are most typically developed through genetic 
modification (e.g. gene insertion or deletion, introduction of targeted mutations), which has 
been suggested to have a potentially negative impact on the welfare of laboratory animals as a 
result of either the procedures employed to achieve the modification (e.g. microinjection of 
transgene) or of the modification itself. For instance, the introduction of a new gene may 
impact the health of the mouse481. It has also been suggested that experimental animals may 
be compromised immunologically which might, in turn, render them inappropriate for 
research (leading to unreliable conclusions)482. The increasing production of genetically 
modified animals for research (increase of more than 23% per year) further contributes to 
these welfare concerns480.  
 
Overall the use of animals in research has made a recognised contribution to both scientific 
and medical advances, but welfare issues potentially related to this use cannot be ignored. The 
‘3Rs principle’483 (i.e. replacement, reduction and refinement) has been proposed to guide 
research using animals, in a way that minimises their use and potential discomfort. 
Replacement refers to the substitution of animals by non-animal alternatives if available (e.g. 
in vitro techniques using cells or tissues), reduction refers to the decrease of the number of 
animals used in research to the minimum possible (e.g. by standardising procedures) and 
refinement aims at minimising animal discomfort. Modern biotechnology applications may 
facilitate these objectives. For instance, the increasing use of in vitro methods for toxicity 
testing or as screening tools could contribute to the reduction of animal use (full replacement 
may not be possible as in vitro systems cannot completely reflect the complexity of living 
systems). At the same time, the knowledge gained through genomics allows a better (more 
refined and standardised) experimental design which could, in turn, impact the number of 
animals used per experiment. The 3Rs principle has been acknowledged by the existing EU 
legislation on animal protection (Directive 86/609/EEC484) and is also a key component of the 
recently adopted Community Action Plan on the Protection and Welfare of Animals, which 
outlines specific measures for the promotion of animal welfare in the EU until 2010485.  
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4.2.5 Summary 
 
In the previous sections the impact of modern health biotechnology on public health policy 
objectives has been illustrated by means of eight case studies. The results of these analyses 
only allow generalisations to some extent. In all cases, the biotechnology applications have 
some advantages, either by providing for better clinical interventions (like in the case of 
glucocerebrosidase, monoclonal antibodies, cardiac testing or HIV testing) or by improving 
perceived safety and quality of life of the individuals concerned (like in the case of human 
insulin, testing for PKU or hepatitis B vaccinations). In addition, the cost-effectiveness of 
some applications could not yet be established because the necessary long-term trials have not 
yet been carried out, but there is preliminary evidence of cost-effectiveness (like in the case of 
interferon-beta). Therefore, it seems to be warranted to conclude that modern biotechnology 
can indeed contribute to improved warning, monitoring and control of communicable diseases 
and to a reduction of non-communicable diseases incidence by improving the effectiveness of 
health interventions, reducing the burden of disease and/or improving the quality of life of 
those suffering from disease.  
 
Regarding the second policy objective of achieving a reduction of healthcare and social costs 
as well as a reduction of disease burden, the results are less clear. In some cases, the 
application of modern biotechnology in fact increases efficiency in the healthcare sector, 
while in other cases it has simply become the standard application without in-depth evaluation 
of its cost-effectiveness (like in the case of human insulin or the recombinant hepatitis B 
vaccine). In some cases the assessment is only preliminary in nature (like for interferon-beta 
or monoclonal antibodies), or the new drug actually puts a strain on healthcare resources, 
even though this may be justified from an ethical point of view (like in the case of 
glucocerebrosidase). Given the relative novelty of most of these applications, further cost-
effectiveness studies need to be carried out to assess the contribution of modern 
biotechnology to efficiency within healthcare systems.  
 
Modern biotechnology also has implications for animal health and welfare (see also Section 
4.3). On the one hand the use of animals in research has made a recognised contribution to 
both scientific and medical advances. On the other hand, the use of animals in research also 
implies animal welfare issues. Modern biotechnology, e.g. through the development of in 
vitro methods may help to contribute to the replacement, refinement and reduction of animal-
based tests in research.  
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4.3 Agro-food biotechnology 
4.3.1 The relevance of primary production and agro-food to public health 
 
The agro-food sector has both direct and indirect relevance to the EU public health policy 
objectives: on the one hand, it is responsible for the provision of a large share of the food 
products consumed by EU citizens; on the other hand, there is an inherent interaction between 
primary sector activities and the natural environment. The major EU public health policy 
objectives relate to the protection of the EU citizen against health threats and to disease 
prevention, as well as to ensure that healthcare and related social costs are at a minimum, and 
that the objectives are attained cost-effectively. The agro-food sector activities have public 
health implications, mainly in terms of the following:  
• major zoonoses (e.g. BSE and salmonellosis)  
• chemical contaminants in the food chain (e.g. pesticides) 
• food quality (e.g. related to the nutrient profile of the products) 
• animal health and welfare 
• healthcare and related social costs (e.g. public spending on animal disease eradication 
and monitoring). 
 
The importance of food safety within the context of public health has been widely recognised 
by the EU society and EU policymakers. Food safety has emerged as an issue of utmost 
importance in the EU agenda, especially following a series of food scares in the late 1990s, 
which stressed the need for action at EU level. All of the above culminated in the review of 
the general food law at EU level and the creation of the European Food Safety Authority486.  
 
 
Modern biotechnology applied to the agro-food sector may have implications for all the 
public health issues identified above. For example, modern biotechnology applications in the 
propagation and breeding of plants, animals and fish, may aid in the selection of animals for 
better food quality, whereas modern biotechnology-based inputs to primary production, the 
food processing sector and the food chain in general, are of direct relevance for the health 
management of the farmed populations, as well as for the monitoring of the safety of the final 
product offered to consumers.  
 
 
4.3.2 Breeding and propagation 
 
Modern biotechnology currently applied in animal breeding and propagation mainly have 
animal health and welfare implications, and the discussion will therefore be limited to these 
aspects. A number of recent R&D projects, however, are now aiming at other public health 
objectives, such as targeting the development of disease resistant animals (e.g. the 
development of BSE resistant cattle via genetic modification) or the selection for nutritional 
quality traits (e.g. through marker assisted selection).  
                                                 
486 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying 
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4.3.2.1 Animal health and welfare487 
 
Animal welfare has been receiving increased attention by society and the EU policy agenda in 
recent years. Modern biotechnology may have several and contrasting implications for animal 
welfare. On the one hand there are issues with negative connotations, such as the use of what 
are perceived as intrusive techniques or techniques that may involve additional risks for 
animals; on the other hand, modern biotechnology provides solutions that improve animal 
welfare in a variety of ways, such as through replacing the use of animals as tools in chemical 
safety testing or through the provision of novel animal health management tools that decrease 
animal suffering. 
 
Modern biotechnology applications that have been associated negatively in terms of animal 
welfare mainly concern those that are applied directly to animals such as embryo technologies 
in livestock and ploidy and sex manipulation in fish. A baseline concern of some stakeholders 
is the artificial aspect of these technologies, with respect to natural selection and reproduction, 
which however is a common feature of the mainstream agricultural practices in general.  As 
regards embryo transfer (ET), ovum pick-up (OPU), which is part of ET methods, is an 
invasive method and may have a negative impact on the welfare of individual animals that 
needs to be balanced by the benefits obtained by the technology. The acceptance by animal 
welfare organisations of these and other related assisted reproduction technologies (e.g. 
artificial insemination - AI, in vitro fertilisation - IVF, culture of embryos, cloning, and 
others) was reviewed by Kolar and Rusche488. Of the six organisations surveyed, two did not 
accept ET and in vitro embryo production (IVP), while only two generally accepted AI. 
Overall, of importance to most organisations was the specific context of each application, e.g. 
regarding the objectives and potential side effects. Public perception of reproduction 
techniques was also considered for France and the UK in the SEFABAR project489. It was 
found that AI had unanimous acceptability in these two countries with the author interpreting 
this to be as a consequence of both its length of service and its successful application in 
human reproduction. In both countries, IVF and ET were represented as displaying some of 
the same features but some of the participants viewed them negatively in terms of animal 
production. Education, labelling and minimum standards were suggested as the means of 
addressing concerns.  
 
ET is considered a very safe method of disseminating genetic characteristics from an 
infectious disease point of view (under regulations established by IETS490 and OIE491). Thus, 
on a global level it is thought of by some as contributing positively to animal welfare in terms 
of animal health. The effective use of ET in breeding programmes means that there is an 
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200   The Bio4EU Analysis report 
overall reduction in the number of cows required to produce candidate bulls. Sexed semen 
may also be viewed positively from a welfare point of view, as it will mean that replacement 
heifers can be produced from a smaller number of cows, so that the number of unwanted bull 
calves will be significantly reduced. Lastly, it is argued that ET is a key tool for keeping the 
EU cattle sector competitive in the global arena, and that maintaining a production industry 
ensures that production complies with the social requirements within the countries of the EU. 
This will include the development of (animal breeding) approaches that fit into sustainable 
land use programmes (holistic approaches to food chain production). 
 
As far as ploidy and sex manipulation in fish are concerned, both positive and negative views 
on their impacts to animal welfare have been expressed. All-female trout production has been 
associated with a general increase in animal welfare as it is claimed to help alleviate up to 
50% of secondary infections induced through early maturation, and its associated 
characteristics, such as reducing the need for chemotherapeutics. The induction of triploidy, 
has been associated with increased deformity and disease susceptibility (low stress tolerance) 
but also the beneficial avoidance of maturity related stressors. 
 
Assisted breeding through the use of modern biotechnology (molecular markers) has also 
been discussed regarding its impact on animal welfare, although to a smaller extent. Marker 
assisted selection (MAS) is not considered to be different in qualitative terms from the classic 
quantitative genetics-based breeding as the means and targets are similar. The major 
difference brought about by MAS is on the improved efficiency in driving genetic selection. 
Direct impacts to animal welfare will depend on the trait targeted: conventional breeding 
through quantitative genetics has been already criticised for selecting production traits 
without due concern for specific animal welfare issues492; therefore, the relevance of MAS to 
animal welfare depends more on the targeted trait than the technology itself.  
 
A positive aspect for animal welfare is the fact that MAS is directed more towards selecting 
for multi-gene dependent traits that were difficult to address before through conventional 
genetic selection. The focus is therefore moving away from the clearly productivity-related 
attributes to disease resistance and product quality, which have positive animal welfare 
implications. A look at the identified traits targeted in pigs indicates that MAS has already 
been directly applied in favour of animal welfare traits: an example which, according to 
expert opinion, has been extensively applied already in pig production is the selection against 
the ‘Halothane’ gene which has reduced preslaughter mortality in pigs from between 4-16 per 
1000 pigs to nearly zero. Similarly, a survey of two Spanish commercial abattoirs suggested 
that preslaughter deaths (during transport and time in lairage) could be reduced from 0.22% to 
0.02% through selection against the ‘Halothane’ gene493. Another example given was the K88 
marker indicating resistance to diarrhoea in pigs. This disease can result in a large number of 
deaths of young pigs. The interviewee noted that the disease could be controlled cheaply by 
the use of antibiotics but this would result in a loss of public good will and it was therefore 
appropriate to use MAS rather than antibiotics. However, some of the traits targeted, such as 
                                                 
492 See for example: European Commission (2000). The welfare of chickens kept for meat production (broilers). 
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increased litter size, would also require the consideration of potentially negative indirect 
animal welfare effects494. 
 
 
4.3.3 Modern biotechnology-based diagnostics and vaccines  
 
Modern biotechnology-based diagnostics and animal health products have a direct relevance 
for the achievement of major public health policy objectives. As already presented in Section 
2.3.5.2 and Section 2.3.5.3 there are a number of diagnostic and vaccine products available on 
the market while an even larger number is currently under development.  
 
 
4.3.3.1 Zoonoses and food safety 
 
4.3.3.1.1 Diagnostics495 
 
Diagnostics are essential for supporting the operation of the food chain through early and 
quick identification of pathogens, thus avoiding animal suffering from diseases and 
supporting food safety. Furthermore, diagnostics also support the monitoring and compliance 
with regulatory obligations as well as consumers’ freedom of choice, e.g. in the case of 
traceability of genetically modified organisms (GMOs). Contagious diseases such as foot and 
mouth disease are of minor danger for humans but, if not controlled, spread rapidly and 
involve the suffering of many animals, apart from causing significant economic losses. In a 
recent outbreak in the EU in 2001 (mainly in the UK, but also in Ireland, France and the 
Netherlands), about 4 million animals were culled. Rapid and specific diagnostic tests could 
facilitate detection and control of the disease.  
 
Modern biotechnology-based diagnostics are characterised by several advantages over 
conventional diagnostics, the main ones being: i) a decrease in the time needed to conduct an 
analysis, ii) enabling their incorporation in pen-side tests, thereby facilitating on-site testing, 
iii) improving the accuracy and/or sensitivity of an analysis, iv) providing a cost-effective 
solution and iv) providing the sole alternative for the diagnosis of a disease. Overall, the main 
impacts arising from the use of modern biotechnology diagnostics are mainly related to faster 
and accurate diagnosis, thereby indirectly reducing the impact of a potential zoonoses 
outbreak. Moreover, the availability of modern biotechnology diagnostics may be the only 
practical and/or cost-effective option towards meeting regulatory requirements within the 
context of disease surveillance and food safety, thereby indirectly ensuring functional trade 
regimes, trade exchanges and public confidence. Illustrative examples are provided in the 
following paragraphs. 
 
 
 
 
 
                                                 
494 See for example Weary, D.M. et al. (1998). Applied Animal Behaviour Science 61: 103-111. 
http://dx.doi.org/10.1016/S0168-1591(98)00187-7.  
495 Non-referenced information is based on expert opinion and data from (ETEPS (2006). Bio4EU Task 2 Case 
studies report – Primary Production and Agro-food Applications). 
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Foot and mouth disease (FMD) 
 
FMD is one of the most contagious diseases of mammals and has a great potential for causing 
severe economic losses. Since the last outbreak in 2001, there have been no new cases of 
FMD reported across the EU Member States. Since 2001, Member States have increased their 
focus on FMD and their surveillance activities, as well as the development of 
biotechnological tests for the earlier and more rapid confirmation of FMD, mainly for the 
avoidance of misdiagnosis (that is linked to extensive animal culling) and for facilitating 
testing the large numbers of samples. While this may be contributing to the fact that no new 
cases of FMD have been reported since 2001, it is not possible to attribute this fall in 
incidence to new biotechnological approaches for the early diagnosis of FMD. The potential 
impact arising from the avoidance of new outbreaks may be illustrated based on analyses of 
the last outbreak in the UK, where the UK government alone is estimated to have lost GBP 
2.4 billion over two years (mainly due to compensation payments and lower tax returns 
following a decline in economic activities). However, this sum does not include the more 
drastic losses incurred by agricultural export, transport, tourism, hotels and restaurants in the 
UK496. Moreover, the European Commission provided compensation, under an Emergency 
Veterinary Fund, estimated for the period 2001-2002 at EUR 800 million. Last but not least, 
the eradication efforts for the 2001 outbreaks included the killing and destruction of over 4 
million animals. This illustrates the considerable social cost of not detecting FMD early 
enough. 
  
 
Bovine spongiform encephalopathy (BSE) 
 
In the case of BSE, modern biotechnology provides the only method for a rapid processing of 
samples and diagnosis and thus enables the level of surveillance required by EU legislation497. 
BSE monitoring and eradication became very important after the public health risk to nvCJD 
(new variant Creutzfeldt-Jakob Disease) from the consumption of BSE-infected meat was 
identified in 1996. Until end of 2006, approximately 162 cases of nvCJD were identified in 
the UK and 36 more in the rest of the world (of which 30 were in the EU). However, the 
largest impact relates to the loss of consumer confidence, trade implications and the high cost 
of monitoring and eradication. For example, in the UK, sales of beef fell by 40%, the price of 
beef fell by more than 25%, export markets were lost (trade estimated to be about GBP 520 
million), and there were effects on employment, as abattoirs temporarily closed or reduced 
their working hours. It was estimated that, in the year following the start of the BSE crisis, the 
total economic loss to the UK was between GBP 740 million and GBP 980 million (0.1 - 
0.2% of the UK's GDP)498. The cost of the epidemic to the EU has been calculated at 10% of 
the annual value of the EU beef sector, while the discounted present value has been estimated 
                                                 
496 Blake, A., Sinclair, M.T, and Sugiyarto, G. (2001) The Economy-Wide Effects of Foot and Mouth Disease in 
the UK Economy, Discussion Paper 2001/3, Nottingham University Business School, UK 
https://www.nottingham.ac.uk/ttri/pdf/2001_3.PDF. 
497 Regulation (EC) No 999/2001 of the European Parliament and of the Council of 22 May 2001 laying down 
rules for the prevention, control and eradication of certain transmissible spongiform encephalopathies. 
http://ec.europa.eu/food/fs/bse/bse36_en.pdf.  
498 Atkinson, N. (1999). The impact of BSE on the UK economy. Meeting on transmissible spongiform 
encephalopathies (TSE), 9-11 August. Inter-American Institute for Cooperation on Agriculture, San Jose. 
http://www.iica.org.ar/Bse/14-%20Atkinson.html.  
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at EUR 92 billion499. Thirteen different immunoassays have now been approved in the EU for 
BSE testing of slaughtered animals before they enter the food chain, thereby reducing the risk 
of contamination and increasing consumer trust in beef meat. However, food safety and 
consumer confidence come at a cost, which in this case is mainly borne by public authorities 
at the EU and the Member States levels, as well as by the cattle industry and consumers. 
Between 2001 and 2004 around 44.7 million cattle were tested at overall costs of EUR 1835 
million. Considering only healthy animal stock, around EUR 1.56 million were spent per 
identification of a BSE case, whereas EUR 0.07 million per identification of a BSE case were 
spent in at-risk animal stock. Nevertheless, the introduced measures were essential for 
eradication, and restoring public confidence and markets, while the development of rapid test 
kits were necessary in order to cope with the large numbers of samples which were necessary 
to process.  
 
 
Salmonellosis 
 
A new generation of modern biotechnology-diagnostic methods could also enable a faster 
detection of the food pathogen Salmonella bacterium. Salmonella cause food poisoning and is 
the second most prevalent food pathogen after Campylobacter. In 2004, on average 42.2 cases 
per 100 000 inhabitants were registered in the EU. While studies indicate that more than 80% 
of all salmonellosis cases occur individually rather than as outbreaks, early diagnosis may 
allow rapid preventative action in cases of large-scale contamination of the food chain, such 
as in the removal of tainted foods thereby reducing the human incidence of salmonellosis. An 
issue of increasing concern is the reporting of antimicrobial resistance in Member States, 
which is a concern as effective treatment may be compromised; rapid and serotype-specific 
diagnosis through modern biotechnology-based testing may prove especially helpful here.  
 
While there has been a small declining trend in the human incidence of salmonellosis in the 
EU in recent years500, it is difficult to attribute changes in reported disease incidence to 
emergent biotechnology applications for pathogen detection as, in several cases, better 
enforcement by an EU Member State and ‘therapeutic’ or ‘preventative’ techniques such as 
heat-treatment of eggs or vaccination of poultry are identified by the respective Member 
State’s regulatory agencies as the key cause of the falling incidence of human zoonotic cases. 
However, methods using salmonella cultures, dominantly applied, require 4 to 7 days for 
presumptive evidence of salmonella in foodstuffs. This is often too long a time from a public 
health perspective when an outbreak can get expensive and serious in this timeframe. 
Methods that aim to shorten this timeframe often require techniques that combine 
preenrichment or selective enrichment with time saving genetic or immunological tests.  
 
Rapid detection methods for the presumptive identification of salmonella usually rely on 
enrichment times of at least 40 hours. Overall, it is expected that rapid tests reduce testing 
times by 1 to 5 days. The costs for ensuring salmonella control and safety, are borne mainly 
by the food industry (farmers, retailers, processors), while the costs in the cases of human 
                                                 
499 Cunningham, E.P. (ed.) (2003). After BSE: a future for the European livestock sector. EAAP Series no. 108, 
Wageningen Academic Publishers, Wageningen. http://cms2.ibvision.nl/_clientFiles/{7E09414A-876D-45D3-
9E9C-D4BF7C1C6DD8}/more/EAAP108.pdf.  
500 EFSA (2006). The community summary report on trends and sources of zoonoses, zoonotic agents, 
antimicrobial resistance and foodborne outbreaks in the European Union in 2005. The EFSA Journal 94. 
European Food Safety Authority, Parma.  
http://www.efsa.europa.eu/en/science/monitoring_zoonoses/reports/zoonoses_report_2005.html.  
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salmonellosis outbreaks are borne by the patients and public health budgets. To this end, a US 
cost assessment in 2005 provided an estimate of the annualised cost of salmonellosis at about 
USD 2.4 billion with an average cost of USD 1709 per case, of which 89% related to 
premature deaths, 8% to direct medical costs and 3% to costs of productivity loss501. 
 
 
Genetically modified organisms (GMOs) 
 
Modern biotechnology also enables the identification and quantification of genetically 
modified (GM) ingredients in raw material and food. It thus facilitates compliance with EU 
regulations regarding traceability and labelling of food502 and transparency and consumer 
choice regarding GM food. Moreover, the ability to detect and quantify GMOs also provides 
the possibility for the long-term monitoring of the commercial use of GM products. 
Traceability requirements for GM food and feed and the corresponding documentation and 
traceability systems would therefore facilitate the withdrawal of products where unforeseen 
adverse effects on human and animal health or the ecosystems are detected.  
 
 
4.3.3.1.2 Vaccines503 
 
Prevention of diseases in farm animals plays an important role in terms of economics, animal 
welfare and public health (zoonoses). Vaccination is one approach to disease prevention and 
has proven to be effective in the eradication of diseases in the EU Member States. 
Vaccination potentially decreases animal suffering from diseases and avoids the need for 
pharmaceutical treatment. Modern biotechnology is increasingly used to develop vaccines, in 
particular the so-called marker vaccines, which allow the distinction between vaccinated and 
infected animals. This in turn allows disease monitoring and targeted animal culling before 
symptoms appear, limiting the spreading of the disease. The live vaccine against pseudorabies 
or Aujeszky´s disease is one example, which is also the first GMO authorised in the EU.  
 
Aujeszky´s disease primarily affects pigs, a major livestock species produced in the EU. It is 
caused by a virus and results in nervous disorders of affected animals, increased mortality of 
piglets and reduced fertility. The biotechnological vaccine was developed in the early 1980s 
with two main objectives: to develop a live vaccine (known to be more effective than 
inactivated viruses) and to develop a vaccine which allows the distinction between vaccinated 
and infected animals, thus facilitating the eradication of the disease. Genetic engineering was 
used to produce a modified virus, which was approved in 1989, that is not infectious and 
where, due to the deletion of a specific surface protein, vaccinated pigs can be distinguished 
serologically from pigs infected with the natural virus. The vaccine therefore enabled the cost-
effective EU eradication programme of Aujeszky´s disease to take place, with arguably 
                                                 
501 ERS (2006). Foodborne illness cost calculator: salmonella. Economic Research Service, US Department of 
Agriculture, Washington, D.C. http://www.ers.usda.gov/Data/FoodborneIllness/salm_Intro.asp.  
502 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on 
genetically modified food and feed. OJ L 268/1 18.1.2003. http://europa.eu/eur-
lex/pri/en/oj/dat/2003/l_268/l_26820031018en00010023.pdf. And: Regulation (EC) No 1830/2003 of the 
European Parliament and of the Council of 22 September 2003 concerning the traceability and labelling of 
genetically modified organisms and the traceability of food and feed products produced from genetically 
modified organisms and amending Directive 2001/18/EC. OJ L 268/24 18.10.2003. http://europa.eu/eur-
lex/pri/en/oj/dat/2003/l_268/l_26820031018en00240028.pdf.  
503 Non-referenced information is based on expert opinion and data from (ETEPS (2006). Bio4EU Task 2 Case 
studies report – Primary Production and Agro-food Applications). 
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positive implications to the livestock sector, but also to the public budget due to less 
compensation payments. Currently, there are 10 EU Member States where the disease is still 
endemic, while 10 of the 13 EU Member States for which relevant information was available 
are disease-free with or without continuing their vaccination programmes and three are 
currently vaccinating the endemically affected population. 
 
 
4.3.3.2 Animal health and welfare 
 
Besides the implications of modern biotechnology applied directly to animals to animal 
welfare, other modern biotechnology applications may have a range of interactions with 
animal welfare. Modern biotechnology provides improved or novel diagnostics, with positive 
animal welfare effects. For example, modern biotechnology-based diagnostics facilitate early 
diagnosis for a number of animal diseases, which is instrumental in their control and 
eradication, and therefore in the reduction of the number of animals that suffer from diseases 
or that are culled (e.g. FMD, salmonellosis, etc.) or may even provide the sole option in 
detecting a disease (e.g. BSE). Similarly, modern biotechnology-based vaccines are beneficial 
for animal welfare for a number of reasons. For example, vaccines are in general the most 
efficient strategy for the eradication of any disease and they rely on prevention, thus avoiding 
the need for chemical treatment. Moreover, marker vaccines (such as Aujeszky’s disease 
vaccine) have the added benefit in that they allow disease monitoring during the eradication 
programme and therefore targeted animal culling before symptoms appear (they may also be 
the only approved vaccine product available on the market). While some biotechnology-based 
inputs to animal production have received some criticism regarding animal welfare, such as 
the potential risks to animal health through the feeding of GM feed or additives, all 
commercially available products in the EU are placed on the market only after they have gone 
through the obligatory pre-market safety assessments.  
 
 
 
4.3.4 Summary 
 
Modern biotechnology provides essential tools, mainly through diagnostics and vaccines, 
towards the assurance of EU-wide food safety and consumer confidence in the food chain. 
Areas where the highest impacts have already been realised include the monitoring and 
control of some of the most important zoonoses and food safety concerns. Besides the direct 
impacts towards food safety and public health, these modern biotechnology applications have 
indirect implications in the assurance of consumer confidence and the related trade, which 
may manifest themselves in the avoidance of negative economic consequences. On the other 
hand, there are a number of animal welfare issues regarding animal production techniques, 
some of which relate to the use of modern biotechnology. A case by case evaluation may 
therefore be needed when such challenges arise, as they may be specific to particular 
applications. 
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5 Conclusion 
 
Biotechnology, and in particular modern biotechnology, is considered one of the key enabling 
technologies of the 21st century. Its potential for providing economic growth and jobs in a 
wide range of sectors, as well as for sustainable development, has been widely recognised504. 
This study confirmed the considerable diffusion of modern biotechnology, mainly in three 
major areas: human and animal health, agro-food and industrial manufacturing processes. 
Modern biotechnology products and processes are, for example, used in the cultivation of 
crops, in animal husbandry and fisheries (aquaculture), in food processing, in the manufacture 
of textiles and leather, in the production of pulp and paper, in fuel production, in the 
manufacture of chemicals (including pharmaceuticals), in healthcare, and in research.  
 
 
5.1 Contributions of modern biotechnology to the Lisbon Strategy 
5.1.1 Economic significance of modern biotechnology applications 
The broad diffusion that modern biotechnology has experienced as an enabling technology is 
also reflected in the fact that it is estimated to contribute – just through its applications in 
industrial manufacturing processes including food processing – to about 0.88% of EU Gross 
Value-added (GVA). The significance of this figure becomes clearer if compared to, e.g. the 
share of GVA of 2% that is generated by the entire agricultural sector. On a more 
disaggregate level, for instance, biotechnology-based products for human health contributed 
over 5% to the GVA of the pharmaceutical industry, or 0.04% to the EU GVA; this surpassed 
the contribution of other industrial subsectors such as man-made fibres, and points to the 
significant economic value of the corresponding products. 
 
Yet within the EU, the adoption rates of biotechnology-based products and processes in the 
various sectors and fields of application vary considerably. In the health sector, where modern 
biotechnology is widely applied, for example in in vitro diagnostics, biotechnology 
applications contribute about 30% to overall turnover in the EU, whereas in therapeutics, 
biopharmaceuticals have a 9% share of the EU’s total pharmaceuticals turnover. Regarding 
industrial manufacturing, modern biotechnology adoption diverges even more; this is 
reflected in the turnover shares of individual applications, which range from less than 1% in 
the case of biotechnology-based polymers, to 10% in pulp and paper and 30% in detergents, 
all the way up to 100% in some food production processes (e.g. fruit juice). In the agro-food 
sector, modern biotechnology is estimated to directly contribute to 13 - 23% of the overall 
turnover of input sectors such as breeding or feed additive production. Furthermore, the use of 
these biotechnology-based inputs affects more than 30% of the agro-food sector’s total 
turnover. Still, the economic significance of modern biotechnology in this sector also depends 
very much on the specific application. Some modern biotechnology applications are thought 
to have reached their peak in terms of adoption, while, e.g. genetic engineering in crop seed 
production has thus far only played a minor role within the EU. In other cases, such as 
embryo transfer in cattle, the direct adoption rate may be small, but it is economically 
                                                 
504 European Commission COM (2002) 27: Communication form the Commission to the European Parliament, 
the Council, the Economic and Social Committee and the Committee of the Regions Life Sciences and 
Biotechnology – a strategy for Europe. 
http://ec.europa.eu/prelex/detail_dossier_real.cfm?CL=en&DosId=171079. 
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significant because it is used for high value production at the top of the breeding pyramid. 
Given these different degrees of adoption, future growth potential exists and the related 
turnover is expected to grow insofar as modern biotechnology enables the provision of new or 
better products or enhances efficiency. For instance, such dynamic developments can be 
discerned in health biotechnology, where the EU market for biopharmaceuticals grows an 
average of 23% annually, twice as much as the overall EU pharmaceuticals market average 
growth rate (11%).  
 
Overall, modern biotechnology applications relate to the generation of about 1.43 - 1.69% of 
EU GVA. 
 
5.1.2 Effects of modern biotechnology on employment 
In terms of employment, the contribution of modern biotechnology is mainly seen in the 
creation of ‘better jobs’. More highly qualified employment also potentially contributes to 
higher labour productivity. Measuring the quantitative impact (i.e. ‘more jobs’) is hampered 
by limited data availability and the difficulties of integrating indirect employment effects. 
Nevertheless, the order of magnitude of direct employment effects probably corresponds to 
the overall diffusion of biotechnology applications. Just as with the diffusion of 
biotechnology applications, it can be assumed that a portion of the newly-generated jobs 
substitutes existing ones. 
 
5.1.3 Effects of modern biotechnology on competitiveness 
Modern biotechnology also contributes to higher labour productivity via efficiency gains. 
Industrial manufacturing processes that apply modern biotechnology are estimated to have an 
average of 10% to 20% higher labour productivity. This potentially improves 
competitiveness, as well as the development of new products that stem from the application of 
modern biotechnology. However, in other countries several applications of modern 
biotechnology have experienced more comprehensive and quicker adoption, i.e. these 
countries could increase their competitiveness relative to the EU. More specifically, in terms 
of the adoption of modern biotechnology, in many cases the US has now become the 
benchmark. For instance, while the US embarked later than the EU on the production of 
bioethanol, corresponding policy support helped its enterprises gain a large share of world 
production within a few years. Developments in China and India indicate that, at least in 
terms of market size, these countries may also soon outpace the EU. Regarding the market for 
biotechnology-based polymers, here the US also has a strong position, although Japan is the 
world market leader in producing acrylamide. In the field of health biotechnology, for 
instance, only 15% of the biopharmaceuticals on the market were developed by EU 
companies, compared to the more than 50% that were developed by US companies. In the 
agro-food sector, however (apart from the production of GM seeds and the cultivation of GM 
crops, where the EU lags behind), the EU has an important share in those markets for which 
biotechnology-based products are relevant. This is supported by a considerable share in the 
export market for breeding and propagation material, as well as in the markets for veterinary 
products, diagnostics and feed additives.  
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5.2 Contributions of modern biotechnology to environmental sustainability  
 
Modern biotechnology applications in the agro-food sector mostly aim to improve the 
production efficiency of primary production, and thereby contribute to the reduction of 
resource use and the emission of harmful substances. Yet, while these impacts are mostly of 
an indirect nature, direct impacts have been also realised. Examples include replacing drug 
and antibiotic treatments with the use of vaccines in animal production (many of which are 
produced using modern biotechnology), and reducing harmful emissions due to the use of 
improved crop varieties or biotechnology-based feed additives. However, some modern 
biotechnology applications may also raise new challenges, requiring a case-by-case evaluation 
for considering specific aspects or potential risks (e.g. in relation to GMOs or feed additives). 
To this end, the EU has enacted specific legislation that requires comprehensive risk 
assessments to be carried out before placing such products on the EU market. 
 
In the case of industrial production processes, modern biotechnology applications mitigate 
greenhouse gas emissions (mainly carbon dioxide), waste generation and the use of non-
renewable resources. Moreover, modern biotechnology applications also lead to savings in 
energy and water usage, as well as to reductions in the use of chemical inputs. In particular, 
reduced energy demand could lead to a decrease in greenhouse gas emissions, considering 
that industrial fuel combustion for energy generates more than 50% more greenhouse gases 
than the industrial production processes themselves. While the environmental impacts of 
biotechnologically produced chemicals cannot be depicted in their entirety because 
information for many processes is not available or accessible, exemplary information 
indicates that the environmental effects are similar. 
 
Another, indirect impact of modern biotechnology could materialise through the use of 
biofuels in the transport sector, which, with 21% of total greenhouse gas emissions, is one of 
the largest greenhouse gas contributors. More than a third of this share (7.9%) is generated by 
petrol combustion. Hence, the blending of petrol with bioethanol could help to improve the 
environmental impact of this sector. Although the environmental impacts of bioethanol 
compared to fossil fuel depend on a variety of factors, the use of bioethanol currently 
produced in the EU was estimated to lead to greenhouse gas reductions of 35 - 50% compared 
to the conventional fuels they replace.  
 
 
5.3 Contributions of modern biotechnology to public health and food safety  
 
Modern biotechnology applications in the field of human health have major public health 
implications. The case studies presented in this report show that modern health biotechnology 
may provide various benefits, such as better clinical interventions (in the case of enzyme 
replacement therapies, monoclonal antibodies, cardiac testing or HIV testing) or potentially 
improved safety and a higher quality of life for the individuals concerned (in the case of 
human recombinant insulin or recombinant hepatitis B vaccine). Hence, modern health 
biotechnology contributes to improvements in monitoring and controlling communicable 
diseases and also to enhancing the effectiveness of medical interventions, thereby reducing 
the burden of disease or improving the quality of life of those suffering from disease.  
 
The contribution of health biotechnology applications to reducing healthcare and social costs 
is not as clear: in some cases, these applications increase efficiency in the healthcare sector, 
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thus contributing to the objective of reducing healthcare costs; but in other cases, a new drug 
puts an overproportionate strain on healthcare resources. While the latter case is not specific 
to biotechnology-based therapies because it also applies to conventional approaches, it 
nevertheless emphasises the ethical question of how to allocate scarce resources in healthcare 
when efficiency considerations could prevent patients’ access to potentially life-improving or 
even life-saving treatments. Yet, a more general assessment of the cost-effectiveness of health 
biotechnology applications is still pending, given that, in many cases, the results of pertinent 
studies are only preliminary and further studies need to be carried out. Moreover, as the 
technology matures and generic biopharmaceuticals (biosimilars) reach the market, product 
prices may be driven down, thus improving the cost-effectiveness of the related health 
interventions. 
 
Similar to health biotechnology, the public health effects of modern biotechnology 
applications in the agro-food sector build on the availability of new and better diagnostics and 
vaccines. The monitoring and control of some of the most important zoonoses and food safety 
concerns (e.g. salmonella and BSE) especially help in safeguarding EU-wide food safety and 
in assuring consumer confidence in the food chain. Moreover, as some modern 
biotechnologies may present new issues in terms of animal welfare, a case-by-case 
assessment based on robust indicators and guidelines may be needed. 
 
 
5.4 Outlook 
 
Modern biotechnology has been widely diffused in the EU economy through a large variety of 
applications. Many of these are being further developed and improved, e.g. bioethanol 
production from lignocellulosic biomass, thus potentially enhancing their performance in 
economic, environmental and social terms. Many more applications are in the research and 
development stages, e.g. animal cloning, gene therapy or novel biocatalysts, which further 
enlarges the application range of modern biotechnology, but also potentially raises new 
issues. Thus, today’s modern biotechnology significantly contributes to the EU economy and 
sustainable development, but its potential has not yet been fully exploited. The availability of 
data is a critical issue for the assessment of modern biotechnology applications. In particular, 
there is a considerable lack of relevant, statistical data regarding the agro-food sector and 
industrial manufacturing processes. To facilitate monitoring, the development and adoption of 
modern biotechnology applications and their impacts, e.g. for evidence-based policy making, 
a continuous statistical collection of data needs to be established. 
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Annex 1 – Methodology 
 
Objectives  
 
The Analysis Report of the Bio4EU study aims at the identification and quantification (as far 
as possible) of the contributions of modern biotechnology to achieve major EU policy 
objectives, formulated in the Lisbon Strategy and in the Sustainable Development Strategy. 
This concerns in particular: 
• economic growth, competitiveness and employment 
• environment and energy  
• public health (including food safety, animal health and welfare) 
 
 
Scope  
 
Modern biotechnologies 
 
Major modern biotechnologies were identified at the preparatory step of the study505. 
 
Biotechnology can be defined as ‘the application of science and technology to living 
organisms, as well as parts, products and models thereof, to alter living or non-living 
materials for the production of knowledge, goods and services’506. This definition includes 
traditional biotechnological processes that have been used for a very long time in the food and 
drink industry as well as modern biotechnological processes. The study focuses on major 
modern biotechnologies. These encompass DNA- , protein- and cell-based technologies 
utilised in the modification of living or non-living materials for the production of goods and 
services. Under this definition, traditional biotechnologies, such as fermentation and 
conventional animal and plant breeding, are not included. However, modern biotechnologies 
used in combination with traditional biotechnologies, e.g. fermentation processes using 
recombinant organisms, are considered modern biotechnology. 
 
Table 62 provides a list-based definition of the key technologies used in modern 
biotechnology research and production. The list includes four general categories for nucleic 
acid, protein, metabolite, and cell-related technologies, plus a fifth category for supporting 
tools. Some of these tools include a number of technologies.  
 
Biotechnology application areas included  
 
Modern biotechnology applications in the following areas were analysed, as these were 
considered the main application areas: 
• human health  
• primary production and agro-food  
• industrial processes, environment and energy  
                                                 
505 ETEPS (2006) Task 1 – Mapping of modern biotechnology applications and industrial sectors, identification 
of data needs and development of indicators, Final report. http://bio4eu.jrc.ec.europa.eu/documents/Bio4EU-
Task1.pdf. 
506 OECD (2005). A framework for biotechnology statistics.  Organisation for Economic Co-operation and 
Development, Paris. http://www.oecd.org/document/3/0,2340,en_2649_33703_34962243_1_1_1_1,00.html.  
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Table 62: List-based definition of modern biotechnology 
 
Biotechnology Applications 
Nucleic acid-related technologies 
(DNA/RNA) 
• high-throughput sequencing of genomes, genes, DNA 
• DNA synthesis and amplification 
• genetic engineering  
• anti-sense technology 
Protein-related technologies • high throughput protein/peptide identification, quantification 
and sequencing 
• protein/peptide synthesis 
• protein engineering and biocatalysis 
Metabolite-related technologies • high throughput metabolite identification and quantification 
• metabolic pathway engineering 
Cellular- and subcellular-related 
technologies 
• cell hybridisation/fusion 
• tissue engineering 
• embryo technology 
• stem cell-related technologies 
• gene delivery  
• fermentation and downstream processing  
Supporting tools • bioinformatics 
 
 
Geographic area  
 
The analysis focuses on the EU, and competitors, in particular the US and Japan, For specific 
application areas, additional countries have been included if relevant information was 
available.  
 
 
Assessment 
 
General  
 
The impact assessment is based on the use of indicators that were selected after a careful 
review of indicators and data availability507. The impacts of biotechnology were then grouped 
into two categories: direct and indirect. In the context of this study, direct impacts relate to 
effects at the level of biotechnology technique users, while indirect impacts concern the 
effects realised at the level of the users of biotechnology-derived products (downstream 
sectors). 
 
                                                 
507 ETEPS (2006) Task 1 – Mapping of modern biotechnology applications and industrial sectors, identification 
of data needs and development of indicators, Final report. http://bio4eu.jrc.ec.europa.eu/documents/Bio4EU-
Task1.pdf. 
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The direct impacts, therefore, aim to measure the various impacts (sector and EU-wide 
economy) arising from the activity of the producer of modern biotechnology products such as 
pharmaceutical companies producing modern biotechnology-derived products (vaccines, 
therapeutics, etc.), breeding companies employing modern biotechnology for the production 
of seeds or embryos, diagnostic companies producing modern biotechnology-based test kits, 
companies employing modern biotechnology for the production of enzymes, etc.  
 
Table 63: List of Bio4EU case studies 
 
Application area Case study 
Human health 
Therapeutics Insulin for the treatment of diabetes 
 Interferon-beta for the treatment of multiple sclerosis 
 Enzyme replacement therapy for Gaucher’s disease 
 
Anti-CD20 monoclonal antibodies for the treatment of Non-Hodgkin’s 
lymphoma 
Preventives Hepatitis B vaccine 
Diagnostics Cardiac diagnostic assays 
 HIV testing 
 Genetic testing for phenylketonuria 
Animal health 
Diagnostics Foot and mouth disease diagnostics 
Preventives Animal vaccines (Aujeszky’s disease) 
Primary production/agro-food 
Diagnostics BSE testing 
 Detection of Salmonella in food 
 GMO traceability 
Breeding and propagation Marker assisted selection in livestock breeding (pigs) 
 Marker assisted selection in maize  
 GM crops 
 Livestock propagation (cattle) 
 Fish breeding and propagation 
 Micropropagation in plants (horticulture) 
Industrial production 
Processing of biomass to 
biological feedstock as a 
renewable resource Bioethanol production from biomass 
 Biopolymer production from biomass 
Industrial processes using 
biological systems Use of enzymes in detergents 
 Use of enzymes in fruit juice clarification 
 Use of enzymes in the pulp and paper industry 
 Use of enzymes in the textile industry 
 Production of the amino acid lysine 
 Production of the vitamin riboflavin/vitamin B2 
 Production of the antibiotic cephalosporine 
Bioremediation  
Biosensors and bio-based analytical tools used in environmental 
monitoring 
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Indirect impacts mainly relate to the impacts arising from the use of biotechnology-derived 
products, and, depending on the application, may include several levels upstream or 
downstream the production chain. For example, the use of a modern biotechnology-based 
feed enzyme may generate impacts both upstream (raw material producers in the primary 
sector, feed ingredient producers) and downstream (feed producers, the farm gate, through 
processing or even through final retail sale).  
 
The aim of the analysis was to provide results at the most aggregated level possible, both in 
terms of indicators, as well as in terms of the sectors. In addition, a representative set of 29 
case studies was used to analyse in depth the current economic, social or environmental 
impact (see Table 63). The case studies were selected to cover all relevant application areas 
and to cover those applications of modern biotechnology in each of the parts that are 
considered to have the highest current impact in economic, environmental or social terms.  
 
 
Indicators 
 
At the preliminary phase of the study, an assessment was carried out on the availability of 
data for potential indicators507. At the second stage, the useable indicators were selected based 
on whether and how much they were related with the major EU policy objectives.  
 
There is no standard methodology for linking the indicators to EU policy objectives. 
However, a structured approach was developed, based on the identification of the major 
policy objectives and linking indicators to these policy objectives (quantitatively or 
qualitatively). A table illustrating the approach is provided at the end of Annex 2 (see Table 
64).  
 
Data 
 
Data were obtained from a number of sources depending on their availability, and were 
prioritised based on their perceived quality as follows (in descending order): official statistics 
and reports (provided by public institutions); peer reviewed publications; surveys and 
interviews of industry and technical experts; market reports and other available publications; 
and other web-based available information. This information was sourced either through 
direct desk research or through the various ETEPS reports. 
 
Overall, data availability was of the highest quality for the human health sector, followed by 
the industrial sector and lastly by the agro-food sector. While the overall focus was on a 
quantitative analysis, a qualitative analysis was performed when the first was not feasible. 
Where robust data were not available, an effort was made anyway to provide estimates for 
illustrative purposes.  
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Methodological remarks 
 
Sector classification 
 
The sectors in which modern biotechnology is known to be applied were identified. This 
identification was made using the NACE classification framework508 where feasible. For the 
agro-food sector, the sector classification provided by Eurostat was mainly used (e.g. based 
on the European Economic Accounts for Agriculture and Forestry). Where needed, sectors at 
a more disaggregated level were identified, and sourced with estimated data from variable 
sources. 
 
For each identified biotechnology application, the closest matching sector category was 
chosen as a benchmark (using NACE where available), e.g. "NACE D 24.51 Manufacture of 
soap, detergents, cleaning and polishing" as the benchmark for detergents containing 
enzymes. Available data for each individual biotechnology application were then put into 
context with the benchmark sector data. 
 
 
Economic and employment indicators 
 
Gross value-added (GVA) is the main economic indicator used throughout the analysis (for 
the most recent year; therefore, 2004 was used in the majority of cases, with some 
exceptions); value-added was chosen as an indicator because as an economic measure it 
works as well as turnover and GDP figures, but more information is available in public 
databases, particularly in Eurostat. For the analysis of the agro-food sector, especially at more 
disaggregated levels, turnover was used instead, as GVA data were not available. Other 
economic indicators where used were available in quantitative or qualitative terms. 
Competitiveness is discussed in a qualitative manner throughout the analysis and where 
relevant information is available. 
 
The number of direct employees was used as the main employment indicator. If the employee 
figure for a biotechnology application is not known, but the employee number and rate of 
diffusion into the benchmark sector is known (for example: 30 - 50% of all detergents are 
produced using enzymatic processes), then the relation ‘employee number x diffusion rate’ is 
applied to calculate employment figures for the relevant biotechnology application. 
 
If no basis for calculating value-added or employee figures is available, plausible estimates 
are looked for. These might stem from an overview of company reports or market research 
reports, as far as available. The emphasis in this sub-optimal solution lies on the feasibility. 
Where relatively solid estimates could not be obtained, this information is omitted. 
 
The resulting figures are put in relation to statistical totals of the overall economy, in order to 
learn: 
o what the contribution of each individual biotechnology application to GVA of the 
EU is 
                                                 
508 NACE is the statistical classification of economic activities in the European Community. Version 1.1 of 2002 
is used in this report. http://ec.europa.eu/eurostat/ramon/nomenclatures/.  
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o what the contribution of each individual biotechnology application to GVA (or 
turnover) of the various benchmarks used is (e.g. at the most aggregated sector 
level or to the closest matching sector) 
 
For the industrial sector analysis, the following results where also estimated: 
o what the labour productivity of each industrial biotechnology application is, 
calculated as 
AddedValueGrossEUtonapplicatiobiotechindustrialeachofonContributi
employmentEUtonapplicatiobiotechindustrialeachofonContributi
−−
−
25
25
 
o how this labour productivity of manufacturing sectors using enzymes relates to the 
respective NACE sector labour productivity 
o how this labour productivity of manufacturing sectors using enzymes relates to the 
labour productivity of overall EU manufacturing. 
 
This analysis is carried out for direct impacts, i.e. the producers of biotechnology products, 
and for indirect impacts, i.e. the users of biotechnology-derived products. The analysis of the 
contributions of modern biotechnology to the EU economy does not calculate the change in 
economic or employment terms induced through the adoption of modern biotechnology, but 
calculates the economic and employment output that uses biotechnology. Where modern 
biotechnology (direct) or derived products (indirect) are used at some step(s) of a production 
process, the entire output is calculated as an impact of modern biotechnology, even if the 
modern biotechnology-based process is only one production step amongst several non-
biotechnological steps. Therefore the calculated indicator provides a relative measure of the 
diffusion and importance of modern biotechnology to the EU economy rather than an absolute 
measure of the positive and/or negative effects to the EU economy. An additional assumption 
behind this is that modern biotechnology production has been taken up by the producer in 
order to be and remain competitive in the respective product market.  
 
Where more information is available, the changes influenced by the modern biotechnology 
adoption are also presented, i.e. how efficiency increases, decreases, or remains the same, 
when modern biotechnology is applied.  
 
 
Environment and energy, and public health indicators 
 
The assessment of the contribution of modern biotechnology to the environment and energy, 
and public health, is based on a range of indicators, namely: 
• environment and energy: resource productivity, waste prevention, air-soil-water quality, 
biodiversity, greenhouse gas emissions and energy supply security 
• public health: protection against health threats and disease prevention, healthcare and 
social costs. 
 
Due to the inherent differences among the different sectors and the different applications 
within the context of environment and public health, the exact assessment varies for the three 
sectors, and therefore, the details of the assessment are provided in the respective chapters. 
The most relevant indicators were used on a case-by-case basis. 
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Table 64: Concept for the selection of indicators according to policy objectives 
 
            convergence      
 
 
 
Policy Sub-themes Policy objectives Policy indicators Output and impact indicators 
Number and share of companies in the respective sectors active in 
biotechnology  
Total production and shares (area, weight, value) of conventional 
and biotechnology products (by application area) 
Share of biotechnology turnover in each application out of total 
turnover in each application  
Share of biotechnology turnover in each application out of total 
biotechnology turnover 
Market shares and adoption rates 
Share of biotechnology turnover out of total turnover of 
biotechnology active firms in the relevant sector or the case study  
Changes in international market shares of European products Trade Changes in shares of imports in total domestic consumption 
Gross margin of biotechnology product per unit output compared to 
alternative conventional product, in each application Gross margin and production costs Total production costs of biotechnology product per unit output 
compared to alternative conventional product, in each application 
Labour productivity 
Biotechnology turnover per biotechnology employee compared to 
turnover of alternative conventional products per employee, in each 
application 
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Competitiveness and economic growth 
GDP growth Total sector specific biotechnology related GDP out of total sector specific GDP 
Number of biotechnology active employees per application out of 
total employees in each application  
Shares of employment in each application out of total 
biotechnology employment 
Total biotechnology active employees out of total employment in 
biotechnology active firms, in the relevant sector  
L
i
s
b
o
n
 
S
t
r
a
t
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y
 
E
m
p
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e
n
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Employment Employment growth and rates 
Number of jobs created through specific biotechnology applications 
(direct and spillover effects)  
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Policy Sub-themes Policy objectives Policy indicators Output and impact indicators 
Improve resource productivity 
Change of energy, water and 
material inputs 
 
Change of the use of non-
renewable resources 
Change of energy, water and material inputs 
 
 
Change of the use of non-renewable resources 
Waste prevention Change of resulting waste streams in different environmental media  
Change of resulting waste streams in different environmental 
media, in each application 
Improve air quality Change of (risk of) emissions to the air 
Change of emissions to the air: direct and/or indirect via change in 
the use of inputs responsible for emissions to the air (e.g. fossil 
fuels) 
Improve soil quality Change of (risk of) emissions to the soil and reduced land use 
Change of emissions of nutrients/fertilisers, pesticides to the soil, 
change of tillage and of land use: direct and/or indirect via change 
in use of inputs responsible for emissions to the soil (e.g. nutrients)  
Improve water quality Change of (risk of) emissions to the water 
Change of emissions of nutrients/fertilisers, pesticides direct and/or 
indirect via change in use of inputs responsible for emissions to the 
water (e.g. nutrients) 
E
n
v
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n
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e
n
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Preserve biodiversity Preservation of genetic resources and landscape diversity Preservation of genetic resources and landscape diversity 
S
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Climate change: 
(reduction of GHG emissions by 8% by 
2012, compared to 1990) 
Change of (risk of) GHG 
emissions  
Change of GHG emissions: direct and/or indirect via change in use 
of inputs responsible for GHG emissions (e.g. fossil fuels) 
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Policy Sub-themes Policy objectives Policy indicators Output and impact indicators 
Supply security: 
(2010 targets) 
• 12% energy from renewable resources 
• 25% of electricity 
• 5.75% biofuels share 
Change in the use of non-
renewable resources 
Change in the use of non-renewable resources  
 
Change in biofuel production 
Market shares of human health biotechnology products (e.g. 
molecular diagnostic tests, biopharmaceuticals, vaccines) already 
on the market in terms of absolute numbers and revenues 
Adoption by end-users (e.g. number and share of prescriptions, 
number and share of laboatories using biotechnology-based 
diagnostics) 
Number and share of products in the pipeline (e.g. drugs in clinical 
trials) 
Number and share of clinical studies (or equivalent for animal 
health products) for emerging biotechnology applications 
Availability and use of: 
• diagnostics for communicable 
diseases (including novel 
pathogens) 
• vaccines for communicable 
diseases 
• medicines for communicable 
diseases 
Share of processes that use biotechnology for small molecule drug 
development related to chemical processes for the same purpose 
Efficiency of diagnostics and 
vaccines  Cost-effectiveness/cost-utility of biotechnology products 
Change in burden of diseases in relation to diagnostic/treatment 
with biotechnology products 
Incidence of major diseases Impact on food safety: change in numbers of contamination cases; 
number and share of food-related diseases diagnosed through 
modern biotechnology-based diagnostics  
Improved warning, monitoring and 
control of communicable diseases 
(including medical product safety) 
Incidence of zoonoses Animal health: change in number of animals becoming ill and/or dying; changes in number/risk of human zoonotic cases 
Market shares of human health biotechnology products (e.g. 
molecular diagnostic tests, biopharmaceuticals, vaccines) already 
on the market in terms of absolute numbers and revenues 
Adoption by end-users (e.g. number and share of prescriptions, 
number and share of labs using biotechnology-based diagnostics) 
Number and share of products in the pipeline (e.g. drugs in clinical 
trials) 
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Reduction of (major) non-communicable 
disease incidences (e.g. mental illnesses, 
cancer, cardio-vascular diseases, diabetes) 
Availability and use of diagnostics 
and medicines for non-
communicable diseases 
Number and share of clinical studies (or equivalent for animal 
health products) for emerging biotechnology applications 
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Policy Sub-themes Policy objectives Policy indicators Output and impact indicators 
Share of processes that use biotechnology for small molecule drug 
development related to chemical processes for the same purpose 
Efficiency of diagnostics and 
treatments Cost-effectiveness/cost-utility of biotechnology products 
Incidence of (major) diseases Change in burden of diseases in relation to diagnostics/treatment with biotechnology products 
Cost-effectiveness/cost-utility of 
biotechnology products Cost-effectiveness/cost-utility of biotechnology products 
Change in burden of diseases in relation to diagnostics/treatment 
with biotechnology products Reduction of disease burden 
Change in burden for public health budget 
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Reduction of healthcare and social costs 
and reduction of disease burden 
Improvement of animal health and 
welfare Change in animal health and welfare 
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Annex 2 – Human Health Biotechnology 
Table 65: Biopharmaceuticals originated in the EU 1995 - 2005 
 
Generic Name Originator Originating 
Country 
Primary therapy 
description 
Any therapy description 
Factor VIIa Novo Nordisk Denmark Recombinant, other Recombinant, other 
Blood fraction 
Haemostatic 
Glucagon Novo Nordisk Denmark Recombinant, other Recombinant, other 
Antidiabetic 
Glucagon 
Somatropin Novo Nordisk Denmark Recombinant hormone Recombinant hormone 
Growth hormone 
Vulnerary 
Fertility enhancer 
Musculoskeletal 
Anabolic 
Insulin Aspart, 
biphasic 
Novo Nordisk Denmark Formulation, other Formulation, other 
Recombinant hormone 
Insulin 
Antidiabetic 
Insulin glargine Sanofi-Aventis France Recombinant hormone Recombinant hormone 
Insulin 
Antidiabetic 
Lepirudin Sanofi-Aventis France Recombinant, other Recombinant, other 
Antithrombotic 
Haematological 
Antianginal 
Cardiovascular 
Rasburicase Sanofi-Aventis France Recombinant, other Recombinant, other 
Antigout 
Radio/chemoprotective 
Somatropin Sanofi-Aventis France Recombinant hormone Recombinant hormone 
Growth hormone 
Alpha-1, 
antitrypsin 
Bayer Germany Recombinant, other Recombinant, other 
COPD treatment 
Factor VIII-2 Bayer Germany Recombinant, other Recombinant, other 
Blood fraction 
Haemostatic 
Interferon, BI 
(alpha2c) 
Boehringer 
Ingelheim 
Germany Recombinant 
interferon 
Recombinant interferon 
Anticancer, interferon 
Antiviral, interferon 
Cytokine 
Nateplase Bayer Germany Recombinant, other Recombinant, other 
Fibrinolytic 
Tasonermin Boehringer 
Ingelheim 
Germany Recombinant, other Recombinant, other 
Anticancer, 
immunological 
Cytokine 
Scintimun Bayer Germany Immunoconjugate, 
other 
Immunoconjugate, other 
Imaging agent 
RecFSH Akzo Nobel Netherlands Recombinant hormone Recombinant hormone 
Fertility enhancer 
Interferon Crucell Netherlands Recombinant 
interferon 
Recombinant interferon 
Cytokine 
Antiviral, interferon 
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Generic Name Originator Originating 
Country 
Primary therapy 
description 
Any therapy description 
Agalsidase alpha Shire UK Recombinant, other Recombinant, other 
Metabolic and enzyme 
disorders 
131I-
tositumomab 
GlaxoSmithKline UK Immunoconjugate, 
other 
Immunoconjugate, other 
Anticancer, 
immunological 
Alemtuzumab BTG UK Monoclonal antibody, 
humanised 
Monoclonal antibody, 
humanised 
Anticancer, 
immunological 
Multiple sclerosis 
treatment 
Immunosuppressant 
Adalimumab AstraZeneca UK Monoclonal antibody, 
human 
Monoclonal antibody, 
human 
Antiarthritic, 
immunological 
GI inflammatory/bowel 
disorders 
Epoetin delta Shire UK Recombinant growth 
factor 
Recombinant growth 
factor 
Antianaemic 
Radio/chemoprotective 
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Table 66: Case studies summary of economic data 
 
 Companies Turnover Market share 
Biopharmaceuticals (products) 
NN: EUR 2 billion (41% of 
company’s total, 2006) – 
insulin analogues: 26% of 
the company’s total (2005) 
 
SA: EUR 0.162 billion 
(0.75% of total) – insulin 
analogue: 5.45% of 
company’s total (2005) 
EL: EUR 0.798 billion 
(converted from USD) EUR 
0.367 billion estimated to be 
sold in the EU (humulin 
2005) – humalog: EUR 
0.882 billion  
Insulin EU: Novo Nordisk (NN) 
 
 
 
 
EU: Sanofi Aventis (SA) 
 
 
 
US: Eli Lilly (EL) 
 
 
Total EU turnover (human 
insulin): 6.8% (out of total 
turnover of NN and SA) 
2005 
EU: 42% of 
global (EUR 
1.89 billion) 
2004 
 
US: 47% of 
global (EUR 
2.115 billion) 
2004 
 
World: (EUR 
4.5 billion) 
2004 
Schering: EUR 0.867 billion 
(16% of company’s total, 
2005) 
 
SA: EUR 0.902 billion (3% 
of company’s total, 2005) 
Serono: EUR 0.872 billion 
(42% of company’s total, 
2005) 
 
Biogen: EUR 0.56 billion 
(2005) 
Interferon-beta EU: Schering 
 
 
 
EU: Sanofi Aventis (SA) 
 
 
CH: Serono 
 
 
US: Biogen Idec 
Total EU turnover: 5.4% 
(out of total turnover of 
Schering and SA) 2005 
(estimated by IPTS) 
 
Enzyme replacement 
therapy for Gaucher’s 
disease (Cerezyme) 
US: Genzyme Genzyme: EUR 0.932 
billion (35% of company’s 
total, 2005) 
 
CD20 monoclonal 
antibodies 
(Rituxan (rituximab), 
Mabthera (rituximab), 
Zevalin, Bexxar) 
US: Biogen, Genentech, Corixa 
(acquired by GSK in 2005) 
 
CH: Roche (not a producer, just 
marketing the product) 
 
Roche: EUR 2.6 billion 
(11.7% of company’s total, 
2005) 
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 Companies Turnover Market share 
Preventives 
Hepatitis B vaccine EU: GlaxoSmithKline (GSK) 
 
 
 
EU: Sanofi-Aventis (SA) 
 
 
 
And Merck 
GSK: EUR 0.662 billion 
(32% of company’s total 
turnover of vaccines, and 
2.1% of total sales, 2005) 
 
SA: EUR 0.167 billion 
(8.1% of company’s total 
turnover of vaccines, and 
0.6% of total sales, 2005) 
"other vaccines" (includes 
HBV) 
 
 
Diagnostics 
Cardiac assays CH: Roche Diagnostics 
 
US: Dade Behring, Abbott 
Diagnostics, Bayer 
Diagnostics, Beckman Coulter, 
Diagnostics Products Corp. 
Roche Diagnostics: EUR 
0.055 billion (1% of 
company’s total, 2005) 
 
EU: 30% of 
global (EUR 
0.141 billion 
estimated) 2005 
HIV testing EU: BioMerieux, Trinity 
biotech 
 
CH: Roche Diagnostics 
 
US: Dade Behring, Abbott 
Diagnostics, Bayer 
Diagnostics, Beckman Coulter, 
Gen-Probe, OraSure 
Technologies 
Share of biotech/total 
turnover : 18% (firms 
producing HIV diagnostics 
in the EU) 
 
 
 
PKU testing  Share of biotech/total 
turnover : 1%  
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Annex 3 – Agro-Food Biotechnology 
 
Table 67: Economic data on the EU agro-food sector 
Note: Numbers in italics are IPTS estimates; the most likely relationship between GVA and turnover was used in 
the respective sectors509. 
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EU   8 782 817   200 000 000510  
Core production 
Agriculture511 A 01: Agriculture and hunting 314 160 157 403 0.50 1.79   
Forestry512 A 02: Forestry 40 000 20 000 0.50 0.23   
Agriculture and 
forestry 
A: Agriculture, 
hunting and 
forestry 
354 015 177 371 0.50 2.02 9 757 100 4.88 
Fishing, EU-15 BA 05.01Fishing 6185 2412 0.39 0.03 208 852513 0.10 
Aquaculture, 
EU 
BA 05.02 Fish 
Farming 2769 1387 0.50 0.02 65 365
513 0.03 
Fisheries B: Fishing 8954 3799 0.42 0.04 274 217513 0.14 
Primary production sub-total 362 969 181 170 0.50 2.06 10 031 317514 5.02 
Food processing 
DA 15 
Manufacture of 
food products and 
beverages 
797 069 181 220 0.23 2.06 4 434 100 2.22 
 
Core production total 
 
1 160 039 362 390 0.31 4.13 14 465 417 7.23 
                                                 
509 The data have been obtained from EUROSTAT (dataset available online at http://epp.eurostat.ec.europa.eu/), 
and from reports published by the European Commission, DG Agriculture and Rural Development (2006): 
Agriculture in the European Union – Statistical and Economic Information 2005. 
http://ec.europa.eu/agriculture/agrista/2005/table_en/2005enfinal.pdf; And: Rural Development in the European 
Union - Statistical and Economic Information Report 2006. 
http://ec.europa.eu/agriculture/agrista/rurdev2006/RD_Report_2006.pdf. And: P. Salz et al. (2006) Employment 
in the fisheries sector: current situation. 
http://ec.europa.eu/fisheries/publications/studies/employment_study_2006.pdf. 
510 Rounded-up from 192 615 000 
511 The data are based on the Economic Accounts for Agriculture and Forestry, providing complementary 
information and concepts adapted to the particular nature of the agricultural industry. However, the EAA 
agricultural industry differs in some respects from the branch as defined for national accounts purposes. 
512 Estimated as the difference between the estimate for NACE A and the value for NACE A 01. 
513 P. Salz et al. (2006) Employment in the fisheries sector: current situation. 
http://ec.europa.eu/fisheries/publications/studies/employment_study_2006.pdf. The report also estimates the 
employment of the fish processing sector at 147 102. 
514 The sum of the most recent estimates was used. It was estimated at 10 149 000 in the report "Agriculture in 
the European Union - Statistical and economic information 2005", European Commission, DG Agriculture and 
Rural Development (2006). http://ec.europa.eu/agriculture/agrista/2005/table_en/2005enfinal.pdf . 
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Related sectors 
Input sectors (products and services) specific to primary production and the agro-food chain 
Fertilisers  DG 24.15: 
Manufacture of 
fertilisers and 
nitrogen 
compounds 
13 323 2672 0.20 0.03 51 200 0.03 
Pesticides DG 24.2: 
Manufacture of 
pesticides and 
other agro-
chemical products  
12 201 2767 0.23 0.03 29 500 0.01 
Veterinary 
products 
Values are 
estimated at the 
turnover provided 
under "veterinary 
services"515 
5200 1768 0.34 0.02 14 966 0.01 
Diagnostics Estimated from 
various sources 
(see Section 2.3.5) 
700 238 0.34 0.005   
Food and feed 
additives 
DG 24.66: 
Manufacture of 
other chemical 
products (enzymes, 
amino acids, 
vitamins, organic 
acids)516 
2300 600 0.26 0.01 2700  
Input sectors sub-total 33 724 8045 0.24 0.09 98 366 0.05 
Total of production sectors (agro-
food economy) 
1 193 763 370 435 0.31 4.21 14 563 783 7.28 
Wholesale and retail 
  GA 51.2 Wholesale 
of agricultural raw 
materials and live 
animals  
175 754 13 723 0.08 0.16 321 600 0.16 
  GA 51.3 Wholesale 
of food, beverages 
and tobacco 
(except GA 51.35) 
653 812 57 779 0.09 0.66 1 600 200 0.80 
                                                 
515 Due to a lack of disaggregated information in NACE DG 24.4: Manufacture of pharmaceuticals, medicinal 
chemicals and botanical products. 
516 The totals are not comprehensive as they only include specific product categories (turnover: food and feed 
related amino acids, vitamins, organic acids, antibiotics and xanthan, see Section 2.3.5.3; employment: refers 
only to food enzymes related production, assuming that 45% of all enzymes are food related, see Section 
2.3.5.3). 
The Bio4EU Analysis report 227
20
03
 d
at
a 
N
A
C
E
 
se
ct
or
s 
T
ur
no
ve
r 
(E
U
R
 
m
ill
io
n)
 
G
V
A
 
(E
U
R
 
m
ill
io
n)
 
R
el
at
io
n 
G
V
A
/ 
T
ur
no
ve
r 
 
Sh
ar
e 
of
 E
U
 
G
V
A
 (i
n 
%
) 
E
m
pl
oy
m
en
t 
Sh
ar
e 
of
 E
U
 
em
pl
oy
m
en
t 
(in
 %
) 
  GA 52.11 Retail 
sale in non-
specialised stores 
with food, 
beverages or 
tobacco 
predominating  
740 498 102 423 0.14 1.17 4 654 800 2.33 
  GA 52.2 Retail sale 
of food, beverages 
and tobacco in 
specialised stores 
(except GA52.26) 
101 789 20 363 0.20 0.23 1 287 500 0.64 
  HA 55.3 to 55.5: 
Restaurants; bars; 
canteens and 
catering. 
258 241 101 127 0.39 1.15 6 194 200 3.10 
Wholesale and retail sub-total 1 930 094 295 415 0.15 3.36 14 058 300 7.03 
Related sectors total 1 963 818 303 460 0.15 3.45 14 165 432 7.08 
Total 3 123 857 665 850 0.21 7.58 28 630 849 14.31 
 
 
 
Table 68: Main modern biotechnology applications in the agro-food sector 
 
Bi
ot
ec
hn
ol
og
y 
ap
pl
ic
at
io
n 
in
  
Biotechnology 
techniques 
Biotechnology producers – direct 
impacts 
(most disaggregated NACE/EAA 
sectors if available) 
Biotechnology users – 
indirect impacts 
Marker assisted selection 
in plant breeding 
Plant breeders, seed companies: 
-seeds and planting stock  
-nursery plants and flowers  
Plant growers: 
AA 01.1: Growing of 
crops; market gardening; 
horticulture 
Genetic modification in 
plant breeding 
Plant breeders, seed companies: 
-seeds and planting stock 
Plant growers: 
AA 01.11 Growing of 
cereals and other crops 
n.e.c. (includes seed 
multiplication)  
Pl
an
ts
 
Micropropagation in 
plant breeding 
Specialised laboratories, young 
plant companies, etc: 
-nursery plants and flowers  
Plant growers: 
AA 01.12 Growing of 
vegetables, horticultural 
specialities and nursery 
products 
B
re
ed
in
g/
pr
op
ag
at
io
n 
in
 p
ri
m
ar
y 
pr
od
uc
tio
n 
An
im
al
s 
Marker assisted selection 
in livestock breeding 
Livestock breeders, specialised 
genetics companies: 
AA 01.42 Animal husbandry 
service activities, except veterinary 
activities 
NA 85.20: Veterinary activities  
Livestock growers: 
AA 01.2 Farming of 
animals 
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Bi
ot
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y 
ap
pl
ic
at
io
n 
in
  
Biotechnology 
techniques 
Biotechnology producers – direct 
impacts 
(most disaggregated NACE/EAA 
sectors if available) 
Biotechnology users – 
indirect impacts 
Embryo techniques in 
livestock breeding 
Livestock breeders, specialised 
genetics and embryo transfer 
companies: 
AA 01.42 Animal husbandry 
service activities, except veterinary 
activities 
NA 85.20: Veterinary activities  
Livestock growers: 
AA 01.2 Farming of 
animals 
Marker assisted selection 
in fish/shellfish breeding 
Fish/shellfish breeders, specialised 
genetics companies: 
B 05.02 Fish farming 
Fish/shellfish growers: 
B 05.02 Fish farming 
Fi
sh
/ 
Sh
el
lfi
sh
 
Sex/ploidy manipulation 
in fish/shellfish breeding 
Fish/shellfish breeders: 
B 05.02 Fish farming 
Fish/shellfish growers: 
B 05.02 Fish farming 
In
pu
ts
 -d
ia
gn
os
tic
s u
se
d 
th
ro
ug
ho
ut
 th
e 
fo
od
 c
ha
in
 (p
ri
m
ar
y 
pr
od
uc
tio
n,
 fo
od
 
m
an
uf
ac
tu
ri
ng
, t
hr
ou
gh
 r
et
ai
l s
al
e)
 
 
Modern biotechnology-
based diagnostics 
Specialised laboratories, veterinary 
laboratories, specialised 
chemical/pharmaceutical 
companies: 
KA 74.30: Technical testing and 
analysis (as relevant for 
diagnostics in the food chain) 
NA 85.20: Veterinary activities 
19050 Veterinary expenses (incl 
medicines and fees) 
DG 24.4: Manufacture of 
pharmaceuticals, medicinal 
chemicals and botanical products 
(as relevant for veterinary 
products) 
DG 24.66: Manufacture of other 
chemical products (diagnostic 
reagents) 
1st level: Analytical 
laboratories (if not direct 
producer) 
KA 74.30: Technical 
testing and analysis (as 
relevant for diagnostics in 
the food chain) 
NA 85.20: Veterinary 
activities 
2nd level: Food/feed and 
beverages processing 
DA 15 Manufacture of 
food products and 
beverages 
3rd level: Wholesale and 
retail sale 
GA 51.2 Wholesale of 
agricultural raw materials 
and live animals  
GA 51.3 Wholesale of 
food, beverages and 
tobacco (except GA51.35) 
GA 52.11 Retail sale in 
non-specialised stores with 
food, beverages or tobacco 
predominating  
GA 52.2 Retail sale of 
food, beverages and 
tobacco in specialised 
stores (except GA 52.26) 
In
pu
ts
 u
se
d 
in
 p
ri
m
ar
y 
pr
od
uc
tio
n 
 
Veterinary products 
(based on modern 
biotechnology) 
Pharmaceutical companies, 
biotechnology companies, 
fermentation, enzyme producers, 
etc. 
DG 24.4: Manufacture of 
pharmaceuticals, medicinal 
chemicals and botanical products  
DG 24.66: Manufacture of other 
chemical products (enzymes) 
1st level: Pharmaceutical 
companies 
DG 24.4: Manufacture of 
pharmaceuticals, medicinal 
chemicals and botanical 
products  
2nd level: Livestock and 
fish/shellfish producers 
AA 01.2 Farming of 
animals 
B 05.02 Fish farming 
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y 
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ic
at
io
n 
in
  
Biotechnology 
techniques 
Biotechnology producers – direct 
impacts 
(most disaggregated NACE/EAA 
sectors if available) 
Biotechnology users – 
indirect impacts 
 
Other chemical products 
(based on modern 
biotechnology (e.g. amino 
acids, vitamins,enzymes, 
etc.) 
Fermentation, enzyme producers, 
speciality chemical producers 
(amino acids, vitamins) 
DG 24.4: Manufacture of 
pharmaceuticals, medicinal 
chemicals and botanical products  
DG 24.66: Manufacture of other 
chemical products (enzymes) 
DG 24.66: Manufacture of other 
chemical products (amino acids, 
vitamins, etc.) 
1st level: Chemicals 
producers (amino acids, 
vitamins, etc.) 
DG 24.4: Manufacture of 
pharmaceuticals, medicinal 
chemicals and botanical 
products  
DG 24.66: Manufacture of 
other chemical products  
2nd level: feed additive and 
feed producers 
DA 15.Manufacture of 
prepared feeds for farm 
animals 
3rd level: Livestock and fish 
producers 
AA 01.2 Farming of 
animals 
B 05.02 Fish farming 
Fo
od
  
m
an
uf
ac
tu
ri
ng
 
 
Modern biotechnology 
derived 
microorganisms/enzymes 
applied in food processing 
Fermentation-enzyme producers, 
DG 24.66: Manufacture of other 
chemical products (enzymes) 
Food and beverage 
processors 
DA 15 Manufacture of 
food products and 
beverages 
 
 
This list is not exhaustive as there are other techniques and applications, as well as other users, relevant to 
primary production and agro-food. Furthermore, products, such as biopesticides and biofertilisers, are not 
included, as it is still an emerging application area and these applications may not always fall within the scope of 
the modern biotechnology definition used in this study. However, it is believed that the large share of modern 
biotechnology applications and users are captured in this table.  
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Annex 4 – Industrial Biotechnology 
Table 69: Carbon dioxide emissions by industry in 2001 
Source: IPTS calculation based on Eurostat data517; n.e.c.: not elsewhere classified 
 
 Carbon dioxide emissions by industry (1000 tonnes) 
NACE 
section  Denmark Germany Italy UK Total Share (in %) 
DA 
Manufacture of food 
products; beverages 
and tobacco 
1800.55 9117.77 2236.28 9519.30 22 673.90 6.74 
DB 
Manufacture of 
textiles and textile 
products 
101.42 892.35 1819.23 2521.76 5334.76 1.59 
DC 
Manufacture of 
leather and leather 
products 
4.84 70.09 368.75 129.72 573.40 0.17 
DD Manufacture of wood and wood products 502.67 1056.94 595.00 3914.6 6069.21 1.80 
DE 
Manufacture of pulp, 
paper and paper 
products; publishing 
and printing 
260.97 7920.85 6359.01 5522.57 20 063.40 5.97 
DG 
Manufacture of 
chemicals, chemical 
products and man-
made fibres 
570.95 2030.02 1955.43 16691.96 39 520.36 11.75 
DH 
Manufacture of 
rubber and plastic 
products 
130.03 1670.29 1454.67 4524.89 7779.88 2.31 
DI 
Manufacture of other 
non-metallic mineral 
products 
3259.25 33126.36 37716.19 15455.06 89 556.86 26.63 
DJ 
Manufacture of basic 
metals and fabricated 
metal products 
384.25 58 552.19 22 235.16 31 121.79 112 293.39 33.39 
DK 
Manufacture of 
machinery and 
equipment n.e.c. 
227.19 3119.51 2030.54 1609.13 6986.37 1.82 
DL 
Manufacture of 
electrical and optical 
equipment 
97.81 3476.56 980.63 1573.60 6128.60 1.82 
DM Manufacture of transport equipment 65.08 6571.19 2215.72 3336.13 12 188.12 3.62 
DN Manufacturing n.e.c. 221.42 1564.82 741.59 4573.60 7101.43 2.11 
 Total     396 344.07 100.00 
                                                 
517 Eurostat data from online database. http://epp.eurostat.ec.europa.eu/. 
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Table 70: Methane emissions by industry in 2001 
Source: IPTS calculation based on Eurostat data518; n.e.c.: not elsewhere classified 
 
 Methane emissions by industry (1000 tonnes) 
NACE 
section  Denmark Germany Italy UK Total Share (in %) 
DA 
Manufacture of food 
products; beverages 
and tobacco 
0.41 0.48 33.75 0.61 35.25 34.40 
DB 
Manufacture of 
textiles and textile 
products 
0.02 0.04 4.08 0.14 4.28 4.18 
DC 
Manufacture of 
leather and leather 
products 
0.00 0.00 0.07 0.01 0.08 0.08 
DD Manufacture of wood and wood products 0.34 0.15 0.07 0.51 1.07 1.04 
DE 
Manufacture of pulp, 
paper and paper 
products; publishing 
and printing 
0.07 0.43 1.18 0.39 2.07 2.02 
DG 
Manufacture of 
chemicals, chemical 
products and man-
made fibres 
0.11 0.67 27.29 3.09 31.16 30.41 
DH 
Manufacture of 
rubber and plastic 
products 
0.03 0.07 0.17 0.30 0.57 0.56 
DI 
Manufacture of other 
non-metallic mineral 
products 
0.38 1.22 1.54 1.16 4.30 4.20 
DJ 
Manufacture of basic 
metals and fabricated 
metal products 
0.08 2.24 11.53 7.42 21.27 20.76 
DK 
Manufacture of 
machinery and 
equipment n.e.c. 
0.05 0.16 0.28 0.10 0.59 0.58 
DL 
Manufacture of 
electrical and optical 
equipment 
0.03 0.18 0.16 0.12 0.49 0.48 
DM Manufacture of transport equipment 0.02 0.31 0.20 0.22 0.75 0.73 
DN Manufacturing n.e.c. 0.11 0.07 0.10 0.30 0.58 0.57 
 Total     111.90 100.00 
                                                 
518 Eurostat data from online database. http://epp.eurostat.ec.europa.eu/. 
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Table 71: Nitrous oxide emissions by industry in 2001 
Source: IPTS calculation based on Eurostat data519; n.e.c.: not elsewhere classified 
 
 Nitrous Oxide emissions by industry in 2001 (1000 tonnes) 
NACE 
section  Denmark Germany Italy UK Total 
Share  
(in %) 
DA 
Manufacture of food 
products; beverages and 
tobacco 
0.05 0.21 0.40 0.29 0.95 1.16 
DB Manufacture of textiles and textile products 0.00 0.02 0.26 0.07 0.35 0.43 
DC Manufacture of leather and leather products 0.00 0.00 0.05 0.01 0.06 0.07 
DD Manufacture of wood and wood products 0.02 0.03 0.07 0.30 0.42 0.52 
DE 
Manufacture of pulp, 
paper and paper 
products; publishing 
and printing 
0.01 0.19 0.14 0.18 0.52 0.64 
DG 
Manufacture of 
chemicals, chemical 
products and man-made 
fibres 
2.87 21.76 28.85 17.76 71.24 87.36 
DH Manufacture of rubber and plastic products 0.00 0.03 0.12 0.24 0.39 0.48 
DI 
Manufacture of other 
non-metallic mineral 
products 
0.06 0.49 2.63 0.31 3.49 4.28 
DJ 
Manufacture of basic 
metals and fabricated 
metal products 
0.01 1.24 0.59 0.67 2.51 3.08 
DK 
Manufacture of 
machinery and 
equipment n.e.c. 
0.01 0.10 0.23 0.07 0.41 0.50 
DL 
Manufacture of 
electrical and optical 
equipment 
0.00 0.09 0.11 0.06 0.26 0.32 
DM Manufacture of transport equipment 0.00 0.13 0.16 0.12 0.41 0.50 
DN Manufacturing n.e.c. 0.01 0.05 0.11 0.37 0.54 0.66 
 Total     83.10 100.00 
 
 
                                                 
519 Eurostat data from online database. http://epp.eurostat.ec.europa.eu/. 
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